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Chapter 1. 
General Introduction: Synthetic Methods for (E)- and 
(Z)-Stereodefined Alkenes 
 
(E)- and (Z)-stereodefined alkenes are widely distributed in natural products, pharmaceuticals, and functional 
molecules.  Figure 1-1 displays representative examples of these alkenes: aromatic butenolides 
(gymnoascolide A−C),1 protoilludane sesquiterpenes (tsugicoline A−D),2 a promising antiulcer agent 
(nileprost),
3
 antiulcer drug (plaunotol),
4
 an orally active cyclooxygenase-2 inhibitor (vioxx
®
),
5
 a selective 
serotonin reuptake inhibitor (SSRI) antidepressant [(Z)-zimelidine],
6
 an antiestrogenic agent [(Z)-tamoxifen],
7
 
the chiral molecular switch,
8
 and the chiral molecular motor.
9
  Stereodefined alkenes also serve as useful 
scaffolds for a number of elaborated compounds through readily accessible transformations such as 
hydrogenation, epoxidation, and Michael addition to construct contiguous chiral and achiral centers.
10
   
Due to the high demand, a number of stereocontrolled synthetic methods for (E)- and (Z)-multi-substituted 
stereodefined alkenes have been developed, and are generally categorized into six approaches (Scheme 1-1):  
1) Wittig-type reactions, 2) carbometalations of alkynes using Cu, B, Sn, Mg, Pd, and so forth, followed by 
reactions with electrophiles, 3) cross-couplings with halogenovinyl templates, 4) elimination reactions of 
tertiary alcohols, 5) cross-metatheses between different alkenes, and 6) ynolate-mediated reactions derived 
from α,α-dibromoesters.  However, the (E)- and (Z)-stereocomplementary method using the similar common 
starting materials with sufficient substrate-generality is quite limited to date. 
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Figure 1-1.  Examples of representative alkene containing pharmaceutical and functional molecules. 
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Scheme 1-1.  Stereocontrolled synthetic methods for (E)- and (Z)-multi-substituted stereodefined alkenes. 
 
Strategies based on cross-coupling reactions with stereodefined enol sulfonate
11
 and phosphonate
12
 partners 
derived from β-ketoesters, which emerged in recent decades, are considered as promising and reliable 
approaches compared with the above-mentioned methods, due to the following advantages: 1) various starting 
β-ketoester substrates are readily available,13 and 2) parallel approach enhances the versatility of the method. 
In 2005, the Merck process group disclosed a characteristic protocol for (E)- and (Z)-stereocomplementary 
enol tosylations of specific α- or γ-nitrogen-substituted β-ketoesters using respective Ts2O−M(Li or 
Na)HMDS and Ts2O−amine reagents (Scheme 1-2).
14
  The obtained stereodefined enol tosylate scaffolds 
were successfully subjected to stereoretentive Suzuki-Miyaura (SM) cross-couplings for the synthesis of 
γ-aminobutanoic acid (GABA) precursors.  In addition, they also reported a concise synthesis of chiral 
β-cyclopropyl-α-methyldihydrocinnamates.15  This notable pharmacophore was synthesized via (E)- and 
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(Z)-stereocontrolled enol tosylations using a β-cyclopropyl-α-methyl-β-ketoester; the (E)-isomer was prepared 
using Ts2O−NaHMDS at −78 °C, whereas the (Z)-isomer was prepared using the same reagent at room 
temperature.  Throughout the study, they consistently use reactive but highly expensive Ts2O instead of TsCl 
for enol tosylation of β-ketoeste to avoid α-chlorinated by-product. 
 
 
Scheme 1-2.  (E)- and (Z)-stereocomplementary synthesis of γ-amino-substituted (E)- and (Z)-α,β-unsaturated esters utilizing 
stereoselective enol tosylations and stereoretentive cross-couplings reported by the Merck process group. 
 
In 2008, Frantz’s group has reported a practical preparative method for (E)- and (Z)-stereodefined enol 
triflates derived from β-ketoesters (Scheme 1-3).16  Highly reactive these enol sulfonates have served as 
useful building blocks for the synthesis of natural products,
17
 however, enol triflates methods have several 
drawbacks:  (i) Tf2O is ca. 15−30 times more expensive than TsCl, (ii) Tf2O is highly toxic and hazardous 
with a low boiling point (81−83 °C) and reacts violently with water, and (iii) triflates are often unstable under 
cross-couplimg conditions due to their inherent reactivity. 
 
 
Scheme 1-3.  (E)- and (Z)-Stereocomplementary preparation of enol triflates reported by Frantz’s group. 
 
As a part of our ongoing studies on mild but powerful sulfonylations
18
 and silylations
19
 of various alcohols 
and carbonyl compounds, in 2008 and 2009, our group has reported a series of (E)- and 
(Z)-stereocomplementary enol tosylations of not only acyclic “α-nonsubstituted” β-ketoesters (R1 = alkyl or 
aryl, R
2
 = H), but also α-formylesters (R1 = H, R2 = alkyl or aryl), which were conducted by a much more 
accessible TsCl−N-methylimidazole (NMI)−base system (Scheme 1-4).  TsCl−NMI−Et3N was used for the 
(E)-selective reactions, whereas TsCl−NMI−LiOH controlled the (Z)-selective reactions.  Subsequent highly 
(E)- and (Z)-stereoretentive cross-couplings (Negishi,
20a
 Sonogashira,
20a
 Suzuki-Miyaura,
20b
 and Kochi‒
Fürstner
20c
) were successfully performed to produce the corresponding stereodefined α,β-unsaturated esters. 
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Scheme 1-4.  (E)- and (Z)-stereocomplementary synthesis of ‘not fully’-substituted (E)- and (Z)-α,β-unsaturated esters utilizing 
stereoselective enol tosylations and stereoretentive cross-couplings. 
 
As depicted in Scheme 1-5, the current privileged robust and cost-effective protocols have been 
successfully adopted for the synthesis of elaborated natural and unnatural compounds, such as juvenile 
hormones 0 and I,
21a,b
 madangamine A,
21c
 and functionalized steroids,
21d
 etc . 
 
 
Scheme 1-5.  Synthetic applications of “not fully”-substituted (E)- and (Z)-enol tosylates. 
 
This background led the author to envisage a highly substrate-general synthesis of multi-substituted (E)- 
and (Z)-stereodefined alkene scaffolds, and especially with focusing on a parallel and stereocomplementary 
methodology. 
In chapter 2, parallel and practical methods for the preparation of both (E)- and 
(Z)-β-aryl1-β-aryl2-α,β-unsaturated esters and (E)- and (Z)-α-aryl1-β-aryl2-α,β-unsaturated esters are described 
(Scheme 1-6).  These methods involve accessible, robust, stereocomplementary N-methylimidazole 
(NMI)-mediated enol tosylations (14 examples, 70−99% yield), as well as stereoretentive Suzuki-Miyaura 
cross-couplings (36 examples, 64−99% yield).  The highlighted feature of the present protocol is the use of 
parallel and stereocomplementary approaches to obtain (E)- and (Z)-products with high purity by utilizing 
sequential enol tosylations and cross-coupling reactions.  An expeditious and parallel synthesis of (E)- and 
(Z)-zimelidine, which is a highly representative selective serotonin reuptake inhibitor (SSRI), was performed 
by utilizing the present methods. 
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Scheme 1-6.  Parallel and practical methods for the preparation of both (E)- and (Z)-β-aryl1-β-aryl2-α,β-unsaturated esters and 
(E)- and (Z)-α-aryl1-β-aryl2-α,β-unsaturated esters. 
 
In chapter 3, a versatile, robust, and stereocomplementary synthesis of fully-substituted (E)- and 
(Z)-stereodefined α,β-unsaturated esters from accessible α-substituted β-ketoesters via (E)- and (Z)-enol 
phosphonates was achieved (Scheme 1-7).  The present method involves two accessible reaction sequences: 
(i) (E)- and (Z)-stereocomplementary enol phosphorylations of a wide variety of β-ketoesters (24 examples; 
71–99% yield, each >95:5 ds), and (ii) (E)- and (Z)-stereoretentive Suzuki–Miyaura cross-coupling (16 
examples; 71–91% yield, >81:19 ds) and Negishi cross-coupling (32 examples; 65–96% yield, >95:5 ds) 
using (E)- and (Z)-enol phosphonates.  
1
H NMR monitoring for a key reactive N-phosphorylammonium 
(imidazolium) intermediate I and an application in the synthesis of both (E)- and (Z)-tamoxifen precursors are 
described. 
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Scheme 1-7.  Stereocomplementary synthesis of fully-substituted (E)- and (Z)-stereodefined α,β-unsaturated esters from 
accessible α-substituted β-ketoesters via (E)- and (Z)-enol phosphonates. 
 
In chapter 4, a robust method for preparing (E)- and (Z)-stereodefined fully-substituted enol tosylates is 
described (Scheme 1-8).  -Substituted β-ketoesters undergo (E)-selective enol tosylations using TsCl–
Me2N(CH2)6NMe2 as the reagent (method A, 13 examples; 63–96%) and (Z)-selective enol tosylations using 
TsCl–TMEDA–LiCl as the reagent (method B, 13 examples; 62–99%).  A plausible mechanism for the (E)- 
and (Z)-enol tosylation selectivity is proposed.  A 
1
H NMR monitoring experiment revealed that TsCl 
coupled with TMEDA formed a simple N-sulfonylammonium intermediate. 
 
 
Scheme 1-8.  A robust method for preparing (E)- and (Z)-stereodefined fully-substituted enol tosylates. 
 
In chapter 5, a highly substrate-general synthesis of all-carbon-substituted E- and Z-stereodefined olefins is 
performed (Scheme 1-9).  The method comprises two sets of parallel and stereocomplementary preparations 
of (E)- and (Z)-α,β-unsaturated esters involving two robust and distinctive reactions: 1) stereocomplementary 
enol tosylations using readily available TsCl/diamine/(LiCl) base reagents, and 2) stereoretentive Negishi 
cross-coupling using the catalysts [Pd(dppe)Cl2] (for E) and [Pd(dppb)Cl2] (for Z).  The present parallel 
approach is categorized as both type I (convergent approach: 16 examples, 56−87% yield) and type II 
(divergent approach: 18 examples, 70−95% yield).  The following two developments are performed by 
Atsushi Honda, one of the author’s colleagues: (i) The obtained (E)- and (Z)-α,β-unsaturated ester scaffolds 
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are successfully transformed into various E- and Z-stereodefined known and novel olefins (8x2 derivatization 
arrays).  (ii) As a demonstration, application to the parallel synthesis of both (E)- and (Z)-tamoxifens, a 
representative motif of all-carbon-substituted olefins, is accomplished in a total of eight steps with overall 
yields of 58% (average 93%) and 57% (average 93%), respectively. 
 
 
Scheme 1-9.  Parallel and a highly substrate-general synthesis of all-carbon-substituted E- and Z-stereodefined olefins. 
 
In the next two chapters 6 and 7, the author reports two subjects directed for the publication in Organic 
Syntheses.  Unique features of this journal are as follows. 1) Each procedure and all characterization data are 
carefully checked for reproducibility in the laboratory of a member of the Board of Editors.  2) The 
procedure should be resulted in at least 5 g and no more than 50 g of the final product.  3) The purity of the 
final product should be at least 97%.  The author has developed the procedure for two useful and less 
accessible building blocks in line with the criteria of Organic Syntheses. 
In chapter 6, a synthesis of methyl (Z)-3-phenyl-2-butenoate [methyl (Z)-β-methylcinnamate] directed for 
Organic Syntheses is presented (Scheme 1-10).  Despite its simple structure, hitherto reported methods 
require multi-steps or expensive reagents, a low temperature, and a long reaction period.  The enol tosylation 
of methyl acetoacetate utilizing TsCl−TMEDA−LiCl reagent in AcOEt solvent gives 
(Z)-3-(p-toluenesulfonyloxy)but-2-enoate, which is converted to methyl (Z)-3-phenyl-2-butenoate utilizing a 
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highly cost-effective Pd(OAc)2 (1 mol%)/PPh3 (2 mol%)-catalyzed Suzuki-Miyaura cross-coupling with 
nearly perfect (Z)-stereoretention.  Throughout the procedure, tedious column chromatographic purification 
is not required.   In addition, environmentally benign solvents, such as AcOEt, iPrOH, and H2O, are 
employed for both of two reaction steps and the corresponding extraction (work-up) steps.  In addition, the 
synthesis of the aryl analogues including stereocomplementary (E)-isomer are addressed.  
 
 
Scheme 1-10.  A synthesis of methyl (Z)-3-phenyl-2-butenoate directed for Organic Syntheses. 
 
  In chapter 7, a synthesis of methyl 1-formylcyclopropanecarboxylate directerd for Organic Syntheses is 
disclosed (Scheme 1-11).  Despite its utility to install cyclopropane segment into various pharmaceuticals, 
hitherto reported methods require multi-steps or expensive reagents, a low temperature, and a long reaction 
period.  Starting methyl 4-chlorobutanoate, possessing base-sensitive γ-chloro moiety, can be successfully 
α-formylated utilizing distinctive TiCl4/Et3N-mediated (Ti-Claisen) condensation at 0−15 °C to give methyl 
4-chloro-1-formylbutanoate.  Without any purification of the α-formylester, successive cyclopropanation is 
performed in mild basic conditions [Et3N (10 mol%)/K2CO3 (1 equiv) in AcOEt at 0−15 °C] to produce 
methyl 1-formylcyclopropanecarboxylate, which is easily purified by simple distillation (the boiling point was 
documented for the first time).  Throughout the procedure, column chromatographic purification is not 
required. 
 
 
Scheme 1-11.  A synthesis of methyl 1-formylcyclopropanecarboxylate directed for Organic Syntheses. 
 
In chapter 8, a highly regiocontrolled acid-induced Favorskii-type elimination reaction of acyloin mesylates 
proceeded smoothly to give more substituted α,β-unsaturated ketones (Scheme 1-12).  Not only acyclic but 
also cyclic acyloin mesylates produced the corresponding higher substituted enones via 
double-bond-migration pathway.  A mechanistic speculation and application to a synthesis of chiral muscone 
precursor are also described.  
 
10 
 
 
Scheme 1-12.  Regiocontrolled acid-induced Favorskii-type elimination reaction using unsymmetrically-substituted acyloin 
mesylates. 
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Chapter 2. 
(E)-, (Z)-Parallel Preparative Methods for Stereodefined 
β,β-Diaryl- and α,β-Diaryl-α,β-unsaturated Esters: Application to 
Stereocomplementary Concise Synthesis of Zimelidine 
 
 
Abstract 
Parallel and practical methods for the preparation of both (E)- and (Z)-β-aryl1-β-aryl2-α,β-unsaturated 
esters 2-1 and (E)- and (Z)-α-aryl1-β-aryl2-α,β-unsaturated esters 2-2 are described.  These 
methods involve accessible, robust, stereocomplementary N-methylimidazole (NMI)-mediated enol 
tosylations (14 examples, 70−99% yield), as well as stereoretentive Suzuki-Miyaura cross-couplings 
(36 examples, 64−99% yield).  The highlighted feature of the present protocol is the use of parallel 
and stereocomplementary approaches to obtain highly (E)- and (Z)-pure products 2-1 and 2-2 by 
utilizing sequential enol tosylations and cross-coupling reactions.  An expeditious and parallel 
synthesis of (E)- and (Z)-zimelidine (2-3), which is a highly representative selective serotonin 
reuptake inhibitor (SSRI), was performed by utilizing the present methods. 
 
 
 
 
Introduction 
The stereocontrolled preparation of ubiquitous (E)- and (Z)-α,β-unsaturated esters is pivotal in organic 
syntheses because these compounds serve as useful structural scaffolds for various stereodefined olefins and 
conjugate (Michael) addition acceptors.  Both (E)- and (Z)-β-aryl1-β-aryl2-α,β-unsaturated esters 2-1 and (E)- 
and (Z)-α-aryl1-β-aryl2-α,β-unsaturated esters 2-2 are well-recognized synthetic building blocks among 
various α,β-unsaturated esters (Figure 2-1). 
 
Figure 2-1. Examples of (E)- and (Z)-β-aryl1-β-aryl2-α,β-unsaturated esters 2-1 and (E)- and (Z)-α-aryl1-β-aryl2-α,β-unsaturated 
esters 2-2. 
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Despite the reasonable demand for (E)- and (Z)-esters 2-1 and 2-2 for the synthesis of natural products, fine 
and supramolecules, and for process chemistry, stereoselective and general preparative methods have not yet 
been fully established due to the fundamental synthetic difficulty in differentiating between structurally 
similar diaryl (Ar
1
 and Ar
2
) moieties.  A literature survey for the preparation of (E)- and (Z)-2-1 reveals that 
1) Mizoroki−Heck reactions,1 2) a recent notable oxidative Heck reaction sequence (Studer’s group),2 and 3) 
an excellent cooper-catalyzed conjugate addition of ArB(OH)2 to alkynoates (Yamamoto’s group),
3
 are 
representative stereocontrolled methods.  A stereoselective preparative method of (E)- and (Z)-2-2 with 
sufficient substrate generality, however, is more limited.  Sequential stereoretentive Suzuki-Miyaura 
cross-coupling with (E)-β-chloro-α-iodo-α,β-unsaturated esters should also be included as a successful 
example (Ogilvie’s group).4  Condensation of ynolates with acetophenone is a useful method (Shindo’s 
group), but a sole example has been presented with moderate stereoselectivity.
5 
  Consistent with our continued interest in finding a methodology for the stereocomplementary preparation of 
(E)- and (Z)-stereodefined α,β-unsaturated esters,6 we disclose herein a parallel preparative method for (E)- 
and (Z)-2-1 and (E)- and (Z)-2-2.  The present reaction sequence utilizes accessible and robust 
N-methylimidazole (NMI)-mediated enol tosylations and Suzuki-Miyaura cross-couplings, as depicted in 
Scheme 2-1.  The highlighted aspect of the present protocol is parallel and stereocomplementary Approaches 
1 and 2 to obtain highly (E)- and (Z)- pure products 2-1 and 2-2 (or 2-2’) by accessible and robust enol 
tosylations and cross-coupling reactions, which start from readily available β-ketoesters 2-4 (or 2-4’) and 2-6 
(or 2-6’), respectively.  The present dual-mode approach enhances the versatility of the project. To 
demonstrate the utility of the present method, we describe an expeditious and parallel synthesis of (E)- and 
(Z)-zimelidine (2-3),
7
 which is a highly representative selective serotonin reuptake inhibitor (SSRI; Figure 
2-2). 
 
Figure 2-2. Structures of (E)- and (Z)-zimelidine (3-3) synthesized by means of the methodology described herein. 
 
Results and Discussion 
The initial (E)- and (Z)-stereocomplementary enol tosylations
8-10
 of starting readily available β-ketoesters 2-4 
were performed by utilizing a conventional procedure with TsCl/NMI/base, as listed in Table 2-1.  The 
salient features are as follows: 1) (E)-enol tosylation proceeded in good to excellent yield, but poor 
stereoselectivity, despite screening a number of conditions (amine and solvent; Method A-1).  2) In clear 
contrast, the (Z)-enol tosylation exhibited nearly perfect stereoselectivity (Method B-1).  3) Fortunately, (E)- 
and (Z)-enol tosylates 2-5 were easily separated by column chromatography and/or recrystallization.  This 
result markedly contrasted with that obtained when using relevant aliphatic α,β-unsaturated esters,6 which was 
likely to be due to intrinsically more stable (Z)-β-aryl-α,β-unsaturated (cinnamic) ester moiety.11  4) It should 
be noted that all of these stereodefined (E)- and (Z)-enol tosylates 2-5 are novel compounds.  
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Scheme 2-1. Parallel and stereocomplementary syntheses of both (E)- and (Z)-diaryl (Ar1, Ar2) α,β-unsaturated esters 2-4 and 2-6. 
Ts = tosyl. 
 
 
Table 2-1.  (E)- and (Z)-Stereocomplementary enol tosylations using β-Ar1-β-ketoesters 2.4. 
 
Entry Ketoester 2-4
 Method
 
 Product Yield / %  E/Z
 a
 
1 
 
A-1 (E)-2-5a 73 60:40 
2 B-1 (Z)-2-5a 70 2:>98 
3 
 
A-1 (E)-2-5b 96 51:49 
4 B-1 (Z)-2-5b 80
b 
2:>98 
5 
 
A-1 (E)-2-5c 98 59:41 
6 B-1 (Z)-2-5c 85
c 
2:>98 
a) Determined by 
1
H NMR of the crude products.  b) NaOH was used instead of LiOH.  c) TsCl (2.0 equiv), LiOH (2.0 equiv), and NMI 
(2.0 equiv) were used. 
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Subsequent (E)- and (Z)-stereoretentive Suzuki-Miyaura cross-couplings
12
 with (E)-2-5 and (Z)-2-5 were 
performed, as summarized in Table 2-2.  The salient features are as follows:  1) Although reported catalysis 
with Pd(OAc)2–PCy3
6b
 produced disappointing results (decomposition of (E)-2-5; a somewhat undesirable 
isomerization for (Z)-2-5), [Pd(dppb)Cl2]/KF or /K2CO3 catalysis resulted from the reaction with (E)-2-5, 
whereas [Pd(dppf)Cl2]/K2CO3 catalysis produced fruitful results for (Z)-2-5 in good to excellent yield with 
consistent stereoretention.  2) In clear contrast to the case of relevant aliphatic type substrates,
6b
 which  
 
Table 2-2. The (E)- and (Z)-stereoretentive Suzuki–Miyaura cross-coupling of β-Ar1-enol tosylates 2-5.a 
 
Entry Ar
1 
Substrate
b 
Ar
2
 Method Product Yield / % E/Z
c 
1 Ph (E)-2-5a (p-Me)C6H4 C-1 (E)-2-1a 92 (88)
d
 95:5  
(95:5) 
2  (Z)-2-5a  D-1 (Z)-2-1a 88 2:>98 
3 Ph (E)-2-5a (p-MeO)C6H4 C-1 (E)-2-1b 83 95:5 
4  (Z)-2-5a  D-1 (Z)-2-1b 64 2:98 
5 Ph (E)-2-5a (p-Cl)C6H4 C-1 (E)-2-1c 55 (88)
d 
98:2  
6  (Z)-2-5a  D-1 (Z)-2-1c 77 11:89 
7 Ph (E)-2-5a (p-F)C6H4 C-1 (E)-2-1d 82 96:4 
8  (Z)-2-5a  D-1 (Z)-2-1d 80 13:87 
9 Ph (E)-2-5a (p-AcO)C6H4 C-1 (E)-2-1e 88 98:2 
10  (Z)-2-5a D-1 (Z)-2-1e 80 10:90 
11 Ph (E)-2-5a (o-Me)C6H4 C-1 (E)-2-1f 93 96:4 
12  (Z)-2-5a D-1 (Z)-2-1f 80 10:90 
13 Ph (E)-2-5a (o-Cl)C6H4 C-1 (E)-2-1g 93 96:4 
14  (Z)-2-5a D-1 (Z)-2-1g 80 10:90 
15 (p-MeO)C6H4 (E)-2-5b Ph C-1 (Z)-2-1b 88
e 
14:86 
16  (Z)-2-5b D-1 (E)-2-1b 91 90:10 
17 (p-Cl)C6H4 (E)-2-5b Ph C-1 (Z)-2-1c 87
f
 3:97 
18  (Z)-2-5b  D-1 (E)-2-1c 95 95:5 
a) dppb=1,4-bis(diphenylphosphino)butane, dppf=1,1’-bis(diphenylphosphino)ferrocene. b) E- and Z-purities were up to >98% based on the 
1
H NMR spectra.  c) Determined by 
1
H NMR spectroscopy of the crude products.  d) K2CO3 was used instead of KF.  e) 5.0 equivalents of 
PhB(OH)2 were used.  f) 3.0 equivalents of PhB(OH)2 were used. 
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requires harsh conditions (reflux in DMF), the present reaction proceeded smoothly under considerably milder 
conditions (60 °C in iPrOH) to give the corresponding (E)- and (Z)-esters 2-1 (Methods C-1 and D-1).  3) 
The parallel preparation mode was performed to afford (E)-2-1b, (Z)-2-1b, (E)-2-1c, and (Z)-2-1c (Table 2-2, 
entries 3−6 and 15−18).  4) Various substituents on Ar1 and/or Ar2, such as p-Me, p-MeO, p-Cl, p-F, p-AcO 
o-Me, and o-Cl, were compatible (Table 2-2).  
Our next study focused on a parallel approach for the preparation of (E)- and 
(Z)-α-aryl1-β-aryl2-α,β-unsaturated esters 2-2.  The reported method using a condensation reaction of 
ynolates with acetophenone produces a variety of tetrasubstituted α,β-unsaturated esters,[5] wherein a sole 
specific example, (E)-2-2a with E/Z = 86:14, is produced.  To the best of our knowledge, there is no (E)- and 
(Z)-stereocomplementary method for the preparation of 2-2 with sufficient substrate-generality. 
Table 2-3 lists successful (E)- and (Z)-stereocomplementary enol tosylations starting from β-ketoesters 2-6.  
Notably, refinement of the reaction conditions led to highly satisfactory results (excellent yield and nearly 
perfect (E)- and (Z)-stereoselectivity); replacement of MeCN with DMF was effective for the preparation of 
(E)-2-7 (Method A-2), and the combined use of TMEDA/LiCl displaced with NMI/LiOH was effective for 
(Z)-2-7 (Method B-2).  Similar to the case of 2-5, all of these stereodefined (E)- and (Z)-enol tosylates 2-7 
are novel compounds. 
 
Table 2-3. The (E)- and (Z)-stereocomplementary enol tosylations of α-Ar1-β-ketoesters 2-6.a 
 
Entry Ketoesters 2-6 Method
 
 Product Yield / %  E/Z
b
 
1 
2-6a 
A-2 (E)-2-7a 94 >98:2 
2 B-2 (Z)-2-7a 93 2:>98 
3 
2-6b 
A-2 (E)-2-7b 98 >98:2 
4 B-2 (Z)-2-7b 99 2:>98 
5 
2-6c 
A-2 (E)-2-7c 98 >98:2 
6 B-2 (Z)-2-7c 99 2:>98 
7 
2-6d 
A-2 (E)-2-7d 92 >98:2 
8 B-2 (Z)-2-7d 98 2:>98 
a) TMEDA = N,N,N’,N’-tetramethylethylenediamine.  b) Determined by 1H NMR spectroscopic analysis of the crude products. 
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A plausible mechanism for the successful emergence of (E)-, (Z)-enol tosylation stereoselectivity is 
depicted in Scheme 2-2, wherein substrate 2-6a is exemplified.  The addition of TsCl and NMI forms key a 
highly reactive sulfonyl ammonium salt, the existence of which is supported by 
1
H NMR spectroscopic 
analysis.
6a
  The (E)-stereoselective reaction proceeds through a non-chelation pathway to give (E)-2-7a; the 
quaternary ammonium cation aids (E)-enolate formation formation through dipole−dipole repulsive 
interactions between the oxy anion and ester function.  In clear contrast, the (Z)-stereoselective reaction 
proceeds through a chelation mechanism to give (Z)-2-7a; Li cation facilitates (Z)-enolate formation.  
 
 
Scheme 2-2. Mechanistic investigation for (E)- and (Z)-stereoselective enol tosylation of 2-6a. 
 
  Successful results of subsequent (E)- and (Z)-stereoretentive Suzuki-Miyaura cross-coupling reactions with 
enol tosylates (E)-2-7 and (Z)-2-7 are listed in Table 2-4.  Unfortunately, the aforementioned catalytic 
reactions with [Pd(dppb)Cl2]/KF and [Pd(dppf)]Cl2/K2CO3 could not be applied for the respective preparation 
of (E)-2-7 and (Z)-2-7; Under identical conditions, Methods C-1 and D-1 resulted in low conversion yield (ca. 
20%).  Several other catalytic reactions, such as those [Pd(PPh3)4], Pd(OAc)2/PCy3/base, and [Pd(PPh3)2Cl2], 
gave similar disappointing results.  After standard screening procedures, to our delight, the reaction with 
Pd(OAc)2/2-dicyclohexylphosphino-2’,6’-dimethoxybiphenyl (SPhos)/iPr2NEt catalysis proceeded smoothly 
to give the desired (E)-2-2 and (Z)-2-2. 
The salient features are as follows: 1) For both (E)-2-7 and (Z)-2-7 substrates, the use of Pd(OAc)2/ 
SPhos/iPr2NEt catalyst system produced fruitful results.  2) Excellent yield was obtained in almost all cases 
examined (entries 1−6, 9−16).  3) Notably, almost perfect stereoretentivity was obtained in every case 
examined.  4) Two sets of the reactions with the (p-Cl)C6H4B(OH)2 nucleophile (Ar
2
) and substrates 
containing (p-Cl)C6H4 group (Ar
1
) were concurrent with further cross-couplings (Table 2-4, entries 7, 8, 17, 
and 18).  The structure of these byproducts was unambiguously determined based on 
1
H NMR and 
13
C NMR 
spectroscopy, IR spectroscopy, and HRMS measurements.  This conspicuous problem was successfully 
resolved by using another catalyst (see below).  5) The addition of H2O to the reaction system dramatically 
affected the results; In the absence of H2O, the yield was decreased to ca. 20%.  6) Several substituents on 
Ar
1
 and/or Ar
2
, such as p-Me, p-MeO, and p-Cl, were compatible (Table 2-4, entries 3−8 and 13−18).  7) 
Heterocyclic furan-3-yl and 3-thiophen-3-yl boronic acids served as suitable nucleophiles (Table 2-4, entries  
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Table 2-4.  The (E)- and (Z)-stereoretentive Suzuki-Miyaura cross-coupling of α-Ar1-enol tosylates 2-7. 
 
Entry    Ar
1 
Substrate
a
 Ar
2 
Method Product Yield/ % E/Z
 b
 
1 Ph (E)-2-7a Ph C-2 (E)-2-2a 94  >98:2 
2  (Z)-2-7a  D-2 (Z)-2-2a 99 2:>98 
3  (E)-2-7a (p-Me)C6H4 C-2 (E)-2-2b 97 >98:2 
4  (Z)-2-7a  D-2 (Z)-2-2b 99 2:>98 
5  (E)-2-7a (p-MeO)C6H4 C-2 (E)-2-2c 97 98:2 
6  (Z)-2-7a  D-2 (Z)-2-2c 99 2:>98 
7  (E)-2-7a (p-Cl)C6H4 C-2 (E)-2-2d 48 (10)
c 
>98:2 
8  (Z)-2-7a  D-2 (Z)-2-2d 41 (10)
d
 2:>98 
9  
(E)-2-7a 
 
C-2 (E)-2-2e 92 >98:2 
10  (Z)-2-7a D-2 (Z)-2-2e 96 2:>98 
11  
(E)-2-7a 
 
C-2 (E)-2-2f 94 >98:2 
12  (Z)-2-7a D-2 (Z)-2-2f 95 2:>98 
13 (p-Me)C6H4 (E)-2-7b Ph C-2 (E)-2-2g 99 >98:2 
14  (Z)-2-7b  D-2 (Z)-2-2g 97 2:>98 
15 (p-MeO)C6H4 (E)-2-7c Ph C-2 (E)-2-2h 99
 
>98:2  
16  (Z)-2-7c  D-2 (Z)-2-2h 99 2:>98 
17 (p-Cl)C6H4 (E)-2-7d Ph C-2 (E)-2-2i 41 (50)
e
 >98:2 
18  (Z)-2-7d  D-2 (Z)-2-2i 58 (39)
f
 2:>98 
a) The E- and Z-purities were up to >98% based on the 
1
H NMR spectra.  b) Determined by 
1
H NMR spectroscopy of the crude products. 
c) 
 
(E)-2d-x d) 
 
(Z)-2d-x 
e) 
 
(E)-2i-x f) 
 
(Z)-2i-x 
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9−12). 
With this successful outcome (Methods A-1, B-1, C-1, D-1) in our hands, we next envisaged an application 
for concise and parallel stereocontrolled synthesis of (E)- and (Z)-2-3.  We referred fully to the pioneering 
works established by the groups of Bäckvall and Högberg.
13,14 
The reported nonstereoselective method
13
 for the synthesis of 2-3 involves the following reaction sequence: 
1) addition of allylmagnesium chloride with p-bromophenyl 3-pyridyl ketone, giving the tertiary allyl alcohol, 
2) successive acid-promoted allyl rearrangement giving the allyl chloride; and 3) final dimethylamination.  
On the other hand, stereoselective synthesis
14
 was performed proficiently by rigorous pH-controlled reductive 
amination procedure.  Due to the difficulty of stereocontrol, and oxidation as a side reaction, reductive 
amination steps were required. 
Our synthetic approach and the successful result are illustrated in Scheme 2-3.  The salient features are as 
follows: 1) Steresoselective enol tosylations of β-ketoestes 2-8a and 2-8b successfully proceeded when using 
Methods A-1 and B-1, conditions [a]−[d].  2) Contrary to our expectation, Suzuki-Miyaura cross-coupling 
with (3-Py)B(OH)2 with (E)-2-9 did not proceed (no reaction) under the identical conditions (Methods C-1 
and D-1).  Fortuitously, the use of small amounts of H2O cosolvent resolved the problem for all four desired 
stereocomplementary reactions, conditions [e]−[h], in excellent yield (79−91%) with almost perfect 
stereoretention (E/Z = >97:3).  3) Despite the labile p-Br substituent, none of the four cross-couplings had 
serious side reactions, such as reduction or further couplings.  4) Compounds (E)- and (Z)-2-3 were 
successfully obtained through the accessible reaction sequences, that is, DIBAL reduction, chlorination with 
SOCl2/catalytic DMF, and final dimethylamination with aqueous solution of Me2NH, conditions [i] and [j].  
Despite the simple operation, undesirable isomerization between E and Z did not occur.  5) Overall yields 
were 33% for (Z)-2-3 and 45% for (E)-2-3 after each five parallel steps.  Compared with extensive studies on 
the synthesis for (E)- and (Z)-2-3,
[13,14]
 which involved MnO2 oxidation of allylic alcohol followed by 
reductive amination or dimethylamination, the present method is of highly concise and orthogonal without 
tedious pH-dependent separation.  
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Scheme 2-3. Parallel and stereocomplementary syntheses of both (E)- and (Z)-2-3. Reagents and conditions: [a] TsCl (1.5 
equiv)/NMI (1.5 equiv)/Et3N (1.5 equiv)/N,N-dimethylacetamide (DMA), 20 – 25 °C, 1 h. 96%, E / Z = 75:25.  Pure (E)-2.9 was 
isolated in 66% (column chromatography).   [b] TsCl (2.0 equiv)/NMI (2.0 equiv)/NaOH (1.5 equiv)/CH2Cl2, 20 – 25 °C, 2 h. 81%, 
E/Z = 8:92, 81%.  Pure (Z)-2-9 was isolated in 66% (washing with hexane).  Notably, the reaction with LiOH is very sluggish 
(only 29% yield).  [c] TsCl (1.5 equiv)/NMI (1.5 equiv)/LiOH (1.5 equiv)/CH2Cl2, 20 – 25 °C, 2 h. 72%, E/Z = 2:>98.  [d] Similar 
conditions to [a], 92%, E/Z = 67:33.  Pure (Z)-2-10 was isolated in 62% (column chromatography).  [e] (p-Br)C6H4B(OH)2 (1.05 
equiv), [Pd(PPh3)2Cl2] (5 mol%), K2CO3 (3.0 equiv), iPrOH/H2O (3:1), 60 – 65 °C, 1 h, 89%, E/Z = 2:>98.  The use of 
[Pd(dppb)Cl2] gave about 35% conversion.  [f] (p-Br)C6H4B(OH)2 (1.05 equiv), [Pd(PPh3)2Cl2] (5 mol%), K2CO3 (3.0 equiv), 
iPrOH/H2O (3:1), 60 – 65 °C, 1 h, 79%, E/Z = >98:2.  [g] (3-Py)B(OH)2 (1.05 equiv), [Pd(dppf)Cl2] (5 mol%), K2CO3 (3.0 equiv), 
iPrOH/H2O (3:1), 60 – 65 °C, 81%, E/Z = 2:>98.  [h] Similar conditions to those given for [g], 81%, E/Z = 97:3.  [i] i) 
diisobutylaluminum hydride (DIBAL; 4.0 equiv)/THF, −78 °C, 0.5 h. 82%; ii) SOCl2 (1.5 equiv), DMF (5 mol%)/CH2Cl2, 20 − 25 °C, 
successive treatment with an aqueous solution of Me2NH (10 equiv), 1 h, 91%, E/Z = 2:>98.  [j] Similar conditions to those given 
for [i], overall 81%, E/Z = 98:2. 
 
Encouraged by the successful synthesis of (E)- and (Z)-2-3, we reinvestigated two sets of cross-couplings 
by using a (p-Cl)C6H4B(OH)2 nucleophile with (E)-2-7a and (Z)-2-7a and a PhB(OH)2 nucleophile with 
acceptors (E)-2-7d and (Z)-2-7d, which contained the (p-Cl)C6H4 group (see unsatisfactory cases in Table 2-4, 
entries 7, 8, 17, and 18).  Gratifyingly, as depicted in Scheme 2-4, the reaction catalyzed by 
[Pd(PPh3)2Cl2]/K2CO3 in iPrOH/H2O (3:1) at 60−65 °C proceeded very smoothly to give the desired products 
(E)-2-2d, (Z)-2-2d, (E)-2-2i, and (Z)-2-2i in good yield with excellent stereoretention; the amounts of 
respective undesirable further-coupled byproducts, (E)-2-2d-x, (Z)-2-2d-x, (E)-2-2i-x, and (Z)-2-2i-x, 
decreased to trace amounts.  The present results contribute towards strengthening the substrate generality of 
Methods C-2 and D-2.  This outcome may be attributed to the milder catalysis with [Pd(PPh3)Cl2] than that 
of powerful Pd(OAc)2/SPhos/base catalysis
15 
with regard to this specific case. 
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Scheme 2-4. Refinement for catalysis with the p-Cl-substituted nucleophile and substrate by using Methods C-2 and D-2. 
 
Conclusion 
An efficient, (E)- and (Z)-stereocomplementary, and parallel synthetic methods have been developed for the 
production of a variety of stereodefined β,β-diaryl- and α,β-diaryl-α,β-unsaturated esters.  The present 
method involves a couple of readily accessible reaction sequences; (i) robust and (E)-, 
(Z)-stereocomplementary enol tosylations of β-ketoesters and (ii) successive stereoretentive Suzuki-Miyaura 
(SM) cross-couplings.  Appropriate (subtle but laborious) tunings of the catalysts for SM cross-coupling 
improved the yield, stereoretentivity, and accessibility of the reaction conditions.  In addition, 3-pyridyl and 
(p-bromo)phenyl group were compatible during the SM cross-coupling stage, which demonstrates the 
performance of the concise and parallel stereocontrolled syntheses of (E)- and (Z)-zimelidines.  This method 
provides a new avenue for the synthesis of these stereodefined β,β-diaryl- and α,β-diaryl-α,β-unsaturated 
esters in the fields of natural product synthesis and process chemistry. 
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Experimental 
 
General  
All reactions were carried out in oven-dried glassware under an argon atmosphere.  Flash column 
chromatography was performed with silica gel (Merck 60, 230−400 mesh ASTM).  TLC analysis was 
performed on 0.25 mm Silica gel Merck 60 F254 plates.  Melting points were determined on a hot stage 
microscope apparatus (AS ONE, ATM-01) and were uncorrected.  IR Spectra were recorded on a JASCO 
FT/IR-5300 spectrophotometer.  NMR spectra were recorded on a JEOL DELTA 300 or JEOLRESONANCE 
ECX-500 spectrometer, operating at 300 MHz or 500 MHz for 
1
H NMR and 75 MHz or 125 MHz for 
13
C 
NMR.  Chemical shifts (δ) (ppm) in CDCl3 are reported downfield from TMS (0 ppm) for 
1
H NMR.  For 
13
C NMR, chemical shifts are reported relative to CDCl3 (77.00 ppm) as an internal reference.    Mass 
spectra were measured on a JEOL JMS-T100LC spectrometer.  E/Z ratios were determined by 
1
H NMR of 
the crude products. 
 
Starting β-ketoesters 2-4, 2-8a, and 2-8b were prepared by the reported methods.[15,16] 
β,β-Diaryl-α,β-unsaturated esters (E)- and (Z)-2-1a,1j (E)-1j and (Z)-2 2-1b, (E)- and (Z)-2-1c,2 (E)- and 
(Z)-2-1d
2
 are known compounds.  α,β-Diaryl α,β-unsaturated esters (E)- and (Z)-2-2a,17 as well as (E)- and 
(Z)-2-2b,
18
 are known compounds.  Starting β-ketoesters 2-6a,19 2-6b,20 2-6c,21 and 2-6d19a were prepared 
according to reported methods. 
 
Syntheses 
Methyl 3-oxo-2-phenylbutanoate 2-6a:
19a
 Methyl phenylacetate (15.0 g, 0.10 mol) and methyl acetate (22.2 
g, 0.30 mol) in THF (50 mL) were successively added dropwise to a stirred suspension of tBuOK (8.42 g, 
0.15 mol) in THF (50 mL) at −78 °C under an argon atmosphere, and the mixture was stirred at the same 
temperature for 2 h and at 40 – 45 °C for 11 h.  1M HCl aqueous solution (ca. 100 mL) was added to the 
mixture, which was extracted twice with AcOEt. The combined organic phase was washed with water and 
brine, dried (Na2SO4), and concentrated. The obtained crude product was purified by distillation to give the 
desired product (9.61 g, 51%) as a colorless oil. B.p. 108–110 °C/0.75 mmHg (ref. 19 92–96 °C /0.6 mmHg); 
1
H NMR (300 MHz, CDCl3): δ = 1.85 (s, 3H × 3.5/10; enol form), 2.18 (s, 3H × 6.5/10; keto form), 3.69 (s, 
3H × 3.5/10; enol form), 3.76 (s, 3H × 6.5/10; keto form), 4.70 (s, 1H × 6.5/10; keto form), 7.12–7.43 ppm (m, 
5H); 
13
C NMR (75 MHz, CDCl3): δ = 19.6, 28.6, 51.6, 52.3, 65.4, 103.9, 126.9, 128.0, 128.1, 128.7, 129.2, 
131.0, 132.5, 134.9, 168.8, 172.8, 173.9, 201.3 ppm; IR (neat): νmax = 2953, 1749, 1718, 1645, 1610, 1438, 
1344, 1264 cm
−1
. 
 
Methyl 3-oxo-2-(p-tolyl)butanoate 2-6b:
20
 Following the procedure for the preparation of 2-6a, the reaction 
of methyl p-tolylacetate (16.4 g, 0.10 mol) with methyl acetate (22.2 g, 0.30 mol) and tBuOK (8.42 g, 0.15 
mol) gave the desired product (10.1 g, 49%) as a colorless oil. 
B.p. 83–84 °C/0.53 mmHg; 1H NMR (300 MHz, CDCl3): δ = 1.85 (s, 3H x 4.0/10; enol form), 2.17 (s, 3H x 
6.0/10; keto form), 2.35 (s, 3H × 6.0/10; keto form), 2.36 (s, 3H × 4.0/10; enol form), 3.69 (s, 3H × 4.0/10; 
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enol form), 3.75 (s, 3H × 6.0/10; keto form), 4.66 (s, 1H × 6.0/10; keto form), 7.02–7.25 ppm (m, 4H); 13C 
NMR (75 MHz, CDCl3): δ = 19.6, 20.9, 20.9, 28.4, 51.5, 52.2, 64.9, 103.6, 128.7, 129.0, 129.4, 130.8, 131.9, 
137.9, 168.9, 172.8, 173.8, 201.4 ppm; IR (neat): νmax = 2953, 1717, 1644, 1514, 1439, 1340, 1264, 1228 
cm
−1
. 
 
Methyl 2-(4-methoxyphenyl)-3-oxobutanoate 2-6c:
21
 Following the procedure for the preparation of 2-6a, 
the reaction of methyl p-methoxyphenylacetate (18.0 g, 0.10 mol) with methyl acetate (22.2 g, 0.30 mol) and 
tBuOK (8.42 g, 0.15 mol) gave the desired product (9.56 g, 43%) as a colorless oil.  
B.p. 93–95 °C/0.56 mmHg; 1H NMR (300 MHz, CDCl3): δ = 1.85 (s, 3H × 3.0/10; enol form), 2.17 (s, 3H × 
7.0/10; keto form), 3.69 (s, 3H × 3.0/10; enol form), 3.75 (s, 3H × 7.0/10; keto form), 3.81 (s, 3H × 7.0/10; 
keto form), 3.82 (s, 3H × 3.0/10; enol form), 4.65 (s, 1H × 7.0/10; keto form), 6.85–7.29 ppm (m, 4H); 13C 
NMR (75 MHz, CDCl3): δ = 19.6, 28.5, 51.6, 52.3, 55.0, 55.1, 64.5, 103.3, 113.3, 113.4, 114.2, 124.5, 127.1, 
130.3, 132.1, 158.5, 159.4, 169.2, 173.0, 174.0, 201.7 ppm; IR (neat): νmax = 2954, 2839, 1714, 1609, 1512, 
1441, 1355, 1247 cm
−1
. 
 
Methyl 2-(4-chlorophenyl)-3-oxobutanoate 2-6d: Following the procedure for the preparation of 2-6a, the 
reaction of methyl p-chlorophenylacetate (18.5 g, 0.10 mol) with methyl acetate (22.2 g, 0.30 mol) and 
tBuOK (8.42 g, 0.15 mol) gave the desired product (8.84 g, 39%) as a colorless oil. B.p. 90–92 °C/0.49 
mmHg; 
1
H NMR (300 MHz, CDCl3): δ = 1.85 (s, 3H × 8.0/10; enol form), 2.20 (s, 3H × 2.0/10; keto form), 
3.69 (s, 3H × 8.0/10; enol form), 3.76 (s, 3H × 2.0/10; keto form), 4.69 (s, 1H × 2.0/10; keto form), 7.07–7.39 
ppm (m, 4H); 
13
C NMR (75 MHz, CDCl3): δ = 19.6, 28.6, 51.6, 52.4, 64.4, 102.8, 128.2, 128.8, 130.6, 130.9, 
132.4, 133.4, 134.2, 168,4, 172.4, 174.1, 200.5 ppm; IR (neat): νmax = 2953, 1718, 1645, 1611, 1492, 1340, 
1266, 1224 cm
−1
; HRMS (ESI): m/z calcd for C11H11O3Cl [M+Na]
+
 249.0294; found: 249.0303. 
 
General procedure for (E)- and (Z)-stereocomplementary enol tosylations. 
Method A-1: TsCl (2.86 g, 15 mmol) in MeCN (10 mL) was added to a stirred solution of β-ketoester 2-4 (10 
mmol), NMI (1.23 g, 15 mmol), and Et3N (1.52 g, 15 mmol) in MeCN (10 mL) at 20 − 25 °C under an Ar 
atmosphere, followed by being stirred for 1 h.  Water was added to the stirred mixture, which was extracted 
with EtOAc.  The organic phase was washed with 1M HCl aqueous solution, brine, dried (Na2SO4), and 
concentrated.  The obtained crude product was purified by silica gel column chromatography (hexane/AcOEt 
= 20/1 – 5/1) or recrystallization to give the corresponding desired product (E)-2-5. 
 
Method B-1: TsCl (2.86 g, 15 mmol) in CH2Cl2 (10 mL) was added to a stirred solution of a β-ketoester 2-4 
(10 mmol), NMI (1.23 g, 15 mmol) and LiOH (359 mg, 15 mmol) in CH2Cl2 (10 mL) at 0 − 5 °C under an Ar 
atmosphere.  The mixture was stirred at same temperature for 1 h and 20 − 25 °C for 1 h.  A similar work 
up to that of Method A-1 gave the corresponding desired product (Z)-2-5. 
 
Method A-2: TsCl (286 mg, 1.50 mmol) in DMF (1.0 mL) was added to a stirred solution of β-ketoester 2-6 
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(1.00 mmol), NMI (124 mg, 1.50 mmol), and Et3N (152 mg, 1.50 mmol) in DMF (1.0 mL) at 0 – 5 °C and the 
mixture was stirred at the same temperature for 1 h and at 20 – 25 °C for 1 h.  A large amount of water was 
added to the mixture, which was extracted twice with AcOEt.  The combined organic phase was washed with 
large amounts of water, a saturated aqueous solution of NaHCO3, and brine; dried (Na2SO4); and concentrated. 
The obtained crude product was purified by column chromatography on silica gel (hexane/AcOEt=50/1 – 
20/1) to give the corresponding desired product (E)-2-7. 
 
Method B-2: TsCl (286 mg, 1.50 mmol) in MeCN (1.0 mL) was added to a stirred solution of β-ketoester 2-6 
(1.00 mmol), TMEDA (258 mg, 1.50 mmol), and LiCl (64 mg, 1.5 mmol) in MeCN (1.0 mL) at 0 − 5 °C and 
the mixture was stirred at the same temperature for 1 h and at 20 − 25 °C for 1 h.  A large amount of water 
was added to the mixture, which was extracted twice with AcOEt.  The combined organic phase was washed 
with large amounts of water, a saturated aqueous solution of NaHCO3, and brine; dried (Na2SO4); and 
concentrated.  The obtained crude product was purified by column chromatography on silica gel 
(hexane/AcOEt= 50/1 – 20/1) to give the corresponding desired product (Z)-2-7. 
 
Methyl (E)-3-phenyl-3-(tosyloxy)prop-2-enoate (E)-2-5a 
Colorless crystals; mp 79−81 °C; 1H NMR (300 MHz, CDCl3): δ = 2.41 (s, 3H), 3.62 (s, 3H), 6.08 (s, 1H), 
7.18−7.38 (m, 7H), 7.66 (d, J = 8.3 Hz, 2H); 13C NMR (75 MHz, CDCl3): δ = 21.6, 51.6, 111.3, 127.7, 128.2, 
129.2, 129.7, 130.4, 131.7, 132.9, 145.5, 159.6, 164.9; IR (neat): νmax = 3058, 2952, 1730, 1645, 1597, 1435, 
1377, 1193, 1038, 806 cm
−1
; HRMS (ESI): m/z calcd for C17H16O5S [M+Na]
+
 355.0616; found: 355.0620. 
 
Methyl (Z)-3-phenyl-3-(tosyloxy)prop-2-enoate (Z)-2-5a 
Colorless crystals; mp 103−105 °C; 1H NMR (300 MHz, CDCl3): δ = 2.40 (s, 3H), 3.69 (s, 3H), 6.11 (s, 1H), 
7.17−7.45 (m, 7H), 7.72 (d, J = 8.3 Hz, 2H); 13C NMR (75 MHz, CDCl3): δ = 21.6, 51.6, 110.3, 126.9, 128.4, 
129.4, 130.7, 133.0, 133.4, 145.2, 155.7, 163.8; IR (neat): νmax = 1732, 1646, 1384, 1270, 1178, 763 cm
−1
. 
 
Methyl (E)-3-(4-methoxyphenyl)-3-(tosyloxy)prop-2-enoate (E)-2-5b 
Pale yellow oil; 
1
H NMR (300 MHz, CDCl3): δ = 2.42 (s, 3H), 3.64 (s, 3H), 3.80 (s, 3H), 5.96 (s, 1H), 6.76 (d, 
J = 8.9 Hz, 2H), 7.24 (d, J = 7.9 Hz, 2H), 7.32 (d, J = 8.9 Hz, 2H), 7.67 (d, J = 8.6 Hz, 2H); 
13
C NMR (75 
MHz, CDCl3): δ = 21.6, 51.6, 55.3, 110.0, 113.1, 123.9, 128.3, 129.7, 131.1, 145.4, 159.7, 161.4, 165.2; IR 
(neat): νmax = 2954, 2841, 1727, 1636, 1606, 1511, 1375, 1176, 1032, 779 cm
−1
. 
 
Methyl (Z)-3-(4-methoxyphenyl)-3-(tosyloxy)prop-2-enoate (Z)-2-5b 
Pale yellow oil; 
1
H NMR (300 MHz, CDCl3): δ = 2.42 (s, 3H), 3.66 (s, 3H), 3.81 (s, 3H), 6.01 (s, 1H), 6.78 (d, 
J = 8.9 Hz, 2H), 7.25 (d, J = 8.0 Hz, 2H), 7.38 (d, J = 8.9 Hz, 2H), 7.75 (d, J = 8.6 Hz, 2H); 
13
C NMR (75 
MHz, CDCl3): δ = 21.5, 51.4, 55.3, 108.1, 113.8, 125.2, 128.4, 128.6, 129.4, 133.5, 145.1, 155.6, 161.7, 
163.9; IR (neat): νmax = 3019, 2952, 1730, 1645, 1605, 1511, 1257, 1176, 1037, 909, 731 cm
−1
; HRMS (ESI): 
m/z calcd for C18H18O6S [M+Na]
+
 385.0722; found: 385.0717. 
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Methyl (E)-3-(4-chlorophenyl)-3-(tosyloxy)prop-2-enoate (E)-2-5c 
Pale yellow oil; 
1
H NMR (300 MHz, CDCl3): δ = 2.43 (s, 3H), 3.64 (s, 3H), 6.07 (s, 1H), 7.17−7.31 (m, 6H), 
7.65 (d, J = 8.3 Hz, 2H); 
13
C NMR (75 MHz, CDCl3): δ = 21.6, 51.7, 111.9, 127.9, 128.2, 129.8, 130.1, 130.6, 
132.7, 136.6, 145.8, 158.4, 164.7; IR (neat): νmax = 3027, 2852, 1730, 1646, 1380, 1217, 1193, 1036, 755 
cm
−1
. 
 
Methyl (Z)-3-(4-chlorophenyl)-3-(tosyloxy)prop-2-enoate (Z)-2-5c 
Pale yellow crystals; mp 73−75 °C; 1H NMR (300 MHz, CDCl3): δ = 2.43 (s, 3H), 3.68 (s, 3H), 6.09 (s, 1H), 
7.20−7.29 (m, 4H), 7.37 (d, J = 8.9 Hz, 2H), 7.74 (d, J = 8.3 Hz, 2H); 13C NMR (75 MHz, CDCl3): δ = 21.5, 
51.4, 55.3, 108.1, 113.8, 125.2, 128.4, 128.6, 129.4, 133.5, 145.1, 155.6, 161.7, 163.9; IR (neat): νmax = 1732, 
1646, 1435, 1268, 1178, 1038, 928, 765 cm
−1
; HRMS (ESI): m/z calcd for C17H15ClO5S [M+Na]
+
 389.0226; 
found: 389.0238. 
 
Methyl (E)-2-phenyl-3-(tosyloxy)but-2-enoate (E)-2-7a 
Colorless crystals; mp 71−72 °C; 1H NMR (300 MHz, CDCl3): δ = 2.37 (s, 3H), 2.53 (s, 3H), 3.70 (s, 3H), 
6.96−7.31 ppm (m, 9H); 13C NMR (75 MHz, CDCl3): δ = 19.9, 21.4, 52.2, 125.9, 127.3, 127.5, 127.7, 129.3, 
129.3, 132.7, 133.0, 144.7, 153.6, 167.2 ppm; IR (neat): νmax = 2359, 1715, 1639, 1433, 1361, 1193, 1154, 
1064 cm
−1
; HRMS (ESI): m/z calcd for C18H18O5S [M+Na]
+
 369.0773; found: 369.0779. 
 
Methyl (Z)-2-phenyl-3-(tosyloxy)but-2-enoate (Z)-2-7a 
Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 1.98 (s, 3H), 2.43 (s, 3H), 3.53 (s, 3H), 7.17−7.40 (m, 7H), 
7.85−7.92 ppm (m, 7H); 13C NMR (75 MHz, CDCl3): δ = 18.7, 21.4, 51.8, 126.2, 127.9, 128.1, 128.3, 128.9, 
129.6, 133.2, 133.5, 145.2, 149.3, 165.4 ppm; IR (neat): νmax = 1727, 1597, 1434, 1371, 1226, 1195, 1092, 
1057 cm
−1
. 
 
Methyl (E)-2-(p-tolyl)-3-(tosyloxy)but-2-enoate (E)-2-7b 
Colorless crystals; mp 79−80 °C; 1H NMR (300 MHz, CDCl3): δ = 2.30 (s, 3H), 2.36 (s, 3H), 2.50 (s, 3H), 
3.68 (s, 3H), 6.84−6.91 (m, 2H), 6.91−6.98 (m, 2H), 7.01−7.08 (m, 2H), 7.26−7.32 ppm (m, 2H); 13C NMR 
(75 MHz, CDCl3): δ = 20.0, 21.1, 21.5, 52.2, 125.9, 127.6, 128.4, 129.1, 129.2, 130.0, 133.0, 137.1, 144.6, 
153.3, 167.4 ppm; IR (neat): νmax = 2951, 1716, 1645, 1352, 1291, 1194, 1178, 1155 cm
−1
; HRMS (ESI): m/z 
calcd for C19H20O5S [M+Na]
+
 383.0929; found: 383.0943. 
 
Methyl (Z)-2-(p-tolyl)-3-(tosyloxy)but-2-enoate (Z)-2-7b 
Colorless crystals; mp 95−96 °C; 1H NMR (300 MHz, CDCl3): δ = 2.00 (s, 3H), 2.35 (s, 3H), 2.46 (s, 3H), 
3.55 (s, 3H), 7.08−7.14 (m, 2H), 7.14−7.20 (m, 2H), 7.34−7.40 (m, 2H), 7.86−7.92 ppm (m, 2H); 13C NMR 
(75 MHz, CDCl3): δ = 18.8, 21.1, 21.5, 51.9, 126.2, 128.0, 128.9, 129.1, 129.7, 130.6, 133.5, 138.1, 145.2, 
149.2, 165.8 ppm; IR (neat): νmax = 1724, 1431, 1365, 1304, 1225, 1193, 1178, 1057 cm
−1
. 
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Methyl (E)-2-(4-methoxyphenyl)-3-(tosyloxy)but-2-enoate (E)-2-7c 
Pale yellow crystals; mp 90−91 °C; 1H NMR (300 MHz, CDCl3): δ = 2.38 (s, 3H), 2.49 (s, 3H), 3.71 (s, 3H), 
3.79 (s, 3H), 6.64−6.70 (m, 2H), 6.88−6.95 (m, 2H), 7.04−7.10 (m, 2H), 7.30−7.36 ppm (m, 2H); 13C NMR 
(75 MHz, CDCl3): δ = 20.1, 21.5, 52.2, 55.0, 113.1, 125.1, 125.6, 127.6, 129.2, 130.5, 132.9, 144.6, 152.9, 
158.8, 167.6 ppm; IR (neat): νmax = 2954, 1715, 1607, 1513, 1435, 1345, 1224, 1177 cm
−1
; HRMS (ESI): m/z 
calcd for C19H20O6S [M+Na]
+
 399.0878; found: 399.0876. 
 
Methyl (Z)-2-(4-methoxyphenyl)-3-(tosyloxy)but-2-enoate (Z)-2-7c 
Pale yellow crystals; mp 67−68 °C; 1H NMR (300 MHz, CDCl3): δ = 1.99 (s, 3H), 2.44 (s, 3H), 3.55 (s, 3H), 
3.78 (s, 3H), 6.84−6.92 (m, 2H), 7.10−7.19 (m, 2H), 7.33−7.41 (m, 2H), 7.84−7.91 ppm (m, 2H); 13C NMR 
(75 MHz, CDCl3): δ = 18.7, 21.4, 51.8, 55.0, 113.8, 125.6, 125.9, 127.9, 129.6, 130.2, 133.4, 145.2, 148.8, 
159.3, 165.9 ppm; IR (neat): νmax = 1725, 1608, 1512, 1435, 1366, 1282, 1092, 1052 cm
−1
. 
 
Methyl (E)-2-(4-chlorophenyl)-3-(tosyloxy)but-2-enoate (E)-2-7d 
Pale yellow crystals; mp 80−81 °C; 1H NMR (300 MHz, CDCl3): δ = 2.41 (s, 3H), 2.55 (s, 3H), 3.70 (s, 3H), 
6.88−6.94 (m, 2H), 7.05−7.15 (m, 4H), 7.28−7.34 ppm (m, 2H); 13C NMR (75 MHz, CDCl3): δ = 20.1, 21.3, 
52.1, 124.5, 127.3, 127.7, 129.3, 130.7, 131.4, 132.9, 133.3, 145.0, 154.7, 166.6 ppm; IR (neat): νmax = 1717, 
1639, 1595, 1491, 1224, 1195, 1178, 1156 cm
−1
; HRMS (ESI): m/z calcd for C18H17O5S [M+Na]
+
 403.0383; 
found: 403.0377. 
 
Methyl (Z)-2-(4-chlorophenyl)-3-(tosyloxy)but-2-enoate (Z)-2-7d 
Colorless crystals; mp 75−76 °C; 1H NMR (300 MHz, CDCl3): δ = 1.98 (s, 3H), 2.47 (s, 3H), 3.57 (s, 3H), 
7.14−7.21 (m, 2H), 7.30−7.42 (m, 4H), 7.85−7.92 ppm (m, 2H); 13C NMR (75 MHz, CDCl3): δ = 19.1, 21.7, 
52.2, 125.2, 128.1, 128.8, 129.8, 130.6, 132.2, 133.5, 134.4, 145.4, 150.3, 165.3 ppm; IR (neat): νmax = 1721, 
1652, 1595, 1491, 1346, 1313, 1223, 1194 cm
−1
. 
 
General procedure of (E)-, (Z)-stereoretentive Suzuki-Miyaura cross couplings 
Method C-1: A suspension of an enol tosylate (E)-2-5 (0.50 mmol), ArB(OH)2 (0.75 mmol), [Pd(dppb)Cl2] (15 
mg, 0.025 mmol), and KF (87 mg, 1.5 mmol) in iPrOH (3.0 mL) was stirred at 60 − 65 °C under an Ar 
atmosphere for 2 h.  After cooling, water was added to the mixture, which was extracted twice with AcOEt.  
The combined organic phase was washed with water, brine, dried (Na2SO4), and concentrated.  The obtained 
crude product was purified by silica gel column chromatography (hexane/Et2O = 100/1 – 20/1) to give the 
corresponding desired product (E)-2-1. 
 
Method D-1: A suspension of an enol tosylate (Z)-2-5 (0.50 mmol), ArB(OH)2 (0.75 mmol), [Pd(dppf)Cl2] (18 
mg, 0.025 mmol), and K2CO3 (207 mg, 1.5 mmol) in iPrOH (3.0 mL) was stirred at 60 − 65 °C under an Ar 
atmosphere for 2 h.  After cooling, water was added to the mixture, which was extracted twice with AcOEt.  
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The combined organic phase was washed with water, brine, dried (Na2SO4), and concentrated.  The obtained 
crude product was purified by silica gel column chromatography (hexane/diethyl ether = 100/1 – 20/1) to give 
the corresponding desired product (Z)-2-1. 
 
Method C-2: A suspension of enol tosylate (E)-2-7 (0.50 mmol), ArB(OH)2 (0.75 mmol), iPr2NEt (194 mg, 
1.50 mmol), Pd(OAc)2 (6 mg, 0.025 mmol), and SPhos (20 mg, 0.05 mmol) in toluene (0.7 mL)/water (3.3 
mL) was stirred at 80 − 85 °C under an argon atmosphere for 2 h.  After cooling, water was added to the 
mixture, which was extracted twice with AcOEt.  The combined organic phase was washed with water and 
brine, dried (Na2SO4), and concentrated.  The obtained crude product was purified by column 
chromatography on silica gel (hexane/Et2O = 200/1 – 100/1) to give the corresponding desired product 
(E)-2-2. 
 
Method D-2: A suspension of enol tosylate (Z)-2-7 (0.50 mmol), ArB(OH)2 (0.75 mmol), iPr2NEt (194 mg, 1.5 
mmol), Pd(OAc)2 (6 mg, 0.025 mmol), and SPhos (20 mg, 0.05 mmol) in toluene (0.7 mL)/water (3.3 mL) 
was stirred at 80 – 85 °C under an argon atmosphere for 2 h.  After cooling, water was added to the mixture, 
which was extracted twice with AcOEt.  The combined organic phase was washed with water and brine, 
dried (Na2SO4), and concentrated.  The obtained crude product was purified by column chromatography on 
silica gel (hexane/Et2O = 200/1 – 100/1) to give the corresponding desired product (Z)-2-2. 
 
Methyl (E)-3-(4-methylphenyl)-3-phenylprop-2-enoate (E)-2-1a
1j 
Pale yellow oil; 
1
H NMR (300 MHz, CDCl3): δ = 2.35 (s, 3H), 3.60 (s, 3H), 6.35 (s, 1H), 7.12 (d, J = 7.9 Hz, 
2H), 7.15−7.23 (m, 2H), 7.32–7.43 (m, 3H); 13C NMR (75 MHz, CDCl3): δ = 21.1, 51.1, 115.8, 127.7, 128.0, 
128.2, 129.0, 137.9, 138.9, 139.6, 157.0, 166.4; IR (neat): νmax = 3022, 2948, 1719, 1608, 1433, 1267, 1164, 
910, 756 cm
−1
. 
 
Methyl (Z)-3-(4-methylphenyl)-3-phenylprop-2-enoate (Z)-2-1a
1j
 
Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 2.39 (s, 3H), 3.63 (s, 3H), 6.32 (s, 1H), 7.10 (d, J = 7.9 Hz, 
2H), 7.19 (d, J = 7.9 Hz, 2H), 7.27−7.42 (m, 5H); 13C NMR (75 MHz, CDCl3): δ = 21.3, 51.1, 116.4, 128.3, 
128.3, 128.6, 129.1, 129.3, 135.7, 138.0, 141.1, 157.3, 166.4; IR (neat): νmax =
 
3024, 2949, 1725, 1610, 1508, 
1362, 1266, 1165, 722 cm
−1
; HRMS (ESI): m/z calcd for C17H16O2 [M+Na]
+
 275.1048; found: 275.1046. 
 
Methyl (E)-3-(4-methoxylphenyl)-3-phenylprop-2-enoate (E)-2-1b
1j
 
Brown colored oil; 
1
H NMR (300 MHz, CDCl3): δ = 3.59 (s, 3H), 3.81 (s, 3H), 6.31 (s, 1H), 6.84 (d, J = 8.9 
Hz, 2H), 7.15−7.27 (m, 4H), 7.35−7.43 (m, 5H); 13C NMR (75 MHz, CDCl3): δ = 51.1, 55.3, 113.7, 114.6, 
127.8, 128.0, 129.0, 129.7, 133.0, 139.0, 156.8, 160.8, 166.5; IR (neat): νmax =
 
2950, 1717, 1607, 1509, 1248, 
1166, 773 cm
−1
. 
 
Methyl (Z)-3-(4-methylphenyl)-3-phenylprop-2-enoate (Z)-2-1b
2
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Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 3.64 (s, 3H), 3.84 (s, 3H), 6.27 (s, 1H), 6.91 (d, J = 8.6 Hz, 
2H), 7.16 (d, J = 8.6 Hz, 2H), 7.23−7.42 (m, 5H); 13C NMR (75 MHz, CDCl3): δ = 51.2, 55.2, 113.2, 116.2, 
128.3, 128.5, 129.3, 130.9, 130.9, 141.5, 157.0, 159.7, 166.6; IR (neat): νmax =
 
3019, 2952, 1717, 1607, 1509, 
1247, 1167, 908, 755 cm
−1
; HRMS (ESI): m/z calcd for C17H16O3 [M+Na]
+
 291.0997; found: 291.1019. 
 
Methyl (E)-3-(4-chlorophenyl)-3-phenylprop-2-enoate (E)-2-1c
2
 
Pale yellow oil; 
1
H NMR (300 MHz, CDCl3): δ = 3.61 (s, 3H), 6.34 (s, 1H), 7.14−7.32 (m, 6H), 7.35−7.45 (m, 
3H); 
13
C NMR (75 MHz, CDCl3): δ = 51.2, 117.1, 127.9, 128.4, 128.6, 129.0, 129.5, 135.5, 138.3, 139.2, 
155.6, 166.1; IR (neat): νmax =
 
3019, 1716, 1617, 1488, 1434, 1215, 1168, 907, 732 cm
−1
; HRMS (ESI): m/z 
calcd for C16H13ClO2 [M+Na]
+
 295.0502; found: 295.0582. 
 
Methyl (Z)-3-(4-chlorophenyl)-3-phenylprop-2-enoate (Z)-2-1c
2
 
Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 3.62 (s, 3H), 6.37 (s, 1H), 7.15 (d, J = 8.6 Hz, 2H), 7.22−7.40 
(m, 7H); 
13
C NMR (75 MHz, CDCl3): δ = 51.2, 117.1, 128.1, 128.2, 128.4, 129.6, 130.5, 134.2, 137.1, 140.3, 
155.8, 166.1; IR (neat): νmax =
 
3021, 2950, 1718, 1617, 1488, 1272, 1167, 908, 756 cm
−1
. 
 
Methyl (E)-3-(4-fluorophenyl)-3-phenylprop-2-enoate (E)-2-1d
2
 
Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 3.61 (s, 3H), 6.31 (s, 1H), 7.00 (t, J = 8.9 Hz, 2H), 7.15−7.22 
(m, 2H), 7.24−7.30 (m, 2H), 7.39 (t, J = 3.1 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ = 51.2, 115.2, 115.5, 
116.6, 127.9, 128.3, 129.0, 130.1, 130.2, 138.6, 155.8, 166.2; IR (neat): νmax =
 
3021, 2950, 1718, 1600, 1507, 
1434, 1362, 1267, 1166, 909, 732 cm
−1
; HRMS (ESI): m/z calcd for C16H13FO2 [M+Na]
+
 279.0797; found: 
279.0827. 
 
Methyl (Z)-3-(4-fluorophenyl)-3-phenylprop-2-enoate (Z)-2-1d
2
 
Pale yellow oil; 
1
H NMR (300 MHz, CDCl3): δ = 3.63 (s, 3H), 6.36 (s, 1H), 7.07 (t, J = 8.6 Hz, 2H), 7.20 (dd, 
J = 5.5, 8.3 Hz, 2H), 7.24−7.42 (m, 5H); 13C NMR (75 MHz, CDCl3): δ = 51.2, 114.7, 115.0, 117.0, 128.2, 
128.4, 129.5, 131.0, 131.1, 140.7, 156.0, 166.2; IR (neat): νmax =
 
3019, 1713, 1602, 1509, 1215, 1172, 908, 
753 cm
−1
. 
 
Methyl (E)-3-(4-acetylphenyl)-3-phenylprop-2-enoate (E)-2-1e 
Pale yellow crystals; mp 97–98 °C; 1H NMR (300 MHz, CDCl3): δ = 2.60 (s, 3H), 3.63 (s, 3H), 6.42 (s, 1H), 
7.16−7.24 (m, 2H), 7.00 (t, J = 8.9 Hz, 2H), 7.34−7.46 (m, 5H), 7.39 (d, J = 8.3 Hz, 2H); 13C NMR (75 MHz, 
CDCl3): δ = 26.6, 51.3, 118.6, 128.0, 128.2, 128.4, 129.0, 137.4, 138.0, 145.2, 155.4, 166.0, 197.3; IR (neat): 
νmax =
 
3019, 1683, 1605, 1435, 1360, 1264, 1215, 906, 730 cm
−1
. 
 
Methyl (Z)-3-(4-acetylphenyl)-3-phenylprop-2-enoate (Z)-2-1e 
Pale yellow oil; 
1
H NMR (300 MHz, CDCl3): δ = 2.63 (s, 3H), 3.62 (s, 3H), 6.44 (s, 1H), 7.22−7.42 (m, 7H), 
8.00 (d, J = 8.6 Hz, 2H); 
13
C NMR (75 MHz, CDCl3): δ = 26.5, 51.3, 117.3, 127.9, 128.0, 128.5, 129.2, 129.7, 
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136.5, 139.7, 143.9, 156.0, 166.0, 197.6; IR (neat): νmax =
 
3020, 1682, 1604, 1434, 1360, 1267, 1215, 1169, 
908, 754 cm
−1
; HRMS (ESI): m/z calcd for C18H16O3 [M+Na]
+
 303.0997; found: 303.1020. 
 
Methyl (E)-3-(2-methylphenyl)-3-phenylprop-2-enoate (E)-2-1f 
Colorless crystals; mp 94−98 °C; 1H NMR (300 MHz, CDCl3): δ = 2.06 (s, 3H), 3.66 (s, 3H), 6.00 (s, 1H), 
7.11−7.37 (m, 9H); 13C NMR (75 MHz, CDCl3): δ = 20.2, 51.2, 119.4, 125.6, 127.6, 128.4, 129.1, 129.5, 
130.6, 135.9, 138.5, 141.9, 157.1, 166.6; IR (neat): νmax =
 
3058, 1722, 1616, 1432, 1359, 1257, 1164, 1033, 
909, 728 cm
−1
. 
 
Methyl (Z)-3-(2-methylphenyl)-3-phenylprop-2-enoate (Z)-2-1f 
Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 2.07 (s, 3H), 3.58 (s, 3H), 6.53 (s, 1H), 7.02−7.11 (m, 1H), 
7.17−7.40 (m, 8H); 13C NMR (75 MHz, CDCl3): δ = 19.5, 51.2, 116.9, 125.4, 127.4, 127.8, 128.3, 128.5, 
129.5, 129.9, 135.3, 138.4, 139.2, 156.5, 166.0; IR (neat): νmax =
 
3059, 2949, 1721, 1618, 1433, 1359, 1264, 
1165, 1016, 908, 729 cm
−1
; HRMS (ESI): m/z calcd for C17H16O2 [M+Na]
+
 275.1048; found: 275.1071. 
 
Methyl (E)-3-(2-chlorolphenyl)-3-phenylprop-2-enoate (E)-2-1g 
Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 3.66 (s, 3H), 6.10 (s, 1H), 7.19−7.40 (m, 9H); 
13
C NMR (75 
MHz, CDCl3): δ = 51.3, 121.0, 126.6, 127.6, 128.5, 129.0, 129.5, 130.1, 130.9, 132.7, 137.8, 140.7, 154.0, 
166.2; IR (neat): νmax =
 
3060, 1724, 1621, 1433, 1360, 1245, 1166, 909, 728 cm
−1
; HRMS (ESI): m/z calcd for 
C16H13ClO2 [M+Na]
+
 295.0502; found: 295.0567. 
 
Methyl (Z)-3-(2-chlorolphenyl)-3-phenylprop-2-enoate (Z)-2-1g 
Pale yellow oil; 
1
H NMR (300 MHz, CDCl3): δ = 3.60 (s, 3H), 6.55 (s, 1H), 7.12−7.21 (m, 1H), 7.23−7.40 (m, 
7H), 7.40−7.49 (m, 1H); 13C NMR (75 MHz, CDCl3): δ = 51.3, 118.1, 126.4, 127.3, 128.6, 129.1, 129.4, 129.6, 
130.0, 132.5, 137.8, 138.5, 153.7, 165.6; IR (neat): νmax =
 
3060, 2949, 1723, 1623, 1432, 1358, 1268, 1165, 
1035, 909, 730 cm
−1
. 
 
Methyl (E)-2,3-diphenylbut-2-enoate (E)-2-2a
17 
Pale yellow oil; 
1
H NMR (300 MHz, CDCl3): δ = 2.36 (s, 3H), 3.76 (s, 3H), 6.95−7.18 (m, 10H); 
13
C NMR 
(75 MHz, CDCl3): δ = 23.2, 51.9, 126.8, 127.0, 127.7, 127.8, 128.4, 129.8, 131.6, 137.1, 141.8, 144.6, 169.8; 
IR (neat): νmax = 2950, 1719, 1599, 1491, 1433, 1375, 1304, 1250 cm
−1
. 
 
Methyl (Z)-2,3-diphenylbut-2-enoate (Z)-2-2a
17 
Pale yellow oil; 
1
H NMR (300 MHz, CDCl3): δ = 2.05 (s, 3H), 3.43 (s, 3H), 7.29−7.44 (m, 10H); 
13
C NMR 
(75 MHz, CDCl3): δ = 22.2, 51.5, 126.8, 127.5, 128.1, 128.3, 129.1, 132.5, 137.1, 142.8, 143.9, 169.6; IR 
(neat): νmax = 2941, 1719, 1491, 1433, 1375, 1304, 1252, 1210 cm
−1
. 
 
Methyl (E)-3-(4-methylphenyl)-2-phenylbut-2-enoate (E)-2-2b
18
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Pale yellow oil; 
1
H NMR (300 MHz, CDCl3): δ = 2.24 (s, 3H), 2.34 (s, 3H), 3.77 (s, 3H), 6.88−6.95 (m, 3H), 
6.99−7.04 (m, 2H), 7.06−7.16 ppm (m, 4H); 13C NMR (75 MHz, CDCl3): δ = 21.0, 23.2, 51.9, 126.7, 127.8, 
128.4, 128.5, 129.9, 131.3, 136.7, 137.4, 138.8, 144.5, 169.9 ppm; IR (neat): νmax = 2949, 2859, 1719, 1624, 
1509, 1433, 1320, 1250 cm
−1
. 
 
Methyl (Z)-3-(4-methylphenyl)-2-phenylbut-2-enoate (Z)-2-2b
18
 
Pale yellow oil; 
1
H NMR (300 MHz, CDCl3): δ = 2.03 (s, 3H), 2.36 (s, 3H), 3.46 (s, 3H), 7.05−7.28 (m, 5H), 
7.29−7.43 ppm (m, 4H); 13C NMR (75 MHz, CDCl3): δ = 21.2, 22.2, 51.6, 126.8, 127.4, 128.3, 128.3, 128.9, 
129.2, 129.8, 137.3, 139.8, 143.9, 169.8 ppm; IR (neat): νmax = 2950, 1721, 1626, 1512, 1433, 1375, 1304, 
1250 cm
−1
. 
 
Methyl (E)-3-(4-methoxyphenyl)-2-phenylbut-2-enoate (E)-2-2c 
Colorless crystals; mp 69−70 °C; 1H NMR (300 MHz, CDCl3): δ = 2.34 (s, 3H), 3.73 (s, 3H), 3.77 (s, 3H), 
6.60−6.70 (m, 2H), 6.88−7.18 ppm (m, 7H); 13C NMR (75 MHz, CDCl3): δ = 23.1, 51.9, 55.0, 113.2, 126.7, 
127.8, 129.8, 129.9, 131.0, 133.9, 137.5, 144.1, 158.5, 170.1 ppm; IR (neat): νmax = 2951, 1719, 1609, 1510, 
1458, 1433, 1248, 1208 cm
−1
; HRMS (ESI): m/z calcd for C18H18O3 [M+Na]
+
 305.1154; found: 305.1157. 
 
Methyl (Z)-3-(4-methoxyphenyl)-2-phenylbut-2-enoate (Z)-2-2c 
Colorless crystals; mp 96−97 °C; 1H NMR (300 MHz, CDCl3): δ = 2.03 (s, 3H), 3.47 (s, 3H), 3.83 (s, 3H), 
6.81−6.94 (m, 2H), 7.17−7.42 ppm (m, 7H); 13C NMR (75 MHz, CDCl3): δ = 22.2, 51.7, 55.2, 113.6, 127.5, 
128.2, 128.3, 129.2, 135.0, 137.4, 143.3, 159.1, 170.1 ppm; IR (neat): νmax = 2945, 2869, 1728, 1607, 1574, 
1499, 1435, 1296 cm
−1
. 
 
Methyl (E)-3-(4-chloro)-2-phenylbut-2-enoate (E)-2-2d 
Colorless crystals; mp 68−69 °C; 1H NMR (300 MHz, CDCl3): δ = 2.33 (s, 3H), 3.78 (s, 3H), 6.91−7.03 (m, 
4H), 7.07−7.17 ppm (m, 5H); 13C NMR (75 MHz, CDCl3): δ = 22.9, 52.0, 127.0, 127.9, 128.1, 129.7, 129.8, 
132.2, 132.8, 136.8, 140.2, 143.0, 169.5 ppm; IR (neat): νmax = 2950, 1718, 1594, 1485, 1433, 1317, 1245, 
1203 cm
−1
; HRMS (ESI): m/z calcd for C17H15O2Cl [M+Na]
+
 309.0658; found: 309.0663. 
 
Methyl (Z)-3-(4-chloro)-2-phenylbut-2-enoate (Z)-2-2d 
Colorless crystals; mp 70−71 °C; 1H NMR (300 MHz, CDCl3): δ = 2.01 (s, 3H), 3.46 (s, 3H), 7.22−7.45 ppm 
(m, 9H); 
13
C NMR (75 MHz, CDCl3): δ = 22.3, 51.8, 127.7, 128.3, 128.4, 128.4, 129.1, 133.0, 133.4, 136.8, 
141.3, 142.8, 169.4 ppm; IR (neat): νmax = 2950, 1717, 1634, 1483, 1432, 1296, 1258, 1208 cm
−1
. 
 
Methyl (E)-3-(3-furyl)-2-phenylbut-2-enoate (E)-2-2e 
Pale yellow oil; 
1
H NMR (300 MHz, CDCl3): δ = 2.37 (s, 3H), 3.76 (s, 3H), 6.55−6.63 (m, 1H), 6.90−6.98 (m, 
1H), 6.98−7.05 (m, 1H), 7.06−7.14 (m, 2H), 7.16−7.25 ppm (m, 3H); 13C NMR (75 MHz, CDCl3): δ = 20.9, 
51.8, 110.3, 126.0, 127.5, 128.4, 129.6, 130.4, 135.5, 138.1, 142.0, 142.4, 169.3 ppm; IR (neat): νmax = 3138, 
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3023, 2950, 1710, 1597, 1433, 1321, 1205 cm
−1
. 
 
Methyl (Z)-3-(3-furyl)-2-phenylbut-2-enoate (Z)-2-2e 
Pale yellow oil; 
1
H NMR (300 MHz, CDCl3): δ = 1.98 (s, 3H), 3.67 (s, 3H), 6.43−6.48 (m, 1H), 7.28−7.44 (m, 
6H), 7.52−7.57 ppm (m, 1H); 13C NMR (75 MHz, CDCl3): δ = 20.1, 52.0, 109.5, 126.0, 127.6, 128.3, 129.0, 
130.8, 131.4, 136.6, 140.6, 142.9, 170.4 ppm; IR (neat): νmax = 2997, 2949, 1716, 1634, 1493, 1434, 1379, 
1207 cm
−1
. 
 
Methyl (E)-2-phenyl-3-(3-thienyl)but-2-enoate (E)-2-2f 
Pale yellow oil; 
1
H NMR (300 MHz, CDCl3): δ = 2.34 (s, 3H), 3.73 (s, 3H), 5.62−5.67 (m, 1H), 7.08−7.14 (m, 
2H), 7.16−7.24 (m, 2H), 7.27−7.37 ppm (m, 3H); 13C NMR (75 MHz, CDCl3): δ = 22.5, 51.8, 124.2, 124.4, 
127.1, 128.0, 128.1, 129.5, 131.2, 137.6, 138.5, 141.7, 169.6 ppm; IR (neat): νmax = 3139, 3026, 2952, 1710, 
1608, 1504, 1433, 1205 cm
−1
; HRMS (ESI): m/z calcd for C15H14O2S [M+Na]
+
 281.0612; found: 281.0603. 
 
Methyl (Z)-2-phenyl-3-(3-thienyl)but-2-enoate (Z)-2-2f 
Pale yellow oil; 
1
H NMR (300 MHz, CDCl3): δ = 2.02 (s, 3H), 3.56 (s, 3H), 7.09−7.14 (m, 1H), 7.27−7.44 
ppm (m, 7H); 
13
C NMR (75 MHz, CDCl3): δ = 21.2, 51.8, 122.4, 125.3, 126.9, 127.6, 128.3, 129.0, 132.3, 
136.1, 136.7, 142.4, 170.2 ppm; IR (neat): νmax = 2993, 2946, 1715, 1623, 1492, 1433, 1299, 1211 cm
−1
. 
 
Methyl (E)-2-(4-methylphenyl)-3-phenylbut-2-enoate (E)-2-2g 
Pale yellow oil; 
1
H NMR (300 MHz, CDCl3): δ = 2.23 (s, 3H), 2.33 (s, 3H), 3.78 (s, 3H), 6.83−6.95 (m, 4H), 
6.98−7.08 (m, 2H), 7.10−7.20 ppm (m, 2H); 13C NMR (75 MHz, CDCl3): δ = 21.1, 23.2, 51.9, 126.9, 127.9, 
128.4, 128.5, 129.1, 129.6, 134.1, 136.5, 142.0, 143.6, 170.1 ppm; IR (neat): νmax = 3023, 1717, 1636, 1509, 
1491, 1435, 1375, 1250 cm
−1
; HRMS (ESI): m/z calcd for C18H18O2 [M+Na]
+
 289.1204; found: 289.1210. 
 
Methyl (Z)-2-(4-methylphenyl)-3-phenylbut-2-enoate (Z)-2-2g 
Pale yellow oil; 
1
H NMR (300 MHz, CDCl3): δ = 2.05 (s, 3H), 2.33 (s, 3H), 3.42 (s, 3H), 7.04−7.45 ppm (m, 
9H); 
13
C NMR (75 MHz, CDCl3): δ = 21.2, 22.3, 51.6, 126.9, 127.5, 128.2, 128.5, 129.1, 129.6, 134.2, 137.3, 
143.0, 143.5, 169.9 ppm; IR (neat): νmax = 2947, 1719, 1636, 1509, 1491, 1435, 1375, 1252 cm
−1
. 
 
Methyl (E)-2-(4-methoxyphenyl)-3-phenylbut-2-enoate (E)-2-2h 
Pale yellow oil; 
1
H NMR (300 MHz, CDCl3): δ = 2.33 (s, 3H), 3.71 (s, 3H), 3.79 (s, 3H), 6.58−6.68 (m, 2H), 
6.85−6.95 (m, 2H), 7.09−7.22 ppm (m, 2H); 13C NMR (75 MHz, CDCl3): δ = 23.1, 51.9, 55.0, 113.3, 126.9, 
127.9, 128.5, 129.4, 131.0, 131.2, 142.0, 143.2, 158.3, 170.2 ppm; IR (neat): νmax = 2951, 1719, 1609, 1576, 
1509, 1458, 1375, 1248 cm
−1
; HRMS (ESI): m/z calcd for C18H18O3 [M+Na]
+
 305.1154; found: 305.1161. 
 
Methyl (Z)-2-(4-methoxyphenyl)-3-phenylbut-2-enoate (Z)-2-2h 
Pale yellow oil; 
1
H NMR (300 MHz, CDCl3): δ = 2.06 (s, 3H), 3.42 (s, 3H), 3.84 (s, 3H), 6.87−6.97 (m, 2H), 
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7.21−7.40 ppm (m, 7H); 13C NMR (75 MHz, CDCl3): δ = 22.2, 51.6, 55.2, 113.8, 126.9, 127.5, 128.2, 129.4, 
130.4, 131.0, 132.2, 143.3, 159.0, 170.0 ppm; IR (neat): νmax = 2951, 1719, 1655, 1601, 1541, 1509, 1437, 
1250 cm
−1
. 
 
Methyl (E)-2-(4-chlorophenyl)-3-phenylbut-2-enoate (E)-2-2i 
Pale yellow oil; 
1
H NMR (300 MHz, CDCl3): δ = 2.37 (s, 3H), 3.78 (s, 3H), 6.88−6.95 (m, 2H), 6.96−7.03 (m, 
2H), 7.03−7.11 (m, 2H), 7.11−7.21 ppm (m, 3H); 13C NMR (75 MHz, CDCl3): δ = 23.3, 52.0, 127.2, 128.0, 
128.0, 128.3, 130.4, 131.3, 132.7, 135.7, 141.6, 146.0, 169.4 ppm; IR (neat): νmax = 2949, 1707, 1619, 1591, 
1489, 1434, 1251, 1206 cm
−1
. 
 
Methyl (E)-2-(biphenyl-4-yl)-3-phenylbut-2-enoate (E)-2i-x 
Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 2.38 (s, 3H), 3.82 (s, 3H), 7.03−7.09 (m, 4H), 7.12−7.17 (m, 
3H), 7.29−7.42 (m, 4H), 7.49−7.54 ppm (m, 2H); 13C NMR (75 MHz, CDCl3): δ = 23.3, 52.0, 126.4, 126.8, 
127.1, 127.2, 127.9, 128.4, 128.6, 130.2, 131.3, 136.1, 139.3, 140.4, 141.8, 144.4, 169.9 ppm; IR (neat): νmax = 
3028, 2949, 1716, 1487, 1433, 1320, 1246, 1206 cm
−1
; HRMS (ESI): m/z calcd for C23H20O2 [M+Na]
+
 
351.1361; found: 351.1375. 
 
Methyl (Z)-2-(4-chlorophenyl)-3-phenylbut-2-enoate (Z)-2-2i 
Colorless crystals; mp 115−116 °C; 1H NMR (300 MHz, CDCl3): δ = 2.04 (s, 3H), 3.42 (s, 3H), 7.24−7.44 
ppm (m, 9H); 
13
C NMR (75 MHz, CDCl3): δ = 22.4, 51.7, 126.8, 127.7, 128.2, 128.6, 130.6, 131.3, 133.5, 
135.6, 142.6, 145.0, 169.2 ppm; IR (neat): νmax = 2951, 1697, 1491, 1428, 1319, 1214, 1088, 1008 cm
−1
; 
HRMS (ESI): m/z calcd for C17H15O2Cl [M+Na]
+
 309.0658; found: 309.0654. 
 
Methyl (Z)-2-(biphenyl-4-yl)-3-phenylbut-2-enoate (Z)-2-2i-x 
Colorless crystals; mp 107−108 °C; 1H NMR (300 MHz, CDCl3): δ = 2.11 (s, 3H), 3.45 (s, 3H), 7.27−7.51 (10 
H, m), 7.58−7.70 ppm (m, 4H); 13C NMR (75 MHz, CDCl3): δ = 22.4, 51.7, 126.9, 127.0, 127.4, 127.6, 128.2, 
128.8, 129.7, 132.2, 136.1, 140.4, 140.6, 142.9, 144.1, 169.8 ppm; IR (neat): νmax = 3028, 2955, 1726, 1600, 
1488, 1434, 1259, 1217 cm
−1
. 
 
Methyl (E)-3-(3-pyridinyl)-3-(tosyloxy)prop-2-enoate (E)-2-9 (Scheme 2-3, [a]) 
TsCl (858 mg, 4.50 mmol) in DMA (3.0 mL) was added to a stirred solution of β-ketoester 2-8a (538 mg, 
3.00 mmol), NMI (369 mg, 4.50 mmol), and Et3N (455 mg, 4.50 mmol) in DMA (3.0 mL) at 20 − 25 °C and 
the mixture was stirred at the same temperature for 1 h.  Water was added to the mixture, which was 
extracted twice with Et2O.  The combined organic phase was washed three times with water, brine, dried 
(Na2SO4), and concentrated.  The obtained crude product (96%, E/Z = 75:25) was purified by column 
chromatography on silica gel (hexane/iPrOH = 10/1) to give the desired product (E)-2-9 (660 mg, 66%). 
Red colored oil; 
1
H NMR (300 MHz, CDCl3): δ = 2.43 (s, 3H), 3.65 (s, 3H), 6.18 (s, 1H), 7.22 (dd, J = 4.5 Hz, 
7.9 Hz, 1H), 7.28 (d, J = 7.2 Hz, 2H), 7.64−7.73 (m, 3H), 8.50 (d, J = 1.7 Hz, 1H), 8.56 (dd, J = 1.4 Hz, 4.8 
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Hz, 1H); 
13
C NMR (75 MHz, CDCl3): δ = 21.7, 51.9, 113.1, 122.4, 128.2, 130.0, 132.5, 136.5, 146.0, 149.7, 
150.9, 156.3, 164.5; IR (neat): νmax = 3036, 2953, 1729, 1650, 1597, 1381, 1231, 1194, 1051, 820, 709 cm
−1
. 
 
Methyl (Z)-3-(3-pyridinyl)-3-(tosyloxy)prop-2-enoate (Z)-2-9 (Scheme 2-3, [b]) 
TsCl (191 mg, 1.00 mmol) in CH2Cl2 (0.50 mL) was added to a stirred solution of β-ketoester 2-8a (90 mg, 
0.50 mmol), NaOH (30 mg, 1.0 mmol), and NMI (82 mg, 0.75 mmol) in CH2Cl2 (0.50 mL) at 20 – 25 °C and 
the mixture was stirred at the same temperature for 1 h.  Water was added to the mixture, which was 
extracted twice with AcOEt.  The combined organic phase was washed with brine, dried (Na2SO4), and 
concentrated.  The obtained crude product was purified by column chromatography on silica gel 
(hexane/AcOEt = 2/1) to give the desired product (Z)-2-9 (135 mg, 81%, E/Z = 8:92), which was washed with 
hexane to yield pure (Z)-2-9 (110 mg, 66%). 
Yellow crystals; mp 87−89 °C; 1H NMR (300 MHz, CDCl3): δ = 2.43 (s, 3H), 3.71 (s, 3H), 6.16 (s, 1H), 7.23 
(dd, J = 4.8 Hz, 8.6 Hz, 1H), 7.27 (d, J = 8.3 Hz, 2H), 7.72−7.79 (m, 3H), 8.59 (dd, J = 1.7 Hz, 4.8 Hz, 1H), 
8.68 (d, J = 2.1 Hz, 1H); 
13
C NMR (75 MHz, CDCl3): δ = 21.6, 51.8, 111.9, 123.1, 128.4, 129.3, 129.7, 132.9, 
134.2, 145.7, 147.6, 151.3, 152.8, 163.2; IR (neat): νmax =
 
3087, 2953, 1728, 1643, 1380, 1316, 1269, 1181, 
1162, 994, 933, 838, 672 cm
−1
; HRMS (ESI): m/z calcd for C16H15NO5S [M+Na]
+
 356.0569; found: 356.0599.   
 
Methyl (Z)-3-(4-bromophenyl)-3-(tosyloxy)prop-2-enoate (Z)-2-10 (Scheme 2-3, [c]) 
TsCl (143 mg, 0.750 mmol) in CH2Cl2 (0.50 mL) was added to a stirred solution of β-ketoester 2-8b (129 
mg, 0.50 mmol), LiOH (18 mg, 0.75 mmol), and NMI (62 mg, 0.75 mmol) in CH2Cl2 (0.50 mL) at 20 − 25 °C 
and the mixture was stirred at the same temperature for 2 h.  Water was added to the mixture, which was 
extracted twice with AcOEt.  The combined organic phase was washed with water, brine, dried (Na2SO4), 
and concentrated.  The obtained crude product was purified by column chromatography on silica gel 
(hexane/AcOEt = 20/1) to give the desired product (Z)-2-10 (149 mg, 72%). 
Colorless crystals; 
1
H NMR (300 MHz, CDCl3): δ = 2.43 (s, 3H), 3.68 (s, 3H), 6.10 (s, 1H), 7.26 (d, J = 8.9 
Hz, 2H), 7.29 (d, J = 8.6 Hz, 2H), 7.41 (d, J = 8.6 Hz, 2H), 7.73 (d, J = 8.3 Hz, 2H); 
13
C NMR (75 MHz, 
CDCl3): δ = 21.6, 51.7, 110.7, 125.4, 128.3, 128.5, 129.6, 131.7, 132.1, 133.2, 145.6, 154.6, 163.6; IR (neat): 
νmax = 2948, 1733, 1649, 1587, 1484, 1433, 1378, 1188, 1152, 1036, 834, 765, 670 cm
−1
.  
 
Methyl (E)-3-(4-bromophenyl)-3-(tosyloxy)prop-2-enoate (E)-2-10 (Scheme 2-3, [d]) 
TsCl (14.3 g, 75.0 mmol) in DMA (50 mL) was added to a stirred solution of β-ketoester 2.8b (12.9 g, 50.0 
mmol), NMI (6.2 g, 75 mmol), and Et3N (7.6 g, 75 mmol) in DMA (50 mL) at 20 − 25 °C for 0.5 h, and the 
mixture was stirred at the same temperature for 1 h.  Water was added to the mixture, and organic layer was 
separated.  Water phase was extracted twice with Et2O.  The combined organic phase was filtered through a 
glass filter followed by washing three times with H2O, brine, dried (Na2SO4), and concentrated.  The 
obtained crude product (92%, E/Z = 67:33) was purified by column chromatography on silica gel 
(hexane/AcOEt = 20/1) to give the desired product (E)-2-10 (12.8 g, 62%). 
Pale yellow oil; 
1
H NMR (300 MHz, CDCl3): δ = 2.44 (s, 3H), 3.64 (s, 3H), 6.08 (s, 1H), 7.19 (d, J = 8.6 Hz, 
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2H), 7.25 (d, J = 7.9 Hz, 2H), 7.38 (d, J = 8.3 Hz, 2H), 7.64 (d, J = 8.3 Hz, 2H); 
13
C NMR (75 MHz, CDCl3): 
δ = 21.7, 51.8, 112.0, 125.1, 128.2, 129.8, 130.6, 130.8, 131.0, 132.7, 145.8, 158.5, 164.7; IR (neat): νmax = 
3069, 2952, 2846, 1727, 1644, 1589, 1487, 1379, 1220, 1177, 1033, 836, 754 cm
−1
; HRMS (ESI): m/z calcd 
for C17H15BrO5S [M+Na]
+
 432.9721; found: 432.9720. 
 
Methyl (Z)-3-(4-bromophenyl)-3-(3-pyridinyl)prop-2-enoate (Z)-2-11 (Scheme 2-3, [e]) 
A 3M K2CO3 aqueous solution (0.25 mL, 0.75 mmol) was added to a stirred suspension of enol tosylate 
(E)-2-9 (83 mg, 0.25 mmol), (p-Br)C6H4B(OH)2 (52 mg, 0.26 mmol), and [Pd(PPh3)2Cl2] (9 mg, 0.01 mmol) 
in iPrOH (0.75 mL) at 60 − 65 °C under an Ar atmosphere, and the mixture was stirred at the same 
temperature for 1 h.  After cooling, water was added to the mixture, which was extracted three times with 
Et2O.  The combined organic phase was washed with brine, dried (Na2SO4), and concentrated. The obtained 
crude product was purified by column chromatography on silica gel (hexane/AcOEt = 3/1) to give the desired 
product (Z)-2-11 (70 mg, 89%, E/Z = 2:>98).  The use of [Pd(dppb)Cl2] catalyst instead of [Pd(PPh3)2Cl2] 
resulted in 35% conversion yield. 
 
Methyl (E)-3-(4-bromophenyl)-3-(3-pyridinyl)prop-2-enoate (E)-2-11 (Scheme 2-3, [f]) 
A 3M K2CO3 aqueous solution (0.25 mL, 0.75 mmol) was added to a stirred suspension of enol tosylate 
(Z)-2-9 (83 mg, 0.25 mmol), (p-Br)C6H4B(OH)2 (52 mg, 0.26 mmol), and [Pd(PPh3)2Cl2] (9 mg, 0.01 mmol) 
in iPrOH (0.75 mL) at 60 − 65 °C under an Ar atmosphere, and the mixture was stirred at the same 
temperature for 1 h.  After cooling, water was added to the mixture, which was extracted three times with 
Et2O.  The combined organic phase was washed with brine, dried (Na2SO4), and concentrated.  The 
obtained crude product was purified by column chromatography on silica gel (hexane/AcOEt = 3/1) to give 
the desired product (E)-2-11 (63 mg, 79%, E/Z = >98:2)  
 
Methyl (Z)-3-(4-bromophenyl)-3-(3-pyridinyl)prop-2-enoate (Z)-2-11 (Scheme 2-3, [g]) 
A 3M K2CO3 aqueous solution (13.0 mL, 39.0 mmol) was added to a stirred suspension of enol tosylate 
(Z)-2-10 (5.35 g, 13.0 mmol), (3-Py)B(OH)2 (2.56 g, 21.0 mmol), and [Pd(dppf)Cl2] (476 mg, 0.65 mmol) in 
iPrOH (39.0 mL) at 60 − 65 °C under an Ar atmosphere, and the mixture was stirred at the same temperature 
for 3 h.  After cooling, water was added to the mixture, which was extracted three times with Et2O.  The 
combined organic phase was washed with brine, dried (Na2SO4), and concentrated.  The obtained crude 
product was purified by column chromatography on silica gel (hexane/AcOEt = 3/1) to give the desired 
product (Z)-2-11 (3.36 g, 81%, E/Z = 2:>98). 
Red colored oil; 
1
H NMR (300 MHz, CDCl3): δ = 3.63 (s, 3H), 6.44 (s, 1H), 7.15 (d, J = 8.6 Hz, 2H), 7.34 (dd, 
J = 4.8 Hz, 7.9 Hz, 1H), 7.45−7.57 (m, 3H), 8.45 (d, J = 2.4 Hz, 1H), 8.64 (dd, J = 1.6 Hz, 4.8 Hz, 1H); 13C 
NMR (75 MHz, CDCl3): δ = 51.5, 118.6, 122.8, 124.4, 129.6, 131.8, 134.0, 136.5, 138.8, 149.5, 149.6, 152.2, 
165.7; IR (neat): νmax = 3435, 3029, 2949, 1849, 1907, 1720, 1618, 1583, 1272, 1166, 1073, 1009, 826, 752, 
713 cm
−1
. 
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Methyl (E)-3-(4-bromophenyl)-3-(3-pyridinyl)prop-2-enoate (E)-2-11 (Scheme 2-3, [h]) 
A 3M K2CO3 aqueous solution (0.50 mL, 1.5 mmol) was added to a stirred suspension of enol tosylate 
(E)-2-10 (206 mg, 0.500 mmol), (3-Py)B(OH)2 (92 mg, 0.75 mmol), and [Pd(dppf)Cl2] (18 mg, 0.025 mmol) 
in iPrOH (1.5 mL) at 60 − 65 °C under an Ar atmosphere, and the mixture was stirred at the same temperature 
for 3 h.  After cooling, water was added to the mixture, which was extracted three times with Et2O.  The 
combined organic phase was washed with brine, dried (Na2SO4), and concentrated.  The obtained crude 
product was purified by column chromatography on silica gel (hexane/AcOEt = 3/1) to give the desired 
product (E)-2-11 (129 mg, 81%, E/Z = 97:3). 
Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 3.66 (s, 3H), 6.39 (s, 1H), 7.09 (d, J = 8.6 Hz, 2H), 7.27 (ddd, 
J = 0.7 Hz, 4.8 Hz, 7.9 Hz, 1H), 7.48−7.58 (m, 3H), 8.58 (d, J = 2.1 Hz, 1H), 8.60 (dd, J = 1.7 Hz, 4.8 Hz, 
1H); 
13
C NMR (75 MHz, CDCl3): δ = 51.5, 118.6, 123.0, 123.2, 130.7, 131.4, 135.5, 136.1, 136.5, 148.9, 
150.5, 152.6, 165.6; IR (neat): νmax = 3427, 3030, 2949, 2841, 1906, 1722, 1619, 1488, 1434, 1360, 1277, 
1165, 1010, 824, 758, 708 cm
−1
. 
 
(Z)-3-(4-Bromophenyl)-3-(3-pyridinyl)prop-2-en-1-ol
14
 (Scheme 2-3, [i]-i)) 
DIBAL (42.4 mL; 1.0 M in toluene) was added to a stirred solution of the ester (Z)-2-11 (3.36 g, 10.6 
mmol) in THF (21 mL) at −78 °C under an argon atmosphere, and the mixture was stirred at the same 
temperature for 0.5 h.  MeOH (ca. 30 mL) and saturated Na/K tartrate aqueous solution (ca. 80 mL) were 
successively added to the mixture, followed by stirring for 1 h, which was extracted twice with AcOEt.  The 
organic phase was dried (Na2SO4) and concentrated.  The obtained pale yellow solid was washed 
(hexane/Et2O = 5/1) to give the desired product (2.42 g, 79%). 
Pale yellow crystals; mp 123−124 °C; 1H NMR (300 MHz, CDCl3): δ = 2.00 (br, 1H), 4.21 (d, J = 6.9 Hz, 2H), 
6.34 (t, J = 6.9 Hz, 1H), 7.08 (d, J = 8.6 Hz, 2H), 7.32 (dd, J = 4.9, 7.9 Hz, 1H), 7.43 (d, J = 8.6 Hz, 2H), 7.48 
(dt, J = 7.6, 2.1 Hz, 1H), 8.40 (d, J = 1.4 Hz, 1H), 8.58 (dd, J = 1.4, 4.8 Hz, 1H); 
13
C NMR (75 MHz, CDCl3): 
δ = 59.8, 122.0, 123.4, 129.0, 130.7, 131.5, 134.5, 137.5, 138.7, 139.8, 148.6, 149.9; IR (neat): νmax = 3241, 
3038, 2922, 2844, 2669, 1488, 1414, 1028, 804, 718 cm
−1
; HRMS (ESI): m/z calcd for C14H12BrNO [M+H]
+
 
290.0181; found: 290.0208. 
 
(E)-3-(4-Bromophenyl)-3-(3-pyridinyl)prop-2-en-1-ol
14
 (Scheme 2-3, [j]- i)) 
DIBAL (4.0 mL; 1.0 M in toluene) was added to a stirred solution of ester 2-11 (318 mg, 1.00 mmol) in 
THF (2.0 mL) at −78 °C under an argon atmosphere, and the mixture was stirred at the same temperature for 
0.5 h.  MeOH (ca. 3 mL) and saturated Na/K tartrate aqueous solution (ca. 8 mL) solution were successively 
added to the mixture, followed by stirring for 0.5 h, which was extracted twice with AcOEt.  The organic 
phase was dried (Na2SO4) and concentrated.  The obtained crude product was purified by column 
chromatography on silica gel (hexane/AcOEt = 1/1) to give the desired product (261 mg, 90%). 
Colorless solid; mp 123–124 °C; 1H NMR (300 MHz, CDCl3): δ = 2.80 (br, 1H), 4.24 (d, J = 6.9 Hz, 2H), 
6.30 (t, J = 6.9 Hz, 1H), 7.02 (d, J = 8.3 Hz, 2H), 7.24 (dd, J = 5.2, 7.9 Hz, 1H), 7.43−7.57 (m, 3H), 8.41–8.64 
(m, 2H); 
13
C NMR (75 MHz, CDCl3): δ = 60.0, 122.2, 123.3, 130.7, 131.2, 131.7, 135.3, 136.7, 137.3, 139.3, 
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148.0, 148.2; IR (neat): νmax = 3296, 2875, 1489, 1398, 1010, 822, 717 cm
−1
. 
 
(Z)-Zimelidine (Z)-2-3
14
 (Scheme 2-3, [i]-ii)) 
SOCl2 (0.10 mL, 1.4 mmol) and DMF (1 drop) were successively added to a stirred solution of the allyl 
alcohol (261 mg, 0.90 mmol) in CH2Cl2 (0.90 mL) at 20 − 25 °C, and the mixture was stirred at the same 
temperature for 10 min.  Then, an aqueous solution of Me2NH solution (0.95 mL; 9.5 M) was added to the 
mixture followed by stirring for 0.5 h.  A saturated aqueous solution of NaHCO3 was added to the mixture, 
which was extracted three times with AcOEt.  The organic phase was washed with brine, dried (Na2SO4) and 
concentrated.  The obtained crude product was purified by column chromatography on silica gel 
(AcOEt/Et3N = 10/1) to give the desired product (Z)-2-3 (260 mg, 91%). 
Yellow oil; 
1
H NMR (300 MHz, CDCl3): δ = 2.23 (s, 6H), 2.98 (d, J = 6.9 Hz, 2H), 6.29 (t, J = 6.9 Hz, 1H), 
7.09 (d, J = 8.6 Hz, 2H), 7.33 (ddd, J = 1.0, 4.8, 7.6 Hz, 1H), 7.42 (d, J = 8.6 Hz, 2H), 7.46 (dt, J = 7.6, 2.1 Hz, 
1H), 8.44 (dd, J = 0.7, 2.4 Hz, 1H), 8.60 (dd, J = 1.7, 4.8 Hz, 1H); 
13
C NMR (75 MHz, CDCl3): δ = 45.3, 58.1, 
121.7, 123.2, 128.8, 129.5, 131.4, 134.7, 137.1, 139.2, 140.2, 148.7, 150.5; IR (neat): νmax = 3457, 3028, 2973, 
2941, 2855, 2817, 2768, 1670, 1585, 1488, 1263, 1024, 817, 717 cm
−1
.  
 
(E)-Zimelidine (E)-2-3
14
 (Scheme 2-3, [j]- ii)) 
SOCl2 (0.06 mL, 0.75 mmol) and DMF (1 drop) were successively added to a stirred solution of the allyl 
alcohol (145 mg, 0.50 mmol) in CH2Cl2 (0.50 mL) at 20 − 25 °C, and the mixture was stirred at the same 
temperature for 10 min.  Then, an aqueous solution of Me2NH (0.53 mL; 9.5 M) was added to the mixture 
followed by stirring for 0.5 h.  A saturated aqueous solution of NaHCO3 was added to the mixture, which 
was extracted twice with AcOEt.  The organic phase was washed with brine, dried (Na2SO4) and 
concentrated.  The obtained crude product was purified by column chromatography on silica gel 
(AcOEt/Et3N = 10/1) to give the desired product (E)-2-3 (144 mg, 91%, E/Z = 92:8). 
Yellow oil; 
1
H NMR (300 MHz, CDCl3): δ = 2.24 (s, 6H), 3.00 (d, J = 6.5 Hz, 2H), 6.25 (t, J = 6.5 Hz, 1H), 
7.04 (d, J = 8.6 Hz, 2H), 7.20 (dd, J = 4.8, 7.9 Hz, 1H), 7.46 (dt, J = 2.1, 7.9 Hz, 1H), 7.53 (d, J = 8.3 Hz, 2H), 
8.49 (dd, J = 1.7, 4.8 Hz, 1H), 8.53 (d, J = 1.7 Hz, 1H); 
13
C NMR (75 MHz, CDCl3): δ = 45.3, 58.0, 121.7, 
122.9, 129.3, 131.3, 131.5, 134.3, 137.1, 137.3, 139.6, 148.3, 148.5; IR (neat): νmax = 3394, 3027, 2971, 2940, 
2854, 2817, 2768, 1669, 1567, 1487, 1412, 1262, 1174, 1011, 825, 732 cm
−1
.  
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Chapter 3. 
(E)- and (Z)-Stereodefined Enol Phosphonates Derived From 
β-Ketoesters: Stereocomplementary Synthesis of Fully-substituted 
α,β-Unsaturated Esters 
 
Abstract 
A versatile, robust, and stereocomplementary synthesis of fully-substituted (E)- and 
(Z)-stereodefined α,β-unsaturated esters 3-3 from accessible α-substituted β-ketoesters 3-1 via (E)- 
and (Z)-enol phosphonates was achieved. The present method involves two accessible reaction 
sequences: (i) (E)- and (Z)-stereocomplementary enol phosphorylations of a wide variety of 
β-ketoesters 3-1 (24 examples; 71–99% yield, each >95:5 ds), and (ii) (E)- and (Z)-stereoretentive 
Suzuki–Miyaura cross-coupling (16 examples; 71–91% yield, >81:19 ds) and Negishi cross-coupling 
(32 examples; 65–96% yield, >95:5 ds) using (E)- and (Z)-enol phosphonates 3-2. 1H-NMR 
monitoring for a key reactive N-phosphorylammonium (imidazolium) intermediate I and an 
application in the synthesis of both (E)- and (Z)-tamoxifen precursors 3-6 are described. 
 
 
 
Introduction 
(E)- and (Z)-α,β-unsaturated esters are widely distributed in natural products, pharmaceuticals, and 
supramolecules as key structural building blocks.  They also serve as well-recognized useful structural 
scaffolds for various stereodefined olefins and conjugate (Michael) addition acceptors in organic synthesis.  
Stereocontrolled preparation of these (E)- and (Z)-esters is pivotal in organic synthesis and has been 
developed over the last few decades.  Despite the demand for fully (tri)-substituted (E)- and 
(Z)-α,β-unsaturated esters, stereoselective synthetic methods are not yet fully established due to the inherent 
higher complexity in differentiating the substituents compared with mono- or di-substituted α,β-unsaturated 
esters.
1
  Several excellent methods utilizing the carbometallation-mediated reaction using α-alkynyl esters,2 
Mizoroki–Heck reaction,3 the ynolate-mediated reaction (Shindo’s group),4 cross-couplings using enol 
phosphonates (Skrydstrup’s group),5 Horner–Wadsworth–Emmons reaction,6 and conjugate addition–
elimination,
7
 have been evaluated to date.  However, the (E)- and (Z)-stereocomplementary method using the 
same common starting materials with sufficient substrate-generality is quite limited. 
To investigate this critical topic, here it is presented a versatile synthesis of fully-substituted both (E)- and 
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(Z)-α,β-unsaturated esters 3-3 utilizing (E)- and (Z)-stereocomplementary enol phosphorylations of accessible 
α-substituted (R2) β-ketoesters 3-1 and the subsequent (E)- and (Z)-stereoretentive Suzuki–Miyaura and 
Negishi cross-couplings (Scheme 3-1).  A literature survey revealed no available general method for 
stereocomplementary enol phosphorylation of β-ketoesters 3-1.  Our longstanding interest in 
N-methylimidazole (NMI)-promoted acylations
8
 and sulfonylations
9
 led us to attempt this objective. 
 
 
Scheme 3-1.  Stereocomplementary synthesis of fully-substituted (E)- and (Z)-α,β-unsaturated esters 3-3. 
 
Results and Discussion 
The initial stereoselective enol phosphorylation was intentionally guided using stereocongested methyl 
2-butyl-3-oxooctanoate 3-1a
10
 as a much less reactive α-substituted β-ketoester probe (Table 3-1).  
Consequently, both (E)- and (Z)-selective phosphorylations of 3-1a successfully proceeded in excellent yields 
with excellent stereoselectivity (>98:2) using (PhO)2POCl–NMI–KOtBu with 18-crown-6 (Method A) and 
(PhO)2POCl–NMI–LiOtBu (Method B) to give, respectively, (E)-3-2a and (Z)-3-2a, (entries 2, 4).  Notably, 
the corresponding enol tosylation using the reported TsCl–NMI–base reagents9 gave inferior results.11  It is 
speculated that the present smooth enol phosphorylation can be attributed to the higher reactivity of 
(PhO)2POCl over TsCl.
12 
Table 3-2 lists the successful results of the present (E)- and (Z)-stereocomplementary enol phosphorylations 
of α-substituted β-ketoesters 3-1 using fine-tuned Methods A–D.  A notable aspect is the high 
substrate-generality.  The salient features are as follows.  (i) All substrates 3-1a–3-1l examined, produced 
good to excellent yields and excellent (E)- and (Z)-selectivities.  (ii) Much less reactive (stereocongested) 
β-ketoesters 3-1a, 3-1i, and 3-1j–3-1l could be applied successfully (entries 1, 2, 17–24).  (iii) Not only 
α-aliphatic substrates but also α-aromatic substrates underwent the reaction smoothly using (E)-selective 
(PhO)2POCl–NMI–DBU (Method C) and (Z)-selective (PhO)2POCl–NMI–iPr2N–LiCl (Method D) (entries 
19–24).  (iv) Several functional groups such as ω-chloro, BnO, and a double bond were compatible (entries 
11–16).  (v) Because of the close Rf values of (E)- and (Z)-enol phosphonates 3-2 on thin layer 
chromatography excellent stereoselectivities of >95/5% are required for complete column chromatographic 
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purification with a high yield.
13 
 
Table 3-1.  (E)- and (Z)-stereocomplementary enol phosphorylation of 3-1a using (PhO)2POCl–NMI–bases. 
 
Entry Base Additive Method Yield / % E/Z
a
 
1 KOtBu − − 44 2:>98 
2 KOtBu 18-Crown-6 A 84 (42
b
) 98:2 
3 LiHMDS − − 93 2:>98 
4 LiOtBu − B 97 (79b) 2:>98 
a) Determined by 
1
H NMR of crude products.  b) In the absence of NMI. 
 
Table 3-2.  (E)- and (Z)-Stereocomplementary enol phosphorylation of α-substituted β-ketoesters 3-1 using Methods A–D. 
 
Entry Substrate Method Product Yield / % E/Z
b
 
1 
 
3-1a A (E)-3-2a 84 98:2 
2 B (Z)-3-2a 97 2:>98 
3 
 
3-1b A (E)-3-2b 90 98:2 
4 B (Z)-3-2b 86 2:>98 
5 
 
3-1c A (E)-3-2c 71 >98:2 
6 B (Z)-3-2c 91 2:>98 
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7 
 
3-1d A (E)-3-2d 83 >98:2 
8 B (Z)-3-2d 94 2:>98 
9 
 
3-1e A (E)-3-2e 87 95:5 
10 B (Z)-3-2e 90 2:>98 
11 
 
3-1f A (E)-3-2f 83 93:7 
12 B (Z)-3-2f 93 2:>98 
13 
 
3-1g A (E)-3-2g 75 >98:2 
14 B (Z)-3-2g 86 2:>98 
15 
 
3-1h A (E)-3-2h 83 97:3 
16 B (Z)-3-2h 98 2:>98 
17 
 
3-1i A (E)-3-2i 74 >98:2 
18 B (Z)-3-2i 86 2:>98 
19 
 
3-1j C (E)-3-2j 74 >98:2 
20 D (Z)-3-2j 86 2:>98 
21 
 
3-1k C (E)-3-2k 88 >98:2 
22 D (Z)-3-2k 97 2:>98 
23 
 
3-1l C (E)-3-2l 86 >98:2 
24 D (Z)-3-2l 88 2:>98 
a) 3-1a was prepared (ref. 10).  3-1b–3-1e, 3-1g, 3-1i–3-1l were commercially available.  3-1f and 3-1h were prepared by the reported 
crossed Ti Claisen condensation (ref. 7b).  b) Determined by 
1
H NMR of the crude products. 
 
As depicted in Figure 3-1, 
1
H-NMR monitoring (−45 °C in CD3CN) revealed that (PhO)2POCl coupled 
with NMI formed a highly reactive N-phosphorylammonium (imidazolium) intermediate I, which functioned 
as the key active species.
14 
 
45 
 
 
Figure 3-1.  Formation of N-phosphorylammonium (imidazolium) intermediate I monitored by 1H NMR measurement at −45 °C. 
 
A plausible mechanism for the successful emergence of (E)- and (Z)-enol phosphorylation stereoselectivity 
is illustrated in Scheme 3-2, wherein substrate 3-1a is exemplified.  The (E)-stereoselective reaction with a 
highly reactive intermediate I proceeds via a non-chelation pathway to give (E)-3-2a; K-cation captured by 
18-crown-6 aids (E)-enolate formation through dipole–dipole repulsive interactions between the oxy anion 
and ester function.  In a clear contrast, the (Z)-stereoselective reaction proceeds via a chelation mechanism to 
give (Z)-3-2a; the Li-cation facilitates (Z)-enolate formation. 
 
  
Scheme 3-2.  Mechanistic investigation into the (E)- and (Z)-stereocomplementary enol phosphorylation of 3-1a. 
 
With the successful results in hand, stereoretentive Suzuki–Miyaura cross-coupling was investigated using 
(E)- and (Z)-stereodefined enol phosphonate partners 3-2a–3-2f to obtain fully-substituted (E)- and 
(Z)-α,β-unsaturated esters 3-3a–3-3f.  Table 3-3 lists the successful results, and the salient features are as 
follows.  (i) Among the various catalysts screened, the Pd(dppb)Cl2 catalyst produced a successful result.
15
 
(ii) Even the less reactive (stereocongested) substrate 3-2a smoothly underwent the reaction (entries 1, 2).  
(iii) Three ArB(OH)2 nucleophiles containing both electron-donating and electron-withdrawing substituents 
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(p-Me, p-OMe, p-Cl) were applicable (entries 5–10).  (iv) High substrate-generality was obtained; good to 
excellent yields, and excellent (E)- and (Z)-stereoretention (>95:5) were achieved for most (E)- and (Z)-3-2 
examined.  (v) Slight isomerization occurred in a few cases, however, likely due to the harsh DMF/reflux 
conditions (entries 1, 15).  Since the substrates (E)-3-2a and (E)-3-2f are considerably less reactive due to the 
stereocongestion, slight isomerization is considered to occur.  To address the obvious problems (high 
temperature and slight isomerization) resulting from Suzuki–Miyaura cross-coupling, Negishi cross-coupling 
was investigated using a variety of (E)- and (Z)-stereodefined enol phosphonate substrates 3-2a, 3-2c, 3-2f–
3-2l.  Table 3-4 (α-aliphatic substrates) and Table 3-5 (α-aromatic substrates) list the positive results, and the 
salient features are as follows.  (i) The substrate-generality was certainly enhanced in every case examined 
when using α-aliphatic as well as α-aromatic substrates with consistent and nearly perfect (E)- and 
(Z)-stereoretention to give the corresponding fully-substituted (E)- and (Z)-α,β-unsaturated esters 3-3a, 
3-3c-1–3-3c-8, 3-3f–3-3l.  (ii) Milder conditions were applicable; MeCN/reflux for (E)-substrates 3-2 and 
THF/reflux for (Z)-substrates 3-2.  (iii) The loading quantity of the Pd(dppb)Cl2 catalyst could be decreased 
from 5 mol% to 2 mol%.  (iv) Various ArZnCl nucleophiles containing both electron-donating and 
electron-withdrawing substituents (p-Me, p-OMe, o-Me, p-Cl) and a bulky 1-naphthyl group, were 
employable (Table 3-4, entries 5–18).  (v) Heterocyclic ZnCl nucleophiles (furan-2-yl and thiophen-2-yl) 
also underwent the reaction smoothly (Table 3-4, entries 15–18).  (vi) Several functional groups, such as 
ω-BnO, ω-chloro, and a double bond were compatible (Table 3-4, entries 19–24).  (vii) The reaction using 
α-aromatic substrates 3-2j–3-2l proceeded smoothly under the identical conditions (Table 3-5). 
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Table 3-3.  Stereoretentive Suzuki–Miyaura cross-coupling of (E)- and (Z)-enol phosphonates 3-2. 
 
Entry R
1 
R
2
 R
3
 Substrate
a
 Ar Product Yield
b
 / % 
1 Pen Bu Me (E)-3-2a Ph (E)-3-3a 83
c
 
2    (Z)-3-2a  (Z)-3-3a 91 
3 Me Me Et (E)-3-2b Ph (E)-3-3b-1 81 
4    (Z)-3-2b  (Z)-3-3b-1 81 
5 Me Me Et (E)-3-2b (p-Me)C6H4 (E)-3-3b-2 83 
6    (Z)-3-2b  (Z)-3-3b-2 83 
7 Me Me Et (E)-3-2b (p-MeO)C6H4 (E)-3-3b-3 83 
8    (Z)-3-2b  (Z)-3-3b-3 84 
9 Me Me Et (E)-3-2b (p-Cl)C6H4 (E)-3-3b-4 71 
10    (Z)-3-2b  (Z)-3-3b-4 82 
11 Me Bn Et (E)-3-2d Ph (E)-3-3d 88 
12    (Z)-3-2d  (Z)-3-3d 83 
13 Pen Me Me (E)-3-2e Ph (E)-3-3e 81 
14    (Z)-3-2e  (Z)-3-3e 80 
15 BnO(CH2)5 Me Me (E)-3-2f Ph (E)-3-3f 90
d
 
16    (Z)-3-2f  (Z)-3-3f 80 
a) (E) or (Z): >98% purity based on 
1
H NMR analysis. b) Isolated.  Unless otherwise noted, E/Z = >95:5 for (E)-3-3 and E/Z = 5:>95 for 
(Z)-3-3.  c) E/Z = 83:17.  d) E/Z = 81:19. 
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Table 3-4.  Stereoretentive Negishi cross-coupling of aliphatic (E)- and (Z)-enol phosphonates 3-2. 
 
Entry R
1
 R
2
 Substrate
a
 Ar Product Yield
b
 / % 
1 Pen Bu (E)-3-2a Ph (E)-3-3a 78 
2   (Z)-3-2a  (Z)-3-3a 84 
3 Me Me (E)-3-2c Ph (E)-3-3c-1 82 
4   (Z)-3-2c  (Z)-3-3c-1 81 
5 Me Me (E)-3-2c (p-Me)C6H4 (E)-3-3c-2 91 
6   (Z)-3-2c  (Z)-3-3c-2 81 
7 Me Me (E)-3-2c (p-MeO)C6H4 (E)-3-3c-3 79 
8   (Z)-3-2c  (Z)-3-3c-3 85 
9 Me Me (E)-3-2c (p-Cl)C6H4 (E)-3-3c-4 83
c
 
10   (Z)-3-2c  (Z)-3-3c-4 72
c
 
11 Me Me (E)-3-2c (o-Me)C6H4 (E)-3-3c-5 96 
12   (Z)-3-2c  (Z)-3-3c-5 81 
13 Me Me (E)-3-2c 1-Naph (E)-3-3c-6 83 
14   (Z)-3-2c  (Z)-3-3c-6 63 
15 Me Me (E)-3-2c 
 
(E)-3-3c-7 59 
16   (Z)-3-2c (Z)-3-3c-7 74 
17 Me Me (E)-3-2c 
 
(E)-3-3c-8 78 
18   (Z)-3-2c (Z)-3-3c-8 82 
19 BnO(CH2)5 Me (E)-3-2f Ph (E)-3-3f 71
d
 
20   (Z)-3-2f  (Z)-3-3f 58
d
 
21 Cl(CH2)4 Me (E)-3-2g Ph (E)-3-3g 74
d
 
22   (Z)-3-2g  (Z)-3-3g 76
d
 
23 CH2=CH(CH2)8 Me (E)-3-2h Ph (E)-3-3h 88
d
 
24   (Z)-3-2h  (Z)-3-3h 66
d
 
25 Cyclohexyl Me (E)-3-2i Ph (E)-3-3i 81
d
 
26   (Z)-3-2i  (Z)-3-3i 81
d
 
(E) or (Z): >98% purity based on 
1
H NMR analysis.  b) Isolated.  E/Z = >95:5 for (E)-3-3 and E/Z = 5:>95 for (Z)-3-3.  c) Reaction time: 1 
h.  d) 2 equiv. of PhZnCl were used. 
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Table 3-5.  Stereoretentive Negishi cross-coupling of aromatic (E)- and (Z)-enol phosphonates 3-2. 
 
Entry Ar Substrate
a
 Product Yield
b
 / % 
1 Ph (E)-3-2j (E)-3-3j 81 
2  (Z)-3-2j (Z)-3-3j 96 
3 (p-MeO)C6H4 (E)-3-2k (E)-3-3k 88
c,d
 
4  (Z)-3-2k (Z)-3-3k 92
c
 
5 (p-Cl)C6H4 (E)-3-2l (E)-3-3l 86
c,d
 
6  (Z)-3-2l (Z)-3-3l 88
c
 
a) (E) or (Z): >98% purity based on 
1
H NMR analysis.  b) Isolated.  E/Z = >95:5 for (E)-3-3 and E/Z = 5:>95 for (Z)-3-3. 
c) Reaction time: 1 h.  d) 2.5 equiv. of ArZnCl was used. 
 
The wide substrate-generality may be ascribed to the high reactivity and mildness of conditions of Negishi 
cross-coupling.  Compared with the reported syntheses for several known compounds, 3-3b-1, 3-3b-2, 
3-3b-3, 3-3b-4, 3-3c-1, 3-3c-3, 3-3d, 3-3e, 3-3j, higher E/Z-selectivity was produced in almost all cases 
(details: Experimental). 
Finally, to display the utility of the present method, a facile stereocomplementary synthesis of the precursor 
3-6 for both (E)- and (Z)-tamoxifen,
16
 an anti-tumor drug, is presented (Scheme 3-3).  The same starting 
β-keto ester 3-417 underwent stereocomplementary enol phosphorylations (Table 3-2, Methods C and D) 
smoothly to give (E)-3-5 and (Z)-3-5, which were successfully converted to the desired (E)-3-6 as well as 
(Z)-3-6 by successive Negishi cross-coupling with certain stereoretention.
18 
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Scheme 3-3.  Stereocomplementary synthesis of fully-substituted (E)- and (Z)-tamoxifen precursor 3-6. 
 
Conclusion 
A versatile synthesis of fully-substituted (E)- and (Z)-α,β-unsaturated esters utilizing (E)- and 
(Z)-stereocomplementary enol phosphorylations of β-ketoesters and the subsequent (E)- and 
(Z)-stereoretentive Suzuki–Miyaura and Negishi cross-couplings was achieved.  Compared with the reported 
methods, the present method exhibits wider substrate-generality for the synthesis of synthetically inaccessible 
fully-substituted (E)- and (Z)-α,β-unsaturated esters.  Further extension, especially for the parallel synthesis 
of fully-substituted olefins is disclosed in chapter 4 and 5. 
  
51 
 
Experimental 
 
Methyl 2-butyl-3-oxooctanoate 3-1a 
TiCl4 (114 g, 0.60 mol) and Et3N (70.8 g, 0.70 mol) were successively added dropwise to a stirred solution of 
methyl hexanoate (65.1 g, 0.50 mol) in CH2Cl2 (500 mL) at 0 – 5 °C under an Ar atmosphere, and the mixture 
was stirred at the same temperature for 1 h.  Water was added to the mixture, which was extracted twice with 
Et2O.  The combined organic phase was washed with sat. aq. NaHCO3 solution, brine, dried (Na2SO4), and 
concentrated.  The obtained crude product was purified by distillation to give the desired product (53.2 g, 
93%). 
Colorless oil; bp 79−81 °C/0.49 mmHg; 1H NMR (300 MHz, CDCl3): δ = 0.89 (t, J = 7.2 Hz, 3H), 0.89 (t, J = 
7.2 Hz, 3H), 1.16−1.39 (m, 8H), 1.58 (quin, J = 7.2 Hz, 2H), 1.78−1.90 (m, 2H), 2.45 (dt, J = 7.2 Hz, Jgem = 
17.2 Hz, 1H), 2.54 (dt, J = 7.2 Hz, Jgem = 17.2 Hz, 1H), 3.43 (t, J = 7.2 Hz, 1H), 3.72 (s, 3H); 
13
C NMR (75 
MHz, CDCl3) δ 13.6, 13.7, 22.2, 22.3, 23.0, 27.8, 29.5, 31.0, 41.6, 52.0, 58.8, 170.2, 205.2. 
 
General procedure for the (E)-stereoselective enol phosphorylation of β-ketoesters (Method A). 
 
 
 
A β-ketoester (5.0 mmol − 1.0 mmol) in THF (5.0 mL − 1.0 mL), (PhO)2POCl (2.01 g − 0.40 g, 7.5 mmol ‒ 
1.5 mmol) in THF (5.0 mL − 1.0 mL), and N-methylimidazole (NMI: 0.62 g − 0.12 g, 7.5 mmol − 1.5 mmol) 
were successively added dropwise to a stirred suspension of KOtBu (0.84 g − 0.17 g, 7.5 mmol − 1.5 mmol) 
and 18-Crown-6 (1.99 g − 0.40 g, 7.5 mmol − 1.5 mmol) in THF (5.0 mL − 1.0 mL) at 0 − 5 °C under an Ar 
atmosphere, and the mixture was stirred at the same temperature for 1 h and at 20 − 25 °C for 1 h.  Water 
was added to the stirred mixture, which was extracted twice with EtOAc.  The organic phase was washed 
with 1M HCl aqueous solution, brine, dried (Na2SO4), and concentrated.  The obtained crude product was 
purified by SiO2-column chromatography (hexane/AcOEt = 20/1 – 5/1) to give the desired product (E)-3-2. 
 
General procedure for the (Z)-stereoselective enol phosphorylation of β-ketoesters (Method B). 
 
 
 
A β-ketoester (5.0 mmol − 1.0 mmol) in THF (5.0 mL − 1.0 mL), (PhO)2POCl (2.01 ‒ 0.40 g, 7.5 mmol − 
1.5 mmol) in THF (5.0 mL − 1.0 mL), and N-methylimidazole (NMI: 0.62 g − 0.12 g, 7.5 mmol ‒ 1.5 mmol) 
were successively added dropwise to a stirred suspension of LiOtBu (0.60 g ‒ 0.12 g, 7.5 mmol − 1.5 mmol) 
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in THF (5.0 mL − 1.0 mL) at 0 − 5 °C under an Ar atmosphere, and the mixture was stirred at the same 
temperature for 1 h and at 20 − 25 °C for 1 h..  Water was added to the stirred mixture, which was extracted 
twice with EtOAc.  The organic phase was washed with 1M HCl aqueous solution, brine, dried (Na2SO4), 
and concentrated.  The obtained crude product was purified by SiO2-column chromatography (hexane/AcOEt 
= 20/1 – 5/1) to give the desired product (Z)-3-2. 
 
General procedure for the (E)-stereoselective enol phosphorylation of α-aryl-β-ketoesters with (Method 
C). 
 
 
(PhO)2POCl (402 mg, 1.5 mmol) was added to a stirred solution of an α-aryl-β-ketoester (1.0 mmol), NMI 
(N-methylimidazole) (123 mg, 1.5 mmol), and DBU (228 mg, 1.5 mmol) in DMF (2.0 mL) at 0 − 5 °C under 
an Ar atmosphere, and the mixture was stirred at the same temperature for 1 h.  Water was added to the 
reaction mixture, which was extracted twice with AcOEt.  The organic phase was washed with water, brine, 
dried (Na2SO4) and concentrated.  The obtained crude product was purified by SiO2-column chromatography 
(hexane/AcOEt = 10/1 – 3/1) to give the desired product. 
 
General procedure for the (Z)-stereoselective enol phosphorylation of α-aryl-β-ketoesters (Method D). 
 
An α-aryl-β-ketoester (1.0 mmol), iPr2NEt (194 mg, 1.5 mmol), NMI (N-methylimidazole) (123 mg, 1.5 
mmol), and (PhO)2POCl (402 mg, 1.5 mmol) were successively added to a stirred suspension of LiCl (64 mg 
1.5 mmol) in THF (1.0 mL) at 0 − 5 °C under an Ar atmosphere, and the mixture was stirred at the same 
temperature for 1 h.  Water was added to the reaction mixture, which was extracted with twice AcOEt.  The 
organic phase was washed with water, brine, dried (Na2SO4) and concentrated.  The obtained crude product 
was purified by SiO2-column chromatography (hexane/AcOEt = 10/1 – 3/1) to give the desired product. 
 
Methyl (E)-2-butyl-3-((diphenoxyphosphoryl)oxy)oct-2-enoate (E)-3-2a 
Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 0.81 (t, J = 7.2 Hz, 3H), 0.83 (t, J = 7.2 Hz, 3H), 1.09−1.34 (m, 
8H), 1.47–1.62 (m, 2H), 2.28 (t, J = 7.2 Hz, 2H), 2.76 (t, J = 7.2 Hz, 2H), 3.74 (s, 3H), 7.17–7.29 (m, 6H), 
7.30–7.40 (m, 4H); 13C NMR (75 MHz, CDCl3): δ = 13.7, 13.8, 22.2, 22.3, 27.0, 27.0, 30.6, 31.2, 32.5, 51.6, 
119.9 [d, 
3
J (
13
C, 
31
P) = 4.3 Hz], 121.6 [d, 
3
J (
13
C, 
31
P) = 8.7 Hz], 125.5, 129.7, 150.3 [d, 
2
J (
13
C, 
31
P) = 7.2 Hz], 
157.9 [d, 
2
J (
13
C, 
31
P) = 8.0 Hz], 168.2; 
31
P NMR (202 MHz, CDCl3): δ = −18.4; IR (neat): νmax = 2957, 2872, 
1721, 1647, 1593, 1489, 1302, 1275 cm
−1
; HRMS (ESI): m/z calcd for C25H33O6P [M+Na]
+
 483.1912; found: 
483.1912. 
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Methyl (Z)-2-butyl-3-((diphenoxyphosphoryl)oxy)oct-2-enoate (Z)-3-2a 
Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 0.85 (t, J = 6.9 Hz, 3H), 0.90 (t, J = 6.9 Hz, 3H), 1.17−1.45 (m, 
8H), 1.47−1.62 (m, 2H), 2.22−2.32 (m, 2H), 2.42 (t, J = 7.2 Hz, 2H), 3.56 (s, 3H), 7.13−7.39 (m, 10H); 13C 
NMR (75 MHz, CDCl3): δ = 13.7, 22.2, 22.2, 26.4, 28.7, 31.0, 31.0, 31.2, 31.3, 51.5, 119.9 [d, 
3
J (
13
C, 
31
P) = 
5.1 Hz], 120.9 [d, 
3
J (
13
C, 
31
P) = 7.2 Hz], 125.2, 129.6, 150.4 [d, 
2
J (
13
C, 
31
P) = 7.2 Hz], 151.5 [d, 
2
J (
13
C, 
31
P) 
= 8.7 Hz], 167.4; 
31
P NMR (202 MHz, CDCl3): δ = −18.4; IR (neat): νmax = 2959, 2872, 1717, 1592, 1489, 
1435, 1314, 1230 cm
−1
. 
 
Ethyl (E)-2-methyl-3-((diphenoxyphosphol)oxy)but-2-enoate (E)-3-2b 
Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 1.29 (t, J = 7.2 Hz, 3H), 1.76–1.82 (m, 3H), 2.44–2.49 (m, 3H), 
4.19 (t, J = 7.2 Hz, 2H), 7.14–7.40 (m, 10H); 13C NMR (75 MHz, CDCl3): δ = 12.5, 13.8, 18.9, 60.3, 116.3 [d, 
3
J (
13
C, 
31
P) = 9.4 Hz], 119.8 [d, 
3
J (
13
C, 
31
P) = 5.1 Hz], 125.4, 129.6, 150.0 [d, 
2
J (
13
C, 
31
P) = 7.2 Hz], 154.8 [d, 
2
J (
13
C, 
31
P) = 8.0 Hz], 167.3; IR (neat): νmax = 2982, 1717, 1655, 1592, 1489, 1456, 1379, 1281 cm
−1
; HRMS 
(ESI): m/z calcd for C19H21O6P [M+Na]
+
 339.0973; found: 339.0973. 
 
Ethyl (Z)-2-methyl-3-((diphenoxyphosphol)oxy)but-2-enoate (Z)-3-2b 
Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 1.20 (t, J = 7.2 Hz, 3H), 1.89 (s, 3H), 2.13 (s, 3H), 4.09 (t, J = 
7.2 Hz, 2H), 7.04–7.42 (m, 10H); 13C NMR (75 MHz, CDCl3): δ = 13.8, 14.5, 17.9, 60.5, 115.4 [d, 
3
J (
13
C, 
31
P) = 8.7 Hz], 119.9 [d, 
3
J (
13
C, 
31
P) = 5.1 Hz], 125.2, 129.5, 147.9 [d, 
2
J (
13
C, 
31
P) = 8.7 Hz], 150.2 [d, 
2
J (
13
C, 
31
P) = 7.2 Hz], 166.6; IR (neat): νmax = 2982, 1717, 1655, 1592, 1489, 1456, 1379, 1281 cm
−1
. 
 
Methyl (E)-2-methyl-3-((diphenoxyphosphoryl)oxy)but-2-enoate (E)-3-2c 
Pale yellow oil: 
1
H NMR (500 MHz, CDCl3): δ = 1.80 (s, 3H), 2.48 (s, 3H), 3.74 (s, 3H), 7.19−7.28 (m, 6H), 
7.33−7.38 (m, 4H); 13C NMR (125 MHz, CDCl3): δ = 12.7, 19.2, 51.7, 116.2 [d, 
3
J (
13
C, 
31
P) = 9.6 Hz], 120.0 
[d, 
3
J (
13
C, 
31
P) = 4.8 Hz], 125.6, 129.8, 150.2 [d, 
2
J (
13
C, 
31
P) = 8.4 Hz], 155.4 [d, 
2
J (
13
C, 
31
P) = 8.4 Hz], 
168.2; IR (neat): νmax = 3066, 2952, 1718, 1655, 1590, 1488, 1284, 1186, 1099, 953, 762, 689 cm
−1
; HRMS 
(ESI): m/z calcd for C18H19O6P [M+Na]
+
 385.0817; found: 385.0826. 
 
Methyl (Z)-2-methyl-3-((diphenoxyphosphoryl)oxy)but-2-enoate (Z)-3-2c 
Colorless oil: 
1
H NMR (500 MHz, CDCl3): δ = 1.89 (s, 3H), 2.13 (s, 3H), 3.56 (s, 3H), 7.16−7.27 (m, 6H), 
7.30−7.39 (m, 4H); 13C NMR (125 MHz, CDCl3): δ = 14.7, 18.2, 51.6, 115.2, [d, 
3
J (
13
C, 
31
P) = 8.4 Hz], 120.0 
[d, 
3
J (
13
C, 
31
P) = 6.0 Hz], 125.4, 129.7, 148.6 [d, 
2
J (
13
C, 
31
P) = 8.4 Hz], 150.4, [d, 
2
J (
13
C, 
31
P) = 8.4 Hz], 
167.2; IR (neat): νmax = 3071, 2952, 1720, 1590, 1488, 1298, 1188, 1136, 1020, 943, 773, 730 cm
−1
. 
 
Ethyl (E)-2-benzyl-3-((diphenoxyphosphol)oxy)but-2-enoate (E)-3-2d 
Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 1.16 (t, J = 7.2 Hz, 3H), 2.57 (s, 3H), 3.65 (s, 2H), 4.11 (t, J = 
7.2 Hz, 2H), 7.05–7.40 (m, 15H); 13C NMR (75 MHz, CDCl3): δ = 13.9, 19.1, 32.5, 60.7 , 119.7 [d, 
3
J (
13
C, 
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31
P) = 9.4 Hz], 121.4 [d, 
3
J (
13
C, 
31
P) = 9.4 Hz], 125.6, 125.9, 128.1, 128.2, 129.8, 139.0, 150.1 [d, 
2
J (
13
C, 
31
P) 
= 8.0 Hz], 155.4 [d, 
2
J (
13
C, 
31
P) = 7.2 Hz], 167.1; IR (neat): νmax = 2982, 1717, 1649, 1592, 1489, 1456, 1383, 
1298 cm
−1
; HRMS (ESI): m/z calcd for C25H25O6P [M+Na]
+
 475.1286; found: 475.1285. 
 
Ethyl (Z)-2-benzyl-3-((diphenoxyphosphol)oxy)but-2-enoate (Z)-3-2d 
Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 1.09 (t, J = 7.2 Hz, 3H), 2.21 (J = 2.1 Hz, 3H), 3.68 (s, 2H), 
4.02 (t, J = 7.2 Hz, 2H), 7.13–7.40 (m, 15H); 13C NMR (75 MHz, CDCl3): δ = 13.9, 18.3, 34.7, 60.8, 119.5 [d, 
3
J (
13
C, 
31
P) = 9.4 Hz], 120.0 [d, 
3
J (
13
C, 
31
P) = 5.1 Hz], 125.5, 126.4, 128.1, 128.5, 129.7, 138.1, 149.7 [d, 
2
J 
(
13
C, 
31
P) = 8.7 Hz], 150.4 [d, 
2
J (
13
C, 
31
P) = 8.0 Hz], 166.3; IR (neat): νmax = 2982, 1719, 1592, 1489, 1456, 
1306, 1190, 1163 cm
−1
. 
 
Methyl (E)-2-methyl-3-((diphenoxyphosphol)oxy)oct-2-enoate (E)-3-2e 
Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 0.85 (t, J = 7.6 Hz, 3H), 1.14–1.33 (m, 4H), 1.44–1.61 (m, 2H), 
1.82 (d, J = 2.4 Hz, 3H), 2.81 (t, J = 7.6 Hz, 2H), 3.73 (s, 3H), 7.15–7.40 (m, 10H); 13C NMR (75 MHz, 
CDCl3): δ = 13.1, 13.9, 22.3, 27.0, 31.3, 32.5, 51.7, 116.6 [d, 
3
J (
13
C, 
31
P) = 8.7 Hz], 120.0 [d, 
3
J (
13
C, 
31
P) = 
5.1 Hz], 125.6, 129.8, 150.3 [d, 
2
J (
13
C, 
31
P) = 7.2 Hz], 159.4 [d, 
2
J (
13
C, 
31
P) = 8.0 Hz], 168.1; IR (neat): νmax 
= 2982, 1719, 1592, 1489, 1456, 1387, 1306, 1223, 1190 cm
−1
; HRMS (ESI): m/z calcd for C22H27O6P 
[M+Na]
+
 441.1443; found: 441.1446. 
 
Methyl (Z)-2-methyl-3-((diphenoxyphosphol)oxy)oct-2-enoate (Z)-3-2e 
colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 0.85 (t, J = 7.2 Hz, 3H), 1.18–1.34 (m, 4H), 1.54 (quin, J = 7.6 
Hz, 2H), 1.91 (d, J = 3.1 Hz, 3H), 2.42 (t, J = 7.7 Hz, 2H), 3.57 (s, 3H), 7.06–7.42 (m, 10H); 13C NMR (75 
MHz, CDCl3): δ = 13.7, 14.5, 22.2, 26.0, 31.1, 31.8, 51.5, 115.3 [d, 
3
J (
13
C, 
31
P) = 7.2 Hz], 119.9 [d, 
3
J (
13
C, 
31
P) = 5.1 Hz], 125.2, 129.6, 150.4 [d, 
2
J (
13
C, 
31
P) = 8.0 Hz], 152.4 [d, 
2
J (
13
C, 
31
P) = 8.0 Hz], 167.3; IR 
(neat): νmax = 2957, 2872, 1725, 1655, 1592, 1489, 1458, 1435 cm
−1
. 
 
Methyl (E)-2-methyl-3-((diphenoxyphosphoryl)oxy)-8-benzyloxyoct-2-enoate (E)-3-2f 
Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 1.37 (t, J = 7.2 Hz, 2H), 1.48−1.63 (m, 4H), 1.82 (d, J = 2.1 
Hz, 3H), 2.83 (t, J = 7.2 Hz, 2H), 3.42 (t, J = 6.6 Hz, 2H), 3.72 (s, 3H), 4.47 (s, 2H), 7.13−7.39 (m, 15H); 13C 
NMR (75 MHz, CDCl3): δ = 13.0, 25.7, 27.0, 29.3, 32.4, 51.7, 70.1, 72.6, 116.7 [d, 
3
J (
13
C, 
31
P) = 8.7 Hz], 
119.9, 119.9, 125.5, 127.4, 128.2, 129.7, 138.5, 150.2 [d, 
2
J (
13
C, 
31
P) = 7.2 Hz], 159.0 [d, 
2
J (
13
C, 
31
P) = 8.7 
Hz], 168.0; IR (neat): νmax = 2936, 2863, 1719, 1655, 1590,1489, 1306, 1228 cm
−1
; HRMS (ESI): m/z calcd 
for C29H33O7P [M+Na]
+
 547.1862; found: 547.1859. 
 
Methyl (Z)-2-methyl-3-((diphenoxyphosphoryl)oxy)-8-benzyloxyoct-2-enoate (Z)-3-2f 
Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 1.27−1.42 (m, 2H), 1.48−1.64 (m, 4H), 1.89 (d, J = 3.8 Hz, 
3H), 2.43 (t, J = 7.2 Hz, 2H), 3.42 (t, J = 6.5 Hz, 2H), 3.57 (s, 3H), 4.47 (s, 2H), 7.06−7.40 (m, 15H); 13C 
NMR (75 MHz, CDCl3  14.6, 25.6, 26.2, 29.3, 31.8, 51.6, 69.9, 72.7, 115.5 [d, 
3
J (
13
C, 
31
P) = 7.2 Hz], 119.9, 
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120.0, 125.3, 127.5, 128.2, 129.6, 138.5, 150.4 [d, 
2
J (
13
C, 
31
P) = 7.2 Hz], 152.2 [d, 
2
J (
13
C, 
31
P) = 9.4 Hz], 
167.2; IR (neat): νmax = 2942, 2865, 1747, 1655, 1590, 1485, 1435, 1296 cm
−1
. 
 
Methyl (E)-2-methyl-3-((diphenoxyphosphoryl)oxy)-7-chlorohept-2-enoate (E)-3-2g 
Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 1.62−1.80 (m, 4H), 1.84 (d, J = 2.4 Hz, 3H), 2.86 (t, J = 7.2 
Hz, 2H), 3.47 (t, J = 6.2 Hz, 2H), 3.74 (s, 3H), 7.11−7.45 (m, 10H); 13C NMR (75 MHz, CDCl3): δ = 13.1, 
24.5, 31.6, 31.8, 44.5, 51.8, 117.3 [d, 
3
J (
13
C, 
31
P) = 8.0 Hz], 120.0 [d, 
3
J (
13
C, 
31
P) = 5.1 Hz], 125.6 [d, 
3
J (
13
C, 
31
P) = 9.4 Hz], 129.8, 150.3 [d, 
2
J (
13
C, 
31
P) = 8.0 Hz], 158.3 [d, 
2
J (
13
C, 
31
P) = 8.0 Hz], 167.9; IR (neat): νmax = 
2953, 2872, 1721, 1649, 1492, 1489, 1458, 1298 cm
−1
; HRMS (ESI): m/z calcd for C21H24O6ClP [M+Na]
+
 
461.0896, found 461.0897. 
 
Methyl (Z)-2-methyl-3-((diphenoxyphosphoryl)oxy)-7-chlorohept-2-enoate (Z)-3-2g 
Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 1.63−1.80 (m, 4H), 1.92 (d, J = 6.9 Hz, 3H), 2.46 (t, J = 6.9 
Hz, 2H), 3.47 (t, J = 6.2 Hz, 2H), 3.58 (s, 3H), 7.12−7.39 (m, 10H); 13C NMR (75 MHz, CDCl3): δ = 14.7, 
23.7, 31.1, 31.7, 44.3, 51.7, 116.2 [d, 
3
J (
13
C, 
31
P) = 8.0 Hz], 120.0 [d, 
3
J (
13
C, 
31
P) = 5.1 Hz], 125.4, 130.0, 
150.5 [d, 
2
J (
13
C, 
31
P) = 7.2 Hz], 151.3 [d, 
2
J (
13
C, 
31
P) = 8.7 Hz], 167.2; IR (neat): νmax = 2951, 2870, 1728, 
1655, 1592, 1489, 1458, 1302 cm
−1
. 
 
Methyl (E)-2-methyl-3-((diphenoxyphosphoryl)oxy)-tridec-2,12-dienoate (E)-3-2h 
Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 1.10–1.61 (m, 12H), 1.82 (d, J = 2.1 Hz, 3H), 1.97–2.08 (m, 
2H), 2.81 (t, J = 7.6 Hz, 2H), 3.73 (s, 3H), 4.89–5.03 (m, 2H), 5.80 (ddt, J = 6.9, 10.3, 17.2 Hz, 1H), 7.11–
7.43 (m, 10H); 
13
C NMR (75 MHz, CDCl3): δ = 12.9, 27.1, 28.7, 28.9, 28.9, 29.0, 29.1, 32.4, 33.6, 51.6, 114.0, 
116.4 [d, 
3
J (
13
C, 
31
P) = 8.0 Hz], 119.9 [d, 
3
J (
13
C, 
31
P) = 4.3 Hz], 125.4, 129.7, 138.9, 150.2 [d, 
2
J (
13
C, 
31
P) = 
7.2 Hz], 159.2 [d, 
2
J (
13
C, 
31
P) = 8.0 Hz], 167.9; IR (neat): νmax = 2953, 2870,1719, 1647, 1592, 1458, 1437, 
1298 cm
−1
; HRMS (ESI): m/z calcd for C27H35O6P [M+Na]
+
 509.2069; found: 509.2073. 
 
Methyl (Z)-2-methyl-3-((diphenoxyphosphoryl)oxy)-tridec-2,12-dienoate (Z)-3-2h 
Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 1.16–1.65 (m, 12H), 1.91 (d, J = 3.1 Hz, 3H), 2.03 (q, J = 7.2 
Hz, 2H), 2.43 (t, J = 7.6 Hz, 2H), 3.57 (s, 3H), 4.90–5.03 (m, 2H), 5.80 (ddt, J = 7.2, 10.3, 16.9 Hz, 1H), 
7.09–7.44 (m, 10H); 13C NMR (75 MHz, CDCl3): δ = 14.5, 25.1, 26.2, 28.6, 28.8, 29.0, 29.0, 31.7, 33.5, 51.4, 
114.0 [d, 
3
J (
13
C, 
31
P) = 8.0 Hz], 115.3 [d, 
3
J (
13
C, 
31
P) = 5.1 Hz], 125.2, 129.5, 138.8, 150.3 [d, 
2
J (
13
C, 
31
P) = 
7.2 Hz], 152.3 [d, 
2
J (
13
C, 
31
P) = 8.7 Hz], 167.1; IR (neat): νmax = 2932, 2855, 1721, 1655, 1593, 1489, 1436, 
1316 cm
−1
. 
 
Methyl (E)-2-methyl-3-((diphenoxyphosphoryl)oxy)-3-cyclohexylpropenoate (E)-3-2i 
Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 1.01–1.86 (m, 10H), 1.93 (d, J = 2.1 Hz, 3H), 3.16–3.31 (m, 
1H), 3.75 (s, 3H) 7.05–7.47 (m, 10H); 13C NMR (75 MHz, CDCl3): δ = 13.8, 25.5, 25.9, 29.2, 41.4, 51.7, 
116.3 [d, 
3
J (
13
C, 
31
P) = 6.5 Hz], 119.8, 125.3, 129.6, 150.4 [d, 
2
J (
13
C, 
31
P) = 7.2 Hz], 161.9 [d, 
2
J (
13
C, 
31
P) = 
56 
 
10.8 Hz], 168.3; IR (neat): νmax = 2932, 2857, 1719, 1647, 1592, 1489, 1456, 1314 cm
−1
; HRMS (ESI): m/z 
calcd for C23H27O6P [M+Na]
+
 453.1443; found: 453.1445. 
 
Methyl (Z)-2-methyl-3-((diphenoxyphosphoryl)oxy)-tridec-2,12-dienoate (Z)-3-2i 
Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 1.46–1.85 (m, 10H), 1.96 (d, J = 3.4 Hz, 3H), 2.50–2.62 (m, 
1H), 3.62 (s, 3H), 7.11–7.37 (m, 10H); 13C NMR (75 MHz, CDCl3): δ = 14.6，25.5，26.0，28.7，41.2，51.7，
114.7 [d, 
3
J (
13
C, 
31
P) = 5.8 Hz], 120.0 [d, 
3
J (
13
C, 
31
P) = 5.1 Hz], 125.2, 129.6, 150.7 [d, 
2
J (
13
C, 
31
P) = 7.2 Hz], 
152.3 [d, 
2
J (
13
C, 
31
P) = 8.7 Hz], 167.8; IR (neat): νmax = 2932, 2857, 1725, 1592, 1491, 1456, 1314, 1192 
cm
−1
. 
 
Methyl (E)-2-phenyl-3-((diphenoxyphosphoryl)oxy)but-2-enoate (E)-3-2j 
Colorless oil: 
1
H NMR (500 MHz, CDCl3): δ = 2.63 (d, J = 1.7 Hz, 3H), 3.69 (s, 3H) 6.89–6.93 (m, 4H), 
7.13–7.30 (m, 11H); 13C NMR (125 MHz, CDCl3): δ = 19.2, 52.1, 119.9 [d, 
3
J (
13
C, 
31
P) = 4.8 Hz], 121.7 [d, 
3
J (
13
C, 
31
P) = 9.6 Hz], 125.4, 127.5, 128.0, 129.6, 129.7, 133.8, 150.0 [d, 
2
J (
13
C, 
31
P) = 8.4 Hz], 155.6 [d, 
2
J 
(
13
C, 
31
P) = 6.0 Hz], 167.5; IR (neat): νmax = 3061, 2951, 1718, 1643, 1589, 1488, 1290, 1216 cm
−1
; HRMS 
(ESI): m/z calcd for C23H21O6P [M+Na]
+
 477.0974; found: 477.0971. 
 
Methyl (Z)-2-chloro-3-((diphenoxyphosphoryl)oxy)but-2-enoate (Z)-3-2j 
Colorless oil: 
1
H NMR (500 MHz, CDCl3): δ = 2.07 (d, J = 1.7 Hz, 3H), 3.56 (s, 3H) 7.19–7.40 (m, 15H); 
13
C 
NMR (125 MHz, CDCl3): δ = 18.7, 52.0, 120.1 [d, 
3
J (
13
C, 
31
P) = 4.8 Hz], 122.3 [d, 
3
J (
13
C, 
31
P) = 9.6 Hz], 
125.5, 128.1, 128.4, 129.4, 129.8, 134.0, 150.1 [d, 
2
J (
13
C, 
31
P) = 8.4 Hz], 150.4 [d, 
2
J (
13
C, 
31
P) = 8.4 Hz], 
166.1; IR (neat): νmax = 3061, 2951, 1724, 1646, 1590, 1488, 1382, 1300 cm
−1
. 
 
Methyl (E)-2-(4-methoxyphenyl)-3-((diphenoxyphosphoryl)oxy)but-2-enoate (E)-3-2k 
Yellow oil: 
1
H NMR (500 MHz, CDCl3): δ = 2.59 (d, J =1.7 Hz, 3H), 3.69 (s, 3H), 3.78 (s, 3H), 6.75–6.79 (m, 
2H), 6.95 (d, J = 7.5 Hz, 4H), 7.09–7.13 (m, 2H), 7.15 (t, J = 7.5 Hz, 2H), 7.25 (t, J = 7.5 Hz, 4H); 13C NMR 
(125 MHz, CDCl3): δ = 19.3, 52.2, 55.1, 113.5, 119.9 [d, 
3
J (
13
C, 
31
P) = 4.8 Hz], 121.5 [d, 
3
J (
13
C, 
31
P) = 9.6 
Hz], 125.4, 125.9, 129.7, 130.8, 150.1 [d, 
2
J (
13
C, 
31
P) = 7.2 Hz], 155.0 [d, 
3
J (
13
C, 
31
P) = 7.2 Hz],158.9; IR 
(neat): νmax = 3068, 2952, 1718, 1590, 1489, 1295, 1181, 1069, 963, 774, 688 cm
−1
; HRMS (ESI): m/z calcd 
for C24H23O7P [M+Na]
+
 477.1079; found: 477.1080. 
 
Methyl (Z)-2-(4-methoxyphenyl)-3-((diphenoxyphosphoryl)oxy)but-2-enoate (Z)-3-2k 
Pale yellow oil: 
1
H NMR (500 MHz, CDCl3): δ = 2.07 (d, J = 1.7 Hz, 3H), 3.55 (s, 3H), 3.81 (s, 3H), 6.87–
6.91 (m, 2H), 7.17–7.24 (m, 4H), 7.29 (d, J = 8.6 Hz, 4H), 7.36 (t, J = 8.6 Hz, 4H); 13C NMR (125 MHz, 
CDCl3): δ = 18.6, 51.9, 55.2, 113.9, 120.1  [d, 
3
J (
13
C, 
31
P) = 4.8 Hz], 121.9 [d, 
3
J (
13
C, 
31
P) = 8.4 Hz], 125.5, 
126.1, 129.6, 129.8, 130.6, 149.6 [d, 
2
J (
13
C, 
31
P) = 8.4 Hz], 150.4 [d, 
2
J (
13
C, 
31
P) = 8.4 Hz], 159.3, 166.5; IR 
(neat): νmax = 3002, 2952, 1725, 1591, 1489, 1292, 1227, 1185, 960, 774, 689 cm
−1
. 
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Methyl (E)-2-(4-chlorophenyl)-3-((diphenoxyphosphoryl)oxy)but-2-enoate (E)-3-2l 
Yellow oil: 
1
H NMR (500 MHz, CDCl3): δ = 2.64 (d, J = 1.7 Hz, 3H), 3.68 (s, 3H), 6.95 (d, J = 7.5 Hz, 4H), 
7.05–7.08 (m, 2H), 7.14–7.21 (m, 4H), 7.27 (t, J = 7.5 Hz, 4H); 13C NMR (125 MHz, CDCl3): δ = 19.2, 52.2, 
119.7 [d, 
3
J (
13
C, 
31
P) = 4.8 Hz], 120.7 [d, 
3
J (
13
C, 
31
P) = 10.8 Hz], 125.6, 128.2, 129.8, 131.0, 132.2, 133.4, 
150.0 [d, 
2
J (
13
C, 
31
P) = 8.4 Hz], 156.4 [d, 
2
J (
13
C, 
31
P) = 7.2 Hz], 167.0; IR (neat): νmax = 3067, 2953, 1719, 
1591, 1490, 1289, 1183, 1071, 963, 774, 688 cm
−1
; HRMS (ESI): m/z calcd for C23H20ClO6P [M+Na]
+
 
481.0584; found: 481.0581. 
 
Methyl (Z)-2-(4-chlorophenyl)-3-((diphenoxyphosphoryl)oxy)but-2-enoate (Z)-3-2l 
Colorless oil: 
1
H NMR (500 MHz, CDCl3): δ = 2.05 (d, J = 1.7 Hz, 3H), 3.56 (s, 3H), 7.18–7.25 (m, 4H), 
7.27–7.30 (m, 4H), 7.32–7.40 (m, 6H); 13C NMR (125 MHz, CDCl3): δ = 18.8, 52.0, 120.1 [d, 
3
J (
13
C, 
31
P) = 
4.80 Hz], 121.2 [d, 
3
J (
13
C, 
31
P) = 8.4 Hz], 125.6, 128.7, 129.8, 130.9, 132.5, 134.2, 150.3 [d, 
2
J (
13
C, 
31
P) = 
8.4 Hz], 150.8 [d, 
2
J (
13
C, 
31
P) = 8.4 Hz], 165.7; IR (neat): νmax = 3069, 2952, 1725, 1591, 1489, 1299, 1224, 
1185, 962, 773, 687 cm
−1
. 
 
General procedure for the (E)-stereoretentive Suzuki−Miyaura cross-coupling using (E)-enol 
phosphonates 3-2.   
 
An (E)-enol phosphate 3-2 (0.50 mmol) was added to a stirred suspension of ArB(OH)2 (0.75 mmol), Na2CO3 
(159 mg, 1.50 mmol), [Pd(dppb)Cl2] (15 mg, 0.025 mmol) in DMF (0.5 mL) at 20 – 25 °C under an Ar 
atmosphere, and the mixture was stirred at 150 – 155 °C for 2 h.  After cooling down, water was added to the 
stirred mixture, which was extracted twice with AcOEt.  The organic phase was washed with brine, dried 
(Na2SO4), and concentrated to give the residue, which was purified by SiO2-column chromatography 
(hexane/AcOEt = 50/1 – 20/1) to give the desired product (E)-3-3. 
 
General procedure for the (Z)-stereoretentive Suzuki−Miyaura cross-coupling using (Z)-enol 
phosphonates 3-2. 
 
An (Z)-enol phosphate 3-2 (0.50 mmol) was added to a stirred suspension of ArB(OH)2 (0.75 mmol), Na2CO3 
(159 mg, 1.50 mmol), [Pd(dppb)Cl2] (15 mg, 0.025 mmol) in DMF (0.5 mL) at 20 – 25 °C under an Ar 
atmosphere, and the mixture was stirred at 150 – 155 °C for 2 h.  After cooling down, water was added to the 
stirred mixture, which was extracted twice with AcOEt.  The organic phase was washed with brine, dried 
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(Na2SO4), and concentrated to give the residue, which was purified by SiO2-column chromatography 
(hexane/AcOEt = 50/1 – 20/1) to give the desired product (Z)-3-3. 
 
General procedure for the (E)-stereoretentive Negishi cross-coupling using (E)-enol phosphonates 3-2 
with aromatic zinc reagents 
 
ArMgBr (0.68 mL; 1.10 M in THF) was added to a stirred suspension of ZnCl2 (102 mg, 0.75 mmol) in 
MeCN (1.0 mL) at 0 − 5 °C under an Ar atmosphere, and the mixture was stirred at the same temperature for 
0.5 h.  An (E)-enol phosphonate 3-2 (0.50 mmol) in MeCN (0.50 mL) and [Pd(dppb)Cl2] (6 mg, 0.01 mmol) 
in MeCN (0.50 mL) were successively added to the mixture, followed by stirring at 60 − 65 °C for 2 h.  
After cooling down, 1M HCl aqueous solution was added to the mixture, which was extracted twice with 
AcOEt.  The combined organic phase was washed with water, brine, dried (Na2SO4) and concentrated.  The 
obtained crude product was purified by SiO2-column chromatography (hexane/AcOEt = 100/0 – 20/1) to give 
the desired product (E)-3-3. 
 
General procedure for the (Z)-stereoretentive Negishi cross-coupling using (Z)-enol phosphonates 3-2 
with aromatic zinc reagents 
 
ArMgBr (0.68 mL; 1.10 M in THF) was added to a stirred suspension of ZnCl2 (102 mg, 0.75 mmol) in 
THF (1.0 mL) at 0 − 5 °C under an Ar atmosphere, and the mixture was stirred at the same temperature for 0.5 
h.  An (Z)-enol phosphonate 3-2 (0.50 mmol) in THF (0.50 mL) and [Pd(dppb)Cl2] (6 mg, 0.01 mmol) in 
THF (0.50 mL) were successively added to the mixture, followed by stirring at 60 − 65 °C for 2 h.  After 
cooling down, 1M HCl aqueous solution was added to the mixture, which was extracted twice with AcOEt.  
The combined organic phase was washed with water, brine, dried (Na2SO4) and concentrated.  The obtained 
crude product was purified by SiO2-column chromatography (hexane/AcOEt = 100/0 – 20/1) to give the 
desired product (Z)-3-3. 
 
General procedure for the (E)-stereoretentive Negishi cross-coupling using (E)-enol phosphonate 3-2c 
with heterocyclic zinc reagents 
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nBuLi (0.92 mL; 1.63 M in hexane) was added to a stirred solution of a (Het)H (1.50 mmol) in THF (1.5 
mL) at 0 − 5 °C under an Ar atmosphere, and the mixture was stirred at the same temperature for 0.5 h.  The 
solution was added to a stirred suspension of ZnCl2 (204 mg, 1.50 mmol) in MeCN (1.0 mL) at 0 − 5 °C under 
an Ar atmosphere, and the mixture was stirred at the same temperature for 0.5 h.  (E)-enol phosphonate 3-2c 
(0.50 mmol) in MeCN (0.50 mL) and [Pd(dppb)Cl2] (6 mg, 0.01 mmol) in MeCN (0.50 mL) were 
successively added to the mixture, followed by stirring at 60 − 65 °C for 2 h.  After cooling down, 1M HCl 
aqueous solution was added to the mixture, which was extracted twice with AcOEt.  The combined organic 
phase was washed with water, brine, dried (Na2SO4) and concentrated.  The obtained crude product was 
purified by SiO2-column chromatography (hexane/AcOEt = 100/1 – 50/1) to give the desired product 
(E)-3-3c-7 or (E)-3-3c-8. 
 
General procedure for the (Z)-stereoretentive Negishi cross-coupling using (Z)-enol phosphonate 3-2c 
with heterocyclic zinc reagents 
 
nBuLi (0.92 mL; 1.63 M in hexane) was added to a stirred solution of (Het)H (1.50 mmol) in THF (1.5 mL) 
at 0 − 5 °C under an Ar atmosphere, and the mixture was stirred at the same temperature for 0.5 h.  The 
solution was added to a stirred suspension of ZnCl2 (204 mg, 1.5 mmol) in THF (1.0 mL) at 0 − 5 °C under an 
Ar atmosphere, and the mixture was stirred at the same temperature for 0.5 h.  An (Z)-enol phosphonate 3-2c 
(0.50 mmol) in THF (0.50 mL) and [Pd(dppb)Cl2] (6 mg, 0.01 mmol) in THF (0.50 mL) were successively 
added to the mixture, followed by stirring at 60 − 65 °C for 2 h.  After cooling down, 1M HCl aqueous 
solution was added to the mixture, which was extracted twice with AcOEt.  The combined organic phase was 
washed with water, brine, dried (Na2SO4) and concentrated.  The obtained crude product was purified by 
SiO2-column chromatography (hexane/AcOEt = 100/1 – 50/1) to give the desired product (Z)-3-3c-7 or 
(Z)-3-3c-8. 
 
Methyl (E)-2-butyl-3-phenyloct-2-enoate (E)-3-3a
 
Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 0.75 (t, J = 7.5 Hz, 3H), 0.82 (t, J = 7.5 Hz, 3H), 1.08–1.35 (m, 
10H), 2.07 (t, J = 7.6 Hz, 2H), 2.46 (t, J = 7.6 Hz, 2H), 3.80 (s, 3H), 7.07–7.12 (m, 2H), 7.24−7.30 (m, 1H), 
7.31–7.37 (m, 2H); 13C NMR (75 MHz, CDCl3): δ = 13.8, 14.0. 22.3, 22.4, 27.6, 30.8, 31.2, 31.7, 36.4, 51.4, 
126.8, 127.8, 128.1, 130.6, 141.4, 147.4, 170.8; IR (neat): νmax = 2959, 1717, 1458, 1379, 1321, 1240, 1206, 
1140 cm
−1
; HRMS (ESI): m/z calcd for C19H28O2 [M+Na]
+
 311.1987; found: 311.1987. 
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Methyl (Z)-2-butyl-3-phenyloct-2-enoate (Z)-3-3a 
Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 0.82 (t, J = 6.9 Hz, 3H), 0.96 (t, J = 7.5 Hz, 3H), 1.19–1.32 (m, 
6H), 1.34–1.48 (m, 4H), 2.44 (t, J = 7.2 Hz, 4H), 3.33 (s, 3H), 7.09–7.14 (m, 2H), 7.20–7.32 (m, 3H); 13C 
NMR (75 MHz, CDCl3): δ = 13.9, 22.4, 22.6, 27.5, 29.9, 31.1, 31.7, 34.0, 51.1, 126.9, 127.4, 127.9, 131.6, 
142.7, 146.2, 171.3; IR (neat): νmax = 2957, 2961, 1719, 1458, 1437, 1246, 1208, 1140 cm
−1
. 
 
Ethyl (E)-2-methyl-3-phenylbut-2-enoate (E)-3-3b-1
19
 
Pale yellow oil; 
1
H NMR (300 MHz, CDCl3): δ = 1.35 (t, J = 7.2 Hz, 3H), 1.75 (d, J = 1.4 Hz, 3H), 2.25 (q, J 
= 1.4 Hz, 3H), 4.27 (q, J = 7.2 Hz, 2H), 7.11–7.18 (m, 2H), 7.22–7.49 (m, 3H); 13C NMR (75 MHz, CDCl3): δ 
= 14.3, 17.3, 23.1, 60.3, 124.8, 126.9, 127.2, 128.2, 143.4, 145.3, 169.9; IR (neat): νmax = 2982, 1713, 1442, 
1312, 1252, 1134, 1098, 1026 cm
−1
. 
 
Ethyl (Z)-2-methyl-3-phenylbut-2-enoate (Z)-3-3b-1 
Pale yellow oil; 
1
H NMR (300 MHz, CDCl3): δ = 0.82 (t, J = 7.2 Hz, 3H), 2.02 (d, J = 1.0 Hz, 3H), 2.09 (d, J 
= 1.0 Hz, 3H), 3.84 (q, J = 7.2 Hz, 2H), 7.07–7.17 (m, 2H), 7.19–7.34 (m, 3H); 13C NMR (75 MHz, CDCl3): δ 
= 13.4, 16.3, 21.6, 60.1, 126.1, 126.8, 126.9, 127.9, 142.9, 142.2, 170.6; IR (neat): νmax = 2982, 1709, 1443, 
1372, 1310, 1244, 1140, 1096 cm
−1
. 
 
Ethyl (E)-2-methyl-3-(4-methylphenyl)but-2-enoate (E)-3-3b-2
20
 
Pale yellow oil; 
1
H NMR (300 MHz, CDCl3): δ = 1.34 (dt, J = 0.7, 7.2 Hz, 3H), 1.75–1.79 (m, 3H), 2.22–2.26 
(m, 3H), 2.36 (s, 3H), 4.26 (q, J = 7.2 Hz, 2H), 7.00–7.09 (m, 2H), 7.14–7.20 (m, 2H); 13C NMR (75 MHz, 
CDCl3): δ = 14.2, 17.3, 21.0, 23.1, 60.2, 124.6, 127.1, 128.8, 136.6, 140.4, 145.3, 169.9; IR (neat): νmax = 1713, 
1630, 1512, 1449, 1316, 1250, 1130 cm
−1
. 
 
Ethyl (Z)-2-methyl-3-(4-methylphenyl)but-2-enoate (Z)-3-3b-2 
Pale yellow oil; 
1
H NMR (300 MHz, CDCl3): δ = 0.87 (t, J = 7.2 Hz, 3H), 2.01 (d, J = 1.4 Hz, 3H), 2.07 (d, J 
= 1.4 Hz, 3H), 2.33 (s, 3H), 3.87 (q, J = 7.2 Hz, 2H), 6.98–7.14 (m, 4H); 13C NMR (75 MHz, CDCl3): δ = 
13.4, 16.2, 21.0, 21.5, 59.9, 125.7, 126.7, 128.5, 136.4, 141.1, 142.6, 170.6; IR (neat): νmax = 1713, 1512, 1445, 
1372, 1306, 1250, 1142 cm
−1
. 
 
Ethyl (E)-2-methyl-3-(4-methoxylphenyl)but-2-enoate (E)-3-3b-3
21
 
Pale yellow oil; 
1
H NMR (300 MHz, CDCl3): δ = 1.34 (t, J = 7.2 Hz, 3H), 1.78 (d, J = 1.0 Hz, 3H), 2.23 (d, J 
= 1.0 Hz, 3H), 3.82 (s, 3H), 4.26 (q, J = 7.2 Hz, 2H), 6.86–6.93 (m, 2H), 7.05–7.13 (m, 2H); 13C NMR (75 
MHz, CDCl3): δ = 14.2, 17.3, 23.1, 55.0, 60.2, 113.5, 124.5, 128.5, 135.5, 144.9, 158.5, 170.0; IR (neat): νmax 
= 2934, 1711, 1609, 1510, 1458, 1510, 1458, 1248, 1134, 1034 cm
−1
. 
 
Ethyl (Z)-2-methyl-3-(4-methoxylphenyl)but-2-enoate (Z)-3-3b-3 
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Pale yellow oil; 
1
H NMR (300 MHz, CDCl3): δ = 0.90 (t, J = 7.2 Hz, 3H), 2.01 (d, J = 1.0 Hz, 3H), 2.07 (d, J 
= 7.2 Hz, 3H), 3.80 (s, 3H), 3.89 (q, J = 7.2 Hz, 2H), 6.78–6.86 (m, 2H), 7.04–7.12 (m, 2H); 13C NMR (75 
MHz, CDCl3): δ = 13.5, 16.3, 21.4, 55.1, 59.9, 113.2, 125.6, 128.0, 136.3, 142.0, 158.5, 170.8; IR (neat): νmax 
= 2934, 1707, 1609, 1510, 1460, 1314, 1248, 1142 cm
−1
. 
 
Ethyl (E)-2-methyl-3-(4-chlorophenyl)but-2-enoate (E)-3-3b-4
22
 
Pale yellow crystals; mp 44−45 °C; 1H NMR (300 MHz, CDCl3): δ = 1.34 (t, J = 7.2 Hz, 3H), 1.72–1.77 (m, 
3H), 2.20–2.24 (m, 3H), 4.26 (q, J = 7.2 Hz, 2H), 7.07–7.10 (m, 2H), 7.32–7.35 (m, 2H); 13C NMR (75 MHz, 
CDCl3): δ = 14.2, 17.3, 22.9, 60.4, 125.5, 128.5, 128.7, 132.8, 141.7, 143.7, 169.6; IR (neat): νmax = 2982, 
1713, 1491, 1314, 1250, 1134, 1092, 1015 cm
−1
. 
 
Ethyl (Z)-2-methyl-3-(4-chlorophenyl) but-2-enoate (Z)-3-3b-4 
Pale yellow oil; 
1
H NMR (300 MHz, CDCl3): δ = 0.90 (t, J = 7.2 Hz, 3H), 2.02 (d, J = 1.0 Hz, 3H), 2.06 (d, J 
= 1.0 Hz, 3H), 3.88 (q, J = 7.2 Hz, 2H), 7.00–7.11 (m, 2H), 7.21–7.31 (m, 2H); 13C NMR (75 MHz, CDCl3): δ 
= 13.5, 16.2, 21.5, 60.1, 126.6, 128.0, 128.2, 132.6, 141.6, 142.5, 170.0; IR (neat): νmax = 2984, 1707, 1491, 
1372, 1312, 1250, 1140, 1092 cm
−1
. 
 
Methyl (E)-2-methyl-3-phenylbut-2-enoate (E)-3-3c-1
4a 
Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 1.75 (q, J = 1.4 Hz, 3H), 2.26 (q, J = 1.4 Hz, 3H), 3.80 (s, 3H), 
7.12–7.15 (m, 2H), 7.27–7.38 (m, 3H); IR (neat): νmax = 2949, 1716, 1433, 1253, 1133, 1099 cm
−1
. 
 
4) (a) E/Z = 80:20; Shindo, M.; Sato, Y.; Yoshikawa, T.; Koretsune, R.; Shishido, K. J. Org. Chem. 2004, 69, 
3912. 
 
Methyl (Z)-2-methyl-3-phenylbut-2-enoate (Z)-3-3c-1
6d 
Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 2.05 (q, J = 0.6 Hz, 3H), 2.09 (q, J = 0.6 Hz, 3H), 3.39 (s, 3H), 
7.12–7.14 (m, 2H), 7.23–7.32 (m, 3H); IR (neat): νmax = 2947, 1714, 1433, 1316, 1243, 1139 cm
−1
.  
 
6) (d) 95% yield (E/Z = 14:86), Sano, S.; Takehisa, T.; Ogawa, S.; Yokoyama, K.; Nagao, Y. Chem. Pharm. 
Bull. 2002, 50, 1300. 
 
Methyl (E)-2-methyl-3-(4-methylphenyl)but-2-enoate (E)-3-3c-2 
Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 1.74–1.78 (m, 3H), 2.22–2.27 (m, 3H), 2.35 (s, 3H), 3.79 (s, 
3H), 7.04 (d, J = 8.3 Hz, 2H), 7.17 (d, J = 8.3 Hz, 2H); 
13
C NMR (75 MHz, CDCl3): δ = 17.3, 21.0, 23.2, 51.3, 
124.2, 127.0, 128.8, 136.6, 140.4, 146.1, 170.2; IR (neat): νmax = 2949, 2866, 1716, 1629, 1511, 1433, 1317, 
1252, 1132, 820 cm
−1
; HRMS (ESI): m/z calcd for C13H16O2 [M+Na]
+
 227.1048; found: 227.1046. 
 
Methyl (Z)-2-methyl-3-(4-methylphenyl)but-2-enoate (Z)-3-3c-2 
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Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 2.01 (s, 3H), 2.07 (s, 3H), 2.33 (s, 3H), 3.43 (s, 3H), 7.03 (d, J 
= 7.9 Hz, 2H), 7.10 (d, J = 7.9 Hz, 2H); 
13
C NMR (75 MHz, CDCl3): δ = 16.3, 21.0, 21.5, 51.1, 125.3, 126.6, 
128.6, 136.4, 140.9, 142.9, 170.9; IR (neat): νmax = 2993, 2948, 1712, 1512, 1433, 1317, 1244, 1139, 819, 771 
cm
−1
. 
 
Methyl (E)-2-methyl-3-(4-methoxylphenyl)but-2-enoate (E)-3-3c-3
6d 
Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 1.78 (d, J = 1.4 Hz, 3H), 2.25 (d, J = 1.4 Hz, 3H), 3.79 (s, 3H), 
3.82 (s, 3H), 6.87–6.91 (m, 2H), 7.06–7.10 (m, 2H); IR (neat): νmax = 2950, 1714, 1608, 1510, 1248, 1132, 
1032 cm
−1
.   
 
6) (d) 90% yield (E/Z = 41:59), Sano, S.; Takehisa, T.; Ogawa, S.; Yokoyama, K.; Nagao, Y. Chem. Pharm. 
Bull. 2002, 50, 1300. 
 
Methyl (Z)-2-methyl-3-(4-methoxylphenyl)but-2-enoate (Z)-3-3c-3
6d 
Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 2.01 (d, J = 0.9 Hz, 3H), 2.07 (d, J = 0.9 Hz, 3H), 3.44 (s, 3H), 
3.80 (s, 3H), 6.81–6.85 (m, 2H), 7.05–7.10 (m, 2H); IR (neat): νmax = 2948, 1711, 1608, 1509, 1288, 1247, 
1179, 1138, 1032 cm
−1
.  
 
6) (d) 14% yield (E/Z = 4:96), Sano, S.; Takehisa, T.; Ogawa, S.; Yokoyama, K.; Nagao, Chem. Pharm. Bull. 
2002, 50, 1300. 
 
Methyl (E)-2-methyl-3-(4-chlorophenyl)but-2-enoate (E)-3-3c-4 
Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 1.75 (d, J = 1.4 Hz, 3H), 2.23 (d, J = 1.4 Hz, 3H), 3.80 (s, 3H), 
7.04−7.11 (m, 2H), 7.30−7.37 (m, 2H); 13C NMR (75 MHz, CDCl3): δ = 17.3, 23.0, 51.4, 125.1, 128.5, 128.6, 
132.8, 141.6, 144.6, 169.8; IR (neat): νmax = 2950, 1716, 1631, 1490, 1433, 1316, 1250, 1133, 1092, 1014, 829 
cm
−1
; HRMS (ESI): m/z calcd for C12H13ClO2 [M+Na]
+
 247.0502; found: 247.0499. 
  
Methyl (Z)-2-methyl-3-(4-chlorophenyl)but-2-enoate (Z)-3-3c-4 
Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 2.02 (d, J = 1.0 Hz, 3H), 2.06 (d, J = 1.0 Hz, 3H), 3.44 (s, 3H), 
7.02−7.10 (m, 2H), 7.24−7.31 (m, 2H); 13C NMR (75 MHz, CDCl3): δ = 16.3, 21.5, 51.2, 126.2, 128.1, 132.7, 
142.0, 142.4, 170.4; IR (neat): νmax = 2948, 1713, 1639, 1593, 1486, 1434, 1314, 1247, 1140, 1089, 1013, 828, 
758 cm
−1
.  
 
Methyl (E)-2-methyl-3-(2-methylphenyl)but-2-enoate (E)-3-3c-5 
Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 1.60 (q, J = 1.7 Hz, 3H), 2.18 (s, 3H), 2.22 (q, J = 1.7 Hz, 3H), 
3.80 (s, 3H), 6.91−6.99 (m, 1H), 7.14−7.21 (m, 3H); 13C NMR (75 MHz, CDCl3): δ = 16.7, 18.8, 22.5, 51.3, 
124.6, 125.9, 126.4, 126.9, 130.0, 133.5, 143.0, 147.1, 169.6; IR (neat): νmax = 3017, 2950, 2868, 1716, 1633, 
1433, 1373, 1250, 1197, 1139, 1097, 764, 731 cm
−1
; HRMS (ESI): m/z calcd for C13H16O2 [M+Na]
+
 227.1048; 
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found: 227.1054. 
 
Methyl (Z)-2-methyl-3-(2-methylphenyl)but-2-enoate (Z)-3-3c-5 
Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 2.02 (s, 3H), 2.03 (s, 3H), 2.19 (s, 3H), 3.37 (s, 3H), 
6.85−6.97(m, 1H), 7.06−7.21 (m, 3H); 13C NMR (75 MHz, CDCl3): δ = 15.4, 19.1, 21.8, 51.0, 125.3, 125.4, 
126.4, 126.6, 129.5, 133.9, 144.0, 145.2, 169.4; IR (neat): νmax = 3015, 1949, 2863, 1711, 1641, 1434, 1315, 
1238, 1141, 1087, 761, 726 cm
−1
. 
 
Methyl (E)-2-methyl-3-(1-naphthyl)but-2-enoate (E)-3-3c-6 
Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 1.55−1.61 (m, 3H), 2.33−2.38 (m, 3H), 3.85 (s, 3H), 7.19 (dd, 
J = 1.0, 7.2 Hz, 1H), 7.42−7.52 (m, 3H), 7.71−7.81 (m, 2H), 7.83−7.90 (m, 1H); 13C NMR (75 MHz, CDCl3): 
δ = 17.2, 23.4, 51.4, 123.7, 124.9, 125.5, 125.8, 126.2, 127.1, 128.4, 129.5, 133.6, 141.2, 145.6, 169.6; IR 
(neat): νmax = 3058, 2995, 2949, 1715, 1631, 1506, 1433, 1265, 1193, 1143, 1094, 779 cm
−1
; HRMS (ESI): m/z 
calcd for C16H16O2 [M+Na]
+
 263.1048; found: 63.1050. 
 
Methyl (Z)-2-methyl-3-(1-naphthyl)but-2-enoate (Z)-3-3c-6 
Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 2.16 (s, 3H), 2.18 (s, 3H), 3.16 (s, 3H), 7.12 (d, J = 7.2 Hz, 
1H), 7.33−7.54 (m, 3H), 7.67−7.89 (m, 3H); 13C NMR (75 MHz, CDCl3): δ = 15.7, 22.6, 51.0, 123.4, 125.1, 
125.2, 125.5, 125.8, 126.8, 127.1, 128.2, 130.4, 133.4, 142.4, 143.9, 169.3; IR (neat): νmax = 3058, 2999, 2948, 
1708, 1433, 1313, 1143, 1086, 778 cm
−1
. 
 
Methyl (E)-2-methyl-(2-furyl)but-2-enoate (E)-3-3c-7 
Orange oil; 
1
H NMR (300 MHz, CDCl3): δ = 2.15−2.19 (m, 3H), 2.22−2.26 (m, 3H), 3.79 (s, 3H), 6.43−6.49 
(m, 2H), 7.47 (d, J = 1.0 Hz, 1H); 
13
C NMR (75 MHz, CDCl3): δ = 17.8, 18.5, 51.6, 111.1, 111.7, 124.5, 131.7, 
142.3, 154.1, 170.8; IR (neat): νmax = 3424, 3149, 2952, 1767, 1713, 1610, 1434, 1251, 1134, 743 cm
−1
; 
HRMS (ESI): m/z calcd for C10H12O3 [M+Na]
+
 203.0684; found: 206.0685. 
 
Methyl (Z)-2-methyl-(2-furyl)but-2-enoate (Z)-3-3c-7 
Orange oil; 
1
H NMR (300 MHz, CDCl3): δ = 2.01 (s, 6H), 3.73 (s, 3H), 6.28−6.41 (m, 2H), 7.33 (dd, J = 0.7, 
1.7 Hz, 1H); 
13
C NMR (75 MHz, CDCl3): δ = 16.3, 16.8, 51.7, 108.1, 111.0, 124.9, 125.9, 142.1, 153.6, 172.3; 
IR (neat): νmax = 3433, 3122, 2950, 1768, 1720, 1434, 1312, 1251, 1127, 905, 732 cm
−1
. 
 
Methyl (E)-2-methyl-(2-thienyl)but-2-enoate (E)-3-3c-8 
Pale red oil; 
1
H NMR (300 MHz, CDCl3): δ = 2.04 (q, J = 1.4 Hz, 3H), 2.31 (q, J = 1.4 Hz, 3H), 3.80 (s, 3H), 
6.93−7.10 (m, 2H), 7.33 (dd, J = 1.4, 5.2 Hz, 1H); 13C NMR (75 MHz, CDCl3): δ = 18.0, 23.5, 51.6, 125.5, 
126.1, 126.6, 126.7, 136.7, 144.1, 170.4; IR (neat): νmax = 3104, 2996, 2950, 1715, 1609, 1433, 1279, 1242, 
1121, 834, 701 cm
−1
; HRMS (ESI): m/z calcd for C10H12O2S [M+Na]
+
 219.0456; found: 219.0454. 
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Methyl (Z)-2-methyl-(2-thienyl)but-2-enoate (Z)-3-3c-8 
Pale red oil; 
1
H NMR (300 MHz, CDCl3): δ = 2.02 (d, J = 1.0 Hz, 3H), 2.13 (d, J = 1.0 Hz, 3H), 3.57 (s, 3H), 
6.84−6.97 (m, 1H), 7.23 (dd, J = 1.0, 4.8 Hz, 1H); 13C NMR (75 MHz, CDCl3): δ = 16.9, 21.4, 51.6, 124.9, 
125.0, 126.0, 127.2, 132.6, 144.6, 171.4; IR (neat): νmax = 3106, 2994, 2947, 1714, 1631, 1432, 1298, 1238, 
1134, 852, 697 cm
−1
. 
 
Ethyl (E)-2-benzyl-3-phenylbut-2-enoate (E)-3-3d
23
 
Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 0.73 (t, J = 7.2 Hz, 3H), 2.16 (s, 3H), 3.77 (t, J = 7.2 Hz, 2H), 
3.84 (s, 2H), 7.06–7.39 (m, 10H); 13C NMR (75 MHz, CDCl3): δ = 13.3, 21.7, 36.1, 60.0, 126.0, 126.8, 127.0, 
128.2, 128.3, 129.7, 139.0, 143.9, 144.4, 169.9 cm
−1
; IR (neat): νmax = 2982, 1705, 1495, 1455, 1375, 1314, 
1242, 1134 cm
−1
.  
 
Ethyl (Z)-2-benzyl-3-phenylbut-2-enoate (Z)-3-3d 
Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 1.14 (t, J = 7.2 Hz, 3H), 2.31 (s, 3H), 3.55 (s, 2H), 4.12 (t, J = 
7.2 Hz, 2H), 7.00–7.39 (m, 10H); 13C NMR (75 MHz, CDCl3): δ = 14.0, 23.4, 36.8, 60.2, 125.8, 127.0, 127.2, 
128.0, 128.1, 128.2, 128.4, 139.8, 142.8, 146.0, 169.0; IR (neat): νmax = 2982, 1713, 1495, 1455, 1312, 1254, 
1198, 1051 cm
−1
. 
 
Methyl 2-methyl-3-phenyloct-2-enoate (E)-3-3e
4a 
Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 0.82 (t, J = 6.9 Hz, 3H), 1.11–1.39 (m, 6H), 1.71 (s, 3H), 2.58 
(t, J = 6.9 Hz, 2H), 3.79 (s, 3H), 7.00–7.14 (m, 2H), 7.18–7.41 (m, 3H); 13C NMR (75 MHz, CDCl3): δ = 13.9, 
17.3, 22.3., 27.7, 31.7, 36.1, 51.3, 124.5, 126.9, 127.6, 128.1, 141.8, 150.0, 170.3; IR (neat): νmax = 2955, 2860, 
1720, 1435, 1250, 1190, 1136, 1109 cm
−1
. 
 
Methyl (Z)-2-benzyl-3-phenyloct-2-enoate (Z)-3-3e 
Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 0.84 (t, J = 7.2 Hz, 3H), 1.60–1.37 (m, 6H), 2.03 (s, 3H), 2.44 
(t, J = 7.2 Hz, 2H), 3.36 (s, 3H), 7.05–7.16 (m, 2H), 7.18–7.34 (m, 3H); 13C NMR (75 MHz, CDCl3): δ = 13.8, 
15.8, 22.3, 26.9, 31.6, 34.8, 51.0, 125.7, 126.8, 127.2, 127.8, 142.8, 147.7, 171.0; IR (neat): νmax = 2955, 2861, 
1717, 1458, 1320, 1242, 1190, 1138 cm
−1
.  
 
Methyl (E)-8-benzyloxy-2-methyl-3-phenyloct-2-enoate (E)-3-3f 
Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 1.23–1.39 (m, 4H), 1.47–1.60 (m, 2H), 1.70 (s, 3H), 2.55–2.65 
(m, 2H), 3.96 (t, J = 6.5 Hz, 2H), 3.78 (s, 3H), 4.45 (s, 2H), 7.03–7.13 (m, 2H), 7.17–7.39 (m, 8H); 13C NMR 
(75 MHz, CDCl3): δ = 17.3, 26.0, 27.8, 29.4, 36.0, 51.3, 70.2, 72.7, 124.6, 126.9, 127.3, 127.4, 127.6, 128.1, 
128.2, 138.6, 141.7, 149.8, 170.2; IR (neat): νmax = 2938, 2859, 1717, 1433, 1364, 1254, 1132, 1111 cm
−1
; 
HRMS (ESI): m/z calcd for C23H28O3 [M+Na]
+
 375.1936; found: 375.1933. 
 
Methyl (Z)-8-benzyloxy-2-methyl-3-phenyloct-2-enoate (Z)-3-3f 
65 
 
Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 1.21–1.63 (m, 6H), 2.02 (s, 3H), 2.45 (t, J = 7.6 Hz, 2H), 3.36 
(s, 3H), 3.40 (t, J = 6.5 Hz, 2H), 4.46 (s, 2H), 7.01–7.13 (m, 2H), 7.16–7.36 (m, 8H); 13C NMR (75 MHz, 
CDCl3): δ = 15.8, 25.9, 27.0, 29.4, 34.6, 51.0, 70.0, 72.7, 125.7, 126.7, 127.1, 127.3, 127.4, 127.7, 128.1, 
138.4, 142.6, 147.3, 170.9; IR (neat): νmax = 2940, 2861, 1717, 1433, 1318, 1242, 1138, 1102 cm
−1
. 
 
Methyl (E)-7-chloro-2-methyl-3-phenylhept-2-enoate (E)-3-3g 
Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 1.40–1.51 (m, 2H), 1.70–1.80 (m, 2H), 1.72 (s, 3H), 2.64 (t, J 
= 7.5 Hz, 2H), 3.47 (t, J = 6.9 Hz, 2H), 3.80 (s, 3H), 7.07–7.14 (m, 2H), 7.26–7.32 (m, 1H), 7.34–7.39 (m, 
2H); 
13
C NMR (75 MHz, CDCl3): δ = 17.4, 25.2, 32.2, 35.1, 44.7, 51.5, 125.2, 127.1, 127.6, 128.3, 141.4, 
149.2, 170.1; IR (neat): νmax = 2950, 1714, 1624, 1599, 1491, 1433, 1255, 1122 cm
−1
; HRMS (ESI): m/z calcd 
for C15H19ClO2 [M+Na]
+
 289.0971; found: 289.0971. 
 
Methyl (Z)-7-chloro-2-methyl-3-phenylhept-2-enoate (Z)-3-3g 
Pale yellow oil; 
1
H NMR (300 MHz, CDCl3): δ = 1.40–1.51 (m, 2H), 1.70–1.79 (m, 2H), 2.04 (s, 3H), 2.49 (t, 
J = 8.2 Hz, 2H), 3.37 (s, 3H), 3.47 (t, J = 6.9 Hz, 2H), 7.08–7.13 (m, 2H), 7.22–7.33 (m, 3H); 13C NMR (75 
MHz, CDCl3): δ = 15.9, 24.5, 32.1, 33.8, 44.5, 51.2, 126.4, 127.0, 127.2, 128.0, 142.3, 146.4, 170.8; IR (neat): 
νmax = 2948, 1711, 1633, 1492, 1433, 1311, 1236, 1137 cm
−1
.  
 
Methyl (E)-2-methyl-3-phenyltrideca-2,12-dienoate (E)-3-3h 
Colorless oil: 
1
H NMR (500 MHz, CDCl3): δ = 1.16−1.37 (m, 12H), 1.71 (s, 3H), 1.95−2.07 (m, 2H), 2.58 (t, 
J = 6.9 Hz, 2H), 3.79 (s, 3H), 4.89−5.03 (m, 2H), 5.79 (ddt, J = 17.2 Hz, 10.3 Hz, 6.9 Hz, 1H), 7.08−7.12 (m, 
2H), 7.27−7.30 (m, 1H), 7.33−7.38 (m, 2H); 13C NMR (125 MHz, CDCl3): δ = 17.4, 28.0, 28.9, 29.0, 29.3, 
29.3, 29.533.7, 36.2, 51.4, 114.0, 124.5, 126.9, 127.7, 128.2, 139.2, 141.8, 150.1, 170.4; IR (neat): νmax = 3073, 
2925, 2854, 1718, 1483, 1252, 1118, 994, 910, 772, 703 cm
−1
; HRMS (ESI): m/z calcd for C21H30O2 [M+Na]
+
 
337.2143; found: 337.2173. 
 
Methyl (Z)-2-methyl-3-phenyltrideca-2,12-dienoate (Z)-3-3h 
Colorless oil: 
1
H NMR (500 MHz, CDCl3): δ = 1.19−1.38 (m, 12H), 1.96−2.04 (m, 5H), 2.44 (t, J = 6.9 Hz, 
2H), 3.36 (s, 3H), 4.90−5.01 (m, 2H), 5.80 (ddt, J = 17.2 Hz, 10.3 Hz, 6.9 Hz, 1H), 7.08−7.12 (m, 2H), 
7.21−7.25 (m, 1H), 7.27−7.31 (m, 2H); 13C NMR (125 MHz, CDCl3): δ = 15.9, 27.2, 28.8, 29.0, 29.3, 29.4, 
33.7, 34.9, 51.1, 114.1, 125.7, 126.8, 127.2, 127.8, 139.1, 142.8, 147.8, 171.0; IR (neat): νmax = 3078, 2925, 
2854, 1714, 1639, 1434, 1317, 1238, 1137, 1084, 994, 910, 771, 700 cm
−1
. 
 
Methyl (E)-3-cyclohexyl-2-methyl-3-phenylacrylate (E)-3-3i 
Colorless oil: 
1
H NMR (500 MHz, CDCl3): δ = 0.94 (tq, J = 3.4 Hz, 12.6 Hz, 1H), 1.01 (dq, J = 3.4 Hz, 12.6 
Hz, 2H), 1.29 (tq, J = 3.4 Hz, 12.6 Hz, 2H), 1.53−1.59 (m, 4H), 1.63−1.74 (m, 4H), 2.93 (tt, J = 12.0 Hz, 2.9 
Hz, 1H), 3.80 (s, 3H), 6.96−7.00 (m, 2H), 7.27−7.30 (m, 1H), 7.31−7.36 (m, 2H); 13C NMR (125 MHz, 
CDCl3): δ = 17.4, 25.8, 26.3, 31.6, 42.8, 51.4, 124.5, 126.6, 127.8, 128.2, 139.3, 153.1, 170.7; IR (neat): νmax = 
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2925, 2853, 1718, 1447, 1251, 1125, 775, 707 cm
−1
; HRMS (ESI): m/z calcd for C17H22O2 [M+Na]
+
 281.1517; 
found: 281.1537. 
 
Methyl (Z)-3-cyclohexyl-2-methyl-3-phenylacrylate (Z)-3-3i 
Colorless oil: 
1
H NMR (500 MHz, CDCl3): δ = 1.00 (tq, J = 3.4 Hz, 13.2 Hz, 1H), 1.06 (dq, J = 3.4 Hz, 12.6 
Hz, 2H), 1.30 (tq, J = 3.4 Hz, 13.2 Hz, 2H), 1.57−1.67 (m, 3H), 1.68−1.75 (m, 2H), 2.03 (s, 3H), 2.65 (tt, J = 
3.4 Hz, 12.0 Hz, 1H), 3.29 (s, 3H), 6.98−7.01 (m, 2H), 7.21−7.29 (m, 3H); 13C NMR (125 MHz, CDCl3): δ = 
15.0, 25.7, 26.4, 30.8, 41.5, 51.0, 125.5, 126.4, 127.2, 128.3, 140.4, 151.6, 170.8; IR (neat): νmax = 2928, 2853, 
1715, 1433, 1314, 1247, 1135, 1090, 771, 702 cm
−1
. 
 
Methyl (E)-2,3-diphenylbut-2-enoate (E)-3-3j
23 
Pale yellow oil; 
1
H NMR (300 MHz, CDCl3): δ = 2.36 (s, 3H), 3.76 (s, 3H), 6.95−7.18 (m, 10H); 
13
C NMR 
(75 MHz, CDCl3): δ = 23.2, 51.9, 126.8, 127.0, 127.7, 127.8, 128.4, 129.8, 131.6, 137.1, 141.8, 144.6, 169.8; 
IR (neat): νmax = 2950, 1719, 1599, 1491, 1433, 1375, 1304, 1250 cm
−1
. 
 
Methyl (Z)-2,3-diphenylbut-2-enoate (Z)-3-3j
23 
Pale yellow oil; 
1
H NMR (300 MHz, CDCl3): δ = 2.05 (s, 3H), 3.43 (s, 3H), 7.29−7.44 (m, 10H); 
13
C NMR 
(75 MHz, CDCl3): δ = 22.2, 51.5, 126.8, 127.5, 128.1, 128.3, 129.1, 132.5, 137.1, 142.8, 143.9, 169.6; IR 
(neat): νmax = 2941, 1719, 1491, 1433, 1375, 1304, 1252, 1210 cm
−1
. 
 
Methyl (E)-2-(4-methoxyphenyl)-3-phenylbut-2-enoate (E)-3-3k 
 
Pale yellow oil; 
1
H NMR (300 MHz, CDCl3): δ = 2.33 (s, 3H), 3.72 (s, 3H), 3.79 (s, 3H), 6.60−6.70 (m, 2H), 
6.88−6.96 (m, 2H) , 7.10−7.20 (m, 2H); 13C NMR (75 MHz, CDCl3): δ = 23.0, 51.8, 54.8, 113.2, 126.8, 127.8, 
128.3, 129.3, 130.8, 131.1, 141.9, 143.1, 158.2, 170.1; IR (neat): νmax = 2951, 1719, 1609, 1576, 1509, 1458, 
1375, 1248 cm
−1
; HRMS (ESI): m/z calcd for C18H18O3 [M+Na]
+
 305.1154; found: 305.1161.  
 
Methyl (Z)-2-(4-methoxyphenyl)-3-phenylbut-2-enoate (Z)-3-3k
 
Pale yellow oil; 
1
H NMR (500 MHz, CDCl3): δ = 2.07 (s, 3H), 3.43 (s, 3H), 3.84 (s, 3H), 6.92−6.96 (m, 2H), 
7.27−7.40 (m, 7H); 13C NMR (125 MHz, CDCl3): δ = 22.2, 51.6, 55.2, 113.8, 126.9, 127.5, 128.2, 129.4, 
130.4, 132.2, 143.0, 143.3, 158.9, 170.1; IR (neat): νmax = 2951, 1719, 1655, 1601, 1541, 1509, 1437, 1250 
cm
−1
.  
 
Methyl (E)-2-(4-chlorophenyl)-3-phenylbut-2-enoate (E)-3-3l
 
Pale yellow oil; 
1
H NMR (300 MHz, CDCl3): δ = 2.37 (s, 3H), 3.78 (s, 3H), 6.88−6.95 (m, 2H), 6.97−7.03 (m, 
2H), 7.03−7.11 (m, 2H), 7.11−7.12 (m, 3H); 13C NMR (75 MHz, CDCl3): δ = 23.3, 52.0, 127.2, 128.0, 128.0, 
128.3, 130.4, 131.3, 132.7, 135.7, 141.6, 146.0, 169.4; IR (neat): νmax = 2949, 1707, 1619, 1591, 1489, 1434, 
1251, 1206 cm
−1
. 
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Methyl (Z)-2-(4-chlorophenyl)-3-phenylbut-2-enoate (Z)-3-3l
 
Colorless crystals; mp 115–116 °C; 1H NMR (300 MHz, CDCl3): δ = 2.04 (s, 3H), 3.42 (s, 3H), 7.24−7.44 (m, 
9H); 
13
C NMR (75 MHz, CDCl3): δ = 22.4, 51.7, 126.8, 127.7, 128.2, 128.6, 130.6, 131.3, 133.5, 135.6, 142.6, 
145.0, 169.2; IR (neat): νmax = 2951, 1697, 1491, 1428, 1319, 1214, 1088, 1008 cm
−1
; HRMS (ESI): m/z calcd 
for C17H15O2Cl [M+Na]
+
 309.0658; found: 309.0654. 
 
Methyl 2,3-diphenyl-3-oxopropanoate
24
 utilizing crossed Ti-Claisen condensation 
 
To a vigorously stirred solution of PhCH2CO2Me (15.0 g, 0.10 mol) and PhCOCl (14.1 g, 0.10 mol) in CH2Cl2 
(300 mL), NMI (9.85 g, 0.12 mol) was added dropwise at –45 oC under an Ar atmosphere.  Then, using two 
dropping funnels, TiCl4 (38.4 mL, 0.35 mol) (during ca. 20 min) and Et3N (55.4 mL, 0.40 mol) (during ca. 1 
h) were successively added, and the mixture was stirred at the same temperature for 1 h.  Water was slowly 
added to the mixture, which was extracted twice with Et2O.  The combined organic phase was washed with 
water, brine, dried (Na2SO4), and concentrated to give the crude product (24.5 g), which was purified by 
recrystallization from iPrOH (22 mL) to give the desired product (18.7 g, 74%). 
Colorless crystals; mp 73−74 °C (lit.24a 72−73 °C); 1H NMR (500 MHz, CDCl3): δ = 3.76 (s, 3H), 5.63 (s, 1H), 
7.29–7.45 (m, 7H), 7.51–7.58 (m, 1H), 7.90−8.01 (m, 2H); 13C NMR (125 MHz, CDCl3): δ = 52.7, 60.3, 
128.1, 128.7, 128.8, 128.9, 129.5, 132.8, 133.5, 135.5, 169.3, 193.2. 
 
(E)-Stereoselective enol phosphorylation of methyl 2,3-diphenyl-3-oxopropanoate (3-4) using Method C. 
 
(PhO)2POCl (403 mg, 1.5 mmol) was added to a stirred solution of methyl 2,3-diphenyl-3-oxopropanoate 
(3-4)  (254 mg, 1.0 mmol), NMI (123 mg, 1.5 mmol), and DBU (228 mg, 1.5 mmol) in DMF (2.0 mL) at 
−45 °C under an Ar atmosphere, and the mixture was stirred at the same temperature for 1 h and at the room 
temperature for 1 h.  Water was added to the reaction mixture, which was extracted twice with AcOEt.  The 
organic phase was washed with water, brine, dried (Na2SO4) and concentrated.  The obtained crude product 
was purified by silica-gel column chromatography (hexane/AcOEt = 10/1 – 3/1) to give the crude solid (280 
mg, 58%, E/Z = 88:12), which was purified by recrystallization from hexane/toluene = 8/1 (4.5 mL) to give 
the desired (E)-methyl 2,3-diphenyl-3-(diphenoxyphospholoxy)-2-propenoate [(E)-3-5] (204 mg, 42%, E/Z = 
>98:2).     
 
Colorless crystals; mp 98−99 °C; 1H NMR (500 MHz, CDCl3): δ = 3.50 (s, 3H), 6.71–6.78 (m, 4H), 7.07–7.20 
(m, 6H), 7.28–7.43 (m, 6H), 7.46–7.60 (m, 4H); 13C NMR (125 MHz, CDCl3): δ = 52.2, 119.8 [d, 
3
J (
13
C,
 31
P) 
= 4.8 Hz], 124.2 [d, 
3
J (
13
C,
 31
P) = 9.6 Hz], 125.2, 128.1, 128.1, 128.3, 129.0, 129.3, 129.5, 130.0, 132.9, 133.7, 
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150.1 [d, 
2
J (
13
C,
 31
P) = 7.2 Hz], 150.8 [d, 
2
J (
13
C,
 31
P) = 8.4 Hz], 167.7; IR (neat): νmax = 3017, 2952, 1725, 
1591, 1489, 1295, 1186, 1065 cm
−1
; HRMS (ESI): m/z calcd for C28H23O6P [M+Na]
+
 509.1130; found: 
509.1140.  
 
(Z)-Stereoselective enol phosphorylation of methyl 2,3-diphenyl-3-oxopropanoate (3-4) using Method D. 
 
2,3-Diphenyl-3-oxopropanoate (3-4) (254 mg 1.0 mmol), iPr2NEt (194 mg, 1.5 mmol), NMI (123 mg, 1.5 
mmol,), and (PhO)2POCl (403 mg, 1.5 mmol) were successively added to a stirred suspension of LiCl (64 mg 
1.5 mmol) in THF (2.0 mL) at 0 – 5 °C under an Ar atmosphere, and the mixture was stirred at the same 
temperature for 1 h.  Water was added to the mixture, which was extracted with twice with AcOEt.  The 
organic phase was washed with water, brine, dried (Na2SO4) and concentrated.  The obtained crude product 
was purified by silica-gel column chromatography (hexane/AcOEt = 3/1) to give the desired (Z)-methyl 
2,3-diphenyl-3-(diphenoxyphospholoxy)-2-propenoate [(Z)-3-5] (454 mg, 93%, E/Z = 2:>98). 
Colorless crystals; mp 82−83 °C; 1H NMR (500 MHz, CDCl3): δ = 3.67 (s, 3H), 7.04–7.10 (m, 4H), 7.11–7.34 
(m, 16H); 
13
C NMR (125 MHz, CDCl3): δ = 52.3, 120.0 [d, 
3
J (
13
C,
 31
P) = 4.8 Hz], 120.1, 123.7 [d, 
3
J (
13
C,
 
31
P) = 9.6 Hz], 125.3, 127.9, 127.9, 128.3, 129.6, 129.6, 129.9 [d, 
3
J (
13
C,
 31
P) = 3.6 Hz], 132.7, 133.6, 149.1 
[d, 
2
J (
13
C,
 31
P) = 8.4 Hz], 150.4 [d, 
2
J (
13
C,
 31
P) = 7.2 Hz], 166.8. ; IR (neat): νmax = 3015, 2952, 1726, 1489, 
1297, 1207, 1186, 1011 cm
−1
. 
 
(E)-Stereoretentive Negishi cross-coupling using enol phosphonate (E)-3-5 with (p-MeO)C6H4ZnCl 
 
(p-MeO)C6H4MgBr (2.94 mL; 1.02 M in THF) was added to a stirred suspension of ZnCl2 (409 mg, 3.0 
mmol) in MeCN (1.0 mL) at 0 − 5 °C under an Ar atmosphere, and the mixture was stirred at the same 
temperature for 10 min.  Enol phosphonate (E)-3-5 (486 mg, 1.0 mmol) and [Pd(dppb)Cl2] (30 mg, 0.05 
mmol) in MeCN (1.0 mL) were successively added to the mixture, followed by being stirred at 60 − 65 °C for 
2 h.  After cooling down, 3M HCl aqueous solution was added to the mixture, which was extracted twice 
with AcOEt.  The combined organic phase was washed with water, brine, dried (Na2SO4) and concentrated.  
The obtained crude product was purified by SiO2-column chromatography (hexane/AcOEt = 4/1) to give the 
crude solid (565 mg, E/Z = >98:2), which was purified by recrystallization from hexane/toluene = 13/1 (7 mL) 
to give the desired methyl (E)-2,3-diphenyl-3-(p-methoxyphenyl)prop-2-enoate (E)-3-6 (219 mg, 64%, E/Z = 
>98:2). 
Colorless crystals; mp 113−115 °C; 1H NMR (500 MHz, CDCl3): δ = 3.53 (s, 3H), 3.74 (s, 3H), 6.61–6.68 (m, 
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2H), 6.87–6.94 (m, 2H), 7.08–7.14 (m, 2H), 7.15–7.23 (m, 3H), 7.24–7.29 (m, 2H), 7.29–7.39 (m, 3H); 13C 
NMR (125 MHz, CDCl3): δ = 51.9, 55.1, 113.2, 127.2, 128.1, 128.3, 129.1, 129.8, 132.3, 132.4, 132.7, 137.9, 
142.7, 146.3, 159.1, 171.1; IR (neat): νmax = 3020, 2949, 2837, 1715, 1605, 1508, 1247, 1217, 1176, 1149 
cm
−1
; HRMS (ESI): m/z calcd for C23H20O3 [M+Na]
+
 367.1310; found: 367.1295. 
 
(Z)-Stereoretentive Negishi cross-coupling using enol phosphonate (Z)-3-5 with (p-MeO)C6H4ZnCl 
 
(p-MeO)C6H4MgBr (1.89 mL; 1.06 M in THF) was added to a stirred suspension of ZnCl2 (273 mg, 2.0 
mmol) in THF (1.0 mL) at 0 − 5 °C under an Ar atmosphere, and the mixture was stirred at the same 
temperature for 10 min.  Enol phosphonate (Z)-3-5 (486 mg, 1.0 mmol) and [Pd(dppb)Cl2] (30 mg, 0.05 
mmol) in THF (1.0 mL) were successively added to the mixture, followed by being stirred at 60 − 65 °C for 2 
h.  After cooling down, 3M HCl aqueous solution was added to the mixture, which was extracted twice with 
AcOEt.  The combined organic phase was washed with water, brine, dried (Na2SO4) and concentrated.  The 
obtained crude product was purified by SiO2-column chromatography (hexane/AcOEt = 100/1 – 10/1) to give 
the crude solid (372 mg, E/Z = >98:2), which was purified by recrystallization from hexane/toluene = 7/1 (12 
mL) to give the desired methyl (Z)-2,3-diphenyl-3-(p-methoxyphenyl)prop-2-enoate (Z)-3-6 (192 mg, 56%, 
E/Z = 2:>98). 
Colorless crystals; mp 130−131 °C; 1H NMR (500 MHz, CDCl3): δ = 3.59 (s, 3H), 3.82 (s, 3H), 6.83–6.88 (m, 
2H), 6.97–7.03 (m, 2H), 7.04–7.23 (m, 10H); 13C NMR (125 MHz, CDCl3): δ = 52.0, 55.2, 113.6, 127.2, 
127.6, 127.8, 128.2, 129.8, 130.4, 131.0, 132.4, 134.7, 137.7, 140.7, 146.0, 159.5, 171.2; IR (neat): νmax = 
3019, 2950, 2838, 1714, 1606, 1509, 1248, 1216, 1177, 1150 cm
−1
. 
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Chapter 4. 
General and Robust Method for the Preparation of (E)- and 
(Z)-Stereodefined Fully-substituted Enol Tosylates: A Promising 
Cross-coupling Partner 
 
Abstract 
A robust method for preparing (E)- and (Z)-stereodefined fully-substituted enol tosylates is described.  
-Substituted β-ketoesters undergo (E)-selective enol tosylations using TsCl–Me2N(CH2)6NMe2 as 
the reagent (method A, 13 examples; 63–96%) and (Z)-selective enol tosylations using TsCl–
TMEDA–LiCl as the reagent (method B, 13 examples; 62–99%).  A plausible mechanism for the 
(E)- and (Z)-enol tosylation selectivity is proposed.  A 1H NMR monitoring experiment revealed that 
TsCl coupled with TMEDA formed a simple N-sulfonylammonium intermediate. 
 
 
 
Introduction 
Acyclic (E)- and (Z)-enol sulfonates (tosylates, triflates, etc.) and phosphonates derived from readily 
accessible β-ketoesters are well-recognized synthetic precursors of stereodefined olefins produced using 
stereoretentive cross-coupling methodology.
1
  A number of biologically active compounds and functionally 
useful materials comprise these acyclic stereodefined olefins.   Among several enol sulfonates, (E)- and 
(Z)-enol tosylates are particularly advantageous due to their stability, cost-effectiveness, and sufficient 
reactivity from the standpoints of fine and natural product synthesis and process chemistry.  Representative 
examples of the synthetic utility of acyclic (E)- and (Z)-stereodefined enol sulfonates are addressed as follows.  
The Merck process group disclosed a characteristic protocol for (E)- and (Z)-stereocomplementary enol 
tosylations of specific α- or γ-nitrogen-substituted β-ketoesters using respective Ts2O−M(Li or Na)HMDS and 
Ts2O−amine reagents.
2
  The obtained stereodefined enol tosylate scaffolds were successfully subjected to 
stereoretentive Suzuki-Miyaura (SM) cross-couplings for the synthesis of various pharmaceutical precursors. 
As part of our ongoing studies on mild but powerful sulfonylations
3
 and silylations
4
 of various alcohols and 
carbonyl compounds, we previously presented a series of (E)- and (Z)-stereocomplementary enol tosylations 
of not only acyclic ‘α-nonsubstituted’ β-ketoesters (R1 = alkyl or aryl, R2 = H), but also α-formylesters (R1 = 
H, R
2
 = alkyl or aryl), which were conducted by the TsCl−N-methylimidazole (NMI)−base system (Scheme 
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4-1).  TsCl−NMI−Et3N was used for the (E)-selective reactions, whereas TsCl−NMI−LiOH controlled the 
(Z)-selective reactions.   Subsequent highly (E)- and (Z)-stereoretentive cross-couplings (Negishi,
5a
 
Sonogashira,
5a
 SM,
5b,d
 and Kochi‒Fürstner5c) were successfully performed to produce the corresponding 
stereodefined α,β-unsaturated esters.  The current privileged robust and cost-effective protocols have been 
adopted for the synthesis of elaborated natural and unnatural compounds, such as juvenile hormones 0 and 
I,
6a,b
 functionalized steroids,
6c
 madangamine A,
6d
 (E)- and (Z)-zimelidines,
5d
 etc. 
 
 
Scheme 4-1. (E)- and (Z)-Stereocomplementary synthesis of (E)- and (Z)-α,β-unsaturated esters utilizing stereoselective enol 
tosylations and stereoretentive cross-couplings. 
 
Very recently, the Merck process group reported a synthesis of chiral 
β-cyclopropyl-α-methyldihydrocinnamates (Scheme 4-2).7  This notable pharmacophore was synthesized via 
(E)- and (Z)-stereocontrolled enol tosylations using a β-cyclopropyl-α-methyl-β-ketoester; the (E)-isomer was 
prepared using Ts2O−NaHMDS at −78 °C, whereas the (Z)-isomer was prepared using the same reagent at 
room temperature. 
 
 
Scheme 4-2.  A synthesis of chiral β-cyclopropyl-α-methyldihydrocinnamate reported by Merck process group. 
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On the other hand, as exhibited in Chapter 3, our group recently reported (E)- and (Z)-stereocomplementary 
enol phosphorylations of ‘α-substituted’ β-ketoesters as a relevant approach;8 the (PhO)2POCl−NMI−LiOtBu 
reagent being used for preparing (E)-isomers, whereas the (PhO)2POCl−NMI−KOtBu−18-crown-6 reagent 
was employed for the (Z)-isomers.  The application of this protocol to (E)- and (Z)-stereoretentive SM and 
Negishi cross-couplings produced the corresponding stereodefined all-carbon (fully) substituted 
α,β-unsaturated esters (Scheme 4-3).  This approach, however, has several conspicuous drawbacks compared 
with the reaction sequence via the enol tosylations; these include: (i) harsher reaction conditions (DMF, 
reflux) for the SM cross-coupling due to the poor reactivity of the (PhO)2PO- group, (ii) lower atom economy 
of the (PhO)2PO- group, (iii) a considerably more tedious separation procedure between (E)- and (Z)-enol 
phosphonates by column chromatography due to their similar Rf values, and (iv) requires stoichiometric 
amounts of an expensive and highly toxic 18-crown-6 are required. 
 
 
Scheme 4-3.  (E)- and (Z)-Stereocomplementary synthesis of (E)- and (Z)-α,β-unsaturated esters utilizing stereoselective enol 
phosphorylations and stereoretentive cross-couplings. 
 
This background prompted us to search for a more efficient enol tosylation method using less reactive 
‘α-carbon-substituted’ β-ketoesters 4-1 (R1, R2 = alkyl and/or aryl).  We present herein a substrate-general 
and robust method for (E)- and (Z)-stereocomplementary enol tosylations of 4-1 using the 
TsCl−Me2N(CH2)6NMe2 reagent for (E)-enol tosylates (E)-4-2 and the  TsCl−TMEDA–LiCl reagent for 
(Z)-enol tosylates (Z)-4-2.
9
   
 
Results and Discussion 
The initial attempt was intentionally guided using stereocongested methyl 2-butyl-3-oxooctanoate 4-1a
10
 as 
a much less reactive substrate probe (Table 4-1).  As anticipated, the reported NMI-mediated method
6
 
resulted in almost no reaction (Table 4-1, entries 1, 2).  Notably, the use of inexpensive Me2N(CH2)nNMe2 
(n=3 or 6)
11
 alone afforded positive results for the (E)-selective reaction to give the desired enol tosylate 
(E)-4-2a (Table 4-1, entries 3–5).  When using TMEDA, less reactive alcohols are prone to resist the 
tosylation reaction concomitant with the side production of TsNMe2 via Hoffmann degradation of TMEDA 
with TsCl.
3c
  This information led us to use Me2N(CH2)nNMe2 (n=3 or 6). 
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Optimization of the temperature and time (–15 °C, 1 h and 20–25 °C, 1 h) allowed for improvement in both 
the yield (74%) and the stereoselectivity (E/Z = >98:2) (Table 4-1, entry 6).  The best solvent was MeCN; 
EtOAc, DMF, THF, and toluene were apparently inferior (Table 4-1, entry 7).  On the other hand, the 
(Z)-selective reaction proceeded smoothly to give (Z)-4-2a in good yield (93%) with excellent selectivity (E/Z 
= 2:>98) using the available combined reagent, TsCl−TMEDA−LiCl under very accessible conditions (0–5 °C, 
1 h and 20–25 °C, 1 h) (Table 4-1, entry 8).  The use of TMEDA produced satisfactory results eventually 
compared with Me2N(CH2)nNMe2 (n=3 or 6) (Table 4-1, entries 8−12).  EtOAc and toluene gave moderate 
yields and the best solvent was MeCN (Table 4-1, entries 8−10).12 
 
Table 4-1.  (E)- and (Z)-Stereocomplementary enol tosylation of 4-1a using TsCl−N,N,N’,N’-tetramethyldiamine base with or 
without additive. 
 
Entry Base Additive Solvent Yield
a
 / % E/Z
a
 
1 Et3N NMI C6H5Cl NR − 
2 KOtBu NMI, 
18-Crown-6 
THF Trace − 
3 TMEDA − MeCN 17 97:3 
4 Me2N(CH2)6NMe2 − MeCN 48 93:7 
5 Me2N(CH2)6NMe2 − MeCN 44 94:6 
6 Me2N(CH2)6NMe2 − MeCN 74,
b
 60
b,c
 98:2 
7 Me2N(CH2)6NMe2 − EtOAc, DMF, 
THF, Toluene 
Trace
b 
− 
8 TMEDA LiCl MeCN 93
c
 2:>98 
9 TMEDA LiCl EtOAc 38 2:>98 
10 TMEDA LiCl Toluene 50 2:>98 
11 Me2N(CH2)3NMe2 LiCl MeCN 40 2:>98 
12 Me2N(CH2)6NMe2 LiCl MeCN 66 − 
13 Et3N LiCl MeCN Trace (33)
d
 2:>98 
14 LHMDS − Toluene-MeCN 
(1:1) 
11 (43)
d
 36:64 
a) Determined by 
1
H NMR of the crude products.  b) Reaction conditions: −15 °C, 1 h and 20 − 25 °C, 1 h. 
c) Isolated.  d) α-Chlorinated by-product of 4-1a; see the experimental section. 
 
In the two cases using Et3N and LHMDS, considerable amounts of α-chlorinated by-product (methyl 
2-butyl-2-chloro-3-oxooctanoate) of 4-1a were detected (Table 4-1, entries 13 and 14).
13
  The occurrence of 
this side reaction is ascribed to that TsCl cannot be sufficiently activated (vide infra, Scheme 4-6).  
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Accordingly, the present method is obviously more efficient than the NMI-mediated reactions. 
With the successful outcome in hands, Table 4-2 lists the substrate generality using a variety of 
α-substituted β-ketoesters 4-1 [method A for (E)-isomers (E)-4-2 and method B for (Z)-isomers (Z)-4-2].  
The salient features are as follows.  (i) All reactions were completed under the identical optimized conditions 
in good to excellent yield.  (ii) With regard to stereoselectivity, almost all cases produced positive and 
excellent results (>90:10 for method A and 2:>98 for method B).  (iii) As a limitation, (E)-selectivity using 
α,β-diaryl substrates 4-1m and 4-1n was moderate (Table 4-2, entries 25 and 27).  This tendency coincides 
with discussions in the precedent report
5d
 which ascribes to the nature of intrinsically more stable (Z)-isomers.   
Fortunately, these crude products could be enriched to the pure (E)-products (E)-4-2m and (E)-4-2n, by 
recrystallization.  It should be noted that all of these stereodefined (E)- and (Z)-enol tosylates 4-2 are novel 
compounds. 
 
Table 4-2.  (E)- and (Z)-Stereocomplementary enol tosylation of 4-1 using TsCl−Me2N(CH2)6NMe2 (Method A) and 
TsCl−TMEDA−LiCl (Method B) 
 
Entry R
1
 R
2
 Substrate Method Product Yield / % E / Z 
a
 
1 Me Me 4-1b A (E)-4-2b 84 >98:2 
2 Me Me 4-1b B (Z)-4-2b 72 2:>98 
3 Me nBu 4-1c A (E)-4-2c 81 97:3 
4 Me nBu 4-1c B (Z)-4-2c 95 2:>98 
5 Me iPr 4-1d A (E)-4-2d 84
b 
>98:2 
6 Me iPr 4-1d B (Z)-4-2d 85
c 
2:>98 
7 nBu Me 4-1e A (E)-4-2e 74 >98:2 
8 nBu Me 4-1e B (Z)-4-2e 62 2:>98 
9 nPen Me 4-1f A (E)-4-2f 74 >98:2 
10 nPen Me 4-1f B (Z)-4-2f 94 2:>98 
11 Cl(CH2)4 Me 4-1g A (E)-4-2g 77 >98:2 
12 Cl(CH2)4 Me 4-1g B (Z)-4-2g 85 2:>98 
13 CH2=CH(CH2)8 CH2=CH(CH2)7 4-1h A (E)-4-2h 63 95:5 
14 CH2=CH(CH2)8 CH2=CH(CH2)7 4-1h B (Z)-4-2h 91 2:>98 
15 nPen nBu 4-1a A (E)-4-2a 74 >98:2 
16 nPen nBu 4-1a B (Z)-4-2a 93 2:>98 
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17 Ph Me 4-1i A (E)-4-2i 89 94:6 
18 Ph Me 4-1i B (Z)-4-2i 90 2:>98 
19 (p-Me)C6H4 Me 4-1j A (E)-4-2j 80 94:6 
20 (p-Me)C6H4 Me 4-1j B (Z)-4-2j 89 2:>98 
21 (p-MeO)C6H4 Me 4-1k A (E)-4-2k 90 90:10 
22 (p-MeO)C6H4 Me 4-1k B (Z)-4-2k 98 2:>98 
23 (p-Cl)C6H4 Me 4-1l A (E)-4-2l 94 >98:2 
24 (p-Cl)C6H4 Me 4-1l B (Z)-4-2l 96 2:>98 
25 Ph Ph 4-1m A (E)-4-2m 96 (49)
d 
74:26 
(>98:2) 
26 Ph Ph 4-1m B (Z)-4-2m 93 2:>98 
27 (p-MeO)C6H4 Ph 4-1n A (E)-4-2n 95 (26)
d 
66:34 
(>98:2) 
28 (p-MeO)C6H4 Ph 4-1n B (Z)-4-2n 99 2:>98 
a) Determined by 
1
H NMR of the crude products.  b) TsCl (3.0 equiv) and Me2N(CH2)6NMe2 (3.0 equiv) were used. 
c) TsCl (3.0 equiv), TMEDA (3.0 equiv) and LiCl (3.0 equiv) were used. 
d) Yield after recrystallization; see the experimental section for details. 
 
Next, an extension to α-heteroatom (MeO and Cl) substituted β-ketoesters 4-1o and 4-1p was examined 
(Scheme 4-4).  Gratifyingly, the reaction proceeded smoothly to give the desired functionalized products 
(E)-, (Z)-4-2o and (E)-, (Z)-4-2p. (Note: due to the sequence rule, reverse configurations are indicated.) 
The (E)- and (Z)-stereochemistry was determined on the basis of the hitherto reported study.
5
  In addition, 
NOE measurements exemplified by enol tosylates (E)-4-2f and (Z)-4-2f, determined unambiguous assignment 
(Figure 4-1). 
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Scheme 4-4.  (E)- and (Z)-Stereocomplementary enol tosylation of α-heteroatom-substituted β-ketoesters 4-1o and 4-1p 
 
 
Figure 4-1. NOE measurement of (Z)-4-2f 
 
A plausible mechanism for the successful emergence of (E)- and (Z)-enol tosylation selectivity is illustrated 
in Scheme 4-5 and Scheme 4-6.
14
  The (E)-selective reaction with highly reactive intermediate I proceeds 
via a non-chelation pathway to give (E)-4-2; Me2N(CH2)6NMe2 plays two different roles as a base reagent and 
a partner of I through equilibrium.  Me2N(CH2)6NMe2 aids (E)-enolate formation through dipole-dipole 
repulsive interactions between the oxy anion and ester function.  In clear contrast, the (Z)-selective reaction 
proceeds via a chelation mechanism to give (Z)-4-2; the Li cation facilitates (Z)-enolate formation. 
 
 
Scheme 4-5.  A mechanistic investigation into the (E)- and (Z)-stereoselective enol tosylations 
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Scheme 4-6.  Formation of sulfonylammonium intermediate I monitored by 1H NMR measurements at −40 °C 
 
As depicted in Scheme 4-6 and Figure 4-2, a careful 
1H NMR monitoring experiment (−40 °C in CD3CN) 
revealed that TsCl coupled with TMEDA formed a simple N-sulfonylammonium intermediate IA rather than a 
plausible N,N’-chelate-type intermediate IB.  The apparent downfield chemical shifts of the tosyl moiety in 
IA are related to the higher reactivity of the present system.  Based on the result, IA is likely to function as 
the key active species.
15,16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-2.  A 1H NMR monitoring study using a 1:1 mixture of TsCl and TMEDA at −40 °C 
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Meanwhile, at the same time, Frantz’s group reported a practical preparative method for (E)- and 
(Z)-stereodefined enol triflates derived from β-ketoesters (Scheme 4-7).17  Highly reactive these enol 
sulfonates have served as useful building block for the synthesis of natural products,
18
 however, enol triflates 
methods have several drawbacks:  (i) Tf2O is ca. 15−30 times more expensive than TsCl, (ii) Tf2O is highly 
toxic and hazardous with a low boiling point (81−83 °C) and reacts violently with water, and (iii) Triflates are 
often unstable under cross-couplimg conditions due to its inherent reactivity. 
 
 
Scheme 4-7.  (E)- and (Z)-Stereocomplementary preparation of enol triflates reported by Frantz’s group. 
 
Conclusion 
A general and convenient protocol has been developed for the production of (E)- and (Z)- enol tosylates of 
α-substituted β-ketoesters using readily available TsCl and N,N,N’,N’-tetramethyldiamine for E-isomers or 
LiCl base for Z-isomers.  The Me2N(CH2)6NMe2 reagent functions to produce (E)-selective reactions, 
whereas the TMEDA−LiCl reagent functions to produce (Z)-selective reactions.  A plausible mechanism 
accounting for the successful (E)- and (Z)-selectivity is proposed; non-chelation pathway with dipole-dipole 
repulsion for E and Li-chelation pathway for Z.  A 
1
H NMR monitoring experiment revealed that TsCl 
coupled with TMEDA formed a simple N-sulfonylammonium intermediate, plausibly not N,N’-bidentate but 
N-monodentate intermediate.  Chapter 5 disclosed notable application to various (E)- and (Z)-stereoretentive 
cross-couplings using the obtained fully substituted enol tosylates, a pair of latent and potential scaffolds. 
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Experimental 
 
Preparation of β-ketoesters 
 
Methyl 2-butyl-3-oxooctanoate
8,19b
 4-1a 
TiCl4 (114 g, 0.60 mol) and Et3N (70.8 g, 0.70 mol) were successively added dropwise to a stirred solution of 
methyl hexanoate (65.1 g, 0.50 mol) in CH2Cl2 (500 mL) at 0 – 5 °C under an Ar atmosphere, and the mixture 
was stirred at the same temperature for 1 h.  Water was added to the mixture, which was extracted twice with 
Et2O.  The combined organic phase was washed with sat. aq. NaHCO3 solution, brine, dried (Na2SO4), and 
concentrated.  The obtained crude product was purified by distillation to give the desired product (53.2 g, 
93%). 
Colorless oil; bp 79−81 °C/0.49 mmHg; 1H NMR (300 MHz, CDCl3): δ = 0.89 (t, J = 7.2 Hz, 3H), 0.89 (t, J = 
7.2 Hz, 3H), 1.16−1.39 (m, 8H), 1.58 (quin, J = 7.2 Hz, 2H), 1.78−1.90 (m, 2H), 2.45 (dt, J = 7.2 Hz, Jgem = 
17.2 Hz, 1H), 2.54 (dt, J = 7.2 Hz, Jgem = 17.2 Hz, 1H), 3.43 (t, J = 7.2 Hz, 1H), 3.72 (s, 3H); 
13
C NMR (75 
MHz, CDCl3) δ 13.6, 13.7, 22.2, 22.3, 23.0, 27.8, 29.5, 31.0, 41.6, 52.0, 58.8, 170.2, 205.2. 
 
Methyl 2-acetylhexanoate
20
 4-1c 
Methyl acetoacetate (3.49 g, 30 mmol) was added to a stirred suspension of NaH (50%, 1.72 g, 36 mmol) in 
DMF (15 mL) at 0 – 5 °C, and the mixture was stirred at 20 – 25 °C for 0.5 h with H2 gas evolution.  
1-Bromobutane (4.11 g, 30 mmol) was added at the same temperature and the mixture was stirred at 70 – 
75 °C for 15 h.  Water (large amount) was slowly added to the mixture, which was extracted with AcOEt.  
The combined organic phase was washed with water (large amount), brine, dried (Na2SO4), and concentrated.  
The obtained crude product was purified by SiO2-column chromatography (hexane/AcOEt = 80/1 – 50/1) to 
give the desired product (2.16 g, 42%). 
Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 0.89 (t, J = 7.2 Hz, 3H × 8.5/10, keto form), 0.98 (t, J = 7.2 Hz, 
3H × 1.5/10, enol form), 1.17−1.42 (m, 4H), 1.75−1.94 (m, 2H × 8.5/10, keto form), 2.01 (s, 3H × 1.5/10, enol 
form), 2.15 (t, J = 7.2 Hz, 2H × 1.5/10, enol form), 2.23 (s, 3H × 8.5/10, keto form), 3.42 (t, J = 7.2 Hz, 1H × 
8.5/10, keto form), 3.74 (s, 3H × 8.5/10, keto form), 3.75 (s, 3H × 1.5/10, enol form); 
13
C NMR (75 MHz, 
CDCl3): δ = 13.3, 13.5, 18.0, 22.0, 25.3, 27.5, 28.3, 29.1, 31.9, 50.9, 51.7, 59.1, 99.9, 169.9, 171.6, 173.3, 
202.5. 
 
Methyl 2-acetyl-3-methylbutanoate
21
 4-1d 
Following the procedure for the preparation of 4-1c, the reaction of methyl acetoacetate (4.65 g, 40 mmol) 
with 2-iodopropane (13.60 g, 40 mmol) using NaH (50%, 2.30 g, 48 mmol) gave the desired product (2.60 g, 
41%). 
colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 0.93 (d, J = 6.5 Hz, 3H), 0.97 (d, J = 6.5 Hz, 3H), 2.22 (s, 3H), 
2.42 (dsep, J = 6.5, 9.6 Hz, 1H), 3.20 (d, J = 9.6 Hz, 1H), 3.73 (s, 3H); 
13
C NMR (75 MHz, CDCl3): δ = 20.2, 
28.5, 29.0, 51.9, 67.1, 169.4, 202.8. 
82 
 
 
Methyl 2-methyl-3-oxooctanoate
22
 4-1f 
TiCl4 (99.6 g, 0.53 mol) and Bu3N (111 g, 0.60 mol) were successively added dropwise to a stirred solution of 
methyl propanoate (13.2 g, 0.15 mol), hexanoyl chloride (20.2 g, 0.15 mol), and 1,2-dimethylimidazole (17.3 
g, 0.18 mol) in CH2Cl2 (450 mL) at –45 °C under an Ar atmosphere, and the mixture was stirred at the same 
temperature for 1 h.  Water was added to the mixture, which was extracted twice with Et2O.  The combined 
organic phase was washed with saturated NaHCO3 aqueous solution, brine, dried (Na2SO4), and concentrated.  
The obtained crude product was purified by distillation to give the desired product (15.5 g, 55%). 
Colorless oil; bp 88−90 °C/0.30 mmHg; 1H NMR (300 MHz, CDCl3): δ = 0.89 (t, J = 6.9 Hz, 3H), 1.20−1.37 
(m, 4H), 1.34 (d, J = 7.2 Hz, 3H), 1.53−1.65 (m, 2H), 2.48 (dt, J = 7.2 Hz, Jgem = 17.5 Hz, 1H), 2.57 (dt, J = 
7.6 Hz, Jgem = 17.5 Hz, 1H), 3.54 (q, J = 6.9 Hz, 1H), 3.73 (s, 3H); 
13
C NMR (75 MHz, CDCl3): δ = 12.8, 
13.8, 22.37, 23.2, 31.2, 41.3, 52.3, 52.7, 171.1, 205.9. 
 
Methyl 7-chloro-2-methyl-3-oxoheptanoate
22b,23
 4-1g 
Following the procedure for the preparation of 4-1f, the reaction of methyl propanoate (4.41 g, 50 mmol) with 
5-chloropentanoyl chloride (7.75 g, 50 mmol) using 1,2-dimethylimidazole (5.77 g, 60 mmol), TiCl4 (33.20 g, 
175 mmol), and Bu3N (37.10 g, 200 mmol) gave the desired product (4.78 g, 47%). 
Colorless oil; bp 79−80 °C/0.23 mmHg; 1H NMR (300 MHz, CDCl3): δ = 1.35 (d, J = 7.2 Hz, 3H), 1.75−1.79 
(m, 4H), 2.46−2.71 (m, 2H), 3.50−3.57 (m, 3H), 3.74 (s, 3H); 13C NMR (75 MHz, CDCl3): δ = 12.7, 20.7, 
31.6, 40.3, 44.5, 52.4, 52.5, 170.9, 205.2. 
 
Methyl 2-(non-8-en-1-yl)-3-oxotridec-12-enoate 4-1h 
Following the procedure for the preparation of 4-1a, the reaction of methyl undec-10-enoate (198 mg, 1.0 
mmol) using TiCl4 (228 mg, 1.2 mmol) and Et3N (142 mg, 1.4 mmol) gave the desired product (109 mg, 
60%). 
Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 1.16−1.42 (m, 20H), 1.50−1.63 (m, 2H), 1.75−1.88 (m, 2H), 
1.96−2.09 (m, 4H), 2.44 (dt, J = 7.2 Hz, Jgem = 17.2 Hz, 1H), 2.54 (dt, J = 7.2 Hz, Jgem = 17.2 Hz, 1H), 3.43 
(t, J = 7.2 Hz, 1H), 3.72 (s, 3H), 4.88−5.03 (m, 4H), 5.73−5.88 (m, 2H); 13C NMR (75 MHz, CDCl3): δ = 23.4, 
27.4, 28.2, 28.8, 28.8, 28.9, 29.0, 29.0, 29.1, 29.1, 29.2 (2C), 33.7 (2C), 41.8, 52.2, 59.0, 114.1 (2C), 139.1 
(2C), 170.4, 205.4; IR (neat): νmax = 3077, 2925, 2854, 1742, 1716, 1640, 1436, 1196 cm
−1
; HRMS (ESI): m/z 
calcd for C23H40O3 [M+Na]
+
 387.2875; found: 387.2883. 
 
Methyl 2-methyl-3-oxo-3-phenylpropanoate
22b,24
 4-1i 
Following the procedure for the preparation of 4-1f, the reaction of methyl propanoate (2.64 g, 30 mmol) with 
benzoyl chloride (4.22 g, 30 mmol) using N-methylimidazole (2.96 g, 36 mmol), TiCl4 (19.9 g, 105 mmol), 
and Bu3N (22.2 g, 120 mmol) gave the desired product (4.31 g, 75%). 
Colorless oil; bp 110−112 °C / 0.45 mmHg; 1H NMR (300 MHz, CDCl3): δ = 1.50 (d, J = 7.2 Hz, 3H), 3.69 (s, 
3H), 4.41 (q, J = 7.2 Hz, 1H), 7.44−7.52 (m, 2H), 7.55−7.63 (m, 1H), 7.95−8.00 (m, 2H); 13C NMR (75 MHz, 
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CDCl3): δ = 13.8, 48.0, 52.5, 128.6, 128.7, 133.5, 135.7, 171.3, 195.8. 
 
Methyl 2-methyl-3-oxo-3-(p-tolyl)propanoate
22b,25
 4-1j 
Following the procedure for the preparation of 4-1f, the reaction of methyl propanoate (1.76 g, 20 mmol) with 
4-methylbenzoyl chloride (3.09 g, 20 mmol) using N-methylimidazole (1.97 g, 24 mmol), TiCl4 (13.3 g, 70 
mmol), and Bu3N (14.8 g, 80 mmol) gave the desired product (2.97 g, 72%). 
Colorless oil; 
1
H NMR (400 MHz, CDCl3): δ = 1.49 (d, J = 7.3 Hz, 3H), 2.42 (s, 3H), 3.69 (s, 3H), 4.40 (q, J 
= 7.3 Hz, 1H), 7.25−7.30 (m, 2H), 7.87−7.90 (m, 2H); 13C NMR (100 MHz, CDCl3): δ = 13.8, 21.5, 47.8, 52.3, 
128.7, 129.4, 133.1, 144.4, 171.3, 195.4. 
 
Methyl 3-(4-chlorophenyl)-2-methyl-3-oxopropanoate
22b,26
 4-1l 
Following the procedure for the preparation of 4-1f, the reaction of methyl propanoate (1.76 g, 20 mmol) with 
4-chlorobenzoyl chloride (3.50 g, 20 mmol) using N-methylimidazole (1.97 g, 24 mmol), TiCl4 (13.3 g, 70 
mmol), and Bu3N 14.8 g, 80 mmol) gave the desired product (3.35 g, 74%). 
Colorless oil; 
1
H NMR (400 MHz, CDCl3): δ = 1.50 (d, J = 7.3 Hz, 3H), 3.69 (s, 3H), 4.36 (q, J = 7.3 Hz, 1H), 
7.43−7.48 (m, 2H), 7.89−7.95 (m, 2H); 13C NMR (100 MHz, CDCl3): δ = 13.6, 47.9, 52.4, 129.0, 130.0, 134.0, 
140.0, 170.9, 194.5. 
 
Methyl 3-oxo-2,3-diphenylpropanoate
27
 4-1m 
To a vigorously stirred solution of PhCH2CO2Me (4.51 g, 30.0 mmol) and PhCOCl (4.21 g, 30.0 mmol) in 
CH2Cl2 (90 mL), NMI (2.36 g, 36.0 mmol) was added dropwise at –45 °C under an Ar atmosphere.  Then, 
using two dropping funnels, TiCl4 (11.5 mL, 105 mmol) (during ca. 20 min) and Et3N (16.6 mL, 120 mmol) 
(during ca. 1 h) were successively added, and the mixture was stirred at the same temperature for 1 h.  Water 
was slowly added to the mixture, which was extracted twice with Et2O.  The combined organic phase was 
washed with water, brine, dried (Na2SO4), and concentrated to give the crude product (7.82 g).  The obtained 
crude product was purified by SiO2-column chromatography (hexane/AcOEt = 6/1 – 3/1) to give the desired 
product (6.66 g, 87%). 
Colorless crystals; mp 73−74 °C (lit.27 72−73 °C); 1H NMR (500 MHz, CDCl3): δ = 3.76 (s, 3H), 5.63 (s, 1H), 
7.29−7.45 (m, 7H), 7.51−7.58 (m, 1H), 7.90−8.01 (m, 2H); 13C NMR (125 MHz, CDCl3): δ = 52.7, 60.3, 
128.1, 128.7, 128.8, 128.9, 129.5, 132.8, 133.5, 135.5, 169.3, 193.2. 
 
Methyl 3-(4-methoxyphenyl)-3-oxo-2-phenylpropanoate 4-1n 
Following the procedure for the preparation of 4-1m, the reaction of PhCH2CO2Me (1.50 g, 10.0 mmol) with 
(p-MeO)C6H4COCl (1.71 g, 10.0 mmol) using N-methylimidazole (985 mg, 12.0 mmol), TiCl4 (3.84 mL, 35 
mmol), Et3N (5.54 mL, 40.0 mmol) gave the desired product (2.48 g, 87%). 
Colorless crystals; mp 92−94 °C; 1H NMR (500 MHz, CDCl3): δ = 3.76 (s, 3H), 3.84 (s, 3H), 5.59 (s, 1H), 
6.83 (m, 2H), 7.27−7.51 (m, 5H), 7.87−8.01 (m, 2H); 13C NMR (125 MHz, CDCl3): δ = 52.6, 55.4, 60.1, 
113.9, 128.0, 128.4, 128.7, 129.4, 131.3, 133.2, 163.8, 169.4, 191.7; IR (neat): νmax = 1741, 1670, 1595, 1454, 
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1325, 1215 cm
−1
; HRMS (ESI): m/z calcd for C17H16O4 [M+Na]
+
 307.0946; found: 307.0945. 
 
Methyl 2-methoxy-3-oxooctanoate 4-1o 
TiCl4 (664 mg, 3.5 mmol) and Et3N (405 mg, 4.0 mmol) were successively added dropwise to a stirred 
solution of methyl methoxyacetate (104 mg, 1.0 mmol), hexanoyl chloride (135 mg, 1.0 mmol), and 
1,2-dimethylimidazole (115 mg, 1.2 mmol) in CH2Cl2 (3 mL) at –45 °C under an Ar atmosphere, and the 
mixture was stirred at the same temperature for 1 h.  Water was added to the mixture, which was extracted 
twice with Et2O.  The combined organic phase was washed with saturated NaHCO3 aqueous solution, brine, 
dried (Na2SO4), and concentrated.  The obtained crude product was purified by SiO2-column 
chromatography (hexane/AcOEt = 80/1 – 50/1) to give the desired product (162 mg, 80%). 
Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 0.88 (t, J = 7.2 Hz, 3H), 1.20−1.41 (m, 4H), 1.58 (quin, J = 
7.2 Hz, 2H), 2.60 (dt, J = 7.2 Hz, Jgem = 3.4 Hz, 1H), 2.61 (dt, J = 7.2 Hz, Jgem = 3.4 Hz, 1H), 3.47 (s, 3H), 
3.81 (s, 3H), 4.30 (s, 1H); 
13
C NMR (75 MHz, CDCl3): δ = 13.7, 22.2, 22.5, 31.0, 38.4, 52.5, 58.5, 86.6, 167.5, 
203.9.; IR (neat): νmax = 2955, 1750, 1726, 1438, 1402, 1272, 1203, 1119 cm
−1
; HRMS (ESI): m/z calcd for 
C10H18O4 [M+Na]
+
 225.1103; found: 225.1109. 
 
Methyl 2-chloro-3-oxooctanoate 4-1p 
 
TiCl4 (99.7 g, 0.53 mol) and iPr2NEt (77.5 g, 0.60 mmol) were successively added dropwise to a stirred 
solution of methyl acetate (17.8 g, 0.24 mol), hexanoyl chloride (20.2 g, 0.15 mol), and 1,2-dimethylimidazole 
(17.3 g, 0.18 mol) in CH2Cl2 (450 mL) at –45 °C under an Ar atmosphere, and the mixture was stirred at the 
same temperature for 1 h.  Water was added to the mixture, which was extracted twice with Et2O.  The 
combined organic phase was washed with saturated NaHCO3 aqueous solution, brine, dried (Na2SO4), and 
concentrated.  The obtained crude product was purified by distillation to give the corresponding β-ketoester 
S4-1p (18.9 g, 73%). 
S4-1p; Colorless oil; bp 75−77 °C/0.41 mmHg; 1H NMR (300 MHz, CDCl3): δ = 0.89 (t, J = 6.9 Hz, 3H), 
1.20−1.39 (m, 4H), 1.60 (quin, J = 7.6 Hz, 2H), 2.19 (t, J = 7.6 Hz, 2H × 1.0/10, enol form), 2.53 (t, J = 7.6 
Hz, 2H × 9.0/10, keto form), 3.45 (s, 2H × 9.0/10, keto form), 3.73 (s, 3H × 1.0/10, enol form), 3.74 (s, 3H × 
9.0/10, keto form), 4.99 (s, 1H × 1.0/10, enol form), 12.02 (s, 1H × 1.0/10, enol form); 
13
C NMR (75 MHz, 
CDCl3): δ = 13.5, 22.0, 22.8, 25.6, 30.8, 34.6, 42.6, 48.6, 50.6, 51.8, 88.3, 167.4, 172.7, 178.7, 202.5; IR 
(neat): νmax = 2956, 2871, 1748, 1715, 1628, 1438, 1321, 1235 cm
−1
. 
SO2Cl2 (14.6 g, 104 mmol) was added to a stirred solution of the β-ketoester S4-1p (22.4 g, 130 mmol) in 
CH2Cl2 (260 mL) at –20 °C under an Ar atmosphere, and the mixture was stirred at 20 – 25 °C for 1 h.  
Water was added to the mixture, which was extracted twice with AcOEt.  The combined organic phase was 
washed with saturated NaHCO3 aqueous solution, brine, dried (Na2SO4), and concentrated.  The obtained 
crude oil was purified by SiO2-column chromatography (hexane/AcOEt = 80/1 – 50/1) to give the desired 
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product 4-1p (21.0 g, 78%). 
4-1p; Colorless oil; 
1
H NMR (300 MHz, CDCl3) δ 0.84−0.95 (m, 3H), 1.23−1.40 (m, 4H), 1.57−1.70 (m, 2H), 
2.51 (t, J = 7.6 Hz, 2H × 4.0/10, enol form), 2.70 (dt, J = 7.2 Hz, Jgem = 3.1 Hz, 2H × 6.0/10, keto form), 3.84 
(s, 3H × 6.0/10, keto form), 3.85 (s, 3H × 4.0/10, enol form), 4.80 (s, 1H × 6.0/10, keto form), 12.32 (s, 1H × 
4.0/10, enol form); 
13
C NMR (75 MHz, CDCl3): δ = 13.7, 22.2, 23.0, 25.3, 30.9, 31.2, 32.7, 38.8, 52.5, 53.5, 
60.6, 96.1, 165.4, 169.7, 175.9, 198.7; IR (neat): νmax = 2955, 2862, 1734, 1622, 1597, 1435, 1382, 1256 cm
−1
; 
HRMS (ESI): m/z calcd for C9H15O3Cl [M+Na]
+
 229.0607; found: 229.0611. 
 
(E)-Enol Tosylation of β-Ketoesters (method A); General Procedure  
TsCl (286 mg, 1.5 mmol) in MeCN (1.0 mL) was added to a stirred suspension of β-ketoester (1.0 mmol) and 
Me2N(CH2)6NMe2 (258 mg, 1.5 mmol) in MeCN (1.0 mL) at −15 °C and the mixture was stirred at the same 
temperature for 1 h and 20 − 25 °C for 1 h.  Water (large amount) was added to the mixture, which was 
extracted twice with AcOEt.  The combined organic phase was washed with water, saturated NaHCO3 
aqueous solution, brine, dried (Na2SO4), and concentrated.  The obtained crude product was purified by SiO2 
column chromatography (hexane/AcOEt = 50/1 – 15/1) to give the desired product. 
 
(Z)-Enol Tosylations of β-Ketoesters (method B); General Procedure 
TsCl (286 mg, 1.5 mmol) in MeCN (1.0 mL) was added to a stirred suspension of β-ketoester (1.0 mmol), 
TMEDA (258 mg, 1.5 mmol), and LiCl (64 mg, 1.5 mmol) in MeCN (1.0 mL) at 0 – 5 °C and the mixture was 
stirred at the same temperature for 1 h and 20 – 25 °C for 1 h.  Water (large amount) was added to the 
mixture, which was extracted twice with AcOEt.  The combined organic phase was washed with water, 
saturated NaHCO3 aqueous solution, brine, dried (Na2SO4), and concentrated.  The obtained crude product 
was purified by SiO2 column chromatography (hexane/AcOEt = 50/1 – 10/1) to give the desired product. 
 
(E)-4-2a (method A); Typical Gram-Scale Procedure 
TsCl (4.29 g, 23 mmol) in MeCN (15 mL) was added to a stirred solution of methyl 2-butyl-3-oxooctanoate 
(4-1a; 3.42 g, 15 mmol) and Me2N(CH2)6NMe2 (4.85 mL, 23 mmol) in MeCN (15 mL) at −15 °C, and the 
mixture was stirred at the same temperature for 1 h and 20 − 25 °C for 1 h.  Water was added to the mixture, 
which was extracted twice with AcOEt.  The combined organic phase was washed with water, saturated 
NaHCO3 aqueous solution, brine, dried (Na2SO4), and concentrated.  The obtained crude product was 
purified by SiO2 column chromatography (hexane/AcOEt = 15/1) to give the desired product (E)-4-2a (3.46 g, 
60%, E/Z = >98:2). 
 
(Z)-4-2a (method B); Typical Gram-Scale Procedure 
TsCl (4.29 g, 23 mmol) in MeCN (15 mL) was added to a stirred suspension of methyl 2-butyl-3-oxooctanoate 
(4-1a; 3.42 g, 15 mmol), TMEDA (3.35 mL, 23 mmol), and LiCl (954 mg, 23 mmol) in MeCN (15 mL) at 0 − 
5 °C, and the mixture was stirred at the same temperature for 1 h and 20 − 25 °C for 1 h.  Water was added to 
the mixture, which was extracted twice with AcOEt.  The combined organic phase was washed with water, 
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saturated NaHCO3 aqueous solution, brine, dried (Na2SO4), and concentrated.  The obtained crude product 
was purified by SiO2 column chromatography (hexane/AcOEt = 10/1) to give the desired product (Z)-4-2a 
(4.74 g, 82%, E/Z = 2:>98).   
 
Methyl (E)-2-butyl-3-(tosyloxy)oct-2-enoate [(E)-4-2a][=(E)-5-4a] 
Yield: 282 mg (74%); colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 0.81 (t, J = 7.2 Hz, 3H), 0.82 (t, J = 7.2 
Hz, 3H), 1.10−1.27 (m, 8H), 1.43 (quin, J = 7.2 Hz, 2H), 2.18 (t, J = 7.2 Hz, 2H), 2.46 (s, 3H), 2.60 (t, J = 7.6 
Hz, 2H), 3.74 (s, 3H), 7.31−7.40 (m, 2H), 7.80−7.88 (m, 2H); 13C NMR (75 MHz, CDCl3): δ = 13.6, 13.8, 
21.5, 22.1, 22.4, 26.7, 27.6, 30.2, 31.0, 32.0, 51.8, 125.8, 127.7 (2C), 129.8 (2C), 134.2, 145.2, 156.6, 168.1; 
IR (neat): νmax = 2956, 2931, 2872, 1720, 1644, 1598, 1435, 1374 cm
−1
; HRMS (ESI): m/z calcd for 
C20H30O5S [M+Na]
+
 405.1712; found: 405.1710. 
 
Methyl (Z)-2-butyl-3-(tosyloxy)oct-2-enoate [(Z)-4-2a][=(Z)-5-4a] 
Yield: 356 mg (93%); colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 0.78−0.95 (m, 6H), 1.12−1.53 (m, 10H), 
2.25 (t, J = 7.6 Hz, 2H), 2.31 (t, J = 7.6 Hz, 2H), 2.45 (s, 3H), 3.59 (s, 3H), 7.29−7.38 (m, 2H), 7.75−7.85 (m, 
2H); 
13
C NMR (75 MHz, CDCl3): δ = 13.7 (2C), 21.5, 22.17, 22.22, 26.2, 29.0, 30.8, 30.9, 31.1, 51.7, 125.0, 
127.9 (2C), 129.6 (2C), 134.0, 144.9, 151.2, 167.1; IR (neat): νmax = 2959, 2872, 1728, 1655, 1599, 1458, 
1375, 1310 cm
−1
. 
 
Methyl (E)-2-methyl-3-(tosyloxy)but-2-enoate [(E)-4-2b][=(E)-5-4b] 
Yield: 3.57 g (84%) (15 mmol scale); colorless oil; 
1
H NMR (500 MHz, CDCl3): δ = 1.69 (s, 3H), 2.30 (s, 3H), 
2.27 (s, 3H), 3.74 (s, 3H), 7.37 (d, J = 8.6 Hz, 2H), 7.84 (d, J = 8.6 Hz, 2H); 
13
C NMR (125 MHz, CDCl3): δ = 
13.4, 19.8, 21.6, 51.8, 120.6, 127.8 (2C), 129.9 (2C), 133.8, 145.4, 154.9, 167.8; IR (neat): νmax = 2953, 1719, 
1655, 1597, 1369, 1281, 1171, 1080, 968, 899, 808, 723 cm
−1
. 
 
Methyl (Z)-2-methyl-3-(tosyloxy)but-2-enoate [(Z)-4-2b][=(Z)-5-4b] 
Yield: 2.06 g (72%) (10 mmol scale); colorless oil; 
1
H NMR (500 MHz, CDCl3): δ = 1.87 (s, 3H), 2.02 (s, 3H), 
2.46 (s, 3H), 3.58 (s, 3H), 7.35 (d, J = 8.6 Hz, 2H), 7.82 (d, J = 8.6 Hz, 2H); 
13
C NMR (125 MHz, CDCl3): δ = 
14.9, 18.2, 21.5, 51.7, 119. 6, 128.0 (2C), 129.6 (2C), 133.7, 145.1, 147.9, 166.7; IR (neat): νmax = 2953, 1717, 
1597, 1435, 1368, 1306, 1169, 1088, 970, 883, 806, 773, 739, 664 cm
−1
; HRMS (ESI): m/z calcd for 
C13H16O5S [M+Na]
+
 307.0616; found: 307.0616. 
 
Methyl (E)-2-butyl-3-(tosyloxy)but-2-enoate [(E)-4-2c][=(E)-5-4c] 
Yield: 263 mg (81%); colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 0.81 (t, J = 6.9 Hz, 3H), 1.10−1.26 (m, 
4H), 2.17 (t, J = 6.9 Hz, 2H), 2.27 (s, 3H), 2.46 (s, 3H), 3.74 (s, 3H), 7.33−7.42 (m, 2H), 7.80−7.88 (m, 2H); 
13
C NMR (75 MHz, CDCl3): δ = 13.6, 19.4, 21.6, 22.5, 27.4, 30.3, 51.8, 125.4, 127.8 (2C), 129.9 (2C), 134.1, 
145.3, 153.4, 168.0; IR (neat): νmax = 2956, 1719, 1650, 1598, 1435, 1372, 1279, 1088 cm
−1
; HRMS (ESI): 
m/z calcd for C16H22O5S [M+Na]
+
 349.1086; found: 349.1097. 
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Methyl (Z)-2-butyl-3-(tosyloxy)but-2-enoate [(Z)-4-2c][=(Z)-5-4c] 
Yield: 312 mg (96%); colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 0.88 (t, J = 7.2 Hz, 3H), 1.21−1.42 (m, 
4H), 2.02 (s, 3H), 2.23 (t, J = 7.2 Hz, 2H), 2.44 (s, 3H), 3.57 (s, 3H), 7.30−7.39 (m, 2H), 7.75−7.84 (m, 2H); 
13
C NMR (75 MHz, CDCl3): δ = 13.5, 17.7, 21.4, 22.0, 28.9, 30.2, 51.5, 124.7, 127.8 (2C), 129.5 (2C), 133.5, 
145.0, 147.3, 166.6; IR (neat): νmax = 2956, 1724, 1598, 1370, 1306, 1196, 1164, 1090 cm
−1
. 
 
Methyl 2-butyl-2-chloro-3-oxooctanoate (by-product) 
Colorless oil; 
1
H NMR (500 MHz, CDCl3): δ = 0.88 (t, J = 7.2 Hz, 3H), 0.91 (t, J = 7.2 Hz, 3H), 1.20−1.43 (m, 
8H), 1.62 (quin, J = 7.2 Hz, 2H), 2.04−2.25 (m, 2H), 2.58 (dt, J = 7.2 Hz, Jgem = 17.9 Hz, 1H), 2.72 (dt, J = 
7.2 Hz, Jgem = 17.5 Hz, 1H), 3.81 (s, 3H); 
13
C NMR  (125 MHz, CDCl3): δ = 13.7 (2C), 22.3, 22.4, 23.5, 
26.1, 30.9, 36.3, 37.9, 53.4, 75.9, 168.0, 200.8; IR (neat): νmax = 2958, 2873, 1727, 1467, 1436, 1314, 1244, 
1208 cm
−1
; HRMS (ESI): m/z calcd for C13H23ClO3 [M+Na]
+
 285.1233; found: 285.1247. 
 
Methyl (E)-2-isopropyl-3-(tosyloxy)but-2-enoate [(E)-4-2d][=(E)-5-4d] 
Yield: 131 mg (84%) (0.5 mmol scale); pale yellow oil; 
1
H NMR (300 MHz, CDCl3): δ = 0.94 (d, J = 6.9 Hz, 
6H), 2.04 (s, 3H), 2.46 (s, 3H), 2.85 (sep, J = 6.9 Hz, 1H), 3.75 (s, 3H), 7.33−7.39 (m, 2H), 7.80−7.87 (m, 
2H); 
13
C NMR (75 MHz, CDCl3): δ = 18.9, 20.3 (2C), 21.5, 27.2, 51.5, 127.8 (2C), 129.8 (2C), 131.4, 133.8, 
145.3, 147.0, 167.9; IR (neat): νmax = 1968, 1725, 1667, 1598, 1435, 1372, 1276, 1193 cm
−1
; HRMS (ESI): 
m/z calcd for C15H20O5S [M+Na]
+
 335.0929; found: 335.0928. 
 
Methyl (Z)-2-isopropyl-3-(tosyloxy)but-2-enoate [(Z)-4-2d][=(Z)-5-4d] 
Yield: 133 mg (85%) (0.5 mmol scale); pale yellow oil; 
1
H NMR (300 MHz, CDCl3): δ = 1.08 (d, J = 6.9 Hz, 
6H), 2.05 (s, 3H), 2.45 (s, 3H), 2.62 (sep, J = 6.9 Hz, 1H), 3.55 (s, 3H), 7.30−7.38 (m, 2H), 7.76−7.82 (m, 
2H); 
13
C NMR (75 MHz, CDCl3): δ = 16.8, 20.7 (2C), 21.6, 28.7, 51.4, 127.9 (2C), 129.6 (2C), 130.7, 133.8, 
143.9, 145.0, 166.5; IR (neat): νmax = 2929, 2859, 1718, 1621, 1442, 1254, 1200, 1089 cm
−1
. 
 
Methyl (E)-2-methyl-3-(tosyloxy)hept-2-enoate [(E)-4-2e][=(E)-5-4c’] 
Yield: 1.21 g (74%) (5 mmol scale); pale yellow oil; 
1
H NMR (500 MHz, CDCl3): δ = 0.81 (t, J = 7.5 Hz, 3H), 
1.22 (sext, J = 7.5 Hz, 2H), 1.43 (quin, J = 7.5 Hz, 2H), 1.72 (s, 3H), 2.47 (s, 3H), 2.70 (t, J = 7.5 Hz, 2H), 
3.74 (s, 3H), 7.34–7.39 (m, 2H), 7.82–7.87 (m, 2H); 13C NMR (125 MHz, CDCl3): δ = 13.4, 13.7, 21.5, 21.9, 
28.9, 31.7, 51.8, 120.8, 127.7 (2c), 129.8 (2C), 134.0, 145.3, 158.5, 167.8; IR (neat): νmax = 1721, 1435, 1371, 
1308, 1394, 1271, 1192, 1180, 1163 cm
−1
; HRMS (ESI): m/z calcd for C16H22O5S [M+Na]
+
 349.1086; found: 
349.1078. 
 
Methyl (Z)-2-methyl-3-(tosyloxy)hept-2-enoate [(Z)-4-2e][=(Z)-5-4c’] 
Yield: 607 mg (62%) (3 mmol scale); pale yellow oil; 
1
H NMR (500 MHz, CDCl3): δ = 0.83 (t, J = 7.5 Hz, 
3H), 1.25 (sext, J = 7.5 Hz, 2H), 1.44 (quin, J = 7.5 Hz, 2H), 1.90 (s, 3H), 2.33 (t, J = 7.5 Hz, 2H), 2.46 (s, 
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3H), 3.60 (s, 3H), 7.31–7.38 (m, 2H), 7.82–7.85 (m, 2H); 13C NMR (125 MHz, CDCl3): δ = 13.4, 14.7, 21.3, 
21.8, 28.1, 30.9, 51.5, 119.6, 127.8 (2c), 129.5 (2C), 133.9, 144.9, 151.6, 166.8; IR (neat): νmax = 1720, 1435, 
1371, 1306, 1277, 1190, 1179, 1167, 1107 cm
−1
. 
 
Methyl (E)-2-methyl-3-(tosyloxy)oct-2-enoate [(E)-4-2f] 
Yield: 253 mg (74%); colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 0.83 (t, J = 7.2 Hz, 3H), 1.10−1.26 (m, 
4H), 1.43 (quin, J = 7.2 Hz, 2H), 1.73 (s, 3H), 2.47 (s, 3H), 2.68 (t, J = 7.2 Hz, 2H), 3.74 (s, 3H), 7.33−7.40 
(m, 2H), 7.81−7.88 (m, 2H); 13C NMR (75 MHz, CDCl3): δ = 13.8 (2C), 21.5, 22.1, 26.6, 31.1, 32.0, 51.8, 
120.8, 127.7 (2C), 129.8 (2C), 134.1, 145.3, 158.6, 167.8; IR (neat): νmax = 2954, 1720, 1650, 1598, 1435, 
1373, 1276, 1191 cm
−1
; HRMS (ESI): m/z calcd for C17H24O5S [M+Na]
+
 363.1242; found: 363.1246. 
 
Methyl (Z)-2-methyl-3-(tosyloxy)oct-2-enoate [(Z)-4-2f] 
Yield: 319 mg (94%); colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 0.84 (t, J = 7.2 Hz, 3H), 1.11−1.32 (m, 
4H), 1.38−1.52 (m, 2H), 1.89 (s, 3H), 2.32 (t, J = 7.2 Hz, 2H), 2.45 (s, 3H), 3.60 (s, 3H), 7.30−7.39 (m, 2H), 
7.76−7.87 (m, 2H); 13C NMR (75 MHz, CDCl3): δ = 13.7, 14.8, 21.5, 22.1, 25.9, 31.0, 31.3, 51.7, 119.7, 127.9 
(2C), 129.6 (2C), 134.1, 145.0, 151.9, 167.0; IR (neat): νmax = 2954, 2863, 1715, 1598, 1434, 1372, 1306, 
1180 cm
−1
. 
 
Methyl (E)-7-chloro-2-methyl-3-(tosyloxy)hept-2-enoate [(E)-4-2g][= (E)-5-4g] 
Yield: 276 mg (77%); pale yellow oil; 
1
H NMR (300 MHz, CDCl3): δ = 1.57−1.72 (m, 4H), 1.73 (s, 3H), 2.47 
(s, 3H), 2.75 (t, J = 6.5 Hz, 2H), 3.46 (t, J = 6.5 Hz, 2H), 3.75 (s, 3H), 7.34−7.41 (m, 2H), 7.81−7.88 (m, 2H); 
13
C NMR (75 MHz, CDCl3): δ = 13.7, 21.4, 24.0, 31.1, 31.5, 44.2, 51.8, 121.3, 127.6 (2C), 129.8 (2C), 133.7, 
145.4, 157.4, 167.5; IR (neat): νmax = 2952, 1719, 1648, 1435, 1371, 1278, 1191, 1177 cm
−1
; HRMS (ESI): m/z 
calcd for C16H21O5ClS [M+Na]
+
 383.0696; found: 383.0678. 
 
Methyl (Z)-7-chloro-2-methyl-3-(tosyloxy)hept-2-enoate [(Z)-4-2g][= (Z)-5-4g] 
Yield: 306 mg (85%); pale yellow oil; 
1
H NMR (300 MHz, CDCl3): δ = 1.58−1.83 (m, 4H), 1.90 (s, 3H), 2.38 
(t, J = 6.9 Hz, 2H), 2.45 (s, 3H), 3.46 (t, J = 6.5 Hz, 2H), 3.59 (s, 3H), 7.32−7.38 (m, 2H), 7.79−7.85 (m, 2H); 
13
C NMR (75 MHz, CDCl3): δ = 14.6, 21.3, 23.3, 30.2, 31.3, 44.0, 51.5, 120.1, 127.6 (2C), 129.5 (2C), 133.5, 
145.0, 150.5, 166.5; IR (neat): νmax = 2952, 1720, 1598, 1435, 1371, 1307, 1108, 1086 cm
−1
. 
 
Methyl (E)-2-(non-8-en-1-yl)-3-(tosyloxy)trideca-2,12-dienoate [(E)-4-2h] 
Yield: 327 mg (63%); colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 1.08−1.49 (m, 22H), 1.96−2.08 (m, 4H), 
2.17 (t, J = 7.6 Hz, 2H), 2.46 (s, 3H), 2.60 (t, J = 7.6 Hz, 2H), 3.74 (s, 3H), 4.89−5.05 (m, 4H), 5.81 (ddt, J = 
6.9, 10.3, 16.9 Hz, 2H), 7.33−7.39 (m, 2H), 7.81−7.87 (m, 2H); 13C NMR (75 MHz, CDCl3): δ = 21.6, 27.1, 
27.9, 28.1, 28.83, 28.85, 28.91, 28.98, 29.02 (2C), 29.09, 29.2, 29.3, 32.2, 33.7 (2C), 51.8, 114.1 (2C), 125.8, 
127.8 (2C), 129.8 (2C), 134.3, 139.1 (2C), 145.2, 156.7, 168.1 ; IR (neat): νmax = 2927, 2854, 1720, 1640, 
1598, 1376, 1192, 1178 cm
−1
; HRMS (ESI): m/z calcd for C30H46O5S [M+Na]
+
 541.2964; found: 541.2944. 
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Methyl (Z)-2-(non-8-en-1-yl)-3-(tosyloxy)trideca-2,12-dienoate [(Z)-4-2h] 
Yield: 474 mg (91%); colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 1.15−1.52 (m, 22H), 2.03 (q, J = 6.9 Hz, 
4H), 2.24 (t, J = 7.6 Hz, 2H), 2.30 (t, J = 7.6 Hz, 2H), 2.45 (s, 3H), 3.59 (s, 3H), 4.89−5.04 (m, 4H), 5.80 (ddt, 
J = 6.9, 10.3, 16.9 Hz, 1H), 5.81 (ddt, J = 6.9, 10.3, 16.9 Hz, 1H), 7.31−7.37 (m, 2H), 7.78−7.85 (m, 2H); 13C 
NMR (75 MHz, CDCl3): δ = 21.5, 26.5, 28.6, 28.7, 28.7, 28.8, 28.91, 28.93, 28.98, 29.0 (2C), 29.16, 29.18, 
30.9, 33.6 (2C), 51.6, 114.1 (2C), 125.0, 127.9 (2C), 129.5 (2C), 134.0, 138.86, 138.89, 144.9, 151.1, 167.0; 
IR (neat): νmax = 2926, 2855, 1726, 1640, 1599, 1376, 1194, 1180 cm
−1
. 
 
Methyl (E)-2-methyl-3-phenyl-3-(tosyloxy)acrylate [(E)-4-2i][=(E)-5-2a] 
Yield: 309 mg (89%); colorless crystals; mp 68–69 °C; 1H NMR (300 MHz, CDCl3): δ = 2.06 (s, 3H), 2.36 (s, 
3H), 3.51 (s, 3H), 7.07−7.27 (m, 7H), 7.41−7.46 (m, 2H); 13C NMR (75 MHz, CDCl3): δ = 14.8, 21.5, 51.8, 
123.1, 127.6 (2C), 127.8 (2C), 128.7 (2C), 129.2, 129.3 (2C), 133.4, 133.8, 144.8, 151.6, 168.4; IR (neat): νmax 
= 1714, 1657, 1599, 1439, 1364, 1322, 1191, 1176 cm
−1
; HRMS (ESI): m/z calcd for C18H18O5S [M+Na]
+
 
369.0773; found: 369.0758. 
 
Methyl (Z)-2-methyl-3-phenyl-3-(tosyloxy)acrylate [(Z)-4-2i][=(Z)-5-2a] 
Yield: 312 mg (90%); colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 1.94 (s, 3H), 2.35 (s, 3H), 3.81 (s, 3H), 
7.04−7.10 (m, 2H), 7.14−7.30 (m, 5H), 7.38−7.45 (m, 2H); 13C NMR (75 MHz, CDCl3) δ 15.6, 21.1, 51.8, 
120.9, 127.5 (2C), 127.6 (2C), 128.9 (2C), 129.0 (2C), 129.1, 131.8, 133.7, 144.3, 147.9, 166.9; IR (neat): νmax 
= 2952, 1715, 1598, 1434, 1374, 1308, 1255, 1002 cm
−1
. 
 
Methyl (E)-2-methyl-3-(4-tolyl)-3-(tosyloxy)acrylate [(E)-4-2j][=(E)-5-2a’] 
Yield: 864 mg (80%) (3 mmol scale); colorless oil; 
1
H NMR (500 MHz, CDCl3): δ = 2.03 (s, 3H), 2.29 (s, 3H), 
2.43 (m, 3H), 3.53 (s, 3H), 6.92−6.97 (m, 2H), 7.01−7.06 (m, 2H), 7.08−7.14 (m, 2H), 7.43−7.49 (m, 2H); 13C 
NMR (125 MHz, CDCl3): δ = 14.6, 21.1, 21.3, 51.6, 122.1, 127.7 (2C), 128.2 (2C), 128.5 (2C), 129.2 (2C), 
130.3, 133.7, 139.2, 144.6, 151.7, 168.4; IR (neat): νmax = 1717, 1651, 1597, 1435, 1371, 1240, 1190 cm
−1
; 
HRMS (ESI): m/z calcd for C19H20O5S [M+Na]
+
 383.0929; found: 383.0926. 
 
Methyl (Z)-2-methyl-3-(4-tolyl)-3-(tosyloxy)acrylate [(Z)-4-2j][=(Z)-5-2a’] 
Yield: 970 mg (89%) (3 mmol scale); colorless crystals; mp 94–96 °C; 1H NMR (500 MHz, CDCl3): δ = 1.92 
(s, 3H), 2.30 (s, 3H), 2.36 (s, 3H), 3.78 (s, 3H), 6.95−7.01 (m, 2H), 7.04−7.13 (m, 4H), 7.39−7.46 (m, 2H); 
13
C NMR (125 MHz, CDCl3): δ = 15.9, 21.2, 21.4, 52.0, 120.6, 127.9 (2C), 128.5 (2C), 129.1 (2C), 129.2 
(2C), 129.3, 134.2, 140.0, 144.3, 148.5, 167.3; IR (neat): νmax = 1726, 1645, 1425, 1369, 1258, 1179, 1134 
cm
−1
. 
 
Methyl (E)-3-(4-methoxyphenyl)-2-methyl-3-(tosyloxy)acrylate [(E)-4-2k][=(E)-5-2b’] 
Yield: 3.39 g (90%) (10 mmol scale); colorless crystals; mp 73–75 °C; 1H NMR (500 MHz, CDCl3): δ = 2.04 
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(s, 3H), 2.38 (s, 3H), 3.54 (s, 3H), 3.77 (s, 3H), 6.63–6.67 (m, 2H), 7.05–7.09 (m, 2H), 7.11–7.15 (m, 2H), 
7.44–7.49 (m, 2H); 13C NMR (125 MHz, CDCl3): δ = 14.6, 21.3, 51.6, 55.0, 112.9 (2C), 121.6, 125.4, 127.7 
(2C), 129.4 (2C), 130.1 (2C), 133.8, 144.6, 151.6, 160.2, 168.4; IR (neat): νmax = 1717, 1607, 1508, 1369, 
1250, 1190, 1175 cm
−1
; HRMS (ESI): m/z calcd for C19H20O6S [M+Na]
+
 399.0878; found: 399.0864. 
 
Methyl (Z)-3-(4-methoxyphenyl)-2-methyl-3-(tosyloxy)acrylate [(Z)-4-2k][=(Z)-5-2b’] 
Yield: 3.68 g (98%) (10 mmol scale); colorless crystals; mp 70–71 °C; 1H NMR (500 MHz, CDCl3): δ = 1.94 
(s, 3H), 2.37 (s, 3H), 3.78 (s, 3H), 3.79 (s, 3H), 6.66–6.73 (m, 2H), 7.07–7.17 (m, 4H), 7.41–7.49 (m, 2H); 13C 
NMR (125 MHz, CDCl3): δ = 16.0, 21.5, 52.0, 55.3, 113.3 (2C), 120.1, 124.4, 127.9 (2C), 129.2 (2C), 130.9 
(2C), 134.3, 144.4, 148.5, 160.4, 167.4; IR (neat): νmax = 1724, 1645, 1607, 1508, 1456, 1371, 1256, 1244, 
1184 cm
−1
. 
 
Methyl (E)-2-methyl-3-(4-chlorophenyl)-3-(tosyloxy) acrylate [(E)-4-2l][=(E)-5-2c’] 
Yield: 982 mg (94%) (3 mmol scale); colorless crystals; mp 71–73 °C; 1H NMR (500 MHz, CDCl3): δ = 2.06 
(s, 3H), 2.40 (s, 3H), 3.54 (s, 3H), 7.04−7.12 (m, 4H), 7.13−7.17 (m, 2H), 7.42−7.48 (m, 2H); 13C NMR (125 
MHz, CDCl3): δ = 14.7, 21.5, 52.0, 123.5, 127.8 (2C), 127.9 (2C), 129.4 (2C), 130.2 (2C), 131.8, 133.7, 135.3, 
145.2, 150.5, 168.0; IR (neat): IR (neat): νmax = 1722, 1651, 1593, 1487, 1371, 1244, 1190 cm
−1
; HRMS (ESI): 
m/z calcd for C18H17O5ClS [M+Na]
+
 403.0383; found: 403.0377. 
 
Methyl (Z)-2-methyl-3-(4-chlorophenyl)-3-(tosyloxy) acrylate [(Z)-4-2l][=(Z)-5-2c’] 
Yield: 1.01 g (96%) (3 mmol scale); colorless oil; 
1
H NMR (400 MHz, CDCl3): δ = 1.92 (s, 3H), 2.38 (s, 3H), 
3.80 (s, 3H), 7.09−7.18 (m, 4H), 7.13−7.15 (m, 2H), 7.41−7.46 (m, 2H); 13C NMR (100 MHz, CDCl3): δ = 
15.8, 21.4, 52.1, 121.7, 127.8 (2C), 128.2 (2C), 129.2 (2C), 129.5, 130.6 (2C), 133.9, 135.5, 144.8, 146.9, 
166.9; IR (neat): νmax = 1732, 1595, 1489, 1435, 1314, 1248, 1161 cm
−1
. 
 
Methyl (E)-2,3-diphenyl-3-(tosyloxy)acrylate [(E)-4-2m] 
Yield: 3.91 g (96%, E/Z = 74:26), 2.02 g (49%, E/Z = >98:2 after recrystallization from EtOAc) (10 mmol 
scale); colorless crystals; mp 149–152 °C; 1H NMR (500 MHz, CDCl3): δ = 2.35 (s, 3H), 3.50 (s, 3H), 
6.94−7.03 (m, 2H), 7.17−7.50 (m, 12H); 13C NMR (125 MHz, CDCl3): δ = 21.5, 52.3, 127.3, 127.7 (2C), 
128.0 (2C), 128.1 (2C), 128.2, 128.6 (2C), 129.0 (2C), 129.2 (2C), 129.8, 132.2, 133.2, 133.4, 144.6, 149.1, 
167.6; IR (neat): νmax = 1717, 1651, 1595, 1445, 1368, 1302, 1273, 1215, 1175 cm
−1
; HRMS (ESI): m/z calcd 
for C23H20O5S [M+Na]
+
 431.0929; found: 431.0907. 
 
Methyl (Z)-2,3-diphenyl-3-(tosyloxy)acrylate [(Z)-4-2m] 
Yield: 381 mg (93%); colorless crystals; mp 111–112 °C; 1H NMR (300 MHz, CDCl3): δ = 2.38 (s, 3H), 3.80 
(s, 3H), 6.96−7.06 (m, 4H), 7.08−7.22 (m, 8H), 7.47−7.53 (m, 2H); 13C NMR (75 MHz, CDCl3): δ = 21.5, 
52.5, 126.9, 127.0, 127.7 (2C), 128.0 (2C), 128.1, 128.3 (2C), 129.3 (2C), 129.7 (2C), 129.9 (2C), 131.9, 
133.1, 134.0, 144.7, 148.5, 166.5; IR (neat): νmax = 1726, 1448, 1431, 1369, 1253, 1209, 1174, 1053 cm
−1
. 
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Methyl (E)-3-(4-methoxyphenyl)-2-phenyl-3-(tosyloxy)acrylate [(E)-4-2n] 
Yield: 4.17 g (95%, E/Z = 66:34), 1.14 g (26%, E/Z = >98:2, after recrystallization from toluene) (10 mmol 
scale); colorless crystals; mp 116–118 °C; 1H NMR (500 MHz, CDCl3): δ = 2.35 (s, 3H), 3.53 (s, 3H), 3.82 (s, 
3H), 6.73−6.83 (m, 2H), 6.94−7.07 (m, 2H), 7.14−7.30 (m, 5H), 7.34−7.44 (m, 4H); 13C NMR (125 MHz, 
CDCl3): δ = 21.5, 52.3, 55.2, 113.4 (2C), 125.6, 126.1, 127.8 (2C), 128.0 (3C), 129.0 (2C), 129.2 (2C), 130.2 
(2C), 132.5, 133.4, 144.5, 149.3, 160.7, 167.8; IR (neat): νmax = 1720, 1633, 1605, 1506, 1435, 1375, 1206 
cm
−1
; HRMS (ESI): m/z calcd for C24H22O6S [M+Na]
+
 461.1035; found: 461.1030. 
 
Methyl (Z)-3-(4-methoxyphenyl)-2-phenyl-3-(tosyloxy)acrylate [(Z)-4-2n] 
Yield: 13.04 g (99%) (30 mmol scale); colorless crystals; mp 123–125 °C; 1H NMR (500 MHz, CDCl3): δ = 
2.40 (s, 3H), 3.72 (s, 3H), 3.77 (s, 3H), 6.47−7.56 (m, 2H), 6.90−7.00 (m, 2H), 7.06−7.24 (m, 7H), 7.48−7.59 
(m, 2H); 
13
C NMR (125 MHz, CDCl3): δ = 21.5, 52.3, 55.1, 113.2 (2C), 124.1, 125.6, 127.9, 128.0 (2C), 
128.3 (2C),129.2 (2C), 129.7 (2C), 131.5 (2C), 133.5, 134.2, 144.6, 148.8, 160.2, 166.6; IR (neat): νmax = 
1726, 1636, 1608, 1433, 1317, 1252, 1192 cm
−1
. 
 
Methyl (Z)-2-methoxy-3-(tosyloxy)oct-2-enoate [(Z)-4-2o][= (Z)-3.3-4g] 
Yield: 322 mg (90%); pale yellow oil; 
1
H NMR (300 MHz, CDCl3): δ = 0.85 (t, J = 7.2 Hz, 3H), 1.14−1.34 (m, 
4H), 1.50 (quin, J = 7.6 Hz, 2H), 2.45 (s, 3H), 2.71 (t, J = 7.6 Hz, 2H), 3.42 (s, 3H), 3.81 (s, 3H), 7.30−7.37 
(m, 2H), 7.83−7.91 (m, 2H); 13C NMR (75 MHz, CDCl3): δ = 13.7, 21.5, 22.1, 26.2, 30.6, 30.9, 52.0, 60.0, 
127.8 (2C), 129.5 (2C), 134.4, 139.4, 144.9, 151.2, 163.9; IR (neat): νmax = 2935, 1725, 1642, 1598, 1371, 
1297, 1179, 1024 cm
−1
; HRMS (ESI): m/z calcd for C17H24O6S [M+Na]
+
 379.1191; found: 379.1199. 
 
Methyl (E)-2-methoxy-3-(tosyloxy)oct-2-enoate [(E)-4-2o][= (E)-3.3-4g] 
Yield: 325 mg (91%); pale yellow oil; 
1
H NMR (300 MHz, CDCl3): δ = 0.84 (t, J = 7.6 Hz, 3H), 1.11−1.30 (m, 
4H), 1.43 (quin, J = 7.6 Hz, 2H), 2.40 (t, J = 7.6 Hz, 2H), 2.46 (s, 3H), 3.60 (s, 3H), 3.68 (s, 3H), 7.30−7.40 
(m, 2H), 7.77−7.87 (m, 2H); 13C NMR (75 MHz, CDCl3): δ = 13.8, 21.6, 22.1, 25.7, 29.1, 31.0, 51.9, 60.2, 
128.1 (2C), 129.6 (2C), 133.5, 141.1, 145.3, 150.0, 162.2; IR (neat): νmax = 2934, 2862, 1725, 1598, 1436, 
1376, 1294, 1208 cm
−1
. 
 
Methyl (Z)-2-chloro-3-(tosyloxy)oct-2-enoate [(Z)-4-2p] 
Yield: 296 mg (82%); colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 0.86 (t, J = 6.9 Hz, 3H), 1.20−1.33 (m, 
4H), 1.50−1.62 (m, 2H), 2.47 (s, 3H), 2.92 (t, J = 7.6 Hz, 2H), 3.82 (s, 3H), 7.34−7.40 (m, 2H), 7.86−7.93 (m, 
2H); 
13
C NMR (75 MHz, CDCl3): δ = 13.7, 21.5, 22.0, 26.5, 30.9, 32.5, 53.0, 116.2, 128.0 (2C), 129.8 (2C), 
133.6, 145.7, 159.6, 162.7; IR (neat): νmax = 2959, 2866, 1724, 1615, 1384, 1262, 1180, 1047 cm
−1
; HRMS 
(ESI): m/z calcd for C16H21ClO5S [M+Na]
+
 383.0696; found: 383.0711. 
 
Methyl (E)-2-chloro-3-(tosyloxy)oct-2-enoate [(E)-4-2p] 
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Yield: 261 mg (62%); colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 0.85 (t, J = 6.9 Hz, 3H), 1.16−1.30 (m, 
4H), 1.42−1.56 (m, 2H), 2.47 (s, 3H), 2.53 (t, J = 7.6 Hz, 2H), 3.70 (s, 3H), 7.33−7.41 (m, 2H), 7.80−7.89 (m, 
2H); 
13
C NMR (75 MHz, CDCl3): δ = 13.7, 21.6, 22.1, 25.3, 30.9, 32.3, 52.9, 118.4, 128.2 (2C), 129.8 (2C), 
133.3, 145.7, 155.1, 161.6; IR (neat): νmax = 2955, 2862, 1734, 1622, 1597, 1435, 1382, 1256 cm
−1
. 
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Chapter 5. 
Divergent Synthetic Access to E- and Z-Stereodefined 
All-Carbon-Substituted Olefin Scaffolds: Application to Parallel 
Synthesis of (E)- and (Z)-Tamoxifens 
 
Abstract 
A highly substrate-general synthesis of all-carbon-substituted E- and Z-stereodefined olefins is 
performed.  The method comprises two sets of parallel and stereocomplementary preparations of 
(E)- and (Z)-α,β-unsaturated esters involving two robust and distinctive reactions: 1) 
stereocomplementary enol tosylations using readily available TsCl/diamine/(LiCl) base reagents, and 
2) stereoretentive Negishi cross-coupling using the catalysts [Pd(dppe)Cl2] (for E) and [Pd(dppb)Cl2] 
(for Z).  The present parallel approach is categorized as both type I (convergent approach: 16 
examples, 56−87% yield) and type II (divergent approach: 18 examples, 70−95% yield).  The 
following two developments are performed by Atsushi Honda, one of our colleagues: (i) The obtained 
(E)- and (Z)-α,β-unsaturated ester scaffolds are successfully transformed into various E- and 
Z-stereodefined known and novel olefins (8x2 derivatization arrays).  (ii) As a demonstration, 
application to the parallel synthesis of both (E)- and (Z)-tamoxifens, a representative motif of 
all-carbon-substituted olefins, is accomplished in a total of eight steps with an overall yield of 58% 
(average 93%) and 57% (average 93%), respectively. 
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Introduction 
Regio- and stereo-controlled syntheses of E- and Z-stereodefined olefins are of pivotal importance in 
organic chemistry, because of their wide distribution in natural products, pharmaceuticals, and in 
supramolecules as key structural building blocks.  Among the olefins, construction of acyclic stereodefined 
all-carbon-substituted olefins remains a challenge due to their structural complexity.  Considerable efforts 
have been invested in this over the recent decades.  The impressive progress in this area has been 
comprehensively reviewed.
1
  The strategy for the synthesis of acyclic fully-substituted olefins is generally 
categorized into five approaches: 1) carbometalations of alkynes using Cu, B, Sn, Mg, Pd, and so forth, 
followed by reactions with electrophiles, 2) acid-induced carbonyl olefinations of unsymmetrically substituted 
ketones, 3) elimination reactions of tertiary alcohols, 4) cross-metatheses between olefins, and 5) 
ynolate-mediated reactions derived from α,α-dibromoesters. 
Cross-coupling reactions with stereodefined enol sulfonate
2
 and phosphonate
3
 partners derived from 
β-ketoesters, which emerged in recent decades, are considered a promising and reliable approach compared 
with the above-mentioned methods, with the following advantages: 1) various starting β-ketoester substrates 
are readily available,
4
 and 2) the E- and Z-stereocomplementary enol tosylation step is robust and 
costeffective.
5
  E- and Z-stereoretention during the cross-coupling step is guaranteed, especially for 
Suzuki−Miyaura (SM) cross-coupling.  Additionally, recent developments of cross-couplings using enol 
sulfonates facilitate and enhance this strategy.  As depicted in Scheme 5-1, the current privileged protocols 
were adopted for the synthesis of “trisubstituted” (R1 or R2=H) elaborated natural products and 
pharmacophore-containing compounds, such as γ-aminobutanoic acid (GABA) analogues,6 juvenile hormones 
0 and I,
7
 functionalized steroids,
8
 madangamine A,
9
 and (E)- and (Z)-zimelidines.
10
 
 
 
Scheme 5-1.  Synthetic applications of trisubstituted (E)- and (Z)-enol tosylates. 
 
This background led us to envisage a highly substrate-general synthesis of fully all-carbon-substituted E- 
and Z-stereodefined olefins, and especially to focus on a parallel methodology.  The author and co-workers 
present divergent access to a variety of acyclic stereodefined all-carbon-substituted olefins and the first 
97 
 
parallel synthesis of (E)- and (Z)-tamoxifens, representatives of these olefins (Figure 5-1). 
 
 
Figure 5-1.  The structures of (E)- and (Z)-tamoxifens. 
 
Results and Discussion 
Stereocontrolled synthesis of ubiquitous (E)- and (Z)-α,β-unsaturated ester scaffolds occupies a central 
position in organic synthesis.  Due to the intrinsic higher complexity in differentiating the substituents, 
synthesis of all-carbon-substituted E- and Z-stereodefined olefin precursors are not sufficiently established.  
Here we elaborate a plan for two distinctive parallel and stereoretentive syntheses for fully substituted (E)- 
and (Z)-α,β-unsaturated esters 5-3 and 5-5 starting from readily accessible β-ketoesters 5-1a and 5-1b, by 
utilizing type I and type II strategies via dual approaches 1 and 2 (Scheme 5-2). 
 
Scheme 5-2.  Two types of parallel and stereoretentive syntheses of fully substituted (E)- and (Z)-α,β-unsaturated esters 5-3 and 
5-5. 
In 2015, our group reported the synthesis of specific but substrate-general fully substituted 
α,β-diarylbut-2-enoic esters, utilizing a parallel approach.10  Later in 2016, the Merck process group 
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independently disclosed asymmetric synthesis of α-methyl-β-cyclopropyldihydrocinnamates via the 
corresponding (Z)-enol tosylate of methyl 3-cyclopropyl-3-oxopropanoate (Chapter 4, Scheme 4-2).
11
  Both 
methods utilize Suzuki−Miyaura (SM) cross-coupling for construction of the α,β-unsaturated esters.  One 
key difference between the approaches of the two groups is the stereocomplementary enol tosylation reagents 
[our group: TsCl/N-methylimidazole or N,N,N’,N’-tetramethylenediamine (TMEDA)/LiCl; the Merck group: 
para-toluenesulfonic anhydride/lithium bis(trimethylsilyl)amide (LHMDS)].
12
 
As part of our ongoing investigation,
13
 it was recently observed that Negishi cross-coupling tends to exhibit 
higher reactivity with lower catalyst loadings for this type of synthetic approach (unpublished results).  By 
contrast, enol phosphonates serve as effective SM and Negishi cross-coupling partners.
14
  Against this 
background, as a preliminary evaluation, comparable Negishi cross-coupling experiments were examined 
using a 1:1 mixture of enol tosylate (E)-5-4a and enol phosphonate (E)-5-6 (Scheme 5-3).  The result 
indicated the superiority of (E)-5-4a as the cross-coupling partner.  Thus, for this objective the author 
focused his attention on Negishi cross-coupling instead of SM cross-coupling using various enol tosylates 5-4. 
 
 
Scheme 5-3.  Comparative experiment between enol tosylate (E)-5-4a and enol phosphonate (E)-5-6. 
 
Starting enol tosylates 5-2 and 5-4 were conveniently prepared by using a recently improved robust and 
cost-effective method for E- and Z-stereocomplementary reactions of β-ketoesters [E: Me2N(CH2)6NMe2 ; Z: 
LiCl−TMEDA].5 
The initial screening of several Pd catalysts for Negishi crosscoupling was guided by the reaction using 
intentionally less-reactive enol tosylates (E)-5-4a or (Z)-5-4a with PhMgBr/ZnCl2 (in situ generation of 
PhZnCl; Table 5-1).  Among them, [Pd(dppe)Cl2] produced fruitful results in the E-stereoretentive reaction 
to give (E)-5-5a-1 with high yield (82%) and selectivity (E/Z=96:4) in MeCN/THF (Table 5-1, entry 7).  
Notably, in contrast to the E isomer, reactions using (Z)-5-4a proceeded with nearly perfect Z-stereoretention 
in all cases examined to yield (Z)-5-5a-1 and [Pd(dppb)Cl2] afforded the best result (85 %, E/Z=2:98) in THF 
(Table 5-1, entry 5). 
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Table 5-1.  Optimization of Negishi cross-coupling conditions. 
 
Entry Catalyst Solvent Yield / % (E/Z)
a
 
(E)-5-5a-1 (Z)-5-5a-1 
1 [Pd(PPh3)4] THF 4 (48:52) 74 (2:>98) 
2 [Pd(PPh3)2Cl2] THF 8 (49:51) 38 (2:>98) 
3 [Pd(dppe)Cl2] THF 24 (94:6) 39 (2:>98) 
4 [Pd(dppp)Cl2] THF 42 (78:22) 43 (2:>98) 
5 [Pd(dppb)Cl2] THF 47 (72:28) 85 (2:>98) 
6 [Pd(dppf)Cl2] THF 28 (75:25) 12 (2:>98) 
7 [Pd(dppe)Cl2] MeCN/THF (2:1) 82
b,c
 (96:4) − 
a) Determined by 
1
H NMR spectroscopy of the crude products. 
b) [Pd(dppe)Cl2] (2 mol%).  C) 80 – 85 °C. 
 
Table 5-2 shows the successful results of the present parallel synthesis (type I) (convergent oriented 
approach) by using the Negishi cross-coupling method under optimized conditions A and B (Table 5-1).  
Ar
1
ZnCl and Ar
2
ZnCl reagents containing both electron-donating groups (p-Me, p-MeO) and an 
electron-withdrawing (p-Cl) group were applicable.  Two pairs of Ar
1
- and Ar
2
-substituted enol tosylates, 
(E)-5-2, 5-2’ and (Z)-5-2, 5-2’, were transformed into the corresponding products, (E)-5-3, 5-3’ and (Z)-5-3, 
5-3’, respectively, through dual convergent pathways.  The salient features are as follows: 1) for the four sets 
examined, all reactions proceeded in good to excellent yield; 2) excellent Z-selectivity was produced in all 
eight cases; 3) E-selectivity was slightly decreased in a few cases (Table 5-1, entries 5, 9, and 13). 
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Table 5-2.  Parallel and stereoretentive syntheses for fully substituted (E)- and (Z)-α,β-unsaturated esters 5-3 (type I, 
convergent).  Method A: ArMgBr (2.0 equiv), ZnCl2 (2.0 equiv), [Pd(dppe)Cl2] (2 mol%), MeCN/THF (2:1), 60 °C, 2 h.  Method B: 
[Pd(dppb)Cl2] (1 mol%) and THF instead of those given for method A. 
 
Entry Ar
1 
Ar
2
 Substrate
a
 Method Product Yield / % E / Z 
b 
1 Ph (p-Me)C6H4 (E)-5-2a A (E)-5-3a 75
 
84:16 
2   (Z)-5-2a B (Z)-5-3a 84 2:>98 
3   (Z)-5-2a’ B (E)-5-3a 80 >98:2 
4   (E)-5-2a’ A (Z)-5-3a 83 2:>98 
5 Ph (p-MeO)C6H4 (E)-5-2a A (E)-5-3b 77 84:16 
6   (Z)-5-2a B (Z)-5-3b 82 2:>98 
7   (Z)-5-2b’ B (E)-5-3b 80 >98:2 
8   (E)-5-2b’ A (Z)-5-3b 80 2:>98 
9 Ph (p-Cl)C6H4 (E)-5-2a A (E)-5-3c 54 83:17 
10   (Z)-5-2a B (Z)-5-3c 85 2:>98 
11   (Z)-5-2c’ B (E)-5-3c 70 >98:2 
12   (E)-5-2c’ A (Z)-5-3c 70 2:>98 
13 (p-MeO)C6H4 (p-Cl)C6H4 (E)-5-2d A
c
 (E)-5-3d 85 68:32 
14   (Z)-5-2d B (Z)-5-3d 80 2:>98 
15   (Z)-5-2d’ B (E)-5-3d 87 >98:2 
16   (E)-5-2d’ A
c
 (Z)-5-3d 77 10:90 
a) The purities of E and Z isomers were up to >98% based on the 
1
H NMR spectra.  b) Determined by 
1
H NMR spectroscopy of the crude 
products.  c) 3.0 equiv of ArZnCl was used in toluene at reflux. 
 
Conversely, parallel synthesis (type II, divergent oriented approach) was investigated and the results are 
shown in Table 5-3.  The salient features are as follows: 1) in all cases, good to excellent yield and almost 
perfect E and Z selectivities were achieved; 2) α,β-dimethyl enol tosylates (E)-5-4b and (Z)-5-4b were 
transformed into a total of six (E)- and (Z)-α,β-unsaturated ester analogues (E)-5-5b and (Z)-5-5b (Table 5-3, 
entries 1−6); 3) regioisomers (E)- and (Z)-5-4c and 5-4c’ afforded three sets of all four stereoisomers (E)- and 
(Z)-5-5c-1−3 and 5-5c’-1−3 (Table 5-3, entries 7−10, 11−14, 15−18).  To further strengthen the substrate 
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scope, seven syntheses using various (E)- and (Z)-α,β-unsaturated esters 5-5a and 5-5d−g are summarized in 
Table 5-4. 
 
Table 5-3.  Parallel and stereoretentive syntheses for fully substituted (E)- and (Z)-α,β-unsaturated esters 5-5 (type II, 
divergent).  Method A: ArMgBr (2.0 equiv), ZnCl2 (2.0 equiv), [Pd(dppe)Cl2] (2 mol%), MeCN/THF (2:1), 60−65 °C, 2 h.  Method 
B: [Pd(dppe)Cl2] (1 mol%) and THF instead of those given for method A. 
 
Entry R
1 
R
2 
Substrate
a 
Ar Method Product Yield 
/ % 
E / Z 
b 
1 Me Me (E)-5-4b Ph A (E)-5-5b-1 84
 
>98:2 
2   (Z)-5-4b  B (Z)-5-5b-1 83 2:>98 
3 Me Me (E)-5-4b (p-MeO)C6H4 A (E)-5-5b-2 82 95:5 
4   (Z)-5-4b  B (Z)-5-5b-2 95 2:>98 
5 Me Me (E)-5-4b (p-Cl)C6H4 A (E)-5-5b-3 93 98:2 
6   (Z)-5-4b  B (Z)-5-5b-3 80 2:>98 
7 Me nBu (E)-5-4c Ph A (E)-5-5c-1 85 98:2 
8   (Z)-5-4c  B (Z)-5-5c-1 88 2:>98 
9 Me nBu (E)-5-4c’ Ph A (E)-5-5c’-1 72 >98:2 
10   (Z)-5-4c’  B (Z)-5-5c’-1 70 2:>98 
11 Me nBu (E)-5-4c (p-MeO)C6H4 A (E)-5-5c-2 89 91:9 
12   (Z)-5-4c  B (Z)-5-5c-2 91 2:>98 
13 Me nBu (E)-5-4c’ (p-MeO)C6H4 A (E)-5-5c’-2 75 >98:2 
14   (Z)-5-4c’  B (Z)-5-5c’-2 82 2:>98 
15 Me nBu (E)-5-4c (p-Cl)C6H4 A (E)-5-5c-3 88 97:3 
16   (Z)-5-4c  B (Z)-5-5c-3 78 2:>98 
17 Me nBu (E)-5-4c’ (p-Cl)C6H4 A (E)-5-5c’-3 78 >98:2 
18   (Z)-5-4c’  B (Z)-5-5c’-3 70 2:>98 
a) The purities of E and Z isomers were up to >98% based on the 
1
H NMR spectra.  b) Determined by 
1
H NMR spectroscopy of the crude 
products. 
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Table 5-4.  Stereocomplementary syntheses for fully substituted (E)- and (Z)-α,β-unsaturated esters 5-5a and 5-5d−g. 
 
 
The next study was focused on stereoretentive and complementary derivatizations of (E)-5-5b-1 and 
(Z)-5-5b-1 to furnish various E- and Z-stereodefined fully substituted olefin scaffolds.  A literature survey 
revealed few E- and Z-stereoretentive reactions of either α-alkyl- or aryl-substituted α,β-unsaturated esters.1 
Scheme 5-4 shows the success of the derivatization array, which was performed by Atsushi Honda, one of the 
colleagues.  Non-marked compounds 5-7−5-10 are known, whereas compounds 5-11−5-14 are novel.  The 
reaction conditions can be summarized as follows: [a] acid hydrolysis gave acids (E)-5-7 and (Z)-5-7;
15
 [b] 
DIBAL reduction afforded allyl alcohols (E)-5-8 and (Z)-5-8;
16
 [c] MnO2 allylic alcohol oxidation of (E)-5-8 
and (Z)-5-8 yielded aldehydes (E)-5-9 and (Z)-5-9, respectively;
16a
 [d] dimethyl alcohols syn-5-10 and 
isomeric anti-5-10 were obtained by the reported catalytic hydrogenation (H2−Pd/C), followed by lithium 
aluminum hydride (LAH) reduction.
16a
  Conversion steps [b]−[d] were performed following the Serra 
group’s reliable procedures; [e] Wittig methylene formation gave dienes (4E)-5-11 and (4Z)-5-11; [f] 
Horner−Wadsworth−Emmons reaction using methyl phosphonoacetate yielded (2E,4E)-5-12 and 
(2E,4Z)-5-12; [g] Knoevenagel condensation of (E)-5-9 and (Z)-5-9 under the Hayashi group’s mild 
conditions
17
 afforded (4E)-5-13 and (4Z)-5-13; (h) notably, alkylations (Me and nBu) and phenylation using 
acetates of (E)-5-8 and (Z)-5-8 proceeded smoothly to afford the corresponding all-carbon olefins (E)-5-14a−c 
and (Z)-5-14a−c; this finding was successfully applied for the parallel synthesis of (E)- and (Z)-tamoxifens 
(vide infra). 
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Scheme 5-4.  Stereoretentive and complementary derivatization array of α,β-unsaturated esters (E)- and (Z)-5-5b-1.  Reagents 
and conditions: [a] CF3CO2H‒H2O (2:1), 90 °C, 12 h; [b] DIBAL (3.0 equiv), CH2Cl2, RT, 1 h; [c] Using (E)- and (Z)-5-8, MnO2 (40 
equiv), CH2Cl2, RT, 1 h; [d] i) H2/Pd‒C, AcOEt, RT, 1 h; ii) LAH (1.0 equiv), Et2O, 0 °C; [e] Using (E)- and (Z)-5-9,  MeP+Ph3•I‒ (4.0 
equiv), tBuOK (4.0 equiv), CH2Cl2, RT, 1 h; [f] Using (E)- and (Z)-5-9, (MeO)2POCH2CO2Me, DBU (1.2 equiv), LiCl (1.2 equiv), 
MeCN, RT, 1 h; [g] Using (E)- and (Z)-5-9, H2C(CN)2 (1.0 equiv), Ti(OiPr)4 (0.5 equiv), iPrOH, RT, 24 h;  [h] Using (E)- and (Z)-5-8, 
i) Ac2O (1.2 equiv), Et3N (1.2 equiv), DMAP (5 mol%), CH2Cl2, RT, 1 h; ii) RLi (6.0 equiv), CuI (3.5 equiv), THF, RT, 1 h. 
 
Finally, with these successful outcomes in hand, the author introduces the first successful fully parallel 
synthesis of both (E)- and (Z)-tamoxifens,
18
 a representative of all carbon (fully)-substituted olefins, utilizing 
the type I (convergent oriented approach: Table 5-2 which was accomplished by Atsushi Honda, one of the 
colleagues).  Scheme 5-5 (preparation of precursors) and Scheme 5-6 (synthesis in the final stage) illustrate 
this challenging task.  The notable features in Scheme 5-5 are as follows: 1) β-ketoester 5-15 was converted 
to enol tosylates (E)-5-17 and (Z)-5-17 following the reported (E)- and (Z)-stereocomplementary procedures
5
 
(conditions [a] and [b]); 2) in a similar approach, (Z)-5-18 and (E)-5-18 were prepared from β-ketoester 5-16 
(conditions [c] and [d]); 3) Negishi cross-couplings using (E)-5-17 and (Z)-5-17 produced the corresponding 
α,β-unsaturated ester precursors (Z)-5-19 and (E)-5-19 in excellent yield (95% and 93%) with good to almost 
perfect stereoretention, respectively (conditions [e] and [f]); 4) in a similar approach, (Z)-5-18 and (E)-5-18 
were transformed to (Z)-5-19 and (E)-5-19, respectively in excellent yield (91% and 81%) with good to almost 
perfect stereoretention (conditions [g] and [h]). 
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Scheme 5-5.  Parallel syntheses of both tamoxifen precursors (E)- and (Z)-5-19.  Reagents and conditions: [a] TsCl (1.5 equiv), 
Me2N(CH2)6NMe2 (1.5 equiv), MeCN, −15° C, 1 h and 20−25 °C, 1 h, 95%, E/Z=66:34; pure (E)-5-17 was isolated in 26% yield 
(recrystallized from toluene); [b] TsCl (1.5 equiv), TMEDA (1.5 equiv), LiCl (1.5 equiv), MeCN, 0−5 °C, 1 h and 20−25 °C, 1 h, 99%, 
E/Z=2:>98; [c] similar conditions to those given for [b], 97%, E/Z=2:98; [d] similar conditions to those given for [a], 92%, E/Z=74:26; 
pure (E)-5-18 was isolated in 49% yield (recrystallized from AcOEt); [e] PhMgBr (3.0 equiv), ZnCl2 (3.0 equiv), [Pd(dppb)Cl2] (2 
mol%), MeCN/THF (2:3), 60−65 °C, 2 h, 95%, E/Z=16:84; [f] PhMgBr (2.0 equiv), ZnCl2 (2.0 equiv), Pd(OAc)2 (1 mol%), 
1,4-bis(diphenylphosphino)butane (DPPB; 2 mol%), THF, 60−65 °C, 2 h, 93%, E/Z=98:2; [g] (p-MeO)C6H4MgBr (2.0 equiv), ZnCl2 
(2.0 equiv), Pd(OAc)2 (1 mol%), DPPB (2 mol%), THF, 60−65 °C, 2 h, 99%, E/Z=2:98; [h] (p-MeO)C6H4MgBr (3.0 equiv), ZnCl2 (3.0 
equiv), [Pd(dppb)Cl2] (2 mol%), MeCN/THF (2:3), 60−65 °C, 2 h, 81%, E/Z=90:10. 
 
The salient features in Scheme 5-6 are that DIBAL reduction of precursors (E)-5-19 and (Z)-5-19, followed 
by acetylation led to allylic acetates (E)-5-20 and (Z)-5-20, respectively (conditions [a], [b], [f], and [g]).  
Utilizing the method for step [h] (Scheme 5-4), methylation of (E)-5-20 and (Z)-5-20 using MeLi/CuI 
proceeded smoothly to yield the corresponding fully substituted olefins (E)-5-21 and (Z)-5-21 (conditions [c] 
and [h]).  A notable advantage of the present method is the reduced number of steps compared with reported 
transformations
16b, 18c, k, 19
 (Dess−Martin oxidation, Wittig methylene formation, and catalytic hydrogenation). 
 
 
Scheme 5-6.  Parallel syntheses of both (E)- and (Z)-tamoxifens.  Reagents and conditions: [a] DIBAL (3.0 equiv), CH2Cl2, 
0−5 °C, 98%, E/Z= >98:2; [b] Ac2O (1.2 equiv), Et3N (1.2 equiv), DMAP (5 mol%), CH2Cl2, 20−25 °C, 99%, E/Z= >98:2; [c] MeLi 
(4.0 equiv), CuI (2.5 equiv), THF, 0−5 °C, 1 h, 82%, E/Z=2:>98; [d] NaSEt (10 equiv), DMF, reflux, 1 h, 97%, E/Z=2:>98; [e] 
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ClCH2CH2NMe2・HCl (2.0 equiv), K2CO3 (4.0 equiv), toluene/EtOH (1:1), 80−85 °C, 3 h, 93%, E/Z=2:>98; [d] similar conditions to 
those given for [a] , 90% over two steps, E/Z=2:>98; [e] similar conditions to those given for [b], 80%, E/Z= >98:2; [f] similar 
conditions to those given for [c], 96% over two steps, E/Z= >98:2. 
 
At the last stage of the synthesis, Miller and Al-Hassan’s protocol for demethylation and subsequent 
N,N-dimethylethylene formation
20
 furnished both (E)- and (Z)-tamoxifens in a total of 8 steps, with an overall 
58% (average 93%) yield and an overall 57% (average 93%) yield, respectively.  More than 50 syntheses of 
(E)- and/or (Z)-tamoxifens have appeared to date and these achievements are documented in an impressive 
review.
[18a]
  To the best of our knowledge, this work is the first two sets (all four) of fully-parallel syntheses 
of both (E)- and (Z)-tamoxifens with excellent overall yields. 
As a notable further extension, the author envisaged sequential cross-couplings using (E)- and 
(Z)-α-chlorinated enol tosylates 5-23, which derived from readily available α-chloro-β-ketoesters 5-22 
(Scheme 5-7). 
 
 
Scheme 5-7.  Sequential cross-couplings using (E)- and (Z)-α-chlorinated enol tosylates 5-23. 
 
After screening the stereocomplementary enol tosylation conditions, α-chlorinated enol tosylates (E)-5-23 
and (Z)-5-23 were prepared from α-chloro-β-ketoesters 5-22 by using the TsCl−NMI−iPr2NEt reagent for Z 
and the TsCl−TMEDA−NaH reagent for E (Table 5-5).   
 
Table 5-5.  (E)- and (Z)-Stereocomplementary enol tosylation of α-chloro-β-ketoester 5-22. 
 
Entry R
1
 Substrate Product Yield / % E/Z
a
 
1 Me 5-22a (Z)-5-23a 91 2:98 
2  5-22a (E)-5-23a 84 87:13 
3 Ph 5-22b (Z)-5-23b 83 2:98 
4  5-22b (E)-5-23b 89 94:6 
a) Determined by 
1
H NMR spectroscopy of the crude products. 
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TsO-group chemoselective cross-coupling of (E)- and (Z)-5-23 underwent the most accessible 
Suzuki-Miyaura cross-coupling conditions [Pd(OAc)2−PPh3−K2CO3 in iPrOH−H2O] to produce the desired 
(E)- and (Z)-α-chloroacrylates 5-24 in good to exellent yield with almost perfect stereoretention (Table 5-6).  
In the case of β-Ph-containing substrate (Z)-5-23b, however, considerable Z→E isomerization occurred under 
the identical conditions.  This conspicuous isomerization could be successfully suppressed by using more 
refined conditions [Pd(OAc)2−Ph-RuPhos−NaHCO3 in toluene−H2O]. 
 
Table 5-6.  TsO-selective cross-coupling of α-chloro enol tosylates (E)- and (Z)-5-23.   
 
 
Reagents and conditions: [a] ArB(OH)2 (1.2 equiv), Pd(OAc)2 (5 mol%), PPh3 (10 mol%),  
 K2CO3 (1.2 equiv), iPrOH-H2O (3:1), 1 h.  [b] ArB(OH)2 (1.2 equiv), Pd(OAc)2 (1 mol%),  
Ph-RuPhos (2 mol%), NaHCO3 (1.2 equiv), toluene-H2O (3:1), 1 h. 
 
 
Successful results of subsequent (E)- and (Z)-stereoretentive cross-couplings with α-chloroacrylates 
(E)-5-24 and (Z)-5-24 are summarized in Table 5-7.  Suzuki-Miyaura cross-couplings with Ph-, (3-thienyl)-, 
and (n-hexyl)-boronic acids proceeded smoothly to give the desired products (E)- and (Z)-5-25b-1−3 by using 
[Pd(OAc)2−SPhos−K2CO3] catalysis.  In addition, Sonogashira cross-couplings could be applied for the 
respective preparations of (E)-5-25b-4 and (Z)-5-25b-4 by using [Pd(NCMe)2Cl2−XPhos−Cs2CO3] catalysis, 
developed by Buchwald’s group.21  Notably, the synthesis of (E)- and (Z)-5-25b-3, 4 have been inaccessible 
because α-(3-thienyl) and α-alkynyl substituents could be hardly installed into these molecules by other 
reported methods. 
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Table 5-7.  Suzuki-Miyaura and Sonogashira cross-coupling at α-chloro position with α-chloroacrylates (E)- and (Z)-5-24.   
 
 
Reagents and conditions: [a] ArB(OH)2 (1.2 equiv), Pd(OAc)2 (1 mol%), SPhos (1 mol%), K2CO3 (1.2 equiv), 
toluene-H2O (3:1), 80−85 °C, 1 h.  [b] (n-hexyl)B(OH)2 (1.8 equiv), Pd(OAc)2 (3 mol%), SPhos (3 mol%), K2CO3 (1.8 
equiv), toluene-H2O (3:1), 80−85 °C, 1 h.  [c] Phenylacetylene (1.3 equiv)), [Pd(NCMe)2Cl2] (1 mol%), XPhos (3 
mol%), Cs2CO3 (2.6 equiv), MeCN, reflux, 2 h. 
 
 
Conclusion 
Two sets (all four) of parallel and stereocomplementary synthetic pathway to access preparations of 
all-carbon-substituted (E)- and (Z)-α,β-unsaturated esters scaffolds were developed.  This robust and 
distinctive method involves stereocomplementary enol tosylations using readily available TsCl/diamine 
reagents and highly stereoretentive Negishi cross-coupling reactions with fine-tuned catalysis.  The parallel 
approach is categorized into a pair of type I and type II pathways.  Among a number of (E)- and 
(Z)-α,β-unsaturated esters, a set of methyl (E)- and (Z)-α,β-dimethylcinnamates was transformed into various 
E- and Z-stereoretentive novel and known olefins with a total of 16 (8×2) derivatization arrays.  As an 
attractive demonstration, the first parallel synthesis of both (E)- and (Z)-tamoxifens, a representative 
compound of all-carbon-substituted olefins, was accomplished in a total of eight steps with both high overall 
yields and individual step average yields.  As a notable further extension, the sequential cross-couplings of 
(E)- and (Z)-α-chlorinated enol tosylates successfully strengthened the substrate generality of the present 
methodology with installing α-(3-thienyl) and α-alkynyl substituents. 
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Experimental 
 
Methyl (E)-2-butyl-3-phenyloct-2-enoate [(E)-5-5a-1][= (E)-3-3a]
14
 
PhMgBr (0.92 mL, 1.00 mL; 1.09 M in THF) was added to a stirred suspension of ZnCl2 (136 mg, 1.00 mmol) 
in MeCN (0.50 mL) at 0 − 5 °C under an Ar atmosphere, and the mixture was stirred at the same temperature 
for 0.5 h.  Enol tosylate (E)-5-4a
5
 (191 mg, 0.50 mmol) in MeCN (0.5 mL) and [Pd(dppe)Cl2] (5.8 mg, 0.01 
mmol) were successively added to the mixture, followed by being stirred at 60 − 65 °C for 2 h.  After 
cooling to room temperature, 1 M-HCl aq. solution was added to the mixture, which was extracted twice with 
AcOEt.  The combined organic phase was washed with 1 M-HCl aq. solution, water, brine, dried (Na2SO4) 
and concentrated.  The obtained crude product was purified by SiO2-column chromatography (hexane/AcOEt 
= 100:1) to give the desired product [(E)-5-5a-1, 118 mg, 82%, E/Z = 96:4]. 
Physical and spectral data were in accordance with (Z)-3-3a. 
 
Methyl (Z)-2-butyl-3-phenyloct-2-enoate [(Z)-5-5a-1][= (Z)-3-3a]
14
 
PhMgBr (0.92 mL, 1.00 mL; 1.09 M in THF) was added to a stirred suspension of ZnCl2 (136 mg, 1.00 mmol) 
in THF (0.50 mL) at 0 − 5 °C under an Ar atmosphere, and the mixture was stirred at the same temperature for 
0.5 h.  Enol tosylate (Z)-5-4a
5
 (191 mg, 0.50 mmol) in THF (0.5 mL) and [Pd(dppb)Cl2] (3.0 mg, 0.005 
mmol) were successively added to the mixture, followed by being stirred at 60 − 65 °C for 2 h.  After 
cooling to room temperature, 1 M-HCl aq. solution was added to the mixture, which was extracted twice with 
AcOEt.  The combined organic phase was washed with 1 M-HCl aq. solution, water, brine, dried (Na2SO4) 
and concentrated.  The obtained crude product was purified by SiO2-column chromatography (hexane/AcOEt 
= 100:1) to give the desired product [(Z)-5-5a-1, 122 mg, 85%, E/Z = 2:>98]. 
Physical and spectral data were in accordance with (Z)-3-3a. 
 
Methyl (E)-2-methyl-3-phenyl-3-(p-tolyl)acrylate [(E)-5-3a] 
[Method A]  Following the procedure for the preparation of (E)-5-5a-1, the reaction of enol tosylate 
(E)-5-2a
5
 (173 mg, 0.50 mmol) using (p-Me)C6H4MgBr (0.94 mL, 1.00 mmol; 1.06 M in THF), ZnCl2 (136 
mg, 1.00 mmol), and [Pd(dppe)Cl2] (5.8 mg, 0.01 mmol) gave the desired product [(E)-5-3a, 100 mg, 75%, 
E/Z = 84:16]. 
[Method B]  Following the procedure for the preparation of (Z)-5-5a-1, the reaction of tosylate (Z)-5-2a’ 
(188 mg, 0.50 mmol) using PhMgBr (1.04 mL, 1.00 mmol; 0.96 M in THF), ZnCl2 (136 mg, 1.00 mmol), and 
[Pd(dppb)Cl2] (3.0 mg, 0.005 mmol) gave the desired product [(E)-5-3a, 107 mg, 80%, E/Z = >98:2]. 
Colorless oil; 
1
H NMR (500 MHz, CDCl3): δ = 2.04 (s, 3H), 2.35 (s, 3H), 3.47 (s, 3H), 7.02−7.07 (m, 2H), 
7.09−7.16 (m, 4H), 7.20−7.90 (m, 3H); 13C NMR (125 MHz, CDCl3): 18.5, 21.2, 51.4, 127.3 (2C), 127.8 (2C), 
128.6 (2C), 128.7 (2C), 129.5 (2C), 137.4, 137.8, 142.6, 146.8, 171.7; IR (neat): νmax = 3023, 2947, 1710, 
1509, 1432, 1324, 1253, 1123 cm
−1
; HRMS (ESI): m/z calcd for C18H18O2 [M+Na]
+
 289.1204; found: 
289.1186. 
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Methyl (Z)-2-methyl-3-phenyl-3-(p-tolyl)acrylate [(Z)-5-3a] 
[Method A]  Following the procedure for the preparation of (Z)-5-5a-1, the reaction of enol tosylate 
(Z)-5-2a
5
 (173 mg, 0.50 mmol) using (p-Me)C6H4MgBr (0.94 mL, 1.00 mmol; 1.06 M in THF), ZnCl2 (136 
mg, 1.00 mmol), and [Pd(dppb)Cl2] (3.0 mg, 0.005 mmol) gave the desired product [(Z)-5-3a, 112 mg, 84%, 
E/Z = 2:>98]. 
[Method B]  Following the procedure for the preparation of (E)-5-5a-1, the reaction of enol tosylate 
(E)-5-2a’, 188 mg, 0.50 mmol) using PhMgBr (1.04 mL, 1.00 mmol; 0.96 M in THF), ZnCl2 (136 mg, 1.00 
mmol), and [Pd(dppe)Cl2] (5.8 mg, 0.01 mmol) gave the desired product [(Z)-5-3a, 110 mg, 83%, E/Z = 
2:>98]. 
Colorless oil; 
1
H NMR (500 MHz, CDCl3): δ = 2.02 (s, 3H), 2.32 (s, 3H), 3.52 (s, 3H), 6.96−7.02 (m, 2H), 
7.04−7.89 (m, 2H), 7.14−7.86 (m, 2H), 7.32−7.37 (m, 3H); 13C NMR (125 MHz, CDCl3): 18.5, 21.2, 51.5, 
127.3, 127.5, 128.0 (2C), 128.5 (2C), 128.6 (2C), 129.5 (2C), 137.8, 139.4, 141.0, 146.7, 171.7; IR (neat): νmax 
= 3024, 2946, 1710, 1510, 1432, 1325, 1254, 1125 cm
−1
. 
 
Methyl (E)-3-(4-methoxyphenyl)-2-methyl-3-phenylacrylate [(E)-5-3b] 
[Method A]  Following the procedure for the preparation of (E)-5-5a-1, the reaction of enol tosylate 
(E)-5-2a (173 mg, 0.50 mmol) using (p-MeO)C6H4MgBr (0.98 mL, 1.00 mmol; 1.02 M in THF), ZnCl2 (136 
mg, 1.00 mmol), and [Pd(dppe)Cl2] (5.8 mg, 0.01 mmol) gave the desired product [(E)-5-3b, 109 mg, 77%, 
E/Z = 84:16]. 
[Method B]  Following the procedure for the preparation of (Z)-5-5a-1 (method B), the reaction of enol 
tosylate (Z)-5-2b’ (181 mg, 0.50 mmol) using PhMgBr (1.04 mL, 1.00 mmol; 0.96 M in THF), ZnCl2 (136 mg, 
1.00 mmol), and [Pd(dppb)Cl2] (3.0 mg, 0.005 mmol) gave the desired product [(E)-5-3b, 113 mg, 80%, E/Z = 
>98:2]. 
Colorless oil; 
1
H NMR (500 MHz, CDCl3): δ = 2.07 (s, 3H), 3.46 (s, 3H), 3.81 (s, 3H), 6.83−6.89 (m, 2H), 
7.06−7.13 (m, 4H), 7.21−7.30 (m, 3H); 13C NMR (125 MHz, CDCl3): δ = 18.5, 51.4, 55.1, 113.3 (2C), 127.0, 
127.3, 127.8 (2C), 128.6 (2C), 131.0 (2C), 133.0, 142.7, 146.6, 159.0, 171.7; IR (neat): νmax = 1709, 1605, 
1508, 1443, 1325, 1304, 1288, 1277, 1175 cm
−1
; HRMS (ESI): m/z calcd for C18H18O3 [M+Na]
+
 305.1154; 
found: 305.1152. 
 
Methyl (Z)-3-(4-methoxyphenyl)-2-methyl-3-phenylacrylate [(Z)-5-3b] 
[Method A]  Following the procedure for the preparation of (Z)-5-5a-1, the reaction of enol tosylate (Z)-5-2a 
(173 mg, 0.50 mmol) using (p-MeO)C6H4MgBr (1.02 mL, 1.00 mmol; 0.98 M in THF), ZnCl2 (136 mg, 1.00 
mmol), and [Pd(dppb)Cl2] (3.0 mg, 0.005 mmol) gave the desired product [(Z)-5-3b, 115 mg, 82%, E/Z = 
2:>98]. 
[Method B]  Following the procedure for the preparation of (E)-5-5a-1, the reaction of enol tosylate 
(E)-5-2b’ (181 mg, 0.50 mmol) using PhMgBr (1.04 mL, 1.00 mmol; 0.96 M in THF), ZnCl2 (136 mg, 1.00 
mmol), and [Pd(dppe)Cl2] (5.8 mg, 0.01 mmol) gave the desired product [(Z)-5-3b, 113 mg, 80%, E/Z = 
2:>98]. 
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Colorless oil; 
1
H NMR (500 MHz, CDCl3): δ = 2.01 (s, 3H), 3.53 (s, 3H), 3.79 (s, 3H), 6.77–6.81 (m, 2H), 
7.01–7.05 (m, 2H), 7.14–7.17 (m, 2H), 7.26–7.35 (m, 3H); 13C NMR (125 MHz, CDCl3): δ = 18.5, 51.5, 55.1, 
113.3 (2C), 126.9, 127.5, 128.0 (2C), 129.6 (2C), 129.9 (2C), 134.7, 141.0, 146.2, 159.0, 171.9; IR (neat): νmax 
= 2947, 2837, 1709, 1607, 1508, 1244, 1123, 1032, 775, 762, 700 cm
−1
. 
 
Methyl (E)-3-(4-chlorophenyl)-2-methyl-3-phenylacrylate [(E)-5-3c] 
[Method A]  Following the procedure for the preparation of (E)-5-5a-1, the reaction of enol tosylate 
(E)-5-2a (173 mg, 0.50 mmol) using (p-Cl)C6H4MgBr (0.96 mL, 1.00 mmol; 1.04 M in THF), ZnCl2 (136 mg, 
1.00 mmol), and [Pd(dppe)Cl2] (5.8 mg, 0.01 mmol) gave the desired product [(E)-5-3c, 78 mg, 54%, E/Z = 
83:17]. 
[Method B]  Following the procedure for the preparation of (Z)-5-5a-1, the reaction of enol tosylate (Z)-5-2c’ 
(183 mg, 0.50 mmol) using PhMgBr (1.04 mL, 1.00 mmol; 0.96 M in THF), ZnCl2 (136 mg, 1.00 mmol), and 
[Pd(dppb)Cl2] (3.0 mg, 0.005 mmol) gave the desired product [(E)-5-3c, 100 mg, 70%, E/Z = >98:2]. 
Colorless oil; 
1
H NMR (500 MHz, CDCl3): δ = 2.03 (s, 3H), 2.48 (s, 3H), 7.05−7.13 (m, 4H), 7.23−7.38 (m, 
5H); 
13
C NMR (125 MHz, CDCl3): 18.5, 51.6, 127.6 (2C), 128.0 (2C), 128.4 (2C), 128.5 (2C), 130.9 (2C), 
133.6, 139.1, 141.9, 145.4, 171.3; IR (neat): νmax = 1712, 1489, 1433, 1325, 1254, 1016 cm
−1
; HRMS (ESI): 
m/z calcd for C17H15ClO2 [M+Na]
+
 309.0658; found: 309.0665. 
 
Methyl (Z)-3-(4-chlorophenyl)-2-methyl-3-phenylacrylate [(Z)-5-3c] 
[Method A]  Following the procedure for the preparation of (Z)-5-5a-1, the reaction of enol tosylate (Z)-5-2a 
(173 mg, 0.50 mmol) using (p-Cl)C6H4MgBr (0.96 mL, 1.00 mmol; 1.04 M in THF), ZnCl2 (136 mg, 1.00 
mmol), and [Pd(dppb)Cl2] (3.0 mg, 0.005 mmol) gave the desired product [(Z)-5-3c, 122 mg, 85%, E/Z = 
2:>98]. 
[Method B]  Following the procedure for the preparation of (E)-5-5a-1, the reaction of enol tosylate (E)-5-2c’ 
(183 mg, 0.50 mmol) using PhMgBr (1.04 mL, 1.00 mmol; 0.96 M in THF), ZnCl2 (136 mg, 1.00 mmol), and 
[Pd(dppe)Cl2] (5.8 mg, 0.01 mmol) gave the desired product [(Z)-5-3c, 100 mg, 70%, E/Z = 2:>98]. 
Colorless oil; 
1
H NMR (500 MHz, CDCl3): δ = 2.03 (s, 3H), 3.52 (s, 3H), 7.02−7.07 (m, 2H), 7.11−7.15 (m, 
2H), 7.21−7.25 (m, 2H), 7.28−7.38 (m, 3H); 13C NMR (125 MHz, CDCl3): 18.4, 51.6, 127.8 (2C), 128.2 (2C), 
128.4 (2C), 129.4 (2C), 129.9 (2C), 133.3, 140.3, 140.8, 145.5, 171.2; IR (neat): νmax = 1712, 1489, 1443, 
1433, 1323, 1252, 1125 cm
−1
. 
 
Methyl (E)-3-(4-chlorophenyl)-3-(4-methoxyphenyl)-2-methylacrylate [(E)-5-3d] 
[Method A]  Following the procedure for the preparation of (E)-5-5a-1 (the reaction of enol tosylate 
(E)-5-2d (= 5-2b’) (183 mg, 0.50 mmol) using (p-Cl)C6H4MgBr (1.00 mL, 1.00 mmol; 1.00 M in THF), 
ZnCl2 (136 mg, 1.00 mmol), and [Pd(dppe)Cl2] (5.8 mg, 0.01 mmol) in toluene (3 mL) at reflux gave the 
desired product [(E)-5-3d, 136 mg, 85%, E/Z = 68:32]. 
[Method B]  Following the procedure for the preparation of (Z)-5-5a-1, the reaction of enol tosylate (Z)-5-2d 
(= 5-2c’) ( 181 mg, 0.50 mmol) using (p-Cl)C6H4MgBr (1.00 mL, 1.00 mmol; 1.00 M in THF), ZnCl2 (136 
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mg, 1.00 mmol), and [Pd(dppb)Cl2] (3.0 mg, 0.005 mmol) gave the desired product [(E)-5-3d, 122 mg, 77%, 
E/Z = 90:10]. 
Colorless oil; 
1
H NMR (500 MHz, CDCl3): δ = 2.01 (s, 3H), 3.23 (s, 3H), 3.74 (s, 3H), 6.76−6.82 (m, 2H), 
6.98–7.03 (m, 2H), 7.07−7.12 (m, 2H), 7.29–7.34 (m, 2H); 13C NMR (125 MHz, CDCl3): δ = 18.5, 51.5, 55.0, 
113.3 (2C), 127.4, 128.9 (2C), 129.9 (2C), 131.0 (2C), 133.5, 134.1, 139.4, 144.8, 159.1, 171.5; IR (neat): νmax 
= 1713, 1607, 1508, 1487, 1456, 1323, 1306, 1288, 1175 cm
−1
; HRMS (ESI): m/z calcd for C18H17ClO3 
[M+Na]
+
 339.0764; found: 339.0762. 
 
Methyl (Z)-3-(4-chlorophenyl)-3-(4-methoxyphenyl)-2-methylacrylate [(Z)-5-3d] 
[Method A]  Following the procedure for the preparation of (Z)-5-5a-1, the reaction of enol tosylate (Z)-5-2c 
(= 5-2b’) (183 mg, 0.50 mmol) using (p-MeO)C6H4MgBr (1.00 mL, 1.00 mmol; 1.00 M in THF), ZnCl2 (136 
mg, 1.00 mmol), and [Pd(dppe)Cl2] (5.8 mg, 0.01 mmol) in toluene (3 mL) at reflux gave the desired product 
[(Z)-5-3d, 127 mg, 80%, E/Z = 2:>98]. 
[Method B]  Following the procedure for the preparation of (E)-5-5a-1, the reaction of enol tosylate 
[(E)-5-2d’ (= 5-2c’), 181 mg, 0.50 mmol] using (p-Cl)C6H4MgBr (1.00 mL, 1.00 mmol; 1.00 M in THF), 
ZnCl2 (136 mg, 1.00 mmol), and [Pd(dppb)Cl2] (3.0 mg, 0.005 mmol) gave the desired product [(Z)-5-3d’, 
138 mg, 87%, E/Z = 2:>98]. 
Colorless oil; 
1
H NMR (500 MHz, CDCl3): δ = 2.06 (s, 3H), 3.50 (s, 3H), 3.82 (s, 3H), 6.84−6.89 (m, 2H), 
7.01–7.09 (m, 4H), 7.21−7.26 (m, 2H); 13C NMR (125 MHz, CDCl3): δ = 18.6, 51.5, 55.1, 113.5 (2C), 127.5, 
128.0 (2C), 130.0 (2C), 131.0 (2C), 132.6, 133.3, 141.2, 145.5, 159.2, 171.3; IR (neat): νmax = 1605, 1508, 
1489, 1456, 1433, 1321, 1304, 1288 cm
−1
. 
Methyl (E)-2-methyl-3-phenylbut-2-enoate [(E)-5-5b-1][=(E)-3-3c-1]
20
 
[Method A]  Following the procedure for the preparation of (E)-5-5a-1, the reaction of enol tosylate 
(E)-5-4b (142 mg, 0.50 mmol) using PhMgBr (0.98 mL, 1.00 mmol; 1.02 M in THF), ZnCl2 (136 mg, 1.00 
mmol), and [Pd(dppe)Cl2] (5.8 mg, 0.01 mmol) gave the desired product [(E)-5-5b-1, 80 mg, 84%, E/Z = 
98:2]; Ref. [19a]: E/Z = 14:86; Ref. [19b]: E/Z = 80:20. 
Physical and spectral data were in accordance with (E)-3-3c-1. 
 
Methyl (Z)-2-methyl-3-phenylbut-2-enoate [(Z)-5-5b-1][=(Z)-3-3c-1]
20a
 
[Method B]  Following the procedure for the preparation of (Z)-5-5a-1, the reaction of enol tosylate (Z)-5-4b 
(142 mg, 0.50 mmol) using PhMgBr (0.98 mL, 1.00 mmol; 1.02 M in THF), ZnCl2 (136 mg, 1.00 mmol), and 
[Pd(dppb)Cl2] (3.0 mg, 0.005 mmol) gave the desired product [(Z)-5-5b-1, 79 mg, 83%, E/Z = 2:>98]; Ref. 
[19a]: 95% yield, E/Z = 14:86. 
Physical and spectral data were in accordance with (Z)-3-3c-1.  
 
Methyl (E)-3-(4-methoxyphenyl)-2-methylbut-2-enoate [(E)-5-5b-2][=(E)-3-3c-3]
20a
 
[Method A]  Following the procedure for the preparation of (E)-5-5a-1, the reaction of enol tosylate 
(E)-5-4b (142 mg, 0.50 mmol) using (p-MeO)C6H4MgBr (0.98 mL, 1.00 mmol; 1.02 M in THF), ZnCl2 (136 
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mg, 1.00 mmol), and [Pd(dppe)Cl2] (5.8 mg, 0.01 mmol) gave the desired product [(E)-5-5b-2, 90 mg, 82%, 
E/Z = 95:5]; Ref. [19a]: 14% yield, E/Z = 4:96; 90% yield, E/Z = 41:59. 
Physical and spectral data were in accordance with (E)-3-3c-3. 
 
Methyl (Z)-3-(4-methoxyphenyl)-2-methylbut-2-enoate [(Z)-5-5b-2][=(Z)-3-3c-3]
14
 
[Method B]  Following the procedure for the preparation of (Z)-5-5a-1, the reaction of enol tosylate (Z)-5-4b 
(142 mg, 0.50 mmol) using (p-MeO)C6H4MgBr (1.03 mL, 1.00 mmol; 0.97 M in THF), ZnCl2 (136 mg, 1.00 
mmol), and [Pd(dppb)Cl2] (3.0 mg, 0.005 mmol) gave the desired product [(Z)-5-5b-2, 104 mg, 95%, E/Z = 
2:>98]. 
Physical and spectral data were in accordance with (Z)-3-3c-3. 
 
Methyl (E)-3-(4-chlorophenyl)-2-methylbut-2-enoate [(E)-5-5b-3][=(E)-3-3c-4]
14
 
[Method A]  Following the procedure for the preparation of (E)-5-5a-1, the reaction of enol tosylate 
(E)-5-4b (142 mg, 0.50 mmol) using (p-Cl)C6H4MgBr (1.03 mL, 1.00 mmol; 0.97 M in THF), ZnCl2 (136 mg, 
1.00 mmol), and [Pd(dppe)Cl2] (5.8 mg, 0.01 mmol) gave the desired product [(E)-5-5b-3, 104 mg, 93%, E/Z 
= 98:2]. 
Physical and spectral data were in accordance with (E)-3-3c-4. 
 
Methyl (Z)-3-(4-chlorophenyl)-2-methylbut-2-enoate [(Z)-5-5b-3][=(Z)-3-3c-4]
14
 
[Method B]  Following the procedure for the preparation of (Z)-5-5a-1, the reaction of enol tosylate (Z)-5-4b 
(142 mg, 0.50 mmol) using (p-Cl)C6H4MgBr (1.03 mL, 1.00 mmol; 0.97 M in THF), ZnCl2 (136 mg, 1.00 
mmol), and [Pd(dppb)Cl2] (3.0 mg, 0.005 mmol) gave the desired product [(Z)-5-5b-3, 90 mg, 80%, E/Z = 
2:>98]. 
Physical and spectral data were in accordance with (Z)-3-3c-4. 
 
Methyl (E)-2-(1-phenylethylidene)hexanoate [(E)-5-5c-1] 
[Method A]  Following the procedure for the preparation of (E)-5-5a-1, the reaction of enol tosylate (E)-5-4c 
(163 mg, 0.50 mmol) using PhMgBr (0.92 mL, 1.00 mmol; 1.09 M in THF), ZnCl2 (136 mg, 1.00 mmol), and 
[Pd(dppe)Cl2] (5.8 mg, 0.01 mmol) gave the desired product [(E)-5-5c-1, 99 mg, 85%, E/Z = 98:2]. 
Colorless oil; 
1
H NMR (500 MHz, CDCl3): δ = 0.76 (t, J = 7.5 Hz, 3H), 1.15 (sext, J = 7.5 Hz, 2H), 1.23–1.32 
(m, 2H), 2.13 (t, J = 8.0 Hz, 2H), 2.16 (s, 3H), 3.81 (s, 3H), 7.11–7.15 (m, 2H), 7.25–7.29 (m, 1H), 7.32–7.37 
(m, 2H); 
13
C NMR (125 MHz, CDCl3): δ = 13.7, 22.3, 23.3, 30.6, 31.2, 51.4, 126.9, 127.1 (2C), 128.2 (2C), 
130.6, 143.0, 143.5, 170.5; IR (neat): νmax = 2955, 2860, 1718, 1490, 1434, 1316, 1258, 1136 cm
−1
. 
 
Methyl (Z)-2-(1-phenylethylidene)hexanoate [(Z)-5-5c-1] 
[Method B]  Following the procedure for the preparation of (Z)-5-5a-1, the reaction of enol tosylate (Z)-5-4c 
(163 mg, 0.50 mmol) using PhMgBr (0.92 mL, 1.00 mmol; 1.09 M in THF), ZnCl2 (136 mg, 1.00 mmol), and 
[Pd(dppb)Cl2] (3.0 mg, 0.005 mmol) gave the desired product [(Z)-5-5c-1, 88 mg, 88%, E/Z = 2:>98]. 
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Colorless oil; 
1
H NMR (500 MHz, CDCl3): δ = 0.94 (t, J = 7.5 Hz, 3H), 1.34–1.51 (m, 4H), 2.10 (s, 3H), 2.44 
(t, J = 8.0 Hz, 2H), 3.37 (s, 3H), 7.12–7.16 (m, 2H), 7.21–7.25 (m, 1H), 7.27–7.32 (m, 2H); 13C NMR (125 
MHz, CDCl3): δ = 13.9, 20.8, 22.5, 30.4, 30.7, 51.1, 126.8 (2C), 126.9, 127.9 (2C), 131.5, 141.7, 144.0, 171.1; 
IR (neat): νmax = 2955, 2871, 1714, 1492, 1433, 1318, 1240, 1139 cm
−1
; HRMS (ESI): m/z calcd for C15H20O2 
[M+Na]
+
 255.1361; found: 255.1360. 
 
Methyl (E)-2-methyl-3-phenylhept-2-enoate [(E)-5-5c’-1] 
[Method A]  Following the procedure for the preparation of (E)-5-5a-1, the reaction of enol tosylate (E)-5-4c’ 
(163 mg, 0.50 mmol) using PhMgBr (1.04 mL, 1.00 mmol; 0.96 M in THF), ZnCl2 (136 mg, 1.00 mmol), and 
[Pd(dppe)Cl2] (5.8 mg, 0.01 mmol) gave the desired product [(E)-5-5c’-1, 83 mg, 72%, E/Z = >98:2]. 
Colorless oil; 
1
H NMR (500 MHz, CDCl3): δ = 0.82 (t, J = 6.9 Hz, 3H), 1.21–1.34 (m, 4H), 1.71 (s, 3H), 2.59 
(t, J = 6.9 Hz, 2H), 3.79 (s, 3H), 7.08−7.13 (m, 2H), 7.27–7.30 (m, 1H), 7.33−7.38 (m, 2H); 13C NMR (125 
MHz, CDCl3): δ = 13.8, 17.4, 22.6, 30.9, 35.9, 51.4, 124.5, 126.9, 127.7 (2C), 128.1 (2C), 141.8, 150.0, 170.4; 
IR (neat): νmax = 1717, 1441, 1433, 1246, 1190, 1134, 1105 cm
−1
; HRMS (ESI): m/z calcd for C15H20O2 
[M+Na]
+
 255.1361; found: 255.1362. 
 
Methyl (Z)-2-methyl-3-phenylhept-2-enoate [(Z)-5-5c’-1] 
[Method B]  Following the procedure for the preparation of (Z)-5-5a-1, the reaction of enol tosylate (Z)-5-4c’ 
(163 mg, 0.50 mmol) using PhMgBr (10.4 mL, 1.00 mmol; 0.96 M in THF), ZnCl2 (136 mg, 1.00 mmol), and 
[Pd(dppb)Cl2] (3.0 mg, 0.005 mmol) gave the desired product [(Z)-5-5c’-1, 79 mg, 70%, E/Z = 2:>98]. 
Colorless oil; 
1
H NMR (500 MHz, CDCl3): δ = 0.85 (t, J = 6.9 Hz, 3H), 1.24–1.33 (m, 4H), 2.03 (s, 3H), 2.45 
(t, J = 6.9 Hz, 2H), 3.36 (s, 3H), 7.08−7.11 (m, 2H), 7.22–7.31 (m, 3H); 13C NMR (125 MHz, CDCl3): δ = 
13.8, 15.8, 22.5, 29.6, 34.6, 51.1, 125.7, 126.8, 127.2 (2C), 127.8 (2C), 142.8, 147.7, 171.0; IR (neat): νmax = 
1713, 1433, 1315, 1240, 1136, 1084 cm
−1
. 
 
Methyl (E)-2-[1-(4-methoxyphenyl)ethylidene]hexanoate [(E)-5-5c-2] 
[Method A]  Following the procedure for the preparation of (E)-5-5a-1, the reaction of enol tosylate (E)-5-4c 
(163 mg, 0.50 mmol) using (p-MeO)C6H4MgBr (0.98 mL, 1.00 mmol; 1.02 M in THF), ZnCl2 (136 mg, 1.00 
mmol), and [Pd(dppe)Cl2] (5.8 mg, 0.01 mmol) gave the desired product [(E)-5-5c-2, 117 mg, 89%, E/Z = 
91:9]. 
Colorless oil; 
1
H NMR (500 MHz, CDCl3): δ = 0.78 (t, J = 7.5 Hz, 3H), 1.17 (sext, J = 7.5 Hz, 2H), 1.24–1.32 
(m, 2H), 2.14 (s, 3H), 2.15 (t, J = 8.0 Hz, 2H), 3.80 (s, 3H), 3.82 (s, 3H), 6.86–6.90 (m, 2H), 7.04–7.09 (m, 
2H); 
13
C NMR (125 MHz, CDCl3): δ =13.7, 22.3, 23.4, 30.7, 31.3, 51.3, 55.1, 113.6 (2C), 128.3 (2C), 130.5, 
135.3, 143.1, 158.5, 170.7; IR (neat): νmax = 2955, 2837, 1715, 1609, 1508, 1244, 1134, 1032, 831 cm
−1
; 
HRMS (ESI): m/z calcd for C16H22O3 [M+Na]
+
 285.1467; found: 285.1466. 
 
Methyl (Z)-2-[1-(4-methoxyphenyl)ethylidene]hexanoate [(Z)-5-5c-2] 
[Method B]  Following the procedure for the preparation of (Z)-5-5a-1, the reaction of enol tosylate (Z)-5-4c 
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(163 mg, 0.50 mmol) using (p-MeO)C6H4MgBr (0.98 mL, 1.00 mmol; 1.02 M in THF), ZnCl2 (136 mg, 1.00 
mmol), and [Pd(dppb)Cl2] (3.0 mg, 0.005 mmol) gave the desired product [(Z)-5-5c-2, 119 mg, 91%, E/Z = 
2:>98]. 
Colorless oil; 
1
H NMR (500 MHz, CDCl3): δ = 0.93 (t, J = 7.5 Hz, 3H), 1.33–1.49 (m, 4H), 2.07 (s, 3H), 2.42 
(t, J = 7.5 Hz, 2H), 3.41 (s, 3H), 3.80 (s, 3H), 6.81–6.85 (m, 2H), 7.06–7.11 (m, 2H); 13C NMR (125 MHz, 
CDCl3): δ = 13.9, 20.8, 22.6, 30.6, 30.8, 51.2, 55.1, 113.4 (2C), 128.1 (2C), 131.1, 136.3, 141.0, 158.6, 171.6; 
IR (neat): νmax = 2955, 2837, 1711, 1607, 1510, 1244, 1138, 1026, 831 cm
−1
. 
 
Methyl (E)-3-(4-methoxyphenyl)-2-methylhept-2-enoate [(E)-5-5c’-2] 
[Method A]  Following the procedure for the preparation of (E)-5-5a-1, the reaction of enol tosylate (E)-5-4c’ 
(163 mg, 0.50 mmol) using (p-MeO)C6H4MgBr (0.98 mL, 1.00 mmol; 1.02 M in THF), ZnCl2 (136 mg, 1.00 
mmol), and [Pd(dppe)Cl2] (5.8 mg, 0.01 mmol) gave the desired product [(E)-5-5c’-2, 98 mg, 75%, E/Z = 
>98:2]. 
Colorless oil; 
1
H NMR (500 MHz, CDCl3): δ = 0.82 (t, J = 6.9 Hz, 3H), 1.20–1.33 (m, 4H), 1.73 (s, 3H), 2.57 
(t, J = 6.9 Hz, 2H), 3.78 (s, 3H), 3.82 (s, 3H), 6.86−6.92 (m, 2H), 7.02–7.07 (m, 2H); 13C NMR (125 MHz, 
CDCl3): δ = 13.9, 17.5, 22.6, 30.4, 36.1, 51.4, 55.2, 113.5 (2C), 124.4, 129.0 (2C), 134.0, 149.7, 158.5, 170.6; 
IR (neat): νmax = 1715, 1609, 1508, 1456, 1433, 1287, 1242, 1177, 1132 cm
−1
; HRMS (ESI): m/z calcd for 
C16H22O3 [M+Na]
+
 285.1467; found: 285.1458. 
 
Methyl (Z)-3-(4-methoxyphenyl)-2-methylhept-2-enoate [(Z)-5-5c’-2] 
[Method B]  Following the procedure for the preparation of (Z)-5-5a-1, the reaction of enol tosylate (Z)-5-4c’ 
(163 mg, 0.50 mmol) using (p-MeO)C6H4MgBr (0.98 mL, 1.00 mmol; 1.02 M in THF), ZnCl2 (136 mg, 1.00 
mmol), and [Pd(dppb)Cl2] (3.0 mg, 0.005 mmol) gave the desired product [(Z)-5-5c’-2, 108 mg, 82%, E/Z = 
2:>98]. 
Colorless oil; 
1
H NMR (500 MHz, CDCl3): δ = 0.85 (t, J = 6.9 Hz, 3H), 1.22–1.33 (m, 4H), 2.01 (s, 3H), 2.43 
(t, J = 6.9 Hz, 2H), 3.41 (s, 3H), 3.80 (s, 3H), 6.80−6.85 (m, 2H), 7.02–7.07 (m, 2H); 13C NMR (125 MHz, 
CDCl3): δ = 13.8, 15.9, 22.5, 29.5, 34.5, 51.1, 55.0, 113.2 (2C), 125.3, 128.4 (2C), 134.9, 147.0, 158.5, 171.3; 
IR (neat): νmax = 1711, 1607, 1508, 1456, 1433, 1317, 1288 cm
−1
. 
 
Methyl (E)-2-[1-(4-chlorophenyl)ethylidene]hexanoate [(E)-5-5c-3] 
[Method A]  Following the procedure for the preparation of (E)-5-5a-1, the reaction of enol tosylate (E)-5-4c 
(163 mg, 0.50 mmol) using (p-Cl)C6H4MgBr (0.96 mL, 1.00 mmol; 1.04 M in THF), ZnCl2 (136 mg, 1.00 
mmol), and [Pd(dppe)Cl2] (5.8 mg, 0.01 mmol) gave the desired product [(E)-5-5c-3, 117 mg, 88%, E/Z = 
97:3]. 
Colorless oil; 
1
H NMR (500 MHz, CDCl3): δ = 0.77 (t, J = 7.5 Hz, 3H), 1.16 (sext, J = 7.5 Hz, 2H), 1.23–1.30 
(m, 2H), 2.11 (t, J = 8.0 Hz, 2H), 2.13 (s, 3H), 3.80 (s, 3H), 7.05–7.09 (m, 2H), 7.31–7.34 (m, 2H); 13C NMR 
(125 MHz, CDCl3): δ = 13.7, 22.3, 23.2, 30.7, 31.2, 51.5, 128.5 (2C), 128.6 (2C), 131.3, 132.8, 141.3, 142.0, 
170.3; IR (neat): νmax = 2955, 2860, 1717, 1489, 1433, 1258, 1246, 1206, 1136, 1092, 1015, 827 cm
−1
; HRMS 
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(ESI): m/z calcd for C115H19O2Cl [M+Na]
+
 289.0971; found: 289.0966. 
 
Methyl (Z)-2-[1-(4-chlorophenyl)ethylidene]hexanoate [(Z)-5-5c-3] 
[Method B]  Following the procedure for the preparation of (Z)-5-5a-1, the reaction of enol tosylate (Z)-5-4c 
(163 mg, 0.50 mmol) using (p-Cl)C6H4MgBr (0.96 mL, 1.00 mmol; 1.04 M in THF), ZnCl2 (136 mg, 1.00 
mmol), and [Pd(dppb)Cl2] (3.0 mg, 0.005 mmol) gave the desired product [(Z)-5-5c-3, 104 mg, 78%, E/Z = 
2:>98]. 
Colorless oil; 
1
H NMR (500 MHz, CDCl3): δ = 0.94 (t, J = 6.9 Hz, 3H), 1.33–1.49 (m, 4H), 2.06 (s, 3H), 2.43 
(t, J = 6.9 Hz, 2H), 3.41 (s, 3H), 7.06–7.09 (m, 2H), 7.24–7.28 (m, 2H); 13C NMR (125 MHz, CDCl3): δ = 
13.9, 20.8, 22.5, 30.4, 30.7, 51.2, 128.15 (2C), 128.23 (2C), 132.1, 132.7, 140.6, 142.4, 170.7; IR (neat): νmax 
= 2955, 2872, 1713, 1485, 1433, 1315, 1242, 1138, 1090, 1013, 827 cm
−1
. 
 
Methyl (E)-3-(4-chlorophenyl)-2-methylhept-2-enoate [(E)-5-5c’-3] 
[Method A]  Following the procedure for the preparation of (E)-5-5a-1, the reaction of enol tosylate (E)-5-4c’ 
(163 mg, 0.50 mmol) using (p-Cl)C6H4MgBr (0.96 mL, 1.00 mmol; 1.04 M in THF), ZnCl2 (136 mg, 1.00 
mmol), and [Pd(dppe)Cl2] (5.8 mg, 0.01 mmol) in toluene (3 mL) at reflux gave the desired product 
[(E)-5-5c’-3, 104 mg, 78%, E/Z = >98:2]. 
Colorless oil; 
1
H NMR (500 MHz, CDCl3): δ = 0.82 (t, J = 6.9 Hz, 3H), 1.21–1.31 (m, 4H), 1.70 (s, 3H), 2.56 
(t, J = 6.9 Hz, 2H), 3.79 (s, 3H), 7.02−7.07 (m, 2H), 7.31–7.36 (m, 2H); 13C NMR (125 MHz, CDCl3): 13.8, 
17.4, 22.6, 30.2, 35.8, 51.5,125.2, 128.5 (2C), 129.2 (2C), 132.8, 140.1, 148.5, 170.2; IR (neat): νmax = 1717, 
1489, 1456, 1433, 1246, 1134, 1115 cm
−1
; HRMS (ESI): m/z calcd for C15H19ClO2 [M + Na]
+
 289.0971; 
found: 289.0966. 
 
Methyl (Z)-3-(4-chlorophenyl)-2-methylhept-2-enoate [(Z)-5-5c’-3] 
[Method B]  Following the procedure for the preparation of (Z)-5-5a-1, the reaction of enol tosylate (Z)-5-4c’ 
(163 mg, 0.50 mmol) using (p-Cl)C6H4MgBr (0.96 mL, 1.00 mmol; 1.04 M in THF), ZnCl2 (136 mg, 1.00 
mmol), and [Pd(dppb)Cl2] (3.0 mg, 0.005 mmol) gave the desired product [(Z)-5-5c’-3, 93 mg, 70%, E/Z = 
2:>98]. 
Colorless oil; 
1
H NMR (500 MHz, CDCl3): δ = 0.85 (t, J = 6.9 Hz, 3H), 1.22–1.32 (m, 4H), 2.02 (s, 3H), 2.41 
(t, J = 6.9 Hz, 2H), 3.41 (s, 3H), 7.01−7.06 (m, 2H), 7.24–7.29 (m, 2H); 13C NMR (125 MHz, CDCl3): δ = 
13.8, 15.9, 22.5, 29.4, 34.6, 51.3, 126.3, 128.1 (2C), 128.6 (2C), 132.7, 141.3, 146.6, 170.6; IR (neat): νmax = 
1715, 1489, 1433, 1315, 1238, 1136 cm
−1
. 
 
Methyl (E)-2-butyl-3-(4-methoxyphenyl)oct-2-enoate [(E)-5-5a-2] 
[Method A]  Following the procedure for the preparation of (E)-5-5a-1, the reaction of enol tosylate 
(E)-5-4a (191 mg, 0.50 mmol) using (p-MeO)C6H4MgBr (1.00 mL, 1.00 mmol; 1.00 M in THF), ZnCl2 (136 
mg, 1.00 mmol), and [Pd(dppe)Cl2] (5.8 mg, 0.010 mmol) gave the desired product [(E)-5-5a-2, 82 mg, 52%, 
E/Z = 91:9]. 
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Colorless oil; 
1
H NMR (500 MHz, CDCl3): δ = 0.77 (t, J = 6.9 Hz, 3H), 0.82 (t, J = 6.9 Hz, 3H), 1.11–1.34 (m, 
10H), 2.10 (t, J = 8.0 Hz, 2H), 2.43 (t, J = 8.0 Hz, 2H), 3.79 (s, 3H), 3.82 (s, 3H), 6.86−6.90 (m, 2H), 7.00–
7.05 (m, 2H); 
13
C NMR (125 MHz, CDCl3): δ = 13.8, 14.0, 22.37, 22.39, 27.7, 30.8, 31.3, 31.7, 36.6, 51.3, 
55.2, 113.5 (2C), 128.9 (2C), 130.6, 133.7, 147.0, 158.4, 170.9; IR (neat): νmax = 2954, 2927, 2859, 1717, 
1608, 1509, 1463, 1245 cm
−1
; HRMS (ESI): m/z calcd for C20H30O3 [M+Na]
+
 341.2093; found: 341.2095. 
 
Methyl (Z)-2-butyl-3-(4-methoxyphenyl)oct-2-enoate [(Z)-5-5a-2] 
[Method B]  Following the procedure for the preparation of (Z)-5-5a-1, the reaction of enol tosylate (Z)-5-4a 
(191 mg, 0.500 mmol) using (p-MeO)C6H4MgBr (1.00 mL, 1.00 mmol; 1.00 M in THF), ZnCl2 (136 mg, 1.00 
mmol), and [Pd(dppb)Cl2] (3.0 mg, 0.0050 mmol) gave the desired product [(Z)-5-5a-2, 84 mg, 53%, E/Z = 
2:>98]. 
Colorless oil; 
1
H NMR (500 MHz, CDCl3): δ = 0.83 (t, J = 6.9 Hz, 3H), 0.93 (t, J = 7.5 Hz, 3H), 1.20–1.29 (m, 
6H), 1.33–1.46 (m, 4H), 2.38–2.45 (m, 4H), 3.38 (s, 3H), 3.80 (s, 3H), 6.80−6.84 (m, 2H), 7.03–7.07 (m, 2H); 
13
C NMR (125 MHz, CDCl3): δ = 13.9 (2C), 22.4, 22.5, 27.5, 30.0, 31.1, 31.6, 34.0, 51.1, 55.1, 113.3 (2C), 
128.5 (2C), 131.3, 134.8, 145.5, 158.5, 171.6; IR (neat): νmax = 2955, 2871, 1710, 1607, 1509, 1462, 1323, 
1244 cm
−1
. 
 
Methyl (E)-2-butyl-3-(4-chlorophenyl)oct-2-enoate [(E)-5-5a-3] 
[Method A]  Following the procedure for the preparation of (E)-5-5a-1, the reaction of enol tosylate 
(E)-5-4a (191 mg, 0.50 mmol) using (p-Cl)C6H4MgBr (1.00 mL, 1.00 mmol; 1.00 M in THF), ZnCl2 (136 mg, 
1.00 mmol), and [Pd(dppe)Cl2] (5.8 mg, 0.01 mmol) gave the desired product [(E)-5-5a-3, 92 mg, 57%, E/Z = 
>98:2]. 
Colorless oil; 
1
H NMR (500 MHz, CDCl3): δ = 0.77 (t, J = 7.5 Hz, 3H), 0.82 (t, J = 6.9 Hz, 3H), 1.11–1.31 (m, 
10H), 2.06 (t, J = 8.0 Hz, 2H), 2.43 (t, J = 8.0 Hz, 2H), 3.79 (s, 3H), 7.02−7.06 (m, 2H), 7.30–7.34 (m, 2H); 
13
C NMR (125 MHz, CDCl3): δ = 13.8, 13.9, 23.3, 23.4, 27.6, 30.8, 31.1, 31.6, 36.3, 51.4, 128.4 (2C), 129.2 
(2C), 131.3, 132.8, 139.8, 145.8, 170.5; IR (neat): νmax = 2956, 2929, 2860, 1720, 1489, 1462, 1433, 1204 
cm
−1
. 
 
Methyl (Z)-2-butyl-3-(4-chlorophenyl)oct-2-enoate [(Z)-5-5a-3] 
[Method B]  Following the procedure for the preparation of (Z)-5-5a-1, the reaction of enol tosylate (Z)-5-4a 
(191 mg, 0.50 mmol) using (p-Cl)C6H4MgBr (1.00 mL, 1.00 mmol; 1.00 M in THF), ZnCl2 (136 mg, 1.00 
mmol), and [Pd(dppb)Cl2] (3.0 mg, 0.005 mmol) gave the desired product [(Z)-5-5a-3, 96 mg, 59%, E/Z = 
2:>98]. 
Colorless oil; 
1
H NMR (500 MHz, CDCl3): δ = 0.83 (t, J = 6.9 Hz, 3H), 0.93 (t, J = 6.9 Hz, 3H), 1.19–1.29 (m, 
6H), 1.34–1.46 (m, 4H), 2.37–2.45 (m, 4H), 3.38 (s, 3H), 7.02−7.07 (m, 2H), 7.23–7.28 (m, 2H); 13C NMR 
(125 MHz, CDCl3): δ = 13.9 (2C), 22.4, 22.5, 27.4, 29.9, 31.0, 31.6, 34.0, 51.2, 128.1 (2C), 128.8 (2C), 132.2, 
132.7, 141.1, 145.0, 170.9; IR (neat): νmax = 2956, 2860, 1715, 1488, 1466, 1432, 1242, 1139 cm
−1
; HRMS 
(ESI): m/z calcd for C19H27O2Cl [M+Na]
+
 345.1597; found: 345.1611. 
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Methyl (E)-2-isopropyl-3-phenylbut-2-enoate [(E)-5-5d] 
[Method A]  Following the procedure for the preparation of (E)-5-5a-1, the reaction of enol tosylate 
(E)-5-4d (156 mg, 0.50 mmol) using PhMgBr (0.92 mL, 1.00 mmol; 1.09 M in THF), ZnCl2 (136 mg, 1.00 
mmol), and [Pd(dppe)Cl2] (5.8 mg, 0.01 mmol) gave the desired product [(E)-5-5d, 37 mg, 34%, E/Z = 96:4]. 
Colorless oil; 
1
H NMR (500 MHz, CDCl3): δ = 1.00 (d, J = 7.5 Hz, 6H), 1.99 (s, 3H), 2.54 (hept, J = 7.5 Hz, 
1H), 3.82 (s, 3H), 7.14−7.17 (m, 2H), 7.25–7.30 (m, 1H), 7.33–7.38 (m, 2H); 13C NMR (125 MHz, CDCl3): δ 
= 21.4 (2C), 23.3, 29.8, 51.2, 126.9, 127.2 (2C), 128.3 (2C), 136.8, 137.3, 142.2, 170.5; IR (neat): νmax = 2964, 
1723, 1599, 1492, 1433, 1301, 1243, 1143 cm
−1
. 
 
Methyl (Z)-2-isopropyl-3-phenylbut-2-enoate [(Z)-5-5d] 
[Method B]  Following the procedure for the preparation of (Z)-5-5a-1, the reaction of enol tosylate (Z)-5-4d 
(156 mg, 0.50 mmol) using PhMgBr (0.92 mL, 1.00 mmol; 1.09 M in THF), ZnCl2 (136 mg, 1.00 mmol), and 
[Pd(dppb)Cl2] (3.0 mg, 0.005 mmol) gave the desired product [(Z)-5-5d, 86 mg, 79%, E/Z = 2:>98]. 
Colorless oil; 
1
H NMR (500 MHz, CDCl3): δ = 1.17 (d, J = 7.5 Hz, 6H), 2.08 (s, 3H), 2.94 (hept, J = 7.5 Hz, 
1H), 3.36 (s, 3H), 7.16−7.31 (m, 5H); 13C NMR (125 MHz, CDCl3): δ = 19.6, 20.8 (2C), 29.3, 50.8, 126.9, 
127.0 (2C), 128.0 (2C), 136.7, 137.8, 143.7, 170.4; IR (neat): νmax = 2968, 1717, 1431, 1385, 1304, 1239, 
1138, 1014 cm
−1
; HRMS (ESI): m/z calcd for C14H18O2 [M+H]
+
 219.1385; found: 219.1384. 
 
Methyl (E)-2,3-diphenylbut-2-enoate [(E)-5-5e][=(E)-3-3j]
14
 
[Method A]  Following the procedure for the preparation of (E)-5-5a-1, the reaction of enol tosylate (E)-5-4e 
(180 mg, 0.50 mmol) using PhMgBr (0.92 mL, 1.00 mmol; 1.09 M in THF), ZnCl2 (136 mg, 1.00 mmol), and 
[Pd(dppe)Cl2] (5.8 mg, 0.01 mmol) gave the desired product [(E)-5-5e, 126 mg, >99%, E/Z = 97:3]. 
Physical and spectral data were in accordance with (E)-3-3j. 
 
Methyl (Z)-2,3-diphenylbut-2-enoate [(Z)-5-5e][=(Z)-3-3j]
14,22
 
[Method A]  Following the procedure for the preparation of (Z)-5-5a-1, the reaction of enol tosylate (Z)-5-4e 
(180 mg, 0.50 mmol) using PhMgBr (0.92 mL, 1.00 mmol; 1.09 M in THF), ZnCl2 (136 mg, 1.00 mmol), and 
[Pd(dppb)Cl2] (3.0 mg, 0.005 mmol) gave the desired product [(Z)-5-5e, 125 mg, 99%, E/Z = 2:>98]. 
Physical and spectral data were in accordance with (Z)-3-3j. 
 
Methyl (Z)-2-methoxy-3-phenyloct-2-enoate [(Z)-5-5f] 
[Method A]  Following the procedure for the preparation of (E)-5-5a-1, the reaction of enol tosylate (Z)-5-4f 
(178 mg, 0.50 mmol) using PhMgBr (0.92 mL, 1.00 mmol; 1.09 M in THF), ZnCl2 (136 mg, 1.00 mmol), and 
[Pd(dppe)Cl2] (5.8 mg, 0.01 mmol) gave the desired product [(Z)-5-5f, 121 mg, 92%, E/Z = 2:>98]. 
Colorless oil; 
1
H NMR (500 MHz, CDCl3): δ = 0.80−0.86 (m, 3H), 1.19–1.40 (m, 6H), 2.67–2.73 (m, 2H), 
3.34 (s, 3H), 3.85 (s, 3H), 7.24−7.38 (m, 5H); 13C NMR (125 MHz, CDCl3): δ = 13.9, 22.3, 28.0, 31.6, 32.8, 
51.6, 59.5, 127.3, 127.9 (2C), 128.0 (2C), 138.9, 140.6, 142.1, 165.3; IR (neat): νmax = 2929, 2859, 1718, 1442, 
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1254, 1200, 1137, 1089 cm
−1
. 
 
Methyl (E)-2-methoxy-3-phenyloct-2-enoate [(E)-5-5f] 
[Method B]  Following the procedure for the preparation of (Z)-5-5a-1, the reaction of enol tosylate (E)-5-4f 
(178 mg, 0.50 mmol) using PhMgBr (0.92 mL, 1.00 mmol; 1.09 M in THF), ZnCl2 (136 mg, 1.00 mmol), and 
[Pd(dppb)Cl2] (3.0 mg, 5.0 µmol) gave the desired product [(E)-5-5f, 117 mg, 89%, E/Z = >98:2]. 
Colorless oil; 
1
H NMR (500 MHz, CDCl3): δ = 0.81−0.87 (m, 3H), 1.21–1.33 (m, 6H), 2.52 (t, J = 8.0 Hz, 
2H), 3.49 (s, 3H), 3.65 (s, 3H), 7.09−7.14 (m, 2H), 7.24−7.34 (m, 3H); 13C NMR (125 MHz, CDCl3): δ = 13.9, 
22.3, 17.0, 31.6, 32.5, 51.3, 59.0, 127.1, 127.6 (2C), 127.8 (2C), 138.6, 139.4, 142.9, 164.9; IR (neat): νmax = 
2928, 1720, 1631, 1434, 1318, 1259, 1205, 1144 cm
-1
; HRMS (ESI): m/z calcd for C16H22O3 [M+Na]
+
 
285.1467; found: 285.1461. 
 
Methyl (E)-7-chloro-2-methyl-3-phenylhept-2-enoate [(E)-5-5g][=(E)-3-3g]
14
 
[Method A]  Following the procedure for the preparation of (E)-5-5a-1, the reaction of enol tosylate 
(E)-5-4g (180 mg, 0.50 mmol) using PhMgBr (0.92 mL, 1.00 mmol; 1.09 M in THF), ZnCl2 (136 mg, 1.00 
mmol), and [Pd(dppe)Cl2] (5.8 mg, 0.01 mmol) gave the desired product [(E)-5-5g, 119 mg, 89%, E/Z = 
>98:2]. 
Physical and spectral data were in accordance with (E)-3-3g. 
 
Methyl (Z)-7-chloro-2-methyl-3-phenylhept-2-enoate [(Z)-5-5g][=(Z)-3-3g]
14
 
[Method B]  Following the procedure for the preparation of (Z)-5-5a-1, the reaction of enol tosylate (Z)-5-4g 
(180 mg, 0.50 mmol) using PhMgBr (0.92 mL, 1.00 mmol; 1.09 M in THF), ZnCl2 (136 mg, 1.00 mmol), and 
[Pd(dppb)Cl2] (3.0 mg, 0.005 mmol) gave the desired product [(Z)-5-5g, 120 mg, 90%, E/Z = 2:>98]. 
Physical and spectral data were in accordance with (Z)-3-3g. 
 
Methyl (Z)-2-chloro-3-(tosyloxy)but-2-enoate [(Z)-5-23a] 
TsCl (714 mg, 3.75 mmol) in toluene (2.5 mL) was added to a stirred suspension of 2-chloro-3-oxobutanoate 
5-22a (2.50 mmol), NMI (304 mg, 3.75 mmol), and iPr2NEt (484 mg, 3.75 mmol) in toluene (2.5 mL) at 0 − 
5 °C and the mixture was stirred at the same temperature for 1 h.  Water was added to the mixture, which 
was extracted twice with AcOEt.  The combined organic phase was washed with water, brine, dried (Na2SO4), 
and concentrated.  The obtained crude product was purified by SiO2 column chromatography (hexane/AcOEt 
= 10:1) to give the desired product [(Z)-5-23a, 695 mg, 91%, E/Z = 2:98]. 
Colorless crystals; mp 35−36 °C; 1H NMR (500 MHz, CDCl3): δ = 2.47 (s, 3H), 2.53 (s, 3H), 3.82 (s, 3H), 
7.37 (d, J = 8.0 Hz, 2H), 7.89 (d, J = 8.0 Hz, 2H); 
13
C NMR (125 MHz, CDCl3): δ = 20.0, 21.7, 53.1, 115.8, 
128.2 (2C), 129.9 (2C), 133.4, 145.9, 156.0, 162.9; IR (neat): νmax = 2955, 1725, 1626, 1437, 1373, 1271, 
1205, 1169, 1062, 1041, 909, 803, 719 cm
-1
; HRMS (ESI): m/z calcd for C12H13O5ClS [M+Na]
+
 327.0070; 
found: 327.0077. 
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Methyl (E)-2-chloro-3-(tosyloxy)but-2-enoate [(E)-5-23a] 
2-Chloro-3-oxobutanoate 5-22a (150 mg, 1.00 mmol) in toluene (1.0 mL) was added to a stirred suspension of 
NaH (60%; 60 mg, 1.50 mmol) and TMEDA (174 mg, 1.50 mmol) in toluene (1.0 mL) at 0 − 5 °C, followed 
by addition of TsCl (286 mg, 1.50 mmol).  The reaction mixture was stirred at the same temperature for 1 h.  
Water was added to the mixture, which was extracted twice with AcOEt.  The combined organic phase was 
washed with water, brine, dried (Na2SO4), and concentrated.  The obtained crude product was purified by 
SiO2 column chromatography (hexane/AcOEt = 10/1) to give the desired product [(E)-5-23a, 257 mg, 84%, 
E/Z = 87:13]. 
Colorless oil; 
1
H NMR (500 MHz, CDCl3): δ = 2.21 (s, 3H), 2.47 (s, 3H), 3.67 (s, 3H), 7.38 (d, J = 8.0 Hz, 
2H), 7.82−7.86 (m, 2H); 13C NMR (125 MHz, CDCl3): δ = 19.5, 21.6, 52.8, 118.5, 128.2 (2C), 129.8 (2C), 
132.8, 145.8, 151.3, 161.2; IR (neat): νmax = 2955, 1732, 1632, 1435, 1375, 1287, 1258, 1165, 1091, 943, 909, 
814, 723 cm
−1
. 
 
Methyl (Z)-2-chloro-3-phenyl-3-(tosyloxy)acrylate [(Z)-5-23b] 
TsCl (21.1 g, 111 mmol) in toluene (75 mL) was added to a stirred suspension of 
2-chloro-3-phenyl-3-oxobutanoate 5-22b (15.7 g, 73.8 mmol), NMI (9.11 g, 111 mmol), and iPr2NEt (14.3 g, 
111 mmol) in toluene (75 mL) at 0 − 5 °C and the mixture was stirred at the same temperature for 1 h.  Water 
was added to the mixture, which was extracted twice with AcOEt.  The combined organic phase was washed 
with water, brine, dried (Na2SO4), and concentrated.  The obtained crude solid was recrystallized (iPrOH 35 
mL) to give the desired product [(Z)-5-23b, 22.4 g, 83%, E/Z = 2:98]. 
Colorless crystals; mp 82−83 °C; 1H NMR (500 MHz, CDCl3): δ = 2.40 (s, 3H), 3.61 (s, 3H), 7.17 (d, J = 8.6 
Hz, 2H), 7.22−7.28 (m, 4H), 7.33−7.38 (m, 1H), 7.54 (d, J = 8.6 Hz, 2H); 13C NMR (125 MHz, CDCl3): δ = 
21.6, 53.0, 117.1, 128.0 (2C), 128.1 (2C), 129.1 (2C), 129.5 (2C), 130.5, 131.7, 133.6, 145.4, 153.2, 163.1; IR 
(neat): νmax = 2953, 1734, 1598, 1384, 1280, 1192, 1178, 1044, 806 cm
−1
; HRMS (ESI): m/z calcd for 
C17H15O5ClS [M+Na]
+
 389.0226; found: 389.0225. 
 
Methyl (E)-2-chloro-3-phenyl-3-(tosyloxy)acrylate [(E)-5-23b] 
2-Chloro-3-phenyl-3-oxobutanoate 5-22b (106 mg, 0.50 mmol) in toluene (0.50 mL) was added to a stirred 
suspension of NaH (60%; 30 mg, 0.75 mmol) and TMEDA (87 mg, 0.75 mmol) in toluene (0.50 mL) at 0 − 
5 °C, followed by addition of TsCl (143 mg, 0.75 mmol).  The reaction mixture was stirred at the same 
temperature for 1 h.  Water was added to the mixture, which was extracted twice with AcOEt.  The 
combined organic phase was washed with water, brine, dried (Na2SO4), and concentrated.  The obtained 
crude product was purified by SiO2 column chromatography (hexane/AcOEt = 8/1) to give the desired product 
[(E)-5-23b, 160 mg, 89%, E/Z = 94:6]. 
Colorless crystals; mp 69−71 °C; 1H NMR (500 MHz, CDCl3): δ = 2.37 (s, 3H), 3.89 (s, 3H), 7.10 (d, J = 8.6 
Hz, 2H), 7.20 (t, J = 8.0 Hz, 2H), 7.28−7.33 (m, 1H), 7.34−7.38 (m, 2H), 7.44 (d, J = 8.6 Hz, 2H); 13C NMR 
(125 MHz, CDCl3): δ = 21.5, 53.2, 118.5, 127.8 (2C), 128.0 (2C), 129.36 (2C), 129.38 (2C), 130.3, 130.9, 
133.3, 145.1, 150.2, 162.2; IR (neat): νmax = 2954, 1735, 1597, 1384, 1252, 1192, 1178, 1016, 734 cm
-1
. 
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Methyl (Z)-2-chloro-3-phenylbut-2-enoate [(Z)-5-24a] 
A suspension of enol tosylate (Z)-5-23a (152 mg, 0.50 mmol), PhB(OH)2 (73 mg, 0.60 mmol), Pd(OAc)2 (5.6 
mg, 0.025 mmol), PPh3 (13 mg, 0.050 mmol), and K2CO3 (83 mg, 0.60 mmol) in iPrOH (1.5 mL)/water (0.50 
mL) was stirred at 60 − 65 °C under an argon atmosphere for 1 h.  After cooling to room temperature, water 
was added to the mixture, which was extracted twice with AcOEt.  The combined organic phase was washed 
with water and brine, dried (Na2SO4), and concentrated.  The obtained crude product was purified by column 
chromatography on silica gel (hexane/AcOEt = 30:1) to give the desired product [(Z)-5-24a, 90 mg, 86%, E/Z 
= 2:98]. 
Colorless oil; 
1
H NMR (500 MHz, CDCl3): δ = 2.42 (s, 3H), 3.88 (s, 3H), 7.25 (d, J = 7.5 Hz, 2H), 7.33 (t, J = 
7.5 Hz, 1H), 7.40 (t, J = 7.5 Hz, 2H); 
13
C NMR (125 MHz, CDCl3): δ = 23.4, 52.7, 118.5, 126.9 (2C), 127.9, 
128.3 (2C), 141.5, 148.5, 164.4; IR (neat): νmax = 2953, 2843, 1721, 1595, 1491, 1435, 1374, 1254 cm
−1
. 
 
Methyl (E)-2-chloro-3-phenylbut-2-enoate [(E)-5-24a] 
Following the procedure for the preparation of (Z)-5-24a, the reaction of enol tosylate (E)-5-23a (159 mg, 
0.52 mmol) using PhB(OH)2 (76 mg, 0.63 mmol), Pd(OAc)2 (5.8 mg, 0.026 mmol), PPh3 (14 mg, 0.052 
mmol), and K2CO3 (87 mg, 0.63 mmol) gave the desired product [(E)-5-24a, 98 mg, 89%, E/Z = >98:2]. 
Colorless oil; 
1
H NMR (500 MHz, CDCl3): δ = 2.30 (s, 3H), 3.53 (s, 3H), 7.14−7.19 (m, 2H), 7.29−7.37 (m, 
3H); 
13
C NMR (125 MHz, CDCl3): δ = 23.4, 52.4, 120.0, 126.7 (2C), 128.0, 128.2 (2C), 140.8, 146.1, 164.4; 
IR (neat): νmax = 2951, 2845, 1721, 1595, 1491, 1435, 1374, 1254 cm
−1
. 
 
Methyl (Z)-2-chloro-3-phenyl-3-(p-tolyl)acryate [(Z)-5-24b] 
Following the procedure for the preparation of (Z)-5-24a, the reaction of enol tosylate (Z)-5-23b (367 mg, 
1.00 mmol) using (p-Me)C6H4B(OH)2 (163 mg, 1.20 mmol), Pd(OAc)2 (2.2 mg, 0.010 mmol), Ph-RuPhos 
(9.1 mg, 0.020 mmol), and K2CO3 (101 mg, 1.20 mmol) at 20 − 25 °C gave the desired product [(Z)-5-24b, 
238 mg, 83%, E/Z = 7:93]. 
Colorless oil; 
1
H NMR (500 MHz, CDCl3): δ = 2.36 (s, 3H), 3.57 (s, 3H), 7.13−7.22 (m, 6H), 7.29−7.33 (m, 
3H); 
13
C NMR (125 MHz, CDCl3): δ = 21.3, 52.6, 119.2, 128.2 (2C), 128.5, 128.7 (2C), 128.8 (2C), 129.6 
(2C), 136.1, 138.8, 140.3, 148.0, 165.7; IR (neat): νmax = 3065, 2953, 1732, 1597, 1381, 1246, 1177, 1011, 731 
cm
−1
. 
 
Methyl (E)-2-chloro-3-phenyl-3-(p-tolyl)acryate [(E)-5-24b] 
Following the procedure for the preparation of (Z)-5-24a, the reaction of enol tosylate (E)-5-23b (3.67 g, 10.0 
mmol) using (p-Me)C6H4B(OH)2 (1.63 g, 12.0 mmol), Pd(OAc)2 (112 mg, 0.500 mmol), PPh3 (262 mg, 1.00 
mmol), and K2CO3 (1.66 g, 12.0 mmol) at 40 − 45 °C gave the desired product [(E)-5-24b, 2.54 g, 89%, E/Z = 
>98:2]. 
Colorless oil; 
1
H NMR (500 MHz, CDCl3): δ = 2.36 (s, 3H), 3.57 (s, 3H), 7.13−7.22 (m, 6H), 7.29−7.33 (m, 
3H); 
13
C NMR (125 MHz, CDCl3): δ = 21.3, 52.6, 119.2, 128.2 (2C), 128.5, 128.7 (2C), 128.8 (2C), 129.6 
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(2C), 136.1, 138.8, 140.3, 148.0, 165.7; IR (neat): νmax = 3059, 2953, 1722, 1597, 1379, 1298, 1177, 1045, 804, 
733 cm
−1
; HRMS (ESI): m/z calcd for C17H15O2Cl [M+Na]
+
 309.0658; found: 309.0647. 
 
Methyl (E)-2,3-diphenyl-3-(p-tolyl)acrylate [(E)-5-25b-1] 
A suspension of enol tosylate (Z)-5-24b (143 mg, 0.50 mmol), PhB(OH)2 (73 mg, 0.60 mmol), Pd(OAc)2 (1.1 
mg, 0.005 mmol), SPhos (2.0 mg, 0.005 mmol), and K2CO3 (83 mg, 0.60 mmol) in toluene (1.5 mL)/water 
(0.50 mL) was stirred at 80 − 85 °C under an argon atmosphere for 1 h.  After cooling to room temperature, 
water was added to the mixture, which was extracted twice with AcOEt.  The combined organic phase was 
washed with water and brine, dried (Na2SO4), and concentrated.  The obtained crude solid was washed with 
hexane to give the desired product [(E)-5-25b-1, 151 mg, 92%, E/Z = >98:2]. 
Colorless solid; mp 128−129 °C; 1H NMR (500 MHz, CDCl3): δ = 2.26 (s, 3H), 3.53 (s, 3H), 6.87 (d, J = 8.0 
Hz, 2H), 6.93 (d, J = 8.0 Hz, 2H), 7.09−7.13 (m, 2H), 7.16−7.21 (m, 3H), 7.24−7.28 (m, 2H), 7.30−7.34 (m, 
3H); 
13
C NMR (125 MHz, CDCl3): δ = 21.2, 51.9, 127.3, 128.0, 128.1 (2C), 128.2 (2C), 128.5 (2C), 129.0 
(2C), 129.8 (2C), 130.9 (2C), 132.9, 137.49, 137.55, 137.7, 142.6, 146.4, 171.0; IR (neat): νmax = 3022, 2947, 
1717, 1493, 1431, 1217, 1148, 1042, 816, 752, 696 cm
−1
; HRMS (ESI): m/z calcd for C23H20O2 [M+Na]
+
 
351.1361; found: 351.1345. 
 
Methyl (Z)-2,3-diphenyl-3-(p-tolyl)acrylate [(Z)-5-25b-1] 
Following the procedure for the preparation of (E)-5-25b-1, the reaction of enol tosylate (E)-5-24b (143 mg, 
0.50 mmol) using PhB(OH)2 (73 mg, 0.60 mmol), Pd(OAc)2 (1.1 mg, 0.005 mmol), SPhos (2.0 mg, 0.005 
mmol), and K2CO3 (83 mg, 0.60 mmol) gave the desired product [(Z)-5-25b-1, 151 mg, 92%, E/Z = 2:>98]. 
Colorless solid; mp 146−147 °C; 1H NMR (500 MHz, CDCl3): δ = 2.36 (s, 3H), 3.58 (s, 3H), 6.97−7.01 (m, 
2H), 7.06−7.20 (m, 12H); 13C NMR (125 MHz, CDCl3): δ = 21.3, 52.0, 127.3, 127.6, 127.8 (2C), 128.2 (2C), 
128.91 (2C), 128.93 (2C), 129.8 (2C), 130.9 (2C), 132.9, 137.6, 138.0, 139.4, 140.7, 146.3, 171.1; IR (neat): 
νmax = 3021, 2949, 1717, 1429, 1263, 1220, 1146, 1040, 822, 754, 694 cm
−1
. 
 
Methyl (E)-2-(phenyl(p-tolyl)methylene)octanoate [(E)-5-25b-2] 
A suspension of enol tosylate (Z)-5-24b (72 mg, 0.25 mmol), (nhexyl)B(OH)2 (58 mg, 0.45 mmol), Pd(OAc)2 
(1.7 mg, 0.0075 mmol), SPhos (3.1 mg, 0.0075 mmol), and K2CO3 (62 mg, 0.45 mmol) in toluene (0.75 
mL)/water (0.25 mL) was stirred at 80 − 85 °C under an argon atmosphere for 3 h.  After cooling to room 
temperature, water was added to the mixture, which was extracted twice with AcOEt.  The combined organic 
phase was washed with water and brine, dried (Na2SO4), and concentrated.  The obtained crude product was 
purified by column chromatography on silica gel (hexane/AcOEt = 50:1) to give the desired product 
[(E)-5-25b-2, 68 mg, 81%, E/Z = 98:2]. 
Colorless oil; 
1
H NMR (500 MHz, CDCl3): δ = 0.86 (t, J = 6.9 Hz, 3H), 1.19−1.32 (m, 6H), 1.43−1.52 (m, 
2H), 2.33−2.39 (m, 2H), 2.35 (s, 3H), 3.45 (s, 3H), 7.02−7.06 (m, 2H), 7.09−7.16 (m, 4H), 7.19−7.27 (m, 
3H); 
13
C NMR (125 MHz, CDCl3): δ = 14.0, 21.2, 22.5, 28.9, 29.1, 31.5, 32.3, 51.4, 127.3, 127.9 (2C), 128.5 
(2C), 128.8 (2C), 129.1 (2C), 133.5, 137.3, 138.0, 142.6, 145.4, 171.7; IR (neat): νmax = 2924, 2857, 1715, 
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1431, 1325, 1246, 1132, 818, 727, 700 cm
−1
. 
 
Methyl (Z)-2-(phenyl(p-tolyl)methylene)octanoate [(Z)-5-25b-2] 
Following the procedure for the preparation of (E)-5-25b-2, the reaction of enol tosylate (E)-5-24b (72 mg, 
0.25 mmol) using (nhexyl)B(OH)2 (58 mg, 0.45 mmol), Pd(OAc)2 (1.7 mg, 0.0075 mmol), SPhos (3.1 mg, 
0.0075 mmol), and K2CO3 (62 mg, 0.45 mmol) gave the desired product [(Z)-5-25b-2, 57 mg, 68%, E/Z = 2: 
98]. 
Colorless oil; 
1
H NMR (500 MHz, CDCl3): δ = 0.85 (t, J = 6.9 Hz, 3H), 1.16−1.30 (m, 6H), 1.42−1.50 (m, 
2H), 2.29−2.36 (m, 2H), 2.31 (s, 3H), 3.50 (s, 3H), 6.98−7.02 (m, 2H), 7.03−7.07 (m, 2H), 7.13−7.17 (m, 2H), 
7.26−7.35 (m, 3H); 13C NMR (125 MHz, CDCl3): δ = 14.0, 21.2, 22.5, 28.9, 29.1, 31.4, 32.3, 51.4, 127.4, 
128.1 (2C), 128.4 (2C), 128.6 (2C), 129.1 (2C), 133.2, 137.1, 139.3, 141.1, 145.3, 171.7; IR (neat): νmax = 
2924, 2857, 1718, 1431, 1325, 1244, 1132, 908, 818, 731, 700 cm
−1
; HRMS (ESI): m/z calcd for C23H28O2 
[M+Na]
+
 359.1987; found: 359.1993. 
 
Methyl (E)-3-phenyl-2-(thiophen-3-yl)-3-(p-tolyl)acrylate [(E)-5-25b-3] 
Following the procedure for the preparation of (E)-5-25b-2, the reaction of enol tosylate (Z)-5-24b (72 mg, 
0.25 mmol) using (3-thienyl)B(OH)2 (38 mg, 0.30 mmol), Pd(OAc)2 (0.6 mg, 0.0025 mmol), SPhos (1.0 mg, 
0.0025 mmol), and K2CO3 (41 mg, 0.30 mmol) gave the desired product [(E)-5-25b-3, 79 mg, 94%, E/Z = 
98:2]. 
Colorless solid; mp 110−112 °C; 1H NMR (500 MHz, CDCl3): δ = 2.31 (s, 3H), 3.54 (s, 3H), 6.66 (dd, J = 5.2, 
1.2 Hz, 1H), 6.94−6.97 (m, 3H), 7.01 (d, J = 8.0 Hz, 2H), 7.09 (dd, J = 5.2, 2.9 Hz, 1H), 7.22−7.25 (m, 2H), 
7.28−7.33 (m, 3H); 13C NMR (125 MHz, CDCl3): δ = 21.2, 51.9, 124.6, 125.1, 127.7, 128.0, 128.1 (2C), 
128.5, 128.8 (2C), 128.9 (2C), 130.3 (2C), 137.4, 137.8, 137.9, 142.3, 145.7, 170.8; IR (neat): νmax = 3022, 
2947, 1717, 1431, 1219, 1142, 1040, 754, 719 cm
−1
. 
 
Methyl (Z)-3-phenyl-2-(thiophen-3-yl)-3-(p-tolyl)acrylate [(Z)-5-25b-3] 
Following the procedure for the preparation of (E)-5-25b-1, the reaction of enol tosylate (E)-5-24b (72 mg, 
0.25 mmol) using (3-thienyl)B(OH)2 (38 mg, 0.30 mmol), Pd(OAc)2 (0.6 mg, 0.0025 mmol), SPhos (1.0 mg, 
0.0025 mmol), and K2CO3 (41 mg, 0.30 mmol) gave the desired product [(Z)-5-25b-3, 67 mg, 80%, E/Z = 
3:97]. 
Colorless solid; mp 131−133 °C; 1H NMR (500 MHz, CDCl3): δ = 2.35 (s, 3H), 3.59 (s, 3H), 6.62 (d, J = 4.6 
Hz, 1H), 6.93 (d, J = 2.9 Hz, 1H), 7.05−7.15 (m, 7H), 7.18−7.25 (m, 3H); 13C NMR (125 MHz, CDCl3): δ = 
21.3, 52.0, 124.6, 125.1, 127.6, 127.8, 128.0 (2C), 128.5, 128.8 (2C), 128.9 (2C), 130.3 (2C), 137.4, 137.9, 
139.1, 141.0, 145.5, 170.9; IR (neat): νmax = 3022, 2947, 1717, 1431, 1258, 1219, 142, 1036, 743, 698 cm
−1
; 
HRMS (ESI): m/z calcd for C21H18O2S [M+Na]
+
 357.0925; found: 359.0937. 
 
Methyl (E)-4-phenyl-2-(phenyl(p-tolyl)methylene)but-3-ynoate [(E)-5-25b-4] 
A suspension of enol tosylate (Z)-5-24b (72 mg, 0.25 mmol), phenylacetylene (33 mg, 0.33 mmol), 
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[Pd(NCMe)2Cl2] (1.0 mg, 0.0025 mmol), XPhos (3.6 mg, 0.0075 mmol), and Cs2CO3 (212 mg, 0.65 mmol) in 
MeCN (0.50 mL) was stirred at 90 − 95 °C under an argon atmosphere for 3 h.  After cooling to room 
temperature, water was added to the mixture, which was extracted twice with AcOEt.  The combined organic 
phase was washed with water and brine, dried (Na2SO4), and concentrated.  The obtained crude product was 
purified by column chromatography on silica gel (hexane/AcOEt = 30:1) to give the desired product 
[(E)-5-25b-4, 64 mg, 73%, E/Z = 91:9]. 
Orange solid; mp 150−152 °C; 1H NMR (500 MHz, CDCl3): δ = 2.39 (s, 3H), 3.61 (s, 3H), 7.15−7.21 (m, 4H), 
7.27−7.36 (m, 8H), 7.41−7.44 (m, 2H); 13C NMR (125 MHz, CDCl3): δ = 21.4, 52.3, 87.4, 94.1, 113.4, 123.1, 
128.0 (2C), 128.2 (2C), 128.3, 128.4 (2C), 128.6, 129.2 (2C), 130.5 (2C), 131.5 (2C), 137.0, 139.3, 140.9, 
155.9, 167.4; IR (neat): νmax = 3028, 2949, 1726, 1487, 1435, 1327, 1229, 1098, 756 cm
−1
. 
 
Methyl (Z)-4-phenyl-2-(phenyl(p-tolyl)methylene)but-3-ynoate [(Z)-5-25b-4] 
Following the procedure for the preparation of (E)-5-25b-4, the reaction of enol tosylate (E)-5-24b (72 mg, 
0.25 mmol) using phenylacetylene (33 mg, 0.33 mmol), [Pd(NCMe)2Cl2] (1.0 mg, 0.0025 mmol), XPhos (3.6 
mg, 0.0075 mmol), and Cs2CO3 (212 mg, 0.65 mmol) gave the desired product [(Z)-5-25b-4, 66 mg, 75%, E/Z 
= 5:95]. 
Yellow solid; mp 136−137 °C; 1H NMR (500 MHz, CDCl3): δ = 2.36 (s, 3H), 3.66 (s, 3H), 7.08 (d, J = 8.0 Hz, 
2H), 7.14 (d, J = 8.0 Hz, 2H), 7.24−7.30 (m, 5H), 7.34−7.38 (m, 3H) , 7.48−7.53 (m, 2H); 13C NMR (125 
MHz, CDCl3): δ = 21.3, 52.3, 87.4, 94.0, 113.6, 123.0, 127.6 (2C), 128.2 (2C), 128.3, 128.8 (2C), 129.0, 
129.1 (2C), 130.5 (2C), 131.4 (2C), 137.6, 138.7, 140.2, 156.1, 167.4; IR (neat): νmax = 3022, 2953, 1730, 
1487, 1435, 1327, 1225, 1163, 1099, 910, 750, 685 cm
−1
; HRMS (ESI): m/z calcd for C25H20O2 [M+Na]
+
 
375.1361; found: 375.1351. 
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Chapter 6. 
(Z)-Enol p-Tosylate Derived from Methyl Acetoacetate: A Useful 
Cross-coupling Partner for the Synthesis of Methyl (Z)-3-Phenyl 
(or Aryl)-2-butenoate 
 
Abstract 
A synthesis of methyl (Z)-3-phenyl-2-butenoate [methyl (Z)-β-methylcinnamate] (Z)-6-2 directed for 
Organic Syntheses is presented.  Despite its simple structure, hitherto reported methods require 
multi-steps or expensive reagents, low temperature, and long reaction period.  The enol tosylation 
of methyl acetoacetate utilizing TsCl−TMEDA−LiCl reagent in AcOEt solvent gives 
(Z)-3-(p-toluenesulfonyloxy)but-2-enoate (Z)-6-1, which is converted to (Z)-6-2 utilizing a highly 
cost-effective Pd(OAc)2 (1 mol%)/PPh3 (2 mol%)-catalyzed Suzuki-Miyaura cross-coupling with 
nearly perfect (Z)-stereoretention.  Throughout the procedure, tedious column chromatographic 
purification is not required.   In addition, environmentally benign solvents, such as AcOEt, iPrOH, 
and H2O, are employed for both of two reaction steps and the corresponding extraction (work-up) 
steps.  In addition, the synthesis of the aryl analogues including stereocomplementary (E)-isomer 
are addressed. 
 
 
 
In this chapter, according to the policy of “Organic Syntheses” as shown in below, the author describes the 
procedure section in the first place. 
 
“Since 1921, Organic Syntheses has provided the chemistry community with detailed, reliable, and carefully 
checked procedures for the synthesis of organic compounds. Some procedures describe practical methods for 
the preparation of specific compounds of interest, while other procedures illustrate important synthetic 
methods with general utility. Each procedure is written in considerably more detail as compared to typical 
experimental procedures in other journals, and each reaction with its characterization data has been repeated 
several times and carefully "checked" for reproducibility in the laboratory of a member of the Board of 
Editors.” 
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“All organic chemists have experienced frustration at one time or another when attempting to repeat reactions 
based on experimental procedures found in journal articles. To ensure reproducibility, Organic Syntheses 
requires experimental procedures written with considerably more detail as compared to the typical procedures 
found in other journals and in the “Supporting Information” sections of papers. In addition, each Organic 
Syntheses procedure is carefully “checked” for reproducibility in the laboratory of a member of the Board of 
Editors.” 
 
“The appropriate scale for procedures will vary widely depending on the nature of the chemistry and the 
compounds synthesized in the procedure. However, some general guidelines are possible. For procedures in 
which the principal goal is to illustrate a synthetic method or strategy, it is expected, in general, that the 
procedure should result in at least 5 g and no more than 50 g of the final product. In cases where the point of 
the procedure is to provide an efficient method for the preparation of a useful reagent or synthetic building 
block, the appropriate scale also should be between 5 and 50 g of final product. Exceptions to these guidelines 
may be granted in special circumstances. For example, procedures describing the preparation of reagents 
employed as catalysts will often be acceptable on a scale of less than 5 g.” 
 
Procedure 
A. (Z)-3-(p-toluenesulfonyloxy)but-2-enoate  [(Z)-6-1)].  A 500-mL, three-necked, round-bottomed flask 
attached to a CaCl2 drying tube, capped with a glass stopper, and fitted with a thermometer, a Teflon-coated 
magnetic stir bar (Note 1) is charged with methyl 3-oxobutanoate (methyl acetoacetate) (17.4 g, 150 mmol) 
(Note 2) and AcOEt (150 mL).  To a stirred mixture, LiCl (7.63 g, 180 mmol) (Note 3) is added in one 
portion.  TMEDA (26.8 mL, 180 mmol) (Note 4) is added dropwise over 2 min to the suspension.     
The vigorously stirred white-colored suspension is immersed in an ice-cooling bath, and p-toluenesulfonyl 
(tosyl) chloride (TsCl) (34.3 g, 180 mmol) (Note 5) is added portionwise (3 portions) over 10‒15 min after 
temporarily removing the glass stopper while maintaining the inner temperature below 10 °C (Note 6) 
<Figure 6-1>.  The suspension becomes a well-equalized white slurry <Figure 6-2> after ca. 10 min of the 
addition of TsCl. 
 
  
  
  
  Figure 6-1.  Addition of TsCl. Figure 6-2.  The reaction mixture in step A.   
 
The reaction mixture is stirred for 1 h at ~5 °C, and water (75 mL) is added to the resulting mixture for ca. 1 
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min to maintain the inner temperature below 15 °C.  The suspension immediately develops two transparent 
phases <Figure 6-3>.  
 
 
Figure 6-3.  The reaction mixture after quench with H2O. 
 
The mixture is moved into a 500-mL separatory funnel [the flask is rinsed twice with AcOEt (10 x 2 mL)].  
The organic phase is separated and the aqueous phase is re-extracted with AcOEt (50 mL).  The combined 
organic phase is washed with aqueous 1M HCl (75 mL) and brine (75 mL), dried over Na2SO4 (75 g), filtered, 
and concentrated under reduced pressure using a rotary evaporator (15-20 mmHg), (bath temperature, ca. 40‒
45 °C) and a vacuum pump with gentle heating using a dryer to remove the AcOEt completely.      
The obtained slightly orange-colored oil solidifies after a few min (Note 7) <Figure 6-4>.  The crude solid 
(38.9 g) in a 100 mL round bottom flask was crushed into particles, which was transferred to a 100 mL 
Erlenmeyer flask using 2-propanol (40 mL) (Note 8).  The solid was completely dissolved with heating by a 
dryer at 50−55 °C with shaking for ca. 5 min.  The solution was then allowed to cool to room temperature 
(20−25 °C).  Crystallization was initiated by adding a small amounts of seed crystals (crude solid), and the 
flask was kept at 0−5 °C for 15 h.  Using a glass filter (G3, 70 mm diameter) the first crop is collected and 
washed twice with 2-propanol (40 x 2 mL) to yield 30.7 g (76%, ≥98% ds) of the desired product (Z)-6-1 as 
colorless crystals (Note 9) <Figure 6-5>.     
 
 
  
 Figure 6-4.  The crude solid obtained in step A. Figure 6-5.  Pure (Z)-6-1 after recrystallization. 
 
B. Methyl (Z)-3-phenyl (or Aryl)-2-butenoate [(Z)-6-2].  A 100-mL, three-necked, round-bottomed flask 
equipped with a pressure-equalizing Ar baloon, capped with a glass stopper, a thermometer, and a 
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Teflon-coated magnetic stirring bar (Note 10), is charged with 2-propanol (75 mL) and water (25 mL) (Note 
11). 
The stirred white-colored suspension is immersed in a temperature-controlled water bath and (Z)-enol 
tosylate [(Z)-6-1] (13.5 g, 50 mmol), PhB(OH)2 (6.40 g, 52.5 mmol) (Note 12), and K2CO3 (7.26 g, 52.5 
mmol) (Note 13) are successively added, each in one portion after temporarily removing the glass stopper.  
The reaction mixture is warmed to 30‒35 °C (inner temperature) with vigorous stirring.  PPh3 (262 mg, 1.0 
mmol) (Note 14) and Pd(OAc)2 (112 mg, 0.5 mmol) (Note 15) are then successively added to the mixture, 
each in one portion while maintaining the inner temperature below 40 °C, followed by stirring for 1 h (Note 
16). 
Water (50 mL) is added to the reaction mixture, which is filtered through a glass filter (G3, 70 mm 
diameter) with 10 g of Celite
®
 pad washing with AcOEt (100 mL).  The filtrate is moved into a 300-mL 
separatory funnel [the flask is rinsed twice with AcOEt (10 x 2 mL)].  The organic phase is separated and the 
aqueous phase is re-extracted with AcOEt (50 mL).  The combined organic phase is washed with aqueous 
1M NaOH (50 mL) and brine (50 mL), dried over Na2SO4 (50 g), filtered, and concentrated under reduced 
pressure using a rotary evaporator (15−20 mmHg), (bath temperature, ca. 40‒45 °C). 
The obtained black colored oil (8.75 g) is moved into a 20-mL round-bottomed flask, into which a 
Teflon-coated magnetic stir bar is put.  Distillation while immersed in a temperature-controlled oil bath 
under reduced pressure using a vacuum pump gives the desired product (Z)-6-2 (7.64 g, 87% yield, ≥98% ds) 
as a colorless oil (Note 17) <Figure 6-6>. 
 
Figure 6-6.  Distillation set-up in step B. 
 
Notes 
1.  A magnetic stirring bar (for example, egg-shaped, 50 mm length x 20 mm diameter) is used, since the 
reaction mixture produces a large quantity of salts.  The white slurry is smoothly stirred throughout the 
reaction.  
2.  Methyl 3-oxobutanoate (Methyl acetoacetate) (GC purity 99.0%) was purchased from Tokyo Chemical 
Industry Co., Ltd. and used as received. 
3.  Lithium chloride (LiCl) (99.0%) anhydrous was purchased from Wako Pure Chemical Industries, Ltd. and 
used as received. 
4.  N,N,N’,N’-Tetramethylethylenediamine (TMEDA) (>98.0%) was purchased from Tokyo Chemical 
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Industry Co., Ltd. and used as received. 
5.  p-Toluenesulfonyl (tosyl) chloride (TsCl) (>99.0%) was purchased from Tokyo Chemical Industry Co., 
Ltd. and used as received; a fresh lot was used.  Once the cap was opened, it should be surely put the cap 
after the use.  
6.  An exothermic reaction with production of salts. 
7.  Usually, the compound solidified immediately when it is left.   
8.  2-Propanol (>99.7%, GLC) was purchased was purchased from Wako Pure Chemical Industries, Ltd. and 
used as received. 
9.  Stable solids can be stored in a brown colored bottle at room temperature over months.  Physical and 
spectroscopic properties of (Z)-6-1: colorless crystals; mp 67.0–68.0 °C [lit. (Our group, Org. Lett. 2008, 
10, 2131), 62.0–63.0 °C]; 1H NMR (500 MHz, CDCl3): δ = 2.14 (s, 3H), 2.46 (s, 3H), 3.58 (s, 3H), 5.50 (s, 
1H), 7.36 (d, J = 8.0 Hz, 2H), 7.91 ppm (d, J = 8.0 Hz, 2H); 
13
C NMR (125 MHz, CDCl3): δ = 21.6, 51.2, 
110.2, 128.2, 129.6, 133.2, 145.4, 156.4, 163.1 ppm.  IR (KBr): νmax = 3447, 2924, 1738, 1669, 1497, 
1445, 1373, 1335 cm
−1
.  Anal. calcd for C12H14O5S: C, 53.32; H, 5.22. Found; C, 53.30; H, 5.20.  The 
second crop did not appear.  Concentration of 2-propanol of the mother and the washing liquors by 
vacuum pump, gave yellow colored oil (8.59 g), [Molar ratio; (Z)-6-1, (E)-6-1, and unreacted TsCl = c.a. 
1 : 0.4 : 0.6].  The first recrystallization efficiency seems to be sufficient and the total material balance is 
reasonable.   
10. A magnetic stirring bar (for example, egg-shaped, 40 mm length x 20 mm diameter) is used, since the 
reaction mixture produces a large quantity of salts. 
11. Distilled water was used.   
12. Phenylboronic acid [PhB(OH)2] was purchased from Wako Pure Chemical Industries, Ltd. and used as 
received.  
13. Potassium carbonate (K2CO3) (>99.5%) was purchased from Wako Pure Chemical Industries, Ltd. and 
used as received. 
14. Triphenylphosphine (PPh3) (>95.0%) was purchased from Tokyo Chemical Industry Co., Ltd. and used as 
received.  
15. Palladium acetate [Pd(OAc)2] (>97.0%) was purchased from Wako Pure Chemical Industries, Ltd. and 
used as received. 
16. A slight exothermic reaction with production of salts.    
17. Physical and spectroscopic properties of (Z)-6-2: 75−77 °C/0.75 mmHg.  colorless oil; 1H NMR (500 
MHz, CDCl3): δ = 2.19 (d, J = 0.9 Hz, 3H), 3.55 (s, 3H), 7.18−7.23 (m, 2H), 7.29−7.38 (m, 3H); 
13
C NMR 
(125 MHz, CDCl3): δ = 27.1, 50.9, 117.0, 126.7, 127.7, 127.8, 140.5, 155.8, 166.1; νmax = 2950, 1734, 
1637, 1491, 1437, 1375, 1233, 1165 cm
−1
; HRMS (ESI): m/z calcd for C11H12O2 [M+Na]
+
 199.0735; 
found: 199.0735.  The purity of (Z)-6-2 is estimated at least >97%. 
 
Discussion 
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Stereocontrolled preparation of ubiquitous (E)- and (Z)-α,β-unsaturated esters is pivotal in organic syntheses, 
because these important compounds serve as useful structural scaffolds for various (E)- and (Z)-stereodefined 
olefins, conjugate (Michael) addition acceptors, and catalytic asymmetric hydrogenation substrates.    
Methyl (Z)-3-aryl-2-butenoates [methyl (Z)-β-methylcinnamates] [aryl = Ph; (Z)-6-2] have a simple structure, 
but are promising synthetic building blocks for various stereodefined alkenes.  Despite the high demand, 
(Z)-stereoselective synthetic methods are quite limited compared with those for (E)-isomers, due to the 
inherent (E)-stable nature of cinnamate esters.  Here we present a practical, accessible, and robust synthesis 
of (Z)-6-2 and its aryl analogues, including stereocomplementary (E)-isomers.     
The relevant reported methods for the synthesis of (Z)-6-2 are as follows.  Utilization of 
Horner-Wadsworth-Emmons (HWE) reactions between acetophenone and elaborate HWE reagents is 
regarded as the most straightforward method.  A literature survey revealed two methods producing high 
(Z)-stereoselectivity.  One is a Sn(OTf)2 (Tf = SO2CF3)/N-ethylpiperidine-mediated reaction using 
Still-Gennari’s HWE reagent 6-3 with acetophenone to afford 84% yield, E/Z =2:98 ratio, which was 
developed by Sano and Nagao’s group (Scheme 6-1).1  Another noteworthy example developed by Kojima’s 
group
3
 is the reaction using (1-naphthoxy)2P(O)CH2CO2Et HWE reagent 6-4 with acetophenone using NaH to 
afford 80% yield, E/Z = 9:91, although it requires conditions of 0 °C for 48 h.     
These one-step methods produce high yields with good to excellent E/Z-ratios, but a couple of the reagents 
[6-3 and Sn(OTf)2] are very expensive and reagent 6-4 is not commercially available.  Other 
HWE-conducted methods result in moderate to low yield and/or E/Z-selectivity.  On the whole, these 
approaches suffer from a lack of the atom-economy due to use of the specific phosphonate reagents.  In 
addition, the yield and E/Z-selectivity using other aryl methyl ketone acceptors apparently depends on the 
nature of the employed ketones.      
 
 
Scheme 6-1.  Two representative methods utilizing the Horner-Wadsworth-Emmons (HWE) reaction. 
 
Iron-catalyzed cross-coupling of Grignard reagents with an enol triflate of methyl or ethyl acetoacetate 
(Z)-6-5 was developed by Fürstner’s group (Scheme 6-2).3-5  The preparation of (Z)-6-5 utilizes triflic 
anhydride (Tf2O) / NaH (Method A).  This excellent method is the most relevant for our strategy.  A major 
drawback is that Tf2O is ca. 15−30 times more expensive than TsCl.  In addition, Tf2O is highly toxic and 
hazardous with a low boiling point (81−83 °C) and reacts violently with water.  Enol triflate (Z)-6-5 is an oil 
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compound but its stability for distillation is unclear and only flash column chromatography is required for its 
purification.  A practical preparative method for (Z)-6-5, developed by Frantz’s group (Method B) also 
requires flash column chromatographic purification.
6
  This iron-catalyzed cross-coupling requires 1.8 equiv 
of PhMgBr at low temperature (‒30 °C). 
 
 
Scheme 6-2.  Method utilizing iron-catalyzed cross-coupling of enol triflate (Z)-6-5. 
 
Other syntheses of (Z)-6-2 are listed in chronologic order.  (i) Dianion of 
1-(1,2,4-triazolo-1-yl)phenylpropargyl ethyl ether, treated with MeI gave (Z)-6-2 in 87% yield with E/Z = 1:4 
selectivity (Katritzky’s group).7  (ii) MeReO3 (5 mol%)-catalyzed condensation between ethyl diazoacetate 
and acetophenone in the presence of an equimolar amount of PPh3 gave (Z)-6-2 in 65% yield with E/Z = 13:87 
selectivity (Kühn’s group).8  (iii) TMSOTf (equimolar amount)-promoted carbocupration of 
PhMgBr/CuI•2LiCl with a relatively expensive ethyl 2-butynoate gave (Z)-6-2 in 88% yield with E/Z = 1:5 
selectivity (Jennings and Mueller).
9
 
Compared with the above-mentioned methods, the present approach utilizing Suzuki-Miyaura (SM) 
cross-coupling with enol tosylate (Z)-6-1 (≥98% ds) produced methyl (Z)-3-phenyl-2-butenoate (Z)-6-2 and its 
aryl analogues in high yields with excellent (Z)-stereoretention (≥98% ds) in a consistent substrate-general 
manner and functional group compatibility (vide infra).  (Z)-6-1 is an easy-to-handle stable solid that can be 
stored neat without detectable decomposition at ambient temperature.  The original preparative method
10
 of 
(Z)-6-1 utilizes LiOH/N-methylimidazole reagent in C6H5Cl or CH2Cl2 solvent, which was replaced with 
AcOEt solvent for LiCl/TMEDA.  This improvement significantly increases the scalability with accessible 
reaction temperature (0‒40 °C), short reaction periods (1 h), and easy operations for all of the procedures.   
In general, although the enol triflates exhibit higher reactivity than the enol tosylates, (Z)-6-1 is sufficient 
for the synthesis of (Z)-6-2 and its aryl analogues as a robust, productive, and considerably inexpensive SM 
cross-coupling partner.  The reaction proceeded smoothly under mild conditions with nearly perfect 
(Z)-stereoretention.  The present combination of Pd(OAc)2/PPh3 is the most accessible and cost-effective 
catalysis among a myriad of  SM cross-couplings.  The loading quantity of Pd(OAc)2 catalyst and PPh3 
ligand were decreased to 1 mol% and 2 mol%, respectively.  A simple work-up and isolation procedure 
eliminating column chromatographic purification can be partially attributed to this feature.  As an additional 
advantage, environmentally benign solvents, such as AcOEt, 2-propanol, and H2O, could be employed for 
both of two reaction steps and the corresponding extraction (work-up) steps throughout the procedure. 
On the other hand, stereocomplementary isomer (E)-6-1, an oil compound, is readily prepared from the 
same methyl acetoacetate with E/Z = 96:4 (crude product) using a different reagent, 
TsCl/Et3N/N-methylimidazole.
10
  Due to the different Rf values [(E)-6-1: 0.36, (Z)-6-1: 0.21 (hexane/AcOEt 
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= 5:1)], column chromatographic purification of the crude product was easily performed to give (E)-6-1 in 
86% yield (≥98% ds).  A variety of the relevant (Z)- and (E)-enol tosylates derived from other β-ketosters,10 
α-formyl esters,11,12 β-aryl or α-aryl β-ketoesters,13 and α-substituted β-ketoesters14,15 can be almost readily 
prepared by similar approaches.  We speculate that this stereocomplementary method proceeds through a 
Li-chelation pathway for (Z)-6-1, whereas non-chelation pathway for (E)-6-1.
10,13
     
Under the identical conditions, three ArB(OH)2 and (3-pyridyl)B(OH)2 also underwent the present SM 
cross-coupling to afford the corresponding analogues (Z)-6-6, 6-7, 6-8, and 6-9 with similarly good to 
excellent yields and nearly perfect Z-stereoretention (Scheme 6-3).  Naphthalene analog (Z)-6-6 is a known 
compound, but its synthesis results in poor yield (58%) and E/Z selectivity (79:21).
16
  The other analogues, 
(Z)-6-7, 6-8, and 6-9, are new compounds distinct from the known compounds (E)-6-7, 6-8, and 6-9, 
demonstrating the poor accessibility of (Z)-compounds to date.  Noteworthy is the compatibility of labile 
functional groups such as Br- and -CHO groups, which are susceptible to other cross-couplings and 
organometal-mediated methods.  The reaction of heterocyclic 3-pyridyl compound (Z)-6-9 was conducted 
using [Pd(dppf)Cl2] catalyst instead of Pd(OAc)2/PPh3.
13
  SM cross-coupling exhibits superb and reliable 
stereoretention control in the related synthesis of amino acid derivatives using β-ketoester-derived enol 
tosylates.
17,18
   
 
 
Scheme 6-3.  Suzuki-Miyaura (SM) cross-coupling giving methyl (Z)-3-aryl-2-butenoates (Z)-6-6, 6-7, 6-8, and 6-9. 
 
As depicted in Scheme 6-4, (Z)-6-1 as well as (E)-6-1 can also serve as the Negishi and Sonogashira 
cross-couplings partners,
10
 wherein a high and reliable level of E, Z-stereoretention (each ≥98% ds) is 
guaranteed.   
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Scheme 6-4.  (E)- and (Z)-Stereocomplementary Negishi and Sonogashira cross-couplings using (E)-6-1 and (Z)-6-1 partners. 
 
(E)-6-2 type compounds are a representative probe for asymmetric hydrogenation to produce important 
chiral 3-arylbutanoates.
19-21
  The relevant investigation using (Z)-6-2 and its analogues is, however, hitherto 
not reported certainly due to the fatal lack of practical supply of these precursors.  
 
Conclusion 
A simple and useful but inaccessible compound, methyl (Z)-3-phenyl-2-butenoate, has been synthesized by 
user-friendly procedure in practical 10 g scale through 2 steps.  The first (Z)-stereoselective enol tosylation 
of methyl acetoacetate was performed utilizing TsCl−TMEDA−LiCl reagent in AcOEt solvent to give 
(Z)-3-(p-tosyloxy)but-2-enoate.  Recrystallization of the crude product gave pure crystals [mp 67−68 °C].  
The obtained (Z)-enol tosylate was smoothly converted to (Z)-3-phenyl-2-butenoate utilizing Suzuki-Miyaura 
cross-coupling.  A cost-effective catalysis [Pd(OAc)2−PPh3] showed sufficient reactivity and nearly perfect 
(Z)-stereoretentivity [bp 75−77 °C/0.75 mmHg, >97% purity (Q 1H NMR)] in overall 56% yield.  As 
substrate generality, this protocol was applicable to syntheses of the other aryl analogues.  This strategy will 
contribute to produce the construction of a library for (E)-and (Z)-stereodefined α,β-unsaturated esters, which 
provides a new promising avenue for synthetic organic chemistry. 
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Chapter 7. 
Synthesis of Methyl 1-Formylcyclopropanecarboxylate utilizing 
Ti-Claisen Condensation 
 
Abstract 
A synthesis of methyl 1-formylcyclopropanecarboxylate 7-2 directerd for Organic Syntheses is 
disclosed.  Despite its utility to install cyclopropane segment into various pharmaceuticals, hitherto 
reported methods require multi-steps or expensive reagents, low temperature, and long reaction 
period.  Starting methyl 4-chlorobutanoate, possessing base-sensitive γ-chloro moiety, can be 
successfully α-formylated utilizing distinctive TiCl4/Et3N-mediated (Ti-Claisen) condensation at 
0−15 °C to give methyl 4-chloro-1-formylbutanoate 7-1.  Without any purification of 7-1, successive 
cyclopropanation is performed in mild basic conditions [Et3N (10 mol%)/K2CO3 (1 equiv) in AcOEt at 
0−15 °C] to produce methyl 1-formylcyclopropanecarboxylate 7-2, which is easily purified by simple 
distillation (the boiling point was documented for the first time).  Throughout the procedure, column 
chromatographic purification is not required. 
 
 
 
In this chapter, according to the policy of “Organic Syntheses” as shown in chapter 6, the author describes 
the procedure section in the first place. 
 
Procedure 
A. Methyl 4-chloro-2-formylbutanoate (7-1).  An oven-dried 500-mL, threenecked (24/40), 
round-bottomed flask equipped with a Teflon-coated magnetic stirring bar (egg-shaped, 32 mm length x 15 
mm diameter), an internal thermometer, a 50-mL pressure-equalizing addition funnel fitted with a nitrogen 
inlet (central neck), and a second 60-mL pressure-equalizing addition funnel is charged with methyl 
4-chlorobutanoate (12 mL, 13.7 g, 100 mmol, 1 equiv) (Notes 1 and 2), HCO2Me (18 mL, 18 g, 300 mmol, 3 
equiv) (Note 3), and CH2Cl2 (100 mL) (Notes 4 and 5) (Figure 7-1).  The stirred solution is immersed in an 
ice bath, cooling the internal temperature to 0 °C, and TiCl4 (24 mL, 41.7 g, 220 mmol, 2.2 equiv) is added 
dropwise through a 60-mL dropping funnel (Figure 7-1, right side) (Notes 6 and 7) over a period of 20 min, 
while maintaining the internal temperature at 5–10 °C (Note 8). 
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Figure 7-1.  Reaction Set-up for Step A. 
 
Triethylamine (36 mL, 26.3 g, 260 mmol, 2.6 equiv) (Note 9) is then added dropwise to the vigorously 
stirred yellow reaction mixture over a period of 30 min using the 50-mL addition funnel in the center neck of 
the flask, while maintaining the internal temperature at 15 °C or lower (Note 10) (Figure 7-2).  After 
complete addition, the dark orange reaction is stirred (500 rpm) at 0 °C for 1 h (Note 11), then quenched 
dropwise with water (100 mL) over a period of 10 min to maintain the internal temperature at 10 °C or lower 
(Note 12).  The biphasic mixture is then transferred to a 500-mL round-bottomed flask and the initial 
reaction flask is rinsed with EtOAc (2 x 10 mL).  The solution is concentrated using a rotary evaporator 
(22 °C, 46 mmHg).  The mixture is then transferred to a 500-mL separatory funnel with EtOAc (50 mL), and 
the aqueous phase is separated and re-extracted with EtOAc (50 mL).  The combined organic phase is 
washed with water (100 mL) and brine (50 mL), dried over Na2SO4 (20 g), filtered through a 150-mL medium 
porosity sintered glass funnel and concentrated using a rotary evaporator (45 °C, 25 mmHg) to furnish 
α-formyl ester 7-1 as a yellow liquid (16.39 g), which is used for the next step without any purification (Notes 
13 and 14). 
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Figure 7-2.  Color Transitions Observed in Step A. 
after TiCl4 addition after Et3N addition after quench with H2O 
 
B. Methyl 1-formylcyclopropanecarboxylate [7-2] (Note 15).  An oven-dried 250-mL, three-necked 
(24/40), round-bottomed flask equipped with a Teflon-coated magnetic stirring bar (egg-shaped, 26 mm length 
x 13 mm diameter), an internal thermometer, a glass stopper (central neck), and a Dryrite drying tube (Note 
16) (Figure 7-3) is charged with crude α-formylester 7-1 (16.39 g) in AcOEt (100 mL).  The light orange 
solution is stirred and immersed in an ice bath, cooling the internal temperature to 0 °C, and then potassium 
carbonate (K2CO3) (13.9 g, 100 mmol, 1 equiv) (Note 17) is added portionwise (split into five equal parts) 
over 10 min after temporarily removing the glass stopper (Note 18).  Immediately after the addition is 
complete, triethylamine (1.4 mL, 1.00 g, 10.0 mmol, 0.1 equiv) is added in one portion. 
 
 
Figure 7-3.  Reaction Set-up for Step B 
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After stirring (600 rpm) the suspension at 0 °C for 1 h, the reaction is quenched with water (100 mL) and 
transferred to a 500-mL separatory funnel.  The initial reaction flask is rinsed with EtOAc (2 x 5 mL) and 
H2O (2 x 5 mL), which are added to the separatory funnel.  The organic phase is separated and the aqueous 
phase is re-extracted with EtOAc (20 mL).  The combined organic phase is washed with water (20 mL) and 
brine (20 mL), dried over Na2SO4 (20 g), filtered through a 150-mL medium porosity sintered glass funnel, 
then concentrated under reduced pressure using a rotary evaporator (45 °C, 25 mmHg) to furnish an 
amber-colored liquid.  The obtained crude product (ca. 12 g) is moved into a 25-mL roundbottomed flask 
with a Teflon-coated magnetic stir bar (Note 19) (Figure 7-4).  Distillation while immersed in a 
temperature-controlled oil bath under reduced pressure (84–86 °C, 19–25 mmHg) provides the desired 
product 7-2 (8.68 g, 69% overall yield) as a colorless liquid (Notes 20, 21, and 22). 
 
  
Figure 7-4.  Distillation Set-up and Pure Final Product 
 
 
Notes 
1. The methyl 4-chlorobutanoate, methyl formate, and dichloromethane must be added by temporary removal 
of one of the addition funnels followed by purging of the system with nitrogen. 
2. The checkers used methyl 4-chlorobutyrate (98+%) from Acros Organics.  The submitters used methyl 
4-chlorobutanoate (GC purity >98%) purchased from Tokyo Chemical Industry Co., Ltd. and used as 
received. 
3. The checkers used methyl formate (97%, pure) from Acros Organics.  The submitters used methyl formate 
(HCO2Me) (GC purity >95%) purchased from Tokyo Chemical Industry Co., Ltd. and used as received. 
4. The checkers used non-stabilized dichloromethane (20-L drum, ACS Reagent) from J. T. Baker, which was 
then passed through two packed columns of neutral alumina in a solvent purification system manufactured 
by SG Water U.S.A., LLC. The submitters used dichloromethane (CH2Cl2) (purity 99.5%) was purchased 
from Wako Pure Chemical Industries, Ltd. and used as received without any purification. 
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5. The submitters studied the use of CH2Cl2 and toluene as reaction solvents and noted the reaction to be 
homogeneous with the former, whereas the use toluene results in formation of yellow precipitate and a 
viscous reaction mixture.  The checkers employed only CH2Cl2. 
6. The checkers used titanium (IV) chloride (sure-sealed 200 g bottle, ReagentPlus, 99.9% trace metal basis) 
obtained from Sigma-Aldrich.  The submitters used titanium tetrachloride (TiCl4) (99.0%, 500 g bottle) 
purchased from Wako Pure Chemical Industries, Ltd. and used as received. 
7. The checkers charged the 60 mL addition funnel with TiCl4 (from a suresealed bottle) using a syringe.  
The submitters report delivering the TiCl4 using a 10 mL pipet, wherein the operation should be rapidly and 
carefully conducted to take care of white smoke evolution. 
8. The submitters note this step to be slightly exothermic when using addition rates of 24 mL of TiCl4 over 5–
10 min.  However, the checkers observed a steady temperature at 5−10 °C when adding 24 mL TiCl4 
dropwise over 20 min.  A feature not noted by the submitters is the formation of yellow crystals around the 
tip of the addition funnel.  These crystals tend to fall off with time and slowly dissolve in the 
dichloromethane. 
9. The checkers purchased triethylamine (≥99.5%) from Sigma-Aldrich and distilled it from CaH2 
immediately prior to use.  The submitters used triethylamine (Et3N) (purity 99%) purchased from Wako 
Pure Chemical Industries, Ltd. and used it as received. 
10. The submitters note the reaction to be considerably exothermic.  The checkers found that by adding the 
Et3N dropwise over 30 min (approx. 1−1.2 mL per minute) it was possible to maintain an internal 
temperature  at 10 °C or lower without affecting the formation of the expected dark orange reaction 
mixture. 
11. The checkers note that the reaction progress can be monitored by 
1
H NMR. 
12. The submitters caution that this quench is exothermic.  The checkers found that adding the water 
dropwise over 10 min was sufficient to maintain an internal temperature at 10 °C or lower, while the  
submitters’ addition over 5 min was sufficient to maintain temperatures below 20 °C. 
13. The checkers performed two half-scale and two full-scale reaction.  The crude yields were 97% (7.94 g), 
99% (8.14 g), 98% (16.13 g), and 99% (16.39 g) respectively.  Analysis of the crude reaction mixture by 
1
H NMR and 
13
C NMR revealed that the mixture consists of three tautomers 7-1a, (Z)-7-1b, (E)-7-1b and a 
very small amount of by-product tentatively assigned as (E)-7-1x, in an approximate ratio of 36:44:16:4. 
14. Although not necessary for step B the submitters and checkers established in parallel studies that this 
reaction mixture could be purified via flash chromatography through SiO2.  In the checker’s hands 5 g of 
the crude product was purified using 25 g of silica (Silicycle Silica, Flash P60, 40-63 μm, 230-400 mesh) 
loaded into a 30 mm diameter column.  The column was slurry packed, the sample loaded with hexane and 
then eluted with a gradient of EtOAc/hexanes (5% increasing by approximately 2% every 10-12 fractions). 
Fractions were collected (6.7 mL) at a flow rate of 0.8 mL/sec.  Overall, 72 fractions were collected and 
product was observed at fractions 10-32.  These fractions were concentrated in vacuo to furnish 2.51 g of a 
colorless oil, which was determined by 
1
H NMR to be (Z)-7-1b and trace 7-1a.  The submitters note the 
composition of the chromatographed material (5 g) to be a mixture of 7-1 (4.45 g, 85%) with cyclopropane 
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7-2 (ca. 6% based on 
1
H NMR).  The checkers did not observe cyclopropane 7-2 at this stage.  
Compound 7-1 has been found to slightly decompose on silica and distillation results in decomposition.  
Compound 7-1 gradually solidified at ambient temperature, and over a week undergoes slow 
tautomerization to enols (Z)-7-1b and (E)-7-1b.  The checkers note the purified sample of (Z)-7-1b was 
observed to undergo slow crystallization, which upon collection and trituration (hexanes) of the resulting 
white solid revealed them to be (E)-7-1b by 
1
H NMR. 
 
Physical and spectroscopic properties of (Z)-7-1b: colorless oil; 
1
H NMR (400 MHz, CDCl3) δ: 2.52 (td, J = 
7.0, 0.7 Hz, 2H), 3.55 (t, J = 6.9 Hz, 2H), 3.80 (s, 3H), 7.11 (d, J = 12.8 Hz, 1H), 11.49 (d, J = 12.7 Hz, 
1H); 
13
C NMR (101 MHz, CDCl
3) δ: 31.2, 44.05, 51.8, 101.1, 163.3, 172.1; IR (neat) 2957, 1721, 1672, 
1612, 1446, 1397, 1350, 1328, 1281, 1222, 1189, 1166, 1124, 989, 956, 811, 740, 653, 574, 452 cm
−1
; 
HRMS (+ESI) m/z [M+H]
+
 calcd for C6H9ClO3 165.0313, found 165.0313; Anal. Calcd for C6H9ClO3: C, 
43.79; H, 5.51; Cl, 21.54. Found; C, 43.56; H, 5.48; Cl, 21.28. 
Those of (E)-7-1b: colorless crystals; mp 72–80 °C; 1H NMR (400 MHz, CDCl3) δ: 2.77 (t, J = 7.0 Hz, 2H), 
3.63 (t, J = 6.9 Hz, 2H), 3.73 (s, 3H), 6.17 (brs, 1H), 7.77 (d, J = 9.0 Hz, 1H); 
13
C NMR (101 MHz, CDCl3) 
δ: 27.4, 43.6, 51.7, 107.3, 155.3, 168.8; IR (neat) 3208, 1667, 1634, 1444, 1397, 1331, 1308, 1283, 1203, 
1169, 1105, 746, 731 cm
−1
. 
15. Step B should be carried out within a week due to the sensitivity of the starting material. 
16. The half-scale reaction utilized an oven-dried 100-mL, three-necked, round-bottomed flask equipped with 
a Teflon-coated magnetic stirring bar (egg-shaped, 20 mm length x 10 mm diameter), an internal 
thermometer, a glass stopper (central neck) and a CaCl2 drying tube. 
17. The checkers used potassium carbonate (anhydrous, 99%) from Alfa Aesar. 
18. The submitters note this to be a slightly exothermic reaction.  The checkers did not observe a rise in 
temperature when adding the potassium carbonate in five equal portions over 10 min.  However, the 
quench with water after reaction completion is observed to be exothermic, but the temperature can be 
maintained at 5–10 °C if the water is added over 5 min.  Reaction progress monitoring in step B is 
possible by TLC using KMnO4 staining [10% AcOEt in hexanes; Rf = 0.23 (7-1) and 0.33 (7-2)] or by 
1
H 
NMR comparison of aliquots. 
19. Full-scale utilized a 25-mL round-bottomed flask equipped with a magnetic stirring bar (egg-shaped, 18 
mm length x 10 mm diameter) with a short path distillation apparatus (110 mm height x 110 mm width). 
Half scale employed a 10-mL round-bottomed flask and a magnetic stirring bar (rod shaped, 10 mm length 
x 3 mm diameter).  The receiving flask is cooled to 0 °C by immersion in an ice-water bath. 
20. The submitters note: 1st fraction: 42–62 °C / 20 mmHg (bath temp. 82–87 °C), 0.24 g. 2nd fraction: 62–
64 °C / 17 mmHg (bath temp. 87–111 °C), 8.82 g (overall yield, 69% in 2 steps).  3rd fraction: 64–52 
(fade out) °C / 17 mmHg (bath temp. 111–123 °C), 0.17 g.  The submitters also noted the bp to be 59–
63 °C / 16 mmHg and the purity based on quantitative 
1H NMR analysis was 97−99%.  The checkers 
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performed a fractional distillation collecting distillate boiling at 84–86 °C / 25 mmHg (bath temp. 104–
124 °C).  The checkers note: 1
st
 fraction (135 mg, boiling temp. 84–86 °C / 25 mmHg, bath temp. 100–
104 °C).  2nd fraction (8.68 g, boiling temp. 84–86 °C / 25 mmHg, bath temp. 104–124 °C).  The 
collection of the 2nd fraction was not stopped until the internal temperature dropped. 
21. The checkers performed two half-scale and two full-scale reactions.  The yields after distillation were 
73% (4.70 g), 68% (4.33 g), 77% (9.82 g), and 69% (8.68 g) respectively. 
22. Physical and spectroscopic properties of 7-2: colorless liquid; 
1
H NMR (400 MHz, CDCl3) δ: 1.58–1.62 
(m, 2H), 1.64–1.68 (m, 2H), 3.80 (s, 3H), 10.37 (s, 1H); 13C NMR (101 MHz, CDCl3) δ: 22.5, 33.4, 52.3, 
171.4, 198.6; IR (neat) 2958, 2868, 1700, 1440, 1319, 1285, 1196, 1147, 1085, 1047, 1002, 959, 888, 810, 
781, 742, 698, 474 cm
−1
; HRMS (+ESI) m/z [M + H]+ calcd for C6H9O3 129.0546, found 129.0543; 
quantitative 
1
H NMR analysis was performed with ethylene carbonate (purchased from TCI, purity 
>99.0%) as the internal standard and obtained in 97.6% purity. 
 
Discussion 
Methyl or ethyl 1-formylcyclopropanecarboxylate (7-2) or (7-2’) is a unique bifunctional compound with 
both aldehyde and ester functionalities at the same C-1 position in a simple cyclopropane molecule.  
Cyclopropane 7-2 or 7-2’, therefore, serves as a useful synthetic building block, especially for medicinal and 
process chemistry, and natural product synthesis.  As illustrated in Figure 7-5, characteristic cyclopropane 
segments are installed in various pharmaceuticals utilizing 7-2 or 7-2’.  The key feature is the chemoselective 
condensation of the aldehyde group in preference to the ester group. 
(i) A traditional barbituric acid analog I containing a 5-spirocyclopropane moiety for a dihydroorotate 
dehydrogenase inhibitor,
1
  (ii) arylpyrazole compound II containing cyclopropanecarboxamide for a 
parasiticidal agent,
2
  (iii) arylsulfonylpiperazine III containing cyclopropanecarboxamide for a 
11β-hydroxysteroid dehydrogenase inhibitor,3 (iv) 5,7,8,9-tetrahydropyrimido[4,5-b][1,4]diazepin-6-ones 
compound IV containing 3-spirocyclopropane moiety for a protein kinase inhibitor,
4
  (v) oxo-substituted 
aza-heterocylic compound V containing cyclopropane-carboxylic acid for the treatment and/or prevention of 
cardiovascular conditions,
5
  (vi) oxazolo[5,4-b]pyridine-5-yl compound VI containing 
cyclopropanecarboxylate for the treatment of cancer,
6
  (vii) 2,6-disubstituted benzobisoxazole compound VII 
containing cyclopropanecarboxylic acid for lysophosphatidic acid receptor antagonists,
7
  (viii) 
[1,2,4]triazolopyridine compound VIII containing cyclopropanecarboxylate for phosphodiestererase 
inhibitors,
8
 and (ix) 3-pyridyl-substituted benzamide compound IX containing 
1-(difluoromethyl)cyclopropane for purinergic 2X7 (P2X7) receptor inhibitors.
9
 
As described above, 7-2 or 7-2’ has a significant role in the structural scaffolds of a variety of 
pharmaceuticals possessing cyclopropanecarboxylic acid derivatives.  Noteworthy is that application of this 
manipulation has increased as a screening technique to discover new pharmaceuticals, likely because 
cyclopropanes are requisite isosteres for the corresponding dimethyl compounds. 
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Figure 7-1.  Pharmaceuticals incorporating cyclopropanecarboxylic acid or ester segments utilizing methyl or ethyl 
1-formylcyclopropanecarboxylate (2-2) or (2-2’). 
 
On the other hand, cyclopropane 7-2 contributed as the starting compound to a formal synthesis of 
aspidospermine, a distinctive aspidosperma alkaloid,
10,11
 in that a notable acid-catalyzed thermal 
rearrangement of cyclopropyl imine intermediate to 2-pyrroline is the key starting step (Scheme 7-1).
12
 
 
 
Scheme 7-1. Formal synthesis of aspidospermine alkaloid starting from ethyl 1-formylcyclopropanecarboxylate (7-2’). 
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On the whole, the reported synthetic methods for 7-2 or 7-2’ are categorized into four approaches.   
(i) As illustrated in Scheme 7-2, Ayers’ half reduction protocol of methyl and ethyl 
cyclopropanedicarboxylates (7-3 and 7-3’) is the most representative.13  Commercially available 7-3 and 7-3’ 
(ca. twice as expensive as methyl 4-chlorobutanoate) were converted by the treatment with more than 2.0 
equiv of Li(tBuO)3AlH, not to desired aldehyde 7-2 and 7-2’ directly, but to alcohols 7-4 and 7-4’ in 88% and 
79% yield, respectively.
3,5,8
  Dess-Martin (DM) oxidation of 7-4 or 7-4’ using ca. 2 equiv of DM periodinane 
successfully afforded 7-2 (24%) or 7-2’ (76%).  The DIBAL reduction method with 7-3 was also applied, but 
required harsh conditions such as ‒78 °C and 7 h.4   
Although this approach is likely the most accessible, Li(tBuO)3AlH is quite expensive (ca. $ 150 / 100 mL, 
1.0 M) among commercially available hydride reagents and is not hydride atom-economical.  DM 
periodinane is also expensive and problematic with regard to atom-economy.    
(ii) As an alternative method to (i),
6
 7-3 was converted by a half-hydrolysis reaction to monocarboxylic acid 
7-5, which was transformed to 7-2 through mixed anhydride formation and successive NaBH4 reduction to 
give common intermediate 7-4.  TEMPO oxidation of 7-4 with trichloroisocyanuric acid afforded the desired 
product 7-2, although an accurate yield was not described.  This approach, however, is not straightforward 
and requires tedious procedures.        
(iii) As depicted in Scheme 7-3, this approach utilizes the notable protocol of A. I. Meyer’s group.14,15  
Ethyl cyanoacetate was converted to ethyl 1-cyanocyclopropanecarboxylate 7-6 (commercially available in 
5-g scale, but extreamely expensive), which is transformed to masked aldehyde 7-8 through 1,3-dioxadine 
formation and successive NaBH4 reduction.  Finally, acid hydrolysis of 7-8 gave the desired compound 7-2’.  
This method also requires four steps with high (80 °C) and low (‒40 °C) temperature reactions, the use of 
large amounts of conc. H2SO4, and steam distillation purification.   
(iv) Scheme 7-4 depicts a method starting from γ-butyrolactone developed by Kuraray’s group,16 which is 
the most relevant for our strategy.  γ-Butyrolactone was α-formylated using HCO2Me/NaH and protected 
with an ethoxycarbonyl group to give 7-9.  Conventional ring opening with chlorination using SOCl2 and 
ZnCl2 in EtOH gave precursor 7-10.  Finally, cyclopropanation concomitant with deprotection was 
performed to afford 7-2’.  This approach required a protective and deprotective sequence and afforded a 
moderate total yield (26%).                               
Due to the utility of 7-2 or 7-2’, 5−100 g scale production methods have been disclosed in recent medicinal 
chemistry patents.  The reported synthetic methods for 7-2 or 7-2’, however, require column 
chromatographic purification despite the high volatility, or crude product is used in the next condensation step 
without purification.  Our concise and straightforward method involves a simple distillation purification (the 
boiling point was documented for the first time) without the use of column chromatography, and is performed 
within short reaction and purification periods.        
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Scheme 7-2.  Half-reduction method of cyclopropane precursor 3 or 3’ derived from dimethyl malonate.  
 
 
Scheme 7-3.  A. I. Meyers’ transformation method starting from ethyl cyanoacetate. 
 
 
Scheme 7-4.  Kuraray group’s method starting from γ-butyrolactone. 
 
Among the various carbon homologation methods, α-formylation of simple esters with HCO2Me is a 
well-recognized useful reaction.  A literature survey (SciFinder
®
) revealed reports of ca. 100 examples 
utilizing base reagent (e.g. NaOR, NaH, LDA, and LiHMDS)-mediated methods and 5 examples using 
TiCl4/amine-mediated methods.  In general, a major conventional reaction using bases (e.g. NaOR, NaH) 
requires long reaction periods and results in moderate yield in almost all cases.  LDA- and 
LiHMDS-promoted methods are superb with regard to yield but require rigorous procedures (reaction time 
schedule and accurate reagent equivalents) and low temperature (–78 ˚C).   
α-Formylation of simple esters utilizing TiCl4/amine-mediated (Ti-Claisen) condensation
17,18
 for the 
synthesis of α-formylated esters 7-11 is depicted in Table 7-1 (13 examples).  Ti (or Zr)-self-Claisen 
condensations between two of the same esters,
19-21
 Ti-crossed-Claisen condensations between esters or acids 
with acid chlorides,
22,23
 and Ti-Dieckmann (intramolecular Claisen) condensations
24-26
 have several 
advantages, including: (i) powerful C-C bond forming reactivity; (ii) highly available reagents with robust 
reactions; (iii) accessible temperature (0 °C to ambient); (iv) compatibility with base-labile functional groups 
such as γ-halogeno, γ-ketone carbonyl, etc., despite the high reactivity.  On the other hand, a mild variant 
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Ti-Claisen condensation method using ketene silyl acetals with acid chlorides also satisfies the four listed 
features [(i)-(iv)].
27
    
The present α-formylation reaction of methyl 4-chlorobutanoate (7-1) is a distinctive example of the 
compatibility with a base-sensitive γ-chloro group.  Synthesis of 7-2 is not possible using the base-mediated 
α-formylation method due to undesirable and predominant cyclopropane formation leading to methyl 
cyclopropanecarboxylate.     
 
Conclusion  
A unique and useful but inaccessible building block, methyl 1-formylcyclopropanecarboxylate, has been 
synthesized by utilizing straightforward and accessible strategy in practical 10 g scale through 2 steps.  
TiCl4−Et3N-mediated Ti-Claisen condencation (α-formylation) of methyl 4-chlorobutanoate with methyl 
formate proceeded smoothly to afford methyl 4-chloro-1-formylbutanoate in good yield.  As a distinctive 
feature, 4-chloro group was compatible in apparent contrast to base reagent-mediated method.  The obtained 
crude α-formylester smoothly underwent cyclopropanation under mild basic conditions [cat. 
Et3N−K2CO3/AcOEt] to produce the desired methyl 1-formylcyclopropanecarboxylate [bp 84−86 °C/25 
mmHg, 97.6% purity (Q 
1
H NMR)] in overall 69% yield.  The present synthetic strategy provides a new 
promising avenue, especially for pharmaceutical syntheses. 
 
Table 7-1.  α-Formylation of esters utilizing Ti-Claisen condensation. 
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Chapter 8. 
Acid-induced Favorskii-type Reaction: Regiocontrolled 
Elimination of Acyloin Mesylates Leading to α,β-Unsaturated 
Ketones 
 
Abstract  
A highly regiocontrolled acid-induced Favorskii-type elimination reaction of acyloin mesylates 
proceeded smoothly to give more substituted α,β-unsaturated ketones.  Not only acyclic but also 
cyclic acyloin mesylates produced the corresponding higher substituted enones via 
double-bond-migration pathway.  A mechanistic speculation and application to a synthesis of chiral 
muscone precursor are also described. 
 
 
 
Introduction 
The Favorskii rearrangement reaction (FR reaction) is a well-recognized, unique, and useful C-C bond 
transformation among  organic name reactions.
1
  The FR reaction has been successfully applied for natural 
product and fine chemical syntheses in the past few decades.
1c,e
  The most general reaction mode involves a 
base-induced formation of cyclopropane intermediates derived from α-halogenated  (or α-sulfonyloxy) 
ketones, followed by ring cleavage concomitant with one carbon extrusion (Scheme 8-1).  A 
13
C-labeld 
experiment supports this well-known mechanism.  Other relevant homo- and quasi- variants of the FR 
reaction are also documented.
1c−e 
 
 
Scheme 8-1.  Representative Favorskii rearrangement reaction. 
 
These FR reactions are conducted under basic conditions, wherein the elimination of α-leaving groups, such 
as halogens and sulfonyloxy groups adjacent to ketone carbonyls, is a common and crucial process.  Here it 
is presented that a unique cation-induced highly regioselective FR-type elimination reaction using 
methanesulfonates (mesylates) of α-hydroxyketones (acyloins) produces more substituted α,β-unsaturated 
ketones with distinctive double-bond migration as illustrated in Scheme 8-2.  To the best of our knowledge, 
this is the first report of a cation-induced distinctive FR-type reaction. 
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Scheme 8-2.  Regiocontrolled acid-induced Favorskii-type elimination. 
 
Results and Discussion 
In clear contrast to the feasible dehydration of relevant β-hydroxyketones (aldols), isosteric acyloins strongly 
resist a similar type of cation-induced dehydration, because α-cation formation on the ketone carbonyls is 
extreamly thermodynamically unfavorable.  Dehydration reactions of 15-membered acyloin are documented, 
both without the use of a catalyst
2a
 and with the use of a Si-Al heteropolyacid catalyst.
2b
  These methods, 
however, required harsh conditions (>200 °C).  Taking the background into accounts, the initial examination 
was guided by the dehydration of valeroin (8-1) using this Si-Al heteropolyacid catalyst (Scheme 8-3).  
Actually, a reflux conditions in 1,2-dichlorobenzene (ca. 180 
o
C) led to the dehydration of 8-1. 
The reaction afforded not only uneventful dec-6-en-5-one 8-2a, but also unexpected dec-3-en-5-one 8-2b as 
1:1 mixtures in 32% total yield.  Noteworthy is that the crossover reactions using α-hydroxy cyclohexyl 
pentyl ketone regioisomers 8-3 and 8-4 afforded the corresponding endo-product 8-5a exclusively in 99% 
yield as predicted, and in clear contrast exo-product 8-5b in 66% total in a 5:1 ratio. 
The latter abnormal dehydration mode led us to screen milder and higher yield conditions.  A literature 
survey revealed three promising and accessible methods for the elimination using tosylates or mesylates of 
acyloins, mediated by UV-light (neutral),
3
 LiBr–Li2CO3 (weak basic),
4
 and CF3SO3H (acidic)
5
 to give 
α,β-unsaturated ketones via the usual elimination pathway.  Thus, the acid-induced method5 was selected, 
that was developed by Yoda and Takabe group, using mesylate 8-6 derived from 8-1.  The reaction under 
treatment with CF3SO3H at 0 – 5
 o
C for 1 h afforded a 1:1 mixture of the products 8-2a and 8-2b in higher 
52% total yield than that using valeroin 8-1. 
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Scheme 8-3.  Initial examination for acid-induced Favorskii-type elimination. 
 
To obtain a working hypothesis for this outcome we investigated the reactions using three unsymmetrically 
substituted acyclic acyloin mesylates 8-7–8-9.  Table 8-1 lists the successful results.  The desired enones 
8-5a, 8-10, and 8-11 were obtained in good to excellent yield.  The intriguing feature of the present reaction 
is that nearly complete regioselectivity (double-bond migration) emerged to give more thermodynamically 
stable substituted enones. 
Scheme 8-4 depicts a plausible mechanism for the present FR-type elimination.  Initial protonation of an 
acyloin mesylate or an acyloin with isomeric enol and/or cyclopropane formations proceeds to give cationic 
intermediate A-1 and/or cyclopropane intermediate A-2, respectively.  A successive crucial step for 
regioselective MsOH (or H2O) elimination concomitant with H
a
 and
 
H
b
 withdrawal leads to the corresponding 
intermediates, major E1’-like dienol B-1 and minor E1-like dienol B-2.  Final tautomerization affords more 
substituted α,β-unsaturated ketones almost exclusively. 
 
 
Scheme 8-4.  Plausible mechanism for the regiocontrolled cation-induced Favorskii-type elimination. 
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Encouraged by the successful results obtained using acyclic acyloin mesylates 8-7−8-9 listed in Table 8-1, 
we further investigate the scope of the reaction using 6-, 7-, 8-, and 15-membered cyclic substrates 8-12−8-15 
(Table 8-2).  Noteworthy is that a complete regiocontrolled double-bond migration mode was observed in all 
cases examined, affording the desired trisubstituted α,β-unsaturated ketones 8-16−8-19 in good yield.   
 
Table 8-1.  Regiocontrolled cation-induced Favorskii-type reaction using acyclic acyloin mesylates 8-7–8-9.  
 
Entry Substrate  Product  Yield / %
a 
1 
 
8-7 
 
8-5a 97 
2 
 
8-8 
 
8-10 65 
3 
 
8-9 
 
8-11 85
b
 
a) Isolated.  b) Regioisomeric mixture; a:b = ca. 1:1.5. 
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Table 8-2.  Regiocontrolled acid-induced Favorskii-type elimination using cyclic acyloin mesylates 8-12–8-15. 
 
Entry Substrate 
 Product  
Yield / %
a 
exo endo 
1 
 
8-12 
 
8-16 60 
2 
 
8-13 
 
8-17 75
b 
3 
 
8-14 
 
8-18 69
b 
4 
 
8-15 
 
8-19 76
b 
a) Isolated.  b) 2.0 equiv of TfOH was used. 
 
Another intriguing feature of the present reaction is its exo/endo selectivity.  The 6- and 15-membered 
substrates 8-12 and 8-15 produced the corresponding exo-products 8-16 and 8-19 almost exclusively (≥95:5) 
(entries 1, 4), whereas a slight excess of exo-product 8-17 was obtained when using 7-membered substrate 
8-13 (entry 2).  In contrast, the reaction using 8-membered substrate 8-14 afforded endo-product 8-18 
predominantly.  To predict the exo/endo selectivity we performed a computer-assisted calculation
[6]
 for three 
products, 8-16, 8-17, and 8-18, as well as the corresponding key dienol intermediates (B-1).  The results are 
summarized in Table 8-3.  The energy difference, i.e., ∆G/kcal values, indicates that exo-8-16, exo-8-17, and 
endo-8-18 products were more thermodynamically stable, compared with the corresponding isomeric 
endo-8-16, endo-8-17, and exo-8-18 products.  This tendency of the calculation results approximately 
reflects the experimental exo/endo selectivity.  On the other hand, the order of the ∆G/kcal values of the 
comparable data of B-1 did not match that of the experimental exo/endo selectivity.  Together, these results 
suggest that the present reaction afforded thermodynamically stable α,β-unsaturated ketone products 
8-16−8-18. 
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Table 8-3.  MM2 force field calculation utilizing ChemBio3DⓇ. 
Intermediate B-1  Product 
         exo endo  exo endo 
 
 
Finally, a useful synthetic application utilizing the present reaction was demonstrated in the preparation of 
(R)-muscone precursor (Z)-8-21 (Table 8-4).
7
  Practical synthesis of natural macrocyclic musks, especially 
(R)-muscone and (Z)-civetone, is a major topic in perfume chemistry.
8
  Both 3-methylcyclopentadecenones 
(E)- and (Z)-8-21 are valuable precursors for (R)-muscone, because the Takasago group reported that (S)- and 
(R)-Ru-BINAP-catalyzed asymmetric hydrogenation using enones (E)-8-21 and (Z)-8-21, respectively, leads 
to (R)-muscone with nearly perfect enantioselectivity (ca. 99%ee).
7
 
Acyloin mesylate 8-20 was readily prepared from readily available (±)-3-methylcyclopentadecanone 
(racemic muscone) in three reaction sequences; mild enol trimethylsilylation using 
N-TMS-N-methylacetamide/cat. NaH,
9
 mCPBA oxidation, and mesylation (MsCl/Et3N/N-methylimidazole) in 
77% overall yield.  Gratifyingly, 8-20 was successfully converted to the desired enone (Z)-8-21.  Raising 
the reaction temperature led to an increase in both region- and stereoselectivities, and yield.  This strategy 
allows for the formal total synthesis of (R)-muscone from readily available “racemic” muscone. 
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Table 8-4.  Synthesis of (R)-muscone precursor (Z)-8-21. 
 
Entry Temp. / °C (Z)-8-21 : (E)-8-21
a
 Yield
b
 / % 
1 20 – 25 69 : 31 28 
2 40 – 45 95 : 5 55 
3 60 – 65  68 
a) Determined by 
1
H NMR.  b) Isolated. 
Conclusion 
A unique acid-induced (Favorskii-type) elimination reaction of acyloin mesylates has been developed, 
wherein both acyclic and cyclic α,β-unsaturated ketones were produced.  The most characteristic feature of 
the present protocol lies in the regioselectivity of unsymmetrically substituted acyloin mesylates to give a 
variety of alkenes.  Higher substituted (thermodynamically stable) α,β-unsaturated ketones were 
predominantly obtained via distinctive double-bond-migration pathway.  As an application, the formal 
synthesis of (R)-muscone precursor starting from “racemic” muscone is demonstrated.  The present mode of 
reaction provides a new concept and application for the regioselective synthesis of α,β-unsaturated ketone 
structural units. 
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Experimental 
 
Favorskii-type dehydration reaction of valeroin 8-1 leading to unsymmetrical α,β-unsatureted ketones 
8-2a and 8-2b 
 
Dec-6-en-5-one 8-2a
 10a
 and dec-3-en-5-one 8-2b
 10b
 
Commercially available 6-hydroxy-5-decanone (valeroin; 8-1) (172 mg, 1.00 mmol) and Si-Al HA
TM
 (69 
mg) in 1,2-dichlorobenzene (6.0 mL) was refluxed (ca. 180 °C) for 1.5−2 h under an Ar atmosphere.  Water 
was added to the mixture, which was extracted twice with Et2O.  The combined organic phase was washed 
with water, brine, dried (Na2SO4) and concentrated.  The obtained crude product was purified by 
SiO2-column chromatography (hexane) to give the 1:1 mixture of products (49 mg, 32%), dec-6-en-5-one 
(8-2a)
10a
 and dec-3-en-5-one (8-2b).
10b
 
Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 0.87−0.97 (m, 4.5H), 1.80 (t, J = 7.5 Hz, 1.5H), 1.26−1.66 (m, 
6H), 2.15−2.29 (m, 2H), 2.50−2.56 (m, 2H), 6.06−6.13 (m, 1H), 6.77−6.92 (m, 1H); 13C NMR (75 MHz, 
CDCl3): δ = 12.2, 13.6, 13.8, 13.9, 21.3, 22.36, 22.41, 24.0, 25.5, 26.4, 31.5, 34.4, 39.8, 40.0, 129.4, 130.4, 
146.9, 148.4, 200.9, 200.9; IR (neat): νmax = 2935, 2858, 1690, 1661, 1628, 1451, 1373, 1331, 1310, 1294 
cm
−1
. 
 
Preparation of acyloins (8-3) and (8-4) 
 
Methyl 2-butyl-3-cyclohexyl-3-oxopropanoate
11
 
According to a reported method for Ti-crossed Claisen condensation,
11
 cyclohexanecarbonyl chloride (1.47 
g, 10.0 mmol) was added to a solution of methyl haxanoate (1.30 g 10.0 mmol) and N-methylimidazole (985 
mg, 12.0 mmol) in CH2Cl2 (30 mL) at –45 °C under an Ar atmosphere, followed by being stirred at the same 
temperature for 10 min.  Then, TiCl4 (3.84 mL, 35.0 mmol) and Bu3N (9.51 mL, 40.0 mmol) were 
successively added to the mixture, which was stirred at the same temperature for 0.5 h.  Water was added to 
the mixture, which was extracted twice with Et2O.  The combined organic phase was washed with water, 
brine, dried (Na2SO4) and concentrated.  The obtained crude oil was purified by SiO2-column 
chromatography (hexane/AcOEt = 20/1) to give methyl 2-butyl-3-cyclohexyl-3-oxopropanoate (2.24 g, 91%).  
Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 0.89 (t, J = 6.9 Hz, 3H), 1.15−1.46 (m, 9H), 1.62−1.87 (m, 
7H), 2.42-2.58 (m, 1H), 3.60 (t, J = 7.2 Hz, 1H), 3.71 (s, 3H); 
13
C NMR (75 MHz, CDCl3): δ = 13.8, 22.5, 
25.5, 25.6, 25.7, 28.1, 28.2, 28.6, 29.8, 50.5, 52.2, 57.0, 170.4, 208.3; IR (neat): νmax = 2932, 1748, 1713, 1451, 
1246 cm
−1
. 
 
1-Cyclohexylhexan-1-one
12
  
Methyl 2-butyl-3-cyclohexyl-3-oxopropanoate (2.24 g, 9.10 mmol) in 5M KOH aqueous solution (18 mL) 
and THF (18 mL) was refluxed for 4 h.  6M HCl aqueous solution (25 mL) was added to the mixture, 
followed by being refluxed for 6 h.  Water was added to the mixture, which was extracted twice with Et2O.  
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The combined organic phase was washed with water, brine, dried (Na2SO4) and concentrated.  The obtained 
crude oil was purified by SiO2-column chromatography (hexane/AcOEt = 50/1) to give the desired product 
(1.53 g, 92%). 
Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 0.86 (t, J = 6.9 Hz, 3H), 1.07−1.41 (m, 9H), 1.55 (quint, J = 
7.2 Hz, 1H), 1.61−1.90 (m, 6H), 2.33 (tt, J = 3.5, 11.0 Hz, 1H), 2.42 (t, J = 7.6 Hz, 2H); 13C NMR (75 MHz, 
CDCl3): δ = 13.9, 22.5, 23.4, 25.7, 25.9, 28.5, 31.5, 40.6, 50.8, 214.4; IR (neat): νmax = 2930, 2855, 1707 cm
−1
. 
 
1-(1-Hydroxycyclohexyl)hexan-1-one (8-3) and 1-cyclohexyl-2-hydroxyhexan-1-one (8-4) 
According to a reported method,
9
 N-Methl-N-trimethylsilylacetamide (MSA) (2.68 mL, 16.8 mmol) was 
added to a stirred suspension of 1-cyclohexylhexan-1-one (1.53 g, 8.40 mmol) and NaH (17 mg, 0.40 mmol) 
in DMF (27 mL) at 20 − 25 °C under an Ar atmosphere, followed by being stirred at 60 − 65 °C for 1 h.  The 
reaction mixture was poured into ice water, which was extracted twice with hexane.  The combined organic 
phase was washed with ice water, brine, dried (Na2SO4) and concentrated.  The obtained crude product was 
purified by Florisil
®
-chromatography (hexane) to give the intermediary two enol silyl ethers (regioisomers; 
1.39 g, 73%).  mCPBA (70%, 1.65 g, 6.70 mmol) was added to a stirred suspension of the enol silyl esters 
(1.39 g, 6.10 mmol) and NaHCO3 (666 mg, 7.90 mmol) in CH2Cl2 (60 mL) at 0 − 5 °C under an Ar 
atmosphere.  The mixture was stirred at the same temperature for 0.5 h and at 20 − 25 °C for 10 h.  Sat. 
NaHCO3 aqueous solution was added to the mixture, which was extracted twice with Et2O.  The combined 
organic phase was washed with water, brine, dried (Na2SO4) and concentrated to give the crude epoxide.  
Then, a mixture of the crude epoxide and PPTS (77 mg, 0.30 mmol) in THF (15 mL) and H2O (3 mL) was 
stirred at 20 − 25 °C for 12 h.  Sat. NaHCO3 aqueous solution was added to the mixture, which was extracted 
twice with Et2O.  The combined organic phase was washed with water, brine, dried (Na2SO4) and 
concentrated.  The obtained crude product was purified by SiO2-column chromatography (hexane/AcOEt = 
20/1) to give the desired products 8-3 (278 mg, 23%) and 8-4 (484 mg, 40%). 
8-3; Colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 0.87 (t, J = 6.9 Hz, 3H), 1.14−1.86 (m, 16H), 2.53 (t, J = 
7.2 Hz, 2H), 3.61 (s, 1H); 
13
C NMR (75 MHz, CDCl3) δ 13.9, 21.1, 22.4, 23.4, 25.3, 31.4, 33.8, 35.6, 77.9, 
214.9; IR (neat) 3476, 2936, 2861, 1701, 1449, 1379, 1181, 1043, 989 cm
−1
. 
8-4; Colorless oil; 
1
H NMR (400 MHz, CDCl3): δ = 0.92 (t, J = 6.9 Hz, 3H), 1.18-1.57 (m, 10H), 1.61-1.89 (m, 
6H), 2.55 (tt, J = 3.7, 11.0 Hz, 1H), 3.49 (brs, 1H), 4.26−4.33 (m, 1H); 13C NMR (100 MHz, CDCl3) δ 13.8, 
22.5, 25.1, 25.6, 25.8, 27.2, 27.4, 29.7, 33.3, 45.9, 74.9, 215.3; IR (neat): νmax = 3482, 2932, 2859, 1701, 1400, 
1143, 1051 cm
−1
; HRMS (ESI): m/z calcd for C12H22O2 [M+Na]
+
 221.1517; found: 221.1518. 
 
Favorskii-type elimination reaction using valeroin mesylate (8-6) leading to unsymmetrical 
α,β-unsatureted ketones (8-2a) and (8-2b) 
 
6-Oxodecan-5-yl methanesulfonate (8-6) 
 According to a reported method for mild mesylation method,
13
 MsCl (344 mg, 3.00 mmol) was added to a 
stirred solution of 6-hydroxy-5-decanone (valeroin; 8-1) (345 mg, 2.00 mmol), N-methylimidazole (246 mg, 
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3.00 mmol), and Et3N (304 mg, 3.00 mmol) in toluene (10 mL) at 20 − 25 °C under an Ar atomosphere, and 
the mixture was stirred at the same temperature for 1 h.  Water was added to the mixture, which was 
extracted twice with AcOEt.  The organic phase was washed with water, brine, dried (Na2SO4), and 
concentrated.  The crude oil was purified by SiO2-column chromatography (hexane/AcOEt = 20/1) to give 
the desired product 8-6 (473 mg, 95%). 
Colorless oil; 
1
H NMR (400 MHz, CDCl3): δ = 0.89−0.95 (m, 6H), 1.29−1.47 (m, 6H), 1.53−1.64 (m, 2H), 
1.74−1.91 (m, 2H), 2.51−2.56 (m, 2H), 3.12 (s, 3H), 4.96 (dd, J = 4.8, 8.0 Hz, 1H); 13C NMR (100 MHz, 
CDCl3): δ = 13.7, 13.8, 22.1, 22.1, 25.1, 26.9, 31.1, 38.2, 38.8, 84.1, 206.4; IR (neat): νmax = 2961, 2874, 1719, 
1509, 1458, 1364, 1178, 955 cm
−1
; HRMS (ESI): m/z calcd for C11H22O4S [M+Na]
+
 273.1136; found: 
273.1128. 
 
Favorskii-type elimination reaction 
CF3SO3H (60 mg, 0.40 mmol) was added to a stirred solution of 6-oxodecan-5-yl methanesulfonate 8-6 
(250 mg, 1.00 mmol) in hexane (0.50 mL) at 0 − 5 °C under an Ar atmosphere, and the mixture was stirred at 
the same temperature for 1 h.   Sat. NaHCO3 aqueous solution was added to the mixture, which was 
extracted twice with Et2O.  The combined organic phase was washed with water, brine, dried (Na2SO4) and 
concentrated.  The obtained crude product was purified by SiO2-column chromatography (hexane/AcOEt = 
70/1) to give the desired 1 : 1 mixture products of 8-2a
10a
 and 8-2b
10b
 (80 mg, 52%). 
 
Preparation of acyloin mesylates (8-7)-(8-9) 
 
1-Cyclohexyl-1-oxohexan-2-yl methanesulfonate (8-7) 
Following the procedure for the preparation of 8-6, the mesylation reaction of 8-4 (198 mg, 1.00 mmol) 
with MsCl (229 mg, 2.00 mmol), N-methylimidazole (123 mg, 1.50 mmol), and Et3N (152 mg, 1.50 mmol) 
gave the desired product 8-7 (246 mg, 89%). 
Colorless crystals; mp 43−45 °C; 1H NMR (400 MHz, CDCl3): δ = 0.92 (t, J = 7.3 Hz, 3H), 1.16−1.53 (m, 
9H), 1.65−1.96 (m, 7H), 2.56 (tt, J = 11.0, 3.7 Hz, 1H), 3.12 (s, 3H), 5.12 (dd, J = 8.2, 3.7 Hz, 1H); 13C NMR 
(100 MHz, CDCl3): δ = 13.7, 22.1, 25.1, 25.6, 25.7, 27.2, 27.5, 29.3, 30.8, 39.0, 46.7, 83.1, 208.8; IR (KBr): 
νmax = 2928, 2859, 1723, 1360, 1339, 1175, 949 cm
−1; HRMS (ESI): m/z calcd for C13H24O4S [M+Na]
+
 
299.1293; found: 299.1291. 
 
Methyl 2-butyl-3-cyclopentyl-3-oxopropanoate (SSS8-8) 
  Following the procedure for the preparation of methyl 2-butyl-3-cyclohexyl-3-oxopropanoate, Ti-Claisen 
condensation reaction of cyclopentanecarbonyl chloride (2.64 g, 20.0 mmol) and methyl hexanoate (2.60 g, 
20.0 mmol) gave the titled compound SSS8-8 (4.16 g, 92%). 
Colorless oil; 
1
H NMR (400 MHz, CDCl3): δ = 0.89 (t, J = 6.9 Hz, 3H), 1.18−1.39 (m, 4H), 1.51−1.90 (m, 
10H), 3.03 (quin, J = 7.6 Hz, 1H), 3.55 (t, J = 7.3 Hz, 1H), 3.72 (s, 3H); 
13
C NMR (100 MHz, CDCl3): δ = 
13.7, 22.4, 25.9, 28.0, 29.1, 29.5, 29.7, 50.7, 52.2, 58.3, 170.4, 207.9; IR (neat): νmax = 2955, 2870, 1744, 1711, 
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1435, 1167, 1011 cm
−1
; HRMS (ESI): m/z calcd for C13H22O3 [M+Na]
+
 249.1467; found: 249.1469. 
 
1-Cyclopentylhexan-1-one
12
 (SS8-8) 
 Following the procedure for the preparation of 1-cyclohexylhexan-1-one, the reaction of SSS8-8 (4.07 g, 
18.0 mmol) gave the titled ketone SS8-8 (1.85 g, 61%). 
Colorless oil; 
1
H NMR (400 MHz, CDCl3): δ = 0.89 (t, J = 6.9 Hz, 3H), 1.20−1.37 (m, 4H), 1.51−1.85 (m, 
10H), 2.44 (t, J = 7.3 Hz, 2H), 2.86 (quint, J = 7.3 Hz, 1H); 
13
C NMR (100 MHz, CDCl3): δ = 13.9, 22.5, 23.5, 
26.0, 28.9, 31.5, 41.7, 51.3, 213.5; IR (neat): νmax = 2955, 2868, 1709, 1452, 1369, 1128, 756 cm
−1
.  
 
1-Cyclopentyl-2-hydroxyhexan-1-one (S8-8) 
nBuLi (1.60 M in hexane, 6.75 mL, 11.0 mmol) was added to a stirred solution of iPr2NH (1.11 g, 11.0 
mmol) in THF (10 mL) at 0 − 5 °C under an Ar atmosphere.  To the mixture was added a solution of SS8-8 
(1.68 g, 10.0 mmol) in THF (10 mL) at ‒78 °C and the mixture was stirred at the same temperature for 1 h.  
TMSCl (1.96 g, 18.0 mmol) was added to the mixture, followed by being stirred at ‒78 °C and gradually 
warmed to 20 − 25 °C for 2 h.  The mixture was slowly and reversely added to ice-water, which was 
extracted with hexane.  The organic phase was washed with cooled water, brine, dried (Na2SO4) and 
concentrated to give the crude TMS enol ether (2.33 g).  mCPBA (70%, 2.71 g, 11.0 mmol) was added to a 
stirred suspension of the TMS enol ether and NaHCO3 (1.09 g, 13.0 mmol) in CH2Cl2 (30 mL) at 0 − 5 °C 
under an Ar atmosphere, followed by being stirred at 20 − 25 °C for 1 h.  Sat. NaHCO3 aqueous solution was 
added to the mixture, which was extracted twice with AcOEt.  The combined organic phase was washed with 
brine, dried (Na2SO4) and concentrated to give the crude epoxide.  Then, a mixture of the crude epoxide and 
3M HCl aqueous solution in THF (10 mL) and MeOH (5 mL) was stirred at 20 − 25 °C for 1 h.  Sat. 
NaHCO3 aqueous solution was added to the mixture, which was extracted twice with AcOEt.  The combined 
organic phase was washed with 1M NaOH aqueous solution, brine, dried (Na2SO4) and concentrated.  The 
obtained crude product was purified by SiO2-column chromatography (hexane/AcOEt = 25/1) to give the 1 : 1 
mixture of  titled compound S8-8 (286 mg, 16%). 
Colorless oil; 
1
H NMR (400 MHz, CDCl3): δ = 0.92 (t, J = 6.9 Hz, 3H), 1.24−1.98 (m, 14H), 3.01 (quint, J = 
8.2 Hz, 1H), 3.48−3.54 (m, 1H), 4.24−4.31 (m, 1H); 13C NMR (100 MHz, CDCl3): δ = 13.8, 22.5, 25.9, 26.1, 
27.1, 28.7, 31.1, 33.2, 46.4, 75.9, 215.5; IR (neat): νmax = 3478, 2955, 2870, 1703, 1452, 1356, 1076, 1047, 
731 cm
−1
; HRMS (ESI): m/z calcd for C11H20O2 [M+Na]
+
 207.1361; found: 207.1365. 
 
1-Cyclopentyl-1-oxohexan-2-yl methanesulfonate (8-8) 
Following the procedure for the preparation of 8-6, the mesylation reaction of 
1-cyclopentyl-2-hydroxyhexan-1-one S8-8 (400 mg, 2.20 mmol) with MsCl (504 mg, 4.40 mmol), 
N-methylimidazole (268 mg, 3.30 mmol), and Et3N (330 mg, 3.30 mmol) gave the desired product 8-8 (520 
mg, 91%). 
Colorless oil; 
1
H NMR (400 MHz, CDCl3): δ = 0.90−0.95 (m, 3H), 1.23−2.04 (m, 14H), 3.06 (quint, J = 8.7 
Hz, 1H), 3.13 (s, 3H), 5.09 (dd, J = 8.2, 4.1 Hz, 1H); 
13
C NMR (100 MHz, CDCl3): δ = 13.7, 22.1, 26.0, 26.2, 
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27.1, 28.7, 30.5, 30.9, 39.0, 47.0, 83.9, 208.9; IR (neat): νmax = 2961, 2872, 1728, 1360, 1177, 963, 917, 733 
cm
−1
; HRMS (ESI): m/z calcd for C12H22O4S [M+Na]
+
 285.1136; found: 285.1138. 
 
7-Ethyl-5-hydroxyundecan-6-one (S8-9) 
According to the a reported method for prepararion of a solution of SmI2,
14
 suspension of Sm powder (301 
mg, 1.00 mmol, Aldrich, 99%, -40 mesh) in THF (9.0 mL) was sonicated for 15 min under an Ar atmosphere.  
A solution of I2 (254 mg, 1.00 mmol) in THF (1.0 mL) was added to the stirred suspension at 20 − 25 °C, 
which was stirred at 60 − 65 °C for 16 h.  After the resulting blue mixture was cooled to ambient temperature, 
a solution of 2-ethylhexanecarbonyl chloride (73 mg, 0.45 mmol) and pentanal (39 mg, 0.45 mmol) in THF 
(1.0 mL) was successively added dropwise and stirred at the same temparature for 3 h.  1M HCl aqueous 
solution was added to the mixture, which was extracted twice with AcOEt.  The combined organic phase was 
washed with water, brine, dried (Na2SO4) and concentrated.  The obtained crude product was purified by 
SiO2-column chromatography (hexane/AcOEt = 20/1) to give titled compound S8-9 (57 mg, 59%).  
Diastereomixtures; pale yellow oil; 
1
H NMR (400 MHz, CDCl3): δ = 0.83−0.94 (m, 9H), 1.14−1.88 (m, 14H), 
2.55−2.66 (m, 1H), 3.47−3.48 (m, 1H), 4.14−4.22 (m, 1H); 13C NMR (100 MHz, CDCl3): δ = 11.4, 12.1, 13.8, 
13.9, 22.5, 22.8, 22.8, 23.5, 25.9, 27.4, 27.5, 29.2, 29.6, 29.8, 32.5, 32.9, 33.0, 48.3, 48.7, 76.4, 216.1, 216.2; 
IR (neat): νmax = 3480, 2957, 2932, 2874, 2860, 1705, 1460, 1379, 1043 cm
−1
; HRMS (ESI): m/z calcd for 
C13H26O2 [M+Na]
+
 237.1830; found: 237.1833. 
 
7-Ethyl-6-oxoundecan-5-yl methanesulfonate (7.9) 
Following the procedure for the preparation of 8-6, the mesylation reaction of 
7-ethyl-5-hydroxyundecan-6-one S8-9 (279 mg, 1.30 mmol) with MsCl (298 mg, 2.60 mmol), 
N-methylimidazole (160 mg, 1.95 mmol), and Et3N (198 mg, 1.95 mmol) gave the 1 : 1 mixture of desired 
product 8-9 (316 mg, 83%). 
Diastereomixtures; colorless oil; 
1
H NMR (400 MHz, CDCl3): δ = 0.83−0.96 (m, 9H), 1.13−1.54 (m, 10H), 
1.59−1.79 (m, 3H), 1.86−1.96 (m, 1H), 2.57−2.66 (m, 1H), 3.14 (s, 3H x 1/2), 3.14 (s, 3H x 1/2), 5.08 (t, J = 
3.7 Hz, 1H x 1/2), 5.10 (t, J = 3.7 Hz, 1H x 1/2); 
13
C NMR (100 MHz, CDCl3): δ = 11.2, 11.9. 13.7, 13.8, 22.0, 
22.6, 22.7, 23.1, 24.8, 27.1, 29.0, 29.3, 29.6, 30.3, 31.2, 39.1, 48.9, 49.0, 83.8, 83.8, 208.8, 208.8; IR (neat): 
νmax = 2961, 2874, 1730, 1458, 1362, 1177, 961, 841, 735 cm
−1
; HRMS (ESI): m/z calcd for C14H28O4S 
[M+Na]
+
 315.1606; found: 322.1609. 
 
Favorskii-type elimination reaction using acyloin mesylate (8-7)-(8-9) 
 
1-Cyclohexenylhexan-1-one
15
 (8-5a) 
Following the procedure for the case using 8-6, the reaction of 8-7 (111 mg, 0.400 mmol) and CF3SO3H (72 
mg, 0.48 mmol) at 20 − 25 °C gave the desired product 8-5a (72 mg, 97%). 
Colorless oil; 
1
H NMR (400 MHz, CDCl3): δ = 0.89 (t, J = 6.9 Hz, 3H), 1.22−1.38 (m, 4H), 1.55−1.68 (m, 
6H), 2.19−2.28 (m, 4H), 2.61 (t, J = 7.3 Hz, 2H), 6.86−6.92 (s, 1H); 13C NMR (100 MHz, CDCl3): δ = 13.9, 
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21.5, 21.9, 22.5, 23.1, 24.5, 26.0, 31.6, 36.9, 139.2, 139.4, 201.7; IR (neat): νmax = 3431, 2932, 2861, 1667, 
1638, 1458, 1190 cm
−1
; HRMS (ESI): m/z calcd for C12H20O [M+Na]
+
 203.1412; found: 203.1412. 
 
1-Cyclopentenylhexan-1-one (8-10) 
 Following the procedure for the case using 8-6, the reaction of 8-8 (104 mg, 0.400 mmol) and CF3SO3H (72 
mg, 0.48 mmol) at 20 − 25 oC gave the desired product 8-10 (56 mg, 85%). 
Colorless oil; 
1
H NMR (400 MHz, CDCl3): δ = 0.88 (t, J = 7.3 Hz, 3H), 1.24−1.39 (m, 4H), 1.62 (J = 7.3 Hz, 
2H,), 1.92 (quint, J = 7.8 Hz, 2H), 2.49−2.60 (m, 4H), 2.64 (t, J = 7.8 Hz, 2H), 6.70−6.73 (m, 1H); 13C NMR 
(100 MHz, CDCl3): δ = 13.9, 22.4, 22.7, 24.4, 30.6, 31.5, 33.8, 38.9, 143.0, 145.6, 199.4; IR (neat): νmax = 
2957, 2860, 1665, 1615, 1466, 1379, 1298, 1256, 1173 cm
−1
; HRMS (ESI): m/z calcd for C11H18O [M+Na]
+
 
189.1255; found: 189.1255. 
 
5-Ethyl-5-undecen-6-one and 5-Ethyl-7-undecen-6-one (8-11) 
Following the procedure for the case using 8-6, the reaction of 8-9 (117 mg, 0.400 mmol) and CF3SO3H (72 
mg, 0.48 mmol) gave the 1 : 1 mixture of desired product 8-11 (57 mg, 72%). 
Regioisomer mixtures; colorless oil; 
1
H NMR (400 MHz, CDCl3): δ = 0.88−1.00 (m, 12H x 1/2), 1.21−1.37 
(m, 12H x 1/2), 1.46−1.65 (m, 6H x 1/2), 1.86 (d, J = 6.9 Hz, 3H x 1/2), 2.23 (q, J = 6.9 Hz, 2H x 1/2), 
2.26−2.33 (m, 4H x 1/2), 2.61 (t, J = 7.3 Hz, 2H x 1/2), 2.62 (t, J = 7.3 Hz, 2H x 1/2), 6.55 (t, J = 6.9 Hz, 1H x 
1/2), 6.69 (q, J = 6.9 Hz, 1H x 1/2); 
13
C NMR (100 MHz, CDCl3): δ = 13.8, 13.9, 14.5, 18.8, 22.2, 22.5, 22.8, 
24.7, 24.7, 25.0, 30.6, 31.1, 31.5, 37.2, 37.3, 136.6, 141.7, 143.1, 143.4, 201.8, 201.9; IR (neat): νmax = 3424, 
3410, 2959, 2931, 2872, 1671, 1638, 1458 cm
−1
; HRMS (ESI): m/z calcd for C13H24O [M+Na]
+
 219.1725; 
found: 219.1728. 
 
Preparation of acyloin mesylates (8-12)-(8-15) 
 
2-Butyl-6-hydroxycyclohexanone (S8-12) 
nBuLi (1.60 M in hexane, 5.35 mL, 8.56 mmol) was added to a stirred solution of iPr2NH (1.20 mL, 8.56 
mmol) in THF (12 mL) at 0 − 5 °C under an Ar atmosphere.  To the mixture was added a solution of 
2-butylcyclohexanone
16
 (1.20 g, 7.78 mmol) in THF (4.0 mL) at ‒78 °C and the mixture was stirred at the 
same temperature for 1 h.  TMSCl (1.77 mL, 14.0 mmol) was added to the mixture, followed by being stirred 
at ‒78 °C and gradually warmed to 20 − 25 °C for 2 h.  The mixture was slowly and reversely added to 
ice-water, which was extracted with hexane.  The organic phase was washed with cooled water, brine, dried 
(Na2SO4) and concentrated to give the desired crude 1-trimethylsilyloxy-2-butylcyclohexene (1.76 g).  
mCPBA (70%, 2.11 g, 8.56 mmol) was added to a stirred suspension of the TMS enol ether and NaHCO3 (849 
mg, 10.1 mmol) in CH2Cl2 (24 mL) at 0 − 5 °C under an Ar atmosphere, followed by being stirred at 20 − 
25 °C for 1 h.  Sat. NaHCO3 aqueous solution was added to the mixture, which was extracted twice with 
AcOEt.  The combined organic phase was washed with brine, dried (Na2SO4) and concentrated to give crude 
epoxide.  Then, a mixture of the crude epoxide and 3M HCl aqueous solution in THF (10 mL) and MeOH (5 
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mL) was stirred at 20 − 25 °C for 1 h.  Sat. NaHCO3 aqueous solution was added to the mixture, which was 
extracted twice with AcOEt.  The combined organic phase was washed with 1M NaOH aqueous solution, 
brine, dried (Na2SO4) and concentrated.  The obtained crude product was purified by SiO2-column 
chromatography (hexane/AcOEt = 10/1) to give the 1 : 1 mixture of  the desired product  S12 (893 mg, 
67%).   
 
3-Butyl-2-oxocyclohexyl methanesulfonate (8-12) 
MsCl (172 mg, 1.50 mmol) in toluene (1.0 mL) was added to a stirred solution of S8-12 (170 mg, 1.00 
mmol), N-methylimidazole (123 mg, 1.50 mmol), and Et3N (152 mg, 1.50 mmol) in toluene (1.0 mL) at 20 − 
25 °C under an Ar atmosphere, followed by being stirred at the same temperature for 1 h.  Water was added 
to the mixture, which was extracted twice with AcOEt.  The combined organic phase was washed with water, 
brine, dried (Na2SO4) and concentrated.  The obtained crude product was purified by SiO2-column 
chromatography (hexane/AcOEt = 5/1) to give the 1 : 1 mixture of the desired products 8-12 (134 mg, 54%).  
Diasteromixture; colorless crystals; mp 50−53 °C; 1H NMR (300 MHz, CDCl3): δ = 0.84−0.95 (m, 3H), 
1.17−1.49 (m, 6H), 1.65−2.37 (m, 6H), 2.44−2.56 (m, 1H x 1/2), 2.64−2.74 (m, 1H x 1/2), 3.15 (s, 3H x 1/2), 
3.23 (s, 3H x 1/2), 5.03−5.14 (m, 1H); 13C NMR (75 MHz; CDCl3): δ = 13.8, 13.9, 19.5, 22.5, 22.8, 23.1, 28.0, 
29.2, 29.8, 32.1, 33.5, 34.4, 35.0, 39.0, 39.5, 49.5, 49.8, 81.3, 82.9, 205.3, 207.3; IR (neat): νmax = 2951, 2869, 
1730, 1358, 1177, 974, 833, 752 cm
−1
; HRMS (ESI): m/z calcd for C11H20O4S [M+Na]
+
 271.0980; found: 
271.0969. 
 
3-Butyl-2-oxocycloheptyl methanesulfonate (8-13) 
Following the procedure for the preparation of S8-12 and 8-12, the reaction of 2-butylcycloheptanone
17
 
gave 2-butyl-7-hydroxycycloheptan-1-one, and the mesylation reaction of 
2-butyl-7-hydroxycycloheptan-1-one (488 mg, 2.70 mmol) with MsCl (619 mg, 5.40 mmol), 
N-methylimidazole (326 mg, 4.05 mmol), and Et3N (402 mg, 4.05 mmol) gave the desired product 8-13 (598 
mg, 86%). 
Colorless crystals; mp 84−85 °C; 1H NMR (300 MHz, CDCl3): δ = 0.83−0.95 (m, 3H), 1.13−2.07 (m, 13H), 
2.08−2.21 (m, 1H), 2.41−2.54 (m, 1H), 3.11 (s, 3H), 5.21 (dd, J = 11.0, 3.4 Hz, 1H); 13C NMR (75 MHz, 
CDCl3): δ = 13.8, 22.4, 26.2, 26.6, 29.0, 29.4, 32.1, 32.8, 39.1, 50.7, 82.4, 209.1; IR (neat): νmax = 2959, 1721, 
1456, 1366, 1167, 968, 837, 740 cm
−1
; HRMS (ESI): m/z calcd for C12H22O4S [M+Na]
+
 285.1136; found: 
285.1133.   
 
2-Butylcyclooctanone (SS8-14) 
nBuLi (1.60 M in hexane, 20.6 mL, 33.0 mmol) was added to a stirred solution of iPr2NH (3.34 g, 33.0 
mmol) in THF (40 mL) at 0 − 5 °C under an Ar atmosphere.  To the mixture was added a solution of 
cyclooctanone (3.80 g, 30.0 mmol) in THF (15 mL) at ‒78 °C and the mixture was stirred at the same 
temperature for 1 h.  HMPA (4.0 mL) and 1-iodobutane (1.77 mL, 14.0 mmol) were successively added to 
the mixture, followed by being stirred at ‒78 °C and gradually warmed to 20 − 25 °C for 2 h.  The mixture 
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was slowly and reversely added to ice-water, which was extracted twice with AcOEt.  The combined organic 
phase was washed with water, brine, dried (Na2SO4) and concentrated.  The obtained crude product was 
purified by SiO2-column chromatography (hexane : AcOEt = 40/1) to give the titled compound SS8-14 (2.57 g, 
47%,). 
Colorless oil; 
1
H NMR (400 MHz, CDCl3): δ = 0.88 (t, J = 7.3 Hz, 3H), 1.10−1.51 (m, 9H), 1.55−1.70 (m, 
4H), 1.75−1.85 (m, 2H), 1.91−2.05 (m, 1H), 2.28 (ddd, J = 13.3, 6.9, 3.2 Hz, 1H), 2.44 (ddd, J = 13.3, 11.5, 
3.7 Hz, 1H), 2.50−2.60 (m, 1H); 13C NMR (100 MHz, CDCl3): δ = 13.8, 22.7, 24.7, 25.4, 25.8, 27.3, 29.6, 
32.3, 32.7, 41.9, 50.6, 220.3; IR (neat): νmax = 2926, 2857, 1699, 1466, 1375, 1161, 754 cm
−1
; HRMS (ESI): 
m/z calcd for C12H22O [M+Na]
+
 205.1568; found: 205.1570. 
 
2-Butyl-8-hydroxycyclooctanone (S8-14) 
Following the procedure for the preparation of S8-12, the reaction of 2-butylcyclooctanone SS8-14 (1.82 g, 
10.0 mmol) gave 2-butyl-8-hydroxycyclooctan-1-one S8-14 (1.11 g, 56%). 
Colorless oil; 
1
H NMR (400 MHz, CDCl3): δ = 0.88 (t, J = 7.3 Hz, 3H), 1.03−1.80 (m, 14H), 1.82−1.95 (m, 
1H), 2.10−2.19 (m, 1H), 2.44−2.54 (m, 1H), 3.11 (brs, 1H), 4.38 (dd, J = 8.2, 4.6 Hz, 1H); 13C NMR (100 
MHz, CDCl3): δ = 13.8, 21.1, 22.5, 24.9, 26.8, 28.5, 29.3, 33.6, 37.1, 51.5, 72.3, 219.7; IR (neat): νmax = 3449, 
2928, 2859, 1697, 1466, 1030, 752 cm
−1
; HRMS (ESI): m/z calcd for C12H22O2 [M+Na]
+
 221.1517; found: 
221.1524. 
 
3-Butyl-2-oxocyclooctyl methanesulfonate (8-14) 
Following the procedure for the preparation of 8-12, the mesylation reaction of S8-14 (1.00 g, 5.04 mmol) 
with MsCl (1.15 g, 10.1 mmol), N-methylimidazole (621 mg, 7.56 mmol), and Et3N (764 mg, 7.56 mmol) 
gave the desired product 8-14 (1.31 g, 94%). 
Colorless crystals; mp 39−41 °C; 1H NMR (400 MHz, CDCl3): δ = 0.88 (t, J = 6.9 Hz, 3H), 1.15−1.78 (m, 
13H), 1.89−1.98 (m, 1H), 2.06−2.20 (m, 2H), 2.71−2.80 (m, 1H), 3.06 (s, 3H), 5.09 (dd, J = 7.8, 5.0 Hz, 1H); 
13
C NMR (100 MHz, CDCl3): δ = 13.8, 21.2, 22.5, 24.8, 26.1, 29.4, 30.8, 32.1, 33.9, 38.6, 48.9, 81.7, 212.7; 
IR (KBr): νmax = 2959, 2860, 1720, 1707, 1468, 1346, 1174, 970, 845 cm
−1
; HRMS (ESI): m/z calcd for 
C13H24O4S [M+Na]
+
 299.1293; found: 229.1295. 
 
2-Butylcyclopentadecanone (SS8-15) 
Following the procedure for preparation of SS8-14, the alkylation of cyclopentadecanone (4.49 g, 20.0 
mmol) gave a mixture of the desired product SS8-15 and a byproduct (5.96 g). 
Colorless oil; 
1
H NMR (400 MHz, CDCl3): δ = 0.87 (t, J = 6.9 Hz, 3H), 1.10−1.44 (m, 26H), 1.48−1.77 (m, 
4H), 2.36 (dt, J = 16.5, 6.9 Hz, 1H), 2.47 (dt, J = 16.5, 6.9 Hz, 1H), 2.43−2.54 (m, 1H); 13C NMR (100 MHz, 
CDCl3): δ = 13.9, 22.3, 22.8, 26.0, 26.2, 26.3, 26.3, 26.4, 26.6, 27.0, 27.4, 27.5, 29.8, 31.9, 32.0, 41.6, 52.2, 
215.7; IR (neat): νmax = 2926, 2855, 1709, 1458, 1375, 1063, 733 cm
−1
; HRMS (ESI): m/z calcd for C19H36O 
[M+Na]
+
 303.2664; found: 303.2663. 
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2-Butyl-15-hydroxylcyclopentadecanone (S8-15) 
Following the procedure for the preparation of S8-12, 2-butylcyclopentadecan-1-one (5.96 g) gave the 
desired product S8-15 (2.89 g, 49%). 
Diastereomixtures; colorless oil; 
1
H NMR (400 MHz, CDCl3): δ = 0.86 (t, J = 7.3 Hz, 3H x 3/10), 0.88 (t, J = 
7.3 Hz, 3H x 7/10), 1.09−1.97 (m, 30H), 2.64−2.80 (m, 1H), 3.48 (d, J = 5.0 Hz, 1H x 7/10), 3.53 (d, J = 5.5 
Hz, 1H x 3/10), 4.16 (ddd, J = 11.0, 5.0, 2.3 Hz, 1H x 7/10), 4.26 (q, J = 5.5 Hz, 1H x 3/10); 
13
C NMR (100 
MHz, CDCl3): δ = 13.8, 13.9, 22.3, 22.8, 22.9, 23.5, 24.8, 25.2, 25.4, 25.5, 25.6, 25.9, 25.9, 26.3, 26.3, 26.4, 
26.5, 26.6, 26.6, 26.7, 27.1, 27.6, 29.4, 29.7, 30.1, 30.4, 31.2, 32.5, 32.7, 32.9, 45.0, 46.7, 74.7, 76.8, 216.6, 
217.2; IR (neat): νmax = 3480, 2926, 2857, 1703, 1458, 1373, 1238, 1045, 908, 731 cm
−1
; HRMS (ESI): m/z 
calcd for C19H36O2 [M+Na]
+
 319.2613; found: 319.2621. 
 
3-Butyl-2-oxocyclopentadecyl methanesulfonate (8-15) 
Following the procedure for the preparation of 8-12, the mesylation reaction of S8-15 (700 mg, 2.36 mmol) 
with MsCl (541 mg, 4.72 mmol), N-methylimidazole (291 mg, 3.54 mmol), and Et3N (358 mg, 3.54 mmol) 
gave the 7 : 3 mixture of desired product 8-15 (761 mg, 86%). 
Diastereomixtures; colorless crystals; mp 42−45 °C; 1H NMR (400 MHz, CDCl3): δ = 0.84−0.93 (m, 3H), 
1.11−1.52 (m, 26H), 1.59−1.84 (m, 3H), 1.90−2.08 (m, 1H), 2.55−2.65 (m, 1H x 3/10), 2.73−2.82 (m, 1H x 
7/10), 3.14 (s, 3H), 5.05 (dd, J = 9.2, 3.7 Hz, 1H x 7/10), 5.21 (t, J = 5.0 Hz, 1H x 3/10); 
13
C NMR (100 MHz, 
CDCl3): δ = 13.8, 22.5, 22.6, 22.7, 23.0, 25.3, 25.4, 25.6, 25.7, 25.7, 26.1, 26.3, 26.5, 26.6, 27.6, 28.9, 29.1, 
29.5, 29.7, 29.9, 30.6, 31.2, 31.9, 39.0, 39.2, 45.9, 47.7, 83.3, 83.4, 208.4, 209.9; IR (KBr): νmax = 2957, 2849, 
1713, 1460, 1358, 1172, 968, 858 cm
−1
; HRMS (ESI): m/z calcd for C20H38O4S [M+Na]
+
 397.2388; found: 
397.2380. 
 
Favorskii-type elimination reaction using acyloin mesylate (8-12)-(8-15) 
 
2-Butylidenecyclohexanone (8-16)
18
 
Following the procedure for the case using 8-6, the reaction of 8-12 (50 mg, 0.20 mmol) and CF3SO3H (36 
mg, 0.24 mmol) at 20 − 25 °C gave the desired product 8-16 (18 mg, 60%). 
Pale yellow oil; 
1
H NMR (400 MHz, CDCl3): δ = 0.93 (t, J = 7.3 Hz, 3H), 1.48 (sext, J = 7.3 Hz, 2H), 
1.70−1.79 (m, 2H), 1.81−1.89 (m, 2H), 2.08 (q, J = 7.3 Hz, 2H), 2.43 (t, J = 6.4 Hz, 2H), 2.49 (t, J = 6.4 Hz, 
2H), 6.63 (tt, J = 7.3, 1.8 Hz, 1H); 
13
C NMR (100 MHz, CDCl3): δ = 13.9, 21.7, 23.3, 23.6, 26.6, 29.8, 40.1, 
136.3, 139.5, 201.2; IR (neat): νmax = 2926, 1688, 1619, 1456, 1321, 1246, 1175, 941 cm
−1
; HRMS (ESI): m/z 
calcd for C10H16O [M+Na]
+
 175.1099; found: 175.1097.
 
 
2-Butylidenecycloheptanone (exo-8-17) and 2-butylcyclohept-2-enone (endo-8-17) 
Following the procedure for the case using 8-6, the reaction of 8-13 (52 mg, 0.20 mmol) and CF3SO3H (61 
mg, 0.40 mmol) at 20 − 25 °C gave the product (exo-8-17; 13 mg, 39% and endo-8-17; 12 mg, 36%).  
exo-8-17a: colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 0.93 (t, J = 7.2 Hz, 3H), 1.47 (sext, J = 7.2 Hz, 2H), 
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2.12 (dt, J = 7.6, 7.2 Hz, 2H), 2.38−2.46 (m, 2H), 2.56−2.64 (m, 2H), 6.58 (t, J = 7.6 Hz, 1H); 13C NMR (75 
MHz, CDCl3): δ = 14.0, 22.0, 25.2, 27.1, 29.8, 30.0, 31.4, 43.3, 139.1, 140.7, 204.8; IR (neat) 2928, 2856, 
1686, 1619, 1458, 1321, 1177, 943 cm
-1
; HRMS (ESI) calcd for C11H18O (M+Na
+
) 189.1255, found 189.1255. 
endo-8-17b: colorless oil; 
1
H NMR (300 MHz, CDCl3): δ = 0.89 (t, J = 7.2 Hz, 3H), 1.21−1.41 (m, 2H), 
1.65−1.83 (m, 2H), 2.18−2.27 (m, 2H), 2.32−2.41 (m, 2H), 2.52−2.60 (m, 2H), 6.46 (tt, J = 6.2, 1.0 Hz, 1H); 
13
C NMR (75 MHz, CDCl3): δ = 13.9, 21.5, 22.4, 25.0, 27.4, 31.3, 32.8, 42.6, 140.9, 144.0, 205.4; IR (neat): 
νmax = 2934, 2863, 1671, 1458, 1379 cm
−1
. 
 
2-Butylidenecyclooctanone (exo-8-18) and 2-butylcyclooct-2-enone (endo-8-18) 
Following the procedure for the case using 8-6, the reaction of 8-14 (55 mg, 0.20 mmol) and CF3SO3H (61 
mg, 0.40 mmol) at 20 − 25 °C gave the desired product (exo-8-18; 3 mg, 8% and endo-8-18; 22 mg, 61%).  
endo-8-18: colorless oil; 
1
H NMR (400 MHz, CDCl3): δ = 0.89 (t, J = 6.2 Hz, 3H), 1.24−1.38 (m, 4H), 
1.53−1.64 (m, 4H), 1.82−1.90 (m, 2H), 2.15−2.23 (m, 2H), 2.27−2.35 (m, 2H), 2.50−2.56 (m, 2H), 5.91 (tt, J 
= 6.4, 0.9 Hz, 1H); 
13
C NMR (100 MHz, CDCl3): δ = 13.9, 22.3, 22.4, 22.9, 27.4, 29.1, 30.8, 35.3, 44.3, 132.8, 
140.5, 211.3; IR (neat): νmax = 2932, 1684, 1655, 1458, 1379, 1230, 1115 cm
−1
; HRMS (ESI): m/z calcd for 
C12H20O [M+Na]
+
 203.1412; found: 203.1418. 
 
2-Butylidenecyclopentadecanone (exo-8-19) 
Following the procedure for the case using 8-6, the reaction of 8-15 (55 mg, 0.20 mmol) and CF3SO3H (61 
mg, 0.40 mmol) at 20 − 25 °C gave the desired product (exo-8-19; 40 mg, 72% and endo-8-19; 2 mg, 4%).  
Colorless oil; 
1
H NMR (400 MHz, CDCl3): δ = 0.98 (t, J = 7.3 Hz, 3H), 1.12−1.41 (m, 20H), 1.50 (sext, J = 
7.3 Hz, 2H), 1.61−1.70 (m, 2H), 2.23 (q, J = 7.3 Hz, 2H), 2.40 (t, J = 6.4 Hz, 2H), 2.67 (t, J = 6.4 Hz, 2H), 
6.56 (t, J = 7.3 Hz, 1H); 
13
C NMR (100 MHz, CDCl3): δ = 13.9, 22.2, 24.9, 25.0, 26.0, 26.4, 26.4, 26.5, 26.7, 
26.8, 27.2, 27.5, 27.6, 28.5, 30.9, 36.9, 142.1, 142.2, 203.0; IR (neat): νmax = 2928, 2859, 1671, 1636, 1458, 
1281, 1117 cm
−1
; HRMS (ESI): m/z calcd for C19H34O [M+Na]
+
 301.2507; found: 301.2503. 
 
Synthesis of (R)-muscone precursor (Z)-8-21 
 
4-Methyl-2-oxocyclopentadecyl methanesulfonate (8-20) 
Following the procedure for the preparation of 8-4, 3-methylcyclopentadecanone
19
 (4.77 g, 20.0 mmol) 
gave 2-hydroxy-14-methylcyclopentadecanone (1.37 g, 27%).  The mesylation reaction of 
2-hydroxy-14-methylcyclopentadecanone (1.77 g, 7.00 mmol) with MsCl (1.60 g, 14.0 mmol), 
N-methylimidazole (858 mg, 10.5 mmol), and Et3N (1.06 g, 10.5 mmol) gave the desired product 20 (1.79 g, 
77%) 
Diastereomixtures; colorless crystals; mp 64−67 °C; 1H NMR (300 MHz, CDCl3): δ = 0.93−1.03 (m, 3H), 
1.09−1.55 (m, 20H), 1.78−2.26 (m, 3.5H), 2.31 (dd, J = 16.9, 5.5 Hz, 1H x 1/2), 2.52 (dd, J = 17.2, 7.2 Hz, 1H 
x 1/2), 2.73 (dd, J = 17.2, 6.5 Hz, 1H x 1/2), 3.11 (s, 3H x 1/2), 3.14 (s, 3H x 1/2), 4.94 (t, J = 6.2 Hz, 1H x 
1/2), 5.08 (t, J = 5.5 Hz, 1H x 1/2); 
13
C NMR (75 MHz, CDCl3): δ = 20.5, 20.6, 22.4, 22.8, 24.7, 25.0, 25.7, 
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26.1, 26.3, 26.3, 26.7, 26.4, 26.5, 26.5, 26.6, 26.7, 26.8, 27.0, 27.7, 27.9, 30.7, 30.2, 35.5, 38.7, 39.2, 45.2, 
46.1, 83.5, 83.7, 205.3, 207.2; IR (KBr): νmax = 2853, 1721, 1456, 1370, 1284, 1165, 961, 841 cm
−1
; HRMS 
(ESI): m/z calcd for C17H32O4S [M+Na]
+
 362.1919; found: 362.1921. 
 
(Z)-3-Methylcyclopentadec-2-enone [(Z)-8-21]
7f,j
 
Following the procedure for case using 8-6, the reaction of 8-20 (55 mg, 0.20 mmol) and CF3SO3H (36 mg, 
0.24 mmol) at 60 − 65 °C gave the desired product (Z)-8-21 (32 mg, 68%). 
Pale yellow oil; 
1
H (300 MHz, CDCl3): δ = 1.14−1.41 (m, 16H), 1.50−1.72 (m, 4H), 2.14 (d, J = 1.4 Hz, 3H), 
2.15−2.22 (m, 2H), 2.33−2.41 (m, 2H), 6.15 (d, J = 1.4 Hz, 1H); 13C NMR (75 MHz, CDCl3): δ = 18.7, 25.2, 
25.5, 25.6, 26.4, 26.6, 26.7, 26.8, 26.9, 27.1, 40.0, 44.5, 123.7, 159.0, 202.4; IR (neat): νmax = 2928, 2857, 
1684, 1613, 1458, 1389, 1364, 1225 cm
−1
. 
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